[
  {
    "id": 10,
    "user_query": "You MUST give a detailed answer to the following question: Name synonym of Acrokeratosis paraneoplastica.",
    "llama-7b_response": "Acrokeratosis paraneoplastica (AKP) is a cutaneous condition characterized by the development of thick, scaly patches on the skin, typically on the hands and feet. The exact cause of AKP is not fully understood, but it is thought to be related to the presence of a cancerous tumor in the body.\n\nThere are several synonyms for AKP, including:\n\n1. Acrokeratosis paraneoplastica of Bazex\n2. Acrokeratosis paraneoplastica of Jadassohn-Lindau\n3. Acrokeratosis paraneoplastica of Mees\n4. Acrokeratosis paraneoplastica of Rosenthal\n5. Acrokeratosis paraneoplastica of Siemens\n\nThese synonyms are used to refer to the same condition as AKP, but may be used interchangeably depending on the context in which they are used.",
    "llama-7b_fact_raw": "1. Acrokeratosis paraneoplastica is also known as Acrokeratosis paraneoplastica of Bazex.\n2. Acrokeratosis paraneoplastica is alternatively called Acrokeratosis paraneoplastica of Jadassohn-Lindau.\n3. Acrokeratosis paraneoplastica can be referred to as Acrokeratosis paraneoplastica of Mees.\n4. Acrokeratosis paraneoplastica may be termed Acrokeratosis paraneoplastica of Rosenthal.\n5. Acrokeratosis paraneoplastica is sometimes called Acrokeratosis paraneoplastica of Siemens.",
    "llama-7b_fact": [
      "Acrokeratosis paraneoplastica is also known as Acrokeratosis paraneoplastica of Bazex.",
      "Acrokeratosis paraneoplastica is alternatively called Acrokeratosis paraneoplastica of Jadassohn-Lindau.",
      "Acrokeratosis paraneoplastica can be referred to as Acrokeratosis paraneoplastica of Mees.",
      "Acrokeratosis paraneoplastica may be termed Acrokeratosis paraneoplastica of Rosenthal.",
      "Acrokeratosis paraneoplastica is sometimes called Acrokeratosis paraneoplastica of Siemens."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Acrokeratosis paraneoplastica is not known as Acrokeratosis paraneoplastica of Jadassohn-Lindau. Jadassohn-Lewandowsky syndrome, also known as Pachyonychia congenita, is a different condition.\n3. FALSE [correction]: Acrokeratosis paraneoplastica is not referred to as Acrokeratosis paraneoplastica of Mees. Mees' lines are transverse white lines on the nails that can be associated with arsenic poisoning or other systemic conditions.\n4. FALSE [correction]: Acrokeratosis paraneoplastica is not termed Acrokeratosis paraneoplastica of Rosenthal. There is no widely recognized condition known as Acrokeratosis paraneoplastica of Rosenthal in the medical literature.\n5. FALSE [correction]: Acrokeratosis paraneoplastica is not sometimes called Acrokeratosis paraneoplastica of Siemens. Siemens syndrome is another term for hidrotic ectodermal dysplasia, which is a different genetic condition.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 47,
    "user_query": "You MUST give a detailed answer to the following question: Is Weaver syndrome similar to Sotos?",
    "llama-7b_response": "Weaver syndrome and Sotos syndrome are two distinct genetic disorders that share some similarities, but they are not the same condition.\n\nWeaver syndrome, also known as Simpson-Golabi-Behmel syndrome (SGBS), is a genetic disorder caused by a mutation in the MLL2 gene. It is characterized by a distinctive physical appearance, including macrocephaly (abnormally large head), hypotonia (low muscle tone), and distinctive facial features such as a broad forehead, full cheeks, and a single crease in the palm of the hand. Individuals with Weaver syndrome also have an increased risk of developing certain cancers, particularly hepatoblastoma (a type of liver cancer) and rhabdomyosarcoma (a type of soft tissue cancer).\n\nSotos syndrome, also known as 45,X/46,XY mosaicism, is a genetic disorder caused by the presence of an extra copy of chromosome 15 in some of the cells in the body. It is characterized by a distinctive physical appearance, including a large head, short stature, and characteristic facial features such as a broad forehead, full cheeks, and a single crease in the palm of the hand. Individuals with Sotos syndrome also have an increased risk of developing certain cancers, particularly hepatoblastoma and rhabdomyosarcoma.\n\nWhile both Weaver syndrome and Sotos syndrome share some similarities in terms of physical characteristics and an increased risk of certain cancers, they are distinct genetic disorders caused by different genetic mutations. Therefore, a diagnosis of Weaver syndrome does not necessarily mean that an individual has Sotos syndrome, and a diagnosis of Sotos syndrome does not necessarily mean that an individual has Weaver syndrome.",
    "llama-7b_fact_raw": "1. Weaver syndrome is caused by a mutation in the MLL2 gene.\n2. Weaver syndrome is characterized by macrocephaly, hypotonia, and distinctive facial features.\n3. Individuals with Weaver syndrome have an increased risk of developing hepatoblastoma and rhabdomyosarcoma.\n4. Sotos syndrome is caused by the presence of an extra copy of chromosome 15 in some cells.\n5. Sotos syndrome is characterized by a large head, short stature, and characteristic facial features.",
    "llama-7b_fact": [
      "Weaver syndrome is caused by a mutation in the MLL2 gene.",
      "Weaver syndrome is characterized by macrocephaly, hypotonia, and distinctive facial features.",
      "Individuals with Weaver syndrome have an increased risk of developing hepatoblastoma and rhabdomyosarcoma.",
      "Sotos syndrome is caused by the presence of an extra copy of chromosome 15 in some cells.",
      "Sotos syndrome is characterized by a large head, short stature, and characteristic facial features."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Weaver syndrome is caused by a mutation in the EZH2 gene, not the MLL2 gene.\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: Sotos syndrome is typically caused by a mutation in the NSD1 gene, not by the presence of an extra copy of chromosome 15 in some cells.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "You MUST give a detailed answer to the following question: List the releases of JASPAR database",
    "llama-7b_response": "The JASPAR database is a widely used repository of protein-DNA interaction data. As of my knowledge cutoff date of September 2021, there have been several releases of the JASPAR database. Here is a list of the major releases:\n\n1. JASPAR 2004: This was the first release of the JASPAR database, which was published in 2004. It contained data for 184 human transcription factor binding sites.\n2. JASPAR 2008: This release of the JASPAR database was published in 2008 and contained data for 297 human transcription factor binding sites.\n3. JASPAR 2010: This release of the JASPAR database was published in 2010 and contained data for 357 human transcription factor binding sites.\n4. JASPAR 2012: This release of the JASPAR database was published in 2012 and contained data for 417 human transcription factor binding sites.\n5. JASPAR 2014: This release of the JASPAR database was published in 2014 and contained data for 467 human transcription factor binding sites.\n6. JASPAR 2016: This release of the JASPAR database was published in 2016 and contained data for 517 human transcription factor binding sites.\n7. JASPAR 2018: This release of the JASPAR database was published in 2018 and contained data for 567 human transcription factor binding sites.\n8. JASPAR 2020: This release of the JASPAR database was published in 2020 and contained data for 617 human transcription factor binding sites.\n\nIt's worth noting that the JASPAR database is regularly updated with new data, so this list may not be comprehensive or up-to-date.",
    "llama-7b_fact_raw": "1. The first release of the JASPAR database, JASPAR 2004, was published in 2004.\n2. JASPAR 2008 contained data for 297 human transcription factor binding sites.\n3. JASPAR 2010 contained data for 357 human transcription factor binding sites.\n4. JASPAR 2014 contained data for 467 human transcription factor binding sites.\n5. JASPAR 2020 contained data for 617 human transcription factor binding sites.",
    "llama-7b_fact": [
      "The first release of the JASPAR database, JASPAR 2004, was published in 2004.",
      "JASPAR 2008 contained data for 297 human transcription factor binding sites.",
      "JASPAR 2010 contained data for 357 human transcription factor binding sites.",
      "JASPAR 2014 contained data for 467 human transcription factor binding sites.",
      "JASPAR 2020 contained data for 617 human transcription factor binding sites."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: JASPAR 2008 contained data for 123 human transcription factor binding sites.\n3. FALSE [correction]: JASPAR 2010 contained data for 180 human transcription factor binding sites.\n4. FALSE [correction]: JASPAR 2014 contained data for 460 human transcription factor binding sites.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 99,
    "user_query": "You MUST give a detailed answer to the following question: What is the function of the viral KP4 protein?",
    "llama-7b_response": "The KP4 protein is a viral protein that is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV), which is a herpesvirus that is associated with the development of Kaposi's sarcoma, a type of cancer that affects the skin and other organs.\n\nThe KP4 protein is a viral oncoprotein that plays a key role in the transformation of normal cells into cancer cells. It is thought to do this by promoting cell growth and proliferation, as well as by inhibiting apoptosis, or programmed cell death.\n\nThe KP4 protein also plays a role in the immune evasion strategies of KSHV, as it can suppress the activity of immune cells and prevent them from recognizing and attacking the virus.\n\nOverall, the function of the KP4 protein is to promote the growth and survival of cancer cells and to evade the immune system, which allows the virus to persist and cause disease.",
    "llama-7b_fact_raw": "1. The KP4 protein is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV).\n2. Kaposi's sarcoma is a type of cancer that affects the skin and other organs.\n3. The KP4 protein is considered a viral oncoprotein.\n4. The KP4 protein is involved in transforming normal cells into cancer cells by promoting cell growth and proliferation.\n5. The KP4 protein inhibits apoptosis, or programmed cell death.",
    "llama-7b_fact": [
      "The KP4 protein is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV).",
      "Kaposi's sarcoma is a type of cancer that affects the skin and other organs.",
      "The KP4 protein is considered a viral oncoprotein.",
      "The KP4 protein is involved in transforming normal cells into cancer cells by promoting cell growth and proliferation.",
      "The KP4 protein inhibits apoptosis, or programmed cell death."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The KSHV protein associated with Kaposi's sarcoma is known as Kaposin B, not KP4.\n2. TRUE\n3. UNKNOWN: Without specific information on the KP4 protein, it's unclear whether it is considered a viral oncoprotein, especially since the correct protein associated with KSHV is Kaposin B.\n4. UNKNOWN: As the KP4 protein is not correctly associated with KSHV, the statement about its role in transforming cells is uncertain. The correct protein, Kaposin B, is involved in promoting cell growth and proliferation.\n5. UNKNOWN: Since the KP4 protein is not the correct protein associated with KSHV, the statement about its role in inhibiting apoptosis is uncertain. Kaposin B, the correct protein, does have roles in manipulating cell survival pathways, which could include inhibiting apoptosis.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "You MUST give a detailed answer to the following question: Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-7b_response": "Yes, 3,5-diiodo-L-thyronine (DITPA) is a thyroid hormone analog that has been utilized in both experimental and clinical studies. DITPA is structurally similar to triiodothyronine (T3), one of the two primary hormones produced by the thyroid gland. However, DITPA has an iodine atom replaced by an iodophenyl group, which results in increased lipophilicity and longer half-life compared to T3.\n\nDITPA has been studied as a potential treatment for various thyroid-related disorders, including hypothyroidism, hyperthyroidism, and thyroid cancer. In experimental studies, DITPA has been shown to have similar effects on metabolism and body weight regulation as T3, but with fewer side effects.\n\nIn clinical studies, DITPA has been used as an investigational new drug in the treatment of hypothyroidism, hyperthyroidism, and thyroid cancer. However, the use of DITPA in clinical settings is still experimental and more research is needed to fully understand its safety and efficacy.\n\nIn summary, DITPA is a thyroid hormone analog that has been studied in both experimental and clinical settings as a potential treatment for thyroid-related disorders. However, its use in clinical settings is still experimental and more research is needed to fully understand its safety and efficacy.",
    "llama-7b_fact_raw": "1. 3,5-diiodo-L-thyronine (DITPA) is a thyroid hormone analog used in experimental and clinical studies.\n2. DITPA is structurally similar to triiodothyronine (T3), a primary hormone produced by the thyroid gland.\n3. DITPA has an iodine atom replaced by an iodophenyl group, which results in increased lipophilicity and a longer half-life compared to T3.\n4. DITPA has been studied as a potential treatment for thyroid-related disorders such as hypothyroidism, hyperthyroidism, and thyroid cancer.\n5. DITPA's use in clinical settings is still considered experimental, and more research is needed to fully understand its safety and efficacy.",
    "llama-7b_fact": [
      "3,5-diiodo-L-thyronine (DITPA) is a thyroid hormone analog used in experimental and clinical studies.",
      "DITPA is structurally similar to triiodothyronine (T3), a primary hormone produced by the thyroid gland.",
      "DITPA has an iodine atom replaced by an iodophenyl group, which results in increased lipophilicity and a longer half-life compared to T3.",
      "DITPA has been studied as a potential treatment for thyroid-related disorders such as hypothyroidism, hyperthyroidism, and thyroid cancer.",
      "DITPA's use in clinical settings is still considered experimental, and more research is needed to fully understand its safety and efficacy."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: DITPA does not have an iodine atom replaced by an iodophenyl group; instead, it has two fewer iodine atoms than T3, which gives it different properties.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 144,
    "user_query": "You MUST give a detailed answer to the following question: What is the COUGER tool?",
    "llama-7b_response": "The COUGER tool is a software tool developed by the National Institute of Standards and Technology (NIST) that is used to generate cryptographic keys and other cryptographic material. COUGER stands for \"Cryptographic Operations Using Generated Keys.\"\n\nThe COUGER tool is designed to generate cryptographic keys and other cryptographic material in a secure and controlled manner. It can be used to generate a wide range of cryptographic keys, including symmetric keys, asymmetric keys, and key pairs. The tool can also be used to generate other cryptographic material, such as digital signatures and message authentication codes.\n\nOne of the key features of the COUGER tool is its ability to generate keys and other cryptographic material in a controlled and auditable manner. This is achieved through the use of a key generation policy, which defines the rules and procedures for generating keys and other cryptographic material. The COUGER tool can be configured to enforce the key generation policy, ensuring that keys and other cryptographic material are generated in a secure and controlled manner.\n\nThe COUGER tool is also designed to be flexible and customizable, allowing users to tailor the tool to their specific needs. This includes the ability to define custom key generation policies and the ability to generate keys and other cryptographic material using a wide range of algorithms and protocols.\n\nOverall, the COUGER tool is a powerful and flexible tool for generating cryptographic keys and other cryptographic material in a secure and controlled manner. It is widely used in a variety of industries and applications, including government, finance, and healthcare.",
    "llama-7b_fact_raw": "1. The COUGER tool is developed by the National Institute of Standards and Technology (NIST).\n2. COUGER stands for \"Cryptographic Operations Using Generated Keys.\"\n3. The COUGER tool is used to generate cryptographic keys and other cryptographic material such as digital signatures and message authentication codes.\n4. The COUGER tool features a key generation policy to define rules and procedures for generating cryptographic material in a controlled and auditable manner.\n5. The COUGER tool is customizable, allowing users to define custom key generation policies and use a range of algorithms and protocols.",
    "llama-7b_fact": [
      "The COUGER tool is developed by the National Institute of Standards and Technology (NIST).",
      "COUGER stands for \"Cryptographic Operations Using Generated Keys.\"",
      "The COUGER tool is used to generate cryptographic keys and other cryptographic material such as digital signatures and message authentication codes.",
      "The COUGER tool features a key generation policy to define rules and procedures for generating cryptographic material in a controlled and auditable manner.",
      "The COUGER tool is customizable, allowing users to define custom key generation policies and use a range of algorithms and protocols."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the COUGER tool, its developer, its purpose, and its features, it is not possible to determine the truthfulness of these statements. If the COUGER tool is not a widely recognized or documented tool, or if it is a hypothetical or proprietary system not publicly detailed, then the accuracy of these statements cannot be verified with the information provided.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "You MUST give a detailed answer to the following question: Are there drugs for Tick-borne Encephalitis?",
    "llama-7b_response": "Tick-borne encephalitis (TBE) is a viral infection that can affect the brain and nervous system. There are several drugs that may be used to treat TBE, depending on the specific type of TBE and the severity of the infection.\n\nThe most common type of TBE is caused by a virus called Borrelia burgdorferi, which is transmitted to humans through the bite of an infected tick. Treatment for this type of TBE typically involves antibiotics, such as doxycycline or penicillin, which can help reduce symptoms and prevent complications.\n\nAnother type of TBE is caused by a virus called Flavivirus, which is transmitted to humans through the bite of an infected tick. Treatment for this type of TBE typically involves antiviral medications, such as ribavirin or idoxuridine, which can help reduce symptoms and prevent complications.\n\nIn some cases, supportive care may be necessary to manage symptoms of TBE, such as fever, headache, and muscle aches. This may include medications such as acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs), which can help reduce pain and fever.\n\nIt is important for individuals who have been bitten by an infected tick to seek medical attention promptly, as early treatment can help reduce the risk of complications and improve outcomes.",
    "llama-7b_fact_raw": "1. Tick-borne encephalitis (TBE) is a viral infection that can affect the brain and nervous system.\n2. The most common type of TBE is caused by a virus called Borrelia burgdorferi.\n3. Treatment for Borrelia burgdorferi-induced TBE typically involves antibiotics such as doxycycline or penicillin.\n4. Another type of TBE is caused by a virus called Flavivirus.\n5. Treatment for Flavivirus-induced TBE typically involves antiviral medications such as ribavirin or idoxuridine.",
    "llama-7b_fact": [
      "Tick-borne encephalitis (TBE) is a viral infection that can affect the brain and nervous system.",
      "The most common type of TBE is caused by a virus called Borrelia burgdorferi.",
      "Treatment for Borrelia burgdorferi-induced TBE typically involves antibiotics such as doxycycline or penicillin.",
      "Another type of TBE is caused by a virus called Flavivirus.",
      "Treatment for Flavivirus-induced TBE typically involves antiviral medications such as ribavirin or idoxuridine."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The most common type of TBE is caused by a virus belonging to the Flavivirus genus, not Borrelia burgdorferi, which causes Lyme disease.\n3. FALSE [correction]: Treatment for TBE typically involves supportive care, as there is no specific cure for the viral infection. Antibiotics such as doxycycline or penicillin are used to treat Lyme disease, not TBE.\n4. TRUE\n5. FALSE [correction]: There is no specific antiviral treatment for TBE. Treatment usually focuses on relieving symptoms since no antiviral medication has been proven effective for TBE. Ribavirin or idoxuridine are not standard treatments for TBE.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 151,
    "user_query": "You MUST give a detailed answer to the following question: Which genome browser database for DNA shape annotations is available?",
    "llama-7b_response": "There are several genome browser databases for DNA shape annotations that are available. Some of the most well-known and widely used genome browser databases for DNA shape annotations include:\n\n1. UCSC Genome Browser: The UCSC Genome Browser is a free, online genome browser that provides a wide range of features and tools for exploring and analyzing genomic data. The UCSC Genome Browser includes a DNA shape browser that allows users to visualize and annotate DNA shape features such as supercoils, kinks, and bends.\n2. Ensembl Genome Browser: The Ensembl Genome Browser is a genome browser that provides a range of features and tools for exploring and analyzing genomic data. The Ensembl Genome Browser includes a DNA shape browser that allows users to visualize and annotate DNA shape features such as supercoils, kinks, and bends.\n3. NCBI Genome Browser: The NCBI Genome Browser is a free, online genome browser that provides a wide range of features and tools for exploring and analyzing genomic data. The NCBI Genome Browser includes a DNA shape browser that allows users to visualize and annotate DNA shape features such as supercoils, kinks, and bends.\n4. Integrative Genomics Viewer (IGV): The Integrative Genomics Viewer (IGV) is a genome browser that provides a range of features and tools for exploring and analyzing genomic data. The IGV includes a DNA shape browser that allows users to visualize and annotate DNA shape features such as supercoils, kinks, and bends.\n\nThese are just a few examples of genome browser databases for DNA shape annotations that are available. There are many other genome browser databases that provide similar features and tools for exploring and analyzing genomic data.",
    "llama-7b_fact_raw": "1. The UCSC Genome Browser is an online genome browser that includes a DNA shape browser for visualizing and annotating DNA shape features.\n2. The Ensembl Genome Browser is a genome browser that includes a DNA shape browser for visualizing and annotating DNA shape features.\n3. The NCBI Genome Browser is an online genome browser that includes a DNA shape browser for visualizing and annotating DNA shape features.\n4. The Integrative Genomics Viewer (IGV) is a genome browser that includes a DNA shape browser for visualizing and annotating DNA shape features.",
    "llama-7b_fact": [
      "The UCSC Genome Browser is an online genome browser that includes a DNA shape browser for visualizing and annotating DNA shape features.",
      "The Ensembl Genome Browser is a genome browser that includes a DNA shape browser for visualizing and annotating DNA shape features.",
      "The NCBI Genome Browser is an online genome browser that includes a DNA shape browser for visualizing and annotating DNA shape features.",
      "The Integrative Genomics Viewer (IGV) is a genome browser that includes a DNA shape browser for visualizing and annotating DNA shape features."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The Ensembl Genome Browser is a genome browser for visualizing and annotating various genomic features, but it does not specifically include a DNA shape browser.\n3. FALSE [correction]: The NCBI Genome Browser (also known as the NCBI Sequence Viewer) is an online tool for visualizing genomic data, but it does not specifically include a DNA shape browser.\n4. FALSE [correction]: The Integrative Genomics Viewer (IGV) is a high-performance genome browser that allows for the interactive exploration of large, complex genome datasets, but it does not specifically include a DNA shape browser.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 174,
    "user_query": "You MUST give a detailed answer to the following question: Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-7b_response": "EZH2, also known as enhancer of zeste homolog 2, is a histone methyltransferase that plays a crucial role in regulating gene expression. Mutations in the EZH2 gene have been associated with several syndromes, including:\n\n1. Wolf-Hirschhorn syndrome: Wolf-Hirschhorn syndrome is a congenital disorder characterized by growth delay, intellectual disability, and abnormal facial features. Mutations in the EZH2 gene have been found to be associated with this syndrome.\n2. DiGeorge syndrome: DiGeorge syndrome, also known as velocardiofacial syndrome, is a congenital disorder characterized by multiple defects, including cleft palate, heart defects, and immune system abnormalities. Mutations in the EZH2 gene have been found to be associated with this syndrome.\n3. Cornelia de Lange syndrome: Cornelia de Lange syndrome is a congenital disorder characterized by growth delay, intellectual disability, and abnormal facial features. Mutations in the EZH2 gene have been found to be associated with this syndrome.\n4. Microcephaly: Microcephaly is a congenital disorder characterized by abnormally small head size and intellectual disability. Mutations in the EZH2 gene have been found to be associated with this syndrome.\n5. Autism spectrum disorder: Autism spectrum disorder is a neurodevelopmental disorder characterized by social impairment, communication difficulties, and repetitive behaviors. Some studies have suggested that mutations in the EZH2 gene may be associated with autism spectrum disorder.",
    "llama-7b_fact_raw": "1. Mutations in the EZH2 gene have been associated with Wolf-Hirschhorn syndrome.\n2. Mutations in the EZH2 gene have been associated with DiGeorge syndrome.\n3. Mutations in the EZH2 gene have been associated with Cornelia de Lange syndrome.\n4. Mutations in the EZH2 gene have been associated with microcephaly.\n5. Some studies have suggested that mutations in the EZH2 gene may be associated with autism spectrum disorder.",
    "llama-7b_fact": [
      "Mutations in the EZH2 gene have been associated with Wolf-Hirschhorn syndrome.",
      "Mutations in the EZH2 gene have been associated with DiGeorge syndrome.",
      "Mutations in the EZH2 gene have been associated with Cornelia de Lange syndrome.",
      "Mutations in the EZH2 gene have been associated with microcephaly.",
      "Some studies have suggested that mutations in the EZH2 gene may be associated with autism spectrum disorder."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Mutations in the EZH2 gene have been associated with Weaver syndrome, not Wolf-Hirschhorn syndrome.\n2. FALSE [correction]: Mutations in the EZH2 gene have not been commonly associated with DiGeorge syndrome. DiGeorge syndrome is most often associated with a deletion on chromosome 22q11.2.\n3. FALSE [correction]: Mutations in the EZH2 gene have been associated with Weaver syndrome, not Cornelia de Lange syndrome.\n4. UNKNOWN: While EZH2 plays a role in chromatin modification and may be involved in brain development, a direct association between EZH2 mutations and microcephaly is not well-established and would require more specific evidence.\n5. UNKNOWN: While there is ongoing research into the genetic factors contributing to autism spectrum disorder, the association between EZH2 mutations and autism is not conclusively established and may vary depending on the study and the population examined.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 193,
    "user_query": "You MUST give a detailed answer to the following question: List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-7b_response": "There are several human proteins that are known to undergo a dimer-to-tetramer transition. Here are a few examples:\n\n1. Hemoglobin: Hemoglobin is a protein found in red blood cells that plays a key role in transporting oxygen throughout the body. It exists in a dimeric form (two subunits) in the bloodstream, but can undergo a transition to a tetrameric form (four subunits) when it binds to oxygen.\n2. Cytochrome C: Cytochrome C is a protein that plays a role in electron transport and is found in the mitochondria of cells. It exists in a dimeric form in the cytoplasm, but can undergo a transition to a tetrameric form when it is released from the mitochondria and interacts with other cytochrome C molecules.\n3. Ferritin: Ferritin is a protein that stores iron in cells. It exists in a dimeric form in the cytosol, but can undergo a transition to a tetrameric form when it binds to iron.\n\nThese are just a few examples of human proteins that undergo a dimer-to-tetramer transition. There are likely many others that have not yet been discovered or studied in detail.",
    "llama-7b_fact_raw": "1. Hemoglobin is a protein found in red blood cells that can transition from a dimeric to a tetrameric form upon binding to oxygen.\n2. Cytochrome C is a protein involved in electron transport, found in mitochondria, and can transition from a dimeric to a tetrameric form when released from mitochondria.\n3. Ferritin is a protein that stores iron and can transition from a dimeric to a tetrameric form when it binds to iron.",
    "llama-7b_fact": [
      "Hemoglobin is a protein found in red blood cells that can transition from a dimeric to a tetrameric form upon binding to oxygen.",
      "Cytochrome C is a protein involved in electron transport, found in mitochondria, and can transition from a dimeric to a tetrameric form when released from mitochondria.",
      "Ferritin is a protein that stores iron and can transition from a dimeric to a tetrameric form when it binds to iron."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Hemoglobin is a protein found in red blood cells that exists in a tetrameric form and does not transition from a dimeric to a tetrameric form upon binding to oxygen.\n2. FALSE [correction]: Cytochrome C is a protein involved in electron transport, found in mitochondria, but it does not transition from a dimeric to a tetrameric form when released from mitochondria; it is generally a monomeric protein.\n3. FALSE [correction]: Ferritin is a protein that stores iron, but it does not transition from a dimeric to a tetrameric form when it binds to iron. Ferritin can form a much larger complex composed of 24 subunits.",
    "llama-7b_judge": [
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 210,
    "user_query": "You MUST give a detailed answer to the following question: Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-7b_response": "The protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is Bcl-2.\n\nBcl-2 is a member of the Bcl-2 family of proteins, which play a crucial role in regulating programmed cell death (apoptosis). Phospholamban (PLN) is a cardiac muscle protein that is involved in the regulation of intracellular calcium levels and is also known to play a role in the regulation of apoptosis.\n\nSeveral studies have shown that Bcl-2 interacts with PLN and that this interaction plays a role in the regulation of apoptosis in cardiac muscle cells. For example, one study found that overexpression of Bcl-2 in cardiac muscle cells resulted in an increase in the levels of PLN and a decrease in the levels of apoptosis, while knockdown of Bcl-2 resulted in a decrease in the levels of PLN and an increase in the levels of apoptosis.\n\nThese findings suggest that the interaction between Bcl-2 and PLN plays an important role in the regulation of apoptosis in cardiac muscle cells and may have implications for the development of therapeutic strategies for the treatment of cardiac diseases.",
    "llama-7b_fact_raw": "1. Bcl-2 has been found to interact with phospholamban (PLN).\n2. Bcl-2 is an anti-apoptotic protein.\n3. Phospholamban (PLN) is involved in the regulation of intracellular calcium levels in cardiac muscle.\n4. The interaction between Bcl-2 and PLN plays a role in the regulation of apoptosis in cardiac muscle cells.\n5. Overexpression of Bcl-2 in cardiac muscle cells can result in an increase in the levels of PLN and a decrease in the levels of apoptosis.",
    "llama-7b_fact": [
      "Bcl-2 has been found to interact with phospholamban (PLN).",
      "Bcl-2 is an anti-apoptotic protein.",
      "Phospholamban (PLN) is involved in the regulation of intracellular calcium levels in cardiac muscle.",
      "The interaction between Bcl-2 and PLN plays a role in the regulation of apoptosis in cardiac muscle cells.",
      "Overexpression of Bcl-2 in cardiac muscle cells can result in an increase in the levels of PLN and a decrease in the levels of apoptosis."
    ],
    "llama-7b_judge_raw": "1. TRUE: Bcl-2 has been found to interact with various proteins, including phospholamban (PLN), as part of its role in regulating apoptosis and other cellular processes.\n2. TRUE: Bcl-2 is indeed an anti-apoptotic protein that helps to prevent cell death in various cellular contexts.\n3. TRUE: Phospholamban (PLN) is a regulatory protein that is involved in the regulation of intracellular calcium levels in cardiac muscle, particularly by modulating the activity of the sarcoplasmic reticulum Ca²⁺-ATPase (SERCA).\n4. UNKNOWN: The specific role of the interaction between Bcl-2 and PLN in the regulation of apoptosis in cardiac muscle cells is not provided in the context, and it would require specific scientific evidence to confirm.\n5. UNKNOWN: The effects of overexpression of Bcl-2 on the levels of PLN and apoptosis in cardiac muscle cells would depend on the results of specific experimental studies, which are not provided in the context.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 218,
    "user_query": "You MUST give a detailed answer to the following question: Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-7b_response": "Yes, vitamin D has been shown to reduce the incidence of falls in older people in clinical trials. In fact, several studies have found that vitamin D supplementation can reduce the risk of falls by up to 25%.\n\nOne such study was a randomized, double-blind, placebo-controlled trial published in the Journal of the American Geriatrics Society in 2012. The study involved 202 older adults with a history of falls who were randomly assigned to receive either a daily dose of 800 IU of vitamin D or a placebo. After 2 years, the researchers found that the participants who received vitamin D had a 25% lower risk of falling compared to those who received the placebo.\n\nAnother study, published in the American Journal of Clinical Nutrition in 2013, found that vitamin D supplementation can reduce the risk of falls in older adults by up to 19%. This study involved 2,000 older adults with a history of falls who were randomly assigned to receive either a daily dose of 800 IU of vitamin D or a placebo. After 1.5 years, the researchers found that the participants who received vitamin D had a 19% lower risk of falling compared to those who received the placebo.\n\nThese findings suggest that vitamin D supplementation may be an effective way to reduce the risk of falls in older adults, particularly those who are at high risk for falling. However, more research is needed to confirm these findings and to determine the optimal dose and duration of vitamin D supplementation for fall prevention.",
    "llama-7b_fact_raw": "1. Vitamin D supplementation has been shown to reduce the risk of falls in older people by up to 25% in clinical trials.\n2. A study published in the Journal of the American Geriatrics Society in 2012 involved 202 older adults who were randomly assigned to receive either 800 IU of vitamin D or a placebo daily.\n3. The 2012 study found that after 2 years, participants who received vitamin D had a 25% lower risk of falling compared to those who received the placebo.\n4. Another study published in the American Journal of Clinical Nutrition in 2013 involved 2,000 older adults with a history of falls who were randomly assigned to receive either 800 IU of vitamin D or a placebo daily.\n5. The 2013 study found that after 1.5 years, participants who received vitamin D had a 19% lower risk of falling compared to those who received the placebo.",
    "llama-7b_fact": [
      "Vitamin D supplementation has been shown to reduce the risk of falls in older people by up to 25% in clinical trials.",
      "A study published in the Journal of the American Geriatrics Society in 2012 involved 202 older adults who were randomly assigned to receive either 800 IU of vitamin D or a placebo daily.",
      "The 2012 study found that after 2 years, participants who received vitamin D had a 25% lower risk of falling compared to those who received the placebo.",
      "Another study published in the American Journal of Clinical Nutrition in 2013 involved 2,000 older adults with a history of falls who were randomly assigned to receive either 800 IU of vitamin D or a placebo daily.",
      "The 2013 study found that after 1.5 years, participants who received vitamin D had a 19% lower risk of falling compared to those who received the placebo."
    ],
    "llama-7b_judge_raw": "1. TRUE: Vitamin D supplementation has been associated with a reduction in the risk of falls in older people, with some clinical trials showing reductions in the risk of falls by up to 25%.\n2. UNKNOWN: Without access to the specific study from the Journal of the American Geriatrics Society in 2012, the details provided cannot be verified.\n3. UNKNOWN: The outcome of the 2012 study mentioned cannot be verified without access to the specific research article or data.\n4. UNKNOWN: The details of the study published in the American Journal of Clinical Nutrition in 2013 cannot be verified without access to the specific study.\n5. UNKNOWN: The results of the 2013 study and the percentage reduction in the risk of falling cannot be verified without the specific research data or article.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 222,
    "user_query": "You MUST give a detailed answer to the following question: Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-7b_response": "Yes, there is an association between Jarid2 and miR-155 in Th17 cells.\n\nJarid2 is a protein that plays a role in regulating the expression of microRNAs, including miR-155. miR-155 is a microRNA that has been shown to play a role in the differentiation of Th17 cells, a type of immune cell that is involved in the immune response to certain types of infections.\n\nStudies have shown that the expression of Jarid2 and miR-155 is coordinately regulated in Th17 cells. For example, one study found that Jarid2 and miR-155 were both upregulated in Th17 cells compared to other types of immune cells. Additionally, another study found that the expression of Jarid2 and miR-155 was negatively correlated in Th17 cells, meaning that as the expression of one increased, the expression of the other decreased.\n\nThese findings suggest that Jarid2 and miR-155 may work together to regulate the differentiation of Th17 cells. For example, Jarid2 may play a role in the processing and export of miR-155 from the nucleus to the cytoplasm, where it can be used to regulate the expression of target genes. Alternatively, miR-155 may regulate the expression of Jarid2 or other genes that are involved in the regulation of microRNAs.\n\nOverall, the association between Jarid2 and miR-155 in Th17 cells suggests that these two molecules may work together to regulate the differentiation and function of this important type of immune cell.",
    "llama-7b_fact_raw": "1. Jarid2 is a protein that regulates the expression of microRNAs, including miR-155.\n2. miR-155 plays a role in the differentiation of Th17 cells.\n3. The expression of Jarid2 and miR-155 is coordinately regulated in Th17 cells.\n4. Studies have found that Jarid2 and miR-155 were both upregulated in Th17 cells compared to other types of immune cells.\n5. There is a negative correlation between the expression of Jarid2 and miR-155 in Th17 cells, as observed in some studies.",
    "llama-7b_fact": [
      "Jarid2 is a protein that regulates the expression of microRNAs, including miR-155.",
      "miR-155 plays a role in the differentiation of Th17 cells.",
      "The expression of Jarid2 and miR-155 is coordinately regulated in Th17 cells.",
      "Studies have found that Jarid2 and miR-155 were both upregulated in Th17 cells compared to other types of immune cells.",
      "There is a negative correlation between the expression of Jarid2 and miR-155 in Th17 cells, as observed in some studies."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: If Jarid2 and miR-155 are both upregulated in Th17 cells, this would suggest a positive correlation between their expressions in these cells, not a negative one, as stated in the previous statements. However, without specific study references, it's difficult to provide a definitive correction. The relationship between Jarid2 and miR-155 could be complex and context-dependent, and the correlation could vary in different studies or under different conditions.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 224,
    "user_query": "You MUST give a detailed answer to the following question: How many genes does the human hoxD cluster contain?",
    "llama-7b_response": "The human HOXD cluster contains 5 genes: HOXD1, HOXD2, HOXD3, HOXD4, and HOXD5.",
    "llama-7b_fact_raw": "1. The human HOXD cluster contains 5 genes.",
    "llama-7b_fact": [
      "The human HOXD cluster contains 5 genes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The human HOXD cluster contains 9 genes.",
    "llama-7b_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "You MUST give a detailed answer to the following question: List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-7b_response": "Casein Kinase 1 (CK1) is a serine/threonine protein kinase that plays a crucial role in various cellular processes, including cell division, differentiation, and apoptosis. CK1 can phosphorylate a wide range of substrates, including proteins, lipids, and nucleic acids. Here are some of the most common phosphorylation consensus motifs for CK1:\n\n1. S/T-X-X-X-S/T (where X is any amino acid): This is a general consensus motif for serine/threonine kinases, including CK1. It indicates the position of the phosphorylated serine/threonine residue.\n2. S/T-X-X-X-S/T-X-X-X-S/T: This is a more specific consensus motif for CK1, which indicates the position of two phosphorylated serine/threonine residues.\n3. S/T-X-X-X-S/T-X-X-X-S/T-X-X-X-S/T: This is an even more specific consensus motif for CK1, which indicates the position of three phosphorylated serine/threonine residues.\n4. S/T-X-X-X-S/T-X-X-X-S/T-X-X-X-S/T-X-X-X-S/T: This is the most specific consensus motif for CK1, which indicates the position of four phosphorylated serine/threonine residues.\n\nIt's worth noting that these consensus motifs are not absolute and can vary depending on the context and specificity of the kinase. However, they provide a general framework for identifying potential phosphorylation sites by CK1.",
    "llama-7b_fact_raw": "1. Casein Kinase 1 (CK1) is a serine/threonine protein kinase.\n2. CK1 plays a role in cell division, differentiation, and apoptosis.\n3. The consensus motif S/T-X-X-X-S/T is associated with serine/threonine kinases, including CK1.\n4. The specific consensus motif for CK1 is S/T-X-X-X-S/T-X-X-X-S/T, indicating two phosphorylated serine/threonine residues.\n5. The most specific consensus motif for CK1 is S/T-X-X-X-S/T-X-X-X-S/T-X-X-X-S/T-X-X-X-S/T, indicating four phosphorylated serine/threonine residues.",
    "llama-7b_fact": [
      "Casein Kinase 1 (CK1) is a serine/threonine protein kinase.",
      "CK1 plays a role in cell division, differentiation, and apoptosis.",
      "The consensus motif S/T-X-X-X-S/T is associated with serine/threonine kinases, including CK1.",
      "The specific consensus motif for CK1 is S/T-X-X-X-S/T-X-X-X-S/T, indicating two phosphorylated serine/threonine residues.",
      "The most specific consensus motif for CK1 is S/T-X-X-X-S/T-X-X-X-S/T-X-X-X-S/T-X-X-X-S/T, indicating four phosphorylated serine/threonine residues."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The specific consensus motif for CK1 is not S/T-X-X-X-S/T-X-X-X-S/T, indicating two phosphorylated serine/threonine residues. The correct consensus sequence for CK1 substrates is generally S/T-P-X-S/T, where \"P\" stands for a proline residue, and \"X\" can be any amino acid.\n5. FALSE [correction]: The most specific consensus motif for CK1 is not S/T-X-X-X-S/T-X-X-X-S/T-X-X-X-S/T-X-X-X-S/T, indicating four phosphorylated serine/threonine residues. The correct consensus sequence for CK1 substrates is generally S/T-P-X-S/T, where \"P\" stands for a proline residue, and \"X\" can be any amino acid.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 305,
    "user_query": "You MUST give a detailed answer to the following question: Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-7b_response": "The ASPH (aspartate beta-hydroxylase) gene encodes for the enzyme aspartate beta-hydroxylase, which is involved in the metabolism of aspartate and other amino acids. The gene is located on chromosome 11q23.3 and consists of six exons.\n\nThere are several different proteins and isoforms that can be encoded by the ASPH gene in humans. These include:\n\n1. Aspartate beta-hydroxylase: This is the primary form of the enzyme that is produced from the ASPH gene. It is a cytosolic enzyme that catalyzes the conversion of aspartate to beta-alanine and carbon dioxide.\n2. Aspartate beta-hydroxylase (N-terminal processed): This isoform of the enzyme is produced by a process of N-terminal processing, in which the amino-terminal end of the protein is cleaved off. This results in a shorter, more active form of the enzyme that is localized to the mitochondria.\n3. Aspartate beta-hydroxylase (C-terminal processed): This isoform of the enzyme is produced by a process of C-terminal processing, in which the carboxy-terminal end of the protein is cleaved off. This results in a longer, less active form of the enzyme that is localized to the cytosol.\n4. Aspartate beta-hydroxylase (N-terminal deleted): This isoform of the enzyme is produced by a deletion in the N-terminal end of the protein. This results in a shorter, less active form of the enzyme that is localized to the cytosol.\n5. Aspartate beta-hydroxylase (C-terminal deleted): This isoform of the enzyme is produced by a deletion in the C-terminal end of the protein. This results in a longer, less active form of the enzyme that is localized to the cytosol.\n\nOverall, the ASPH gene encodes for several different proteins and isoforms that play important roles in the metabolism of aspart",
    "llama-7b_fact_raw": "1. The ASPH gene is located on chromosome 11q23.3.\n2. The ASPH gene consists of six exons.\n3. The primary form of the enzyme produced from the ASPH gene is aspartate beta-hydroxylase, which is a cytosolic enzyme.\n4. An isoform of aspartate beta-hydroxylase is produced by N-terminal processing and is localized to the mitochondria.\n5. Another isoform of aspartate beta-hydroxylase is produced by C-terminal processing and is localized to the cytosol.",
    "llama-7b_fact": [
      "The ASPH gene is located on chromosome 11q23.3.",
      "The ASPH gene consists of six exons.",
      "The primary form of the enzyme produced from the ASPH gene is aspartate beta-hydroxylase, which is a cytosolic enzyme.",
      "An isoform of aspartate beta-hydroxylase is produced by N-terminal processing and is localized to the mitochondria.",
      "Another isoform of aspartate beta-hydroxylase is produced by C-terminal processing and is localized to the cytosol."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The ASPH gene consists of 23 exons.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The isoform of aspartate beta-hydroxylase produced by C-terminal processing is localized to the endoplasmic reticulum, not the cytosol.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 330,
    "user_query": "You MUST give a detailed answer to the following question: When was empagliflozin FDA approved?",
    "llama-7b_response": "Empagliflozin, also known by the brand name Jardiance, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes in 2014. The FDA granted approval for empagliflozin to be used in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes.",
    "llama-7b_fact_raw": "1. Empagliflozin was approved by the U.S. Food and Drug Administration (FDA) in 2014.\n2. The brand name for empagliflozin is Jardiance.\n3. Empagliflozin is approved for the treatment of type 2 diabetes.\n4. The FDA approved empagliflozin to be used in combination with diet and exercise.\n5. The purpose of empagliflozin approval is to improve glycemic control in adults with type 2 diabetes.",
    "llama-7b_fact": [
      "Empagliflozin was approved by the U.S. Food and Drug Administration (FDA) in 2014.",
      "The brand name for empagliflozin is Jardiance.",
      "Empagliflozin is approved for the treatment of type 2 diabetes.",
      "The FDA approved empagliflozin to be used in combination with diet and exercise.",
      "The purpose of empagliflozin approval is to improve glycemic control in adults with type 2 diabetes."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "You MUST give a detailed answer to the following question: What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-7b_response": "Loss of the protein Lon1 in the plant Arabidopsis has been shown to result in several phenotypes, including:\n\n1. Increased sensitivity to stress: Lon1 plays a role in protecting cells from stress, such as oxidative stress and heat stress. In the absence of Lon1, plants may be more susceptible to these stresses, leading to reduced growth and survival.\n2. Altered protein homeostasis: Lon1 is involved in the degradation of misfolded and damaged proteins, so its absence may lead to an accumulation of misfolded proteins, which can cause cellular stress and damage.\n3. Changes in gene expression: Loss of Lon1 has been shown to alter the expression of genes involved in stress response, cell wall biosynthesis, and other cellular processes.\n4. Impaired growth and development: Loss of Lon1 has been shown to affect plant growth and development, leading to reduced plant size and delayed flowering.\n\nOverall, the loss of Lon1 in Arabidopsis results in a complex set of phenotypes that likely involve changes in protein homeostasis, stress response, and cellular processes. Further research is needed to fully understand the impact of Lon1 loss on plant growth and development.",
    "llama-7b_fact_raw": "1. Loss of the protein Lon1 in Arabidopsis increases the plant's sensitivity to stress, such as oxidative stress and heat stress.\n2. In the absence of Lon1, there may be an accumulation of misfolded and damaged proteins in Arabidopsis.\n3. The loss of Lon1 in Arabidopsis alters the expression of genes involved in stress response and cell wall biosynthesis.\n4. Arabidopsis plants lacking Lon1 exhibit impaired growth and development, including reduced plant size and delayed flowering.",
    "llama-7b_fact": [
      "Loss of the protein Lon1 in Arabidopsis increases the plant's sensitivity to stress, such as oxidative stress and heat stress.",
      "In the absence of Lon1, there may be an accumulation of misfolded and damaged proteins in Arabidopsis.",
      "The loss of Lon1 in Arabidopsis alters the expression of genes involved in stress response and cell wall biosynthesis.",
      "Arabidopsis plants lacking Lon1 exhibit impaired growth and development, including reduced plant size and delayed flowering."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThese statements are consistent with the general understanding of the role of Lon proteases in cellular function. Lon proteases, such as Lon1, are involved in the degradation of misfolded and damaged proteins. Their absence can lead to an accumulation of such proteins, which can affect various cellular processes, including stress responses and development. However, without specific experimental data or a reference to a particular study, it is not possible to confirm the accuracy of these statements with absolute certainty. They are assumed to be true based on the general knowledge of protein homeostasis and stress responses in plants.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "You MUST give a detailed answer to the following question: Does a linker histone exist in the yeast genome?",
    "llama-7b_response": "Yes, a linker histone exists in the yeast genome.\n\nLinker histones are a type of histone protein that plays a crucial role in the organization and regulation of chromatin, the complex of DNA, histone proteins, and other proteins that make up chromosomes. In eukaryotes, including yeast, linker histones are involved in the formation of higher-order chromatin structures, such as nucleosomes and chromatin fibers, and play a role in regulating the accessibility of DNA to transcription factors and other proteins.\n\nThe yeast genome contains several genes that encode different types of histone proteins, including linker histones. For example, the Saccharomyces cerevisiae genome contains four genes that encode different types of linker histones: Htz1, Htz2, Htz3, and Htz4. These genes are located on different chromosomes and are expressed at different levels and patterns, reflecting their distinct functions in chromatin organization and regulation.\n\nOverall, the presence of linker histone genes in the yeast genome demonstrates that linker histones play an important role in the organization and regulation of chromatin in this organism, and highlights the importance of these proteins in the regulation of gene expression and other cellular processes.",
    "llama-7b_fact_raw": "1. Linker histones are a type of histone protein that contributes to the organization and regulation of chromatin in eukaryotes, including yeast.\n2. In yeast, linker histones are involved in the formation of nucleosomes and chromatin fibers.\n3. The Saccharomyces cerevisiae genome contains genes that encode different types of linker histones.\n4. The Saccharomyces cerevisiae genome includes four genes for linker histones: Htz1, Htz2, Htz3, and Htz4.\n5. These linker histone genes in Saccharomyces cerevisiae are located on different chromosomes and have varying expression levels and patterns.",
    "llama-7b_fact": [
      "Linker histones are a type of histone protein that contributes to the organization and regulation of chromatin in eukaryotes, including yeast.",
      "In yeast, linker histones are involved in the formation of nucleosomes and chromatin fibers.",
      "The Saccharomyces cerevisiae genome contains genes that encode different types of linker histones.",
      "The Saccharomyces cerevisiae genome includes four genes for linker histones: Htz1, Htz2, Htz3, and Htz4.",
      "These linker histone genes in Saccharomyces cerevisiae are located on different chromosomes and have varying expression levels and patterns."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The Saccharomyces cerevisiae genome does not contain genes that encode different types of linker histones. Instead, it has a single gene HHO1 that encodes the major linker histone H1.\n4. FALSE [correction]: The Saccharomyces cerevisiae genome does not include four genes for linker histones named Htz1, Htz2, Htz3, and Htz4. Instead, HTZ1 is the gene for the histone variant H2A.Z, which is not a linker histone but a replacement for the canonical histone H2A.\n5. FALSE [correction]: Since the previous statement about the existence of four linker histone genes in Saccharomyces cerevisiae is incorrect, this statement about their location and expression is also incorrect. There is only one known linker histone gene, HHO1, and its expression patterns would not apply to the non-existent genes Htz2, Htz3, and Htz4.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 418,
    "user_query": "You MUST give a detailed answer to the following question: Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-7b_response": "Yes, there is evidence that tomato juice lowers cholesterol levels.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 472,
    "user_query": "You MUST give a detailed answer to the following question: How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-7b_response": "Hsp70 and Hsp110 are heat shock proteins (HSPs) that play important roles in the regulation of mRNA stability.\n\nHsp70 is a molecular chaperone that helps to fold and stabilize proteins. It also plays a role in the regulation of mRNA stability by binding to and stabilizing mRNAs. Hsp70 can help to prevent the degradation of mRNAs by inhibiting the activity of ribonuclease (RNase) enzymes, which break down RNA.\n\nHsp110 is another HSP that also plays a role in the regulation of mRNA stability. Like Hsp70, Hsp110 can help to stabilize mRNAs by binding to them and preventing their degradation by RNase enzymes. Hsp110 can also help to recruit other proteins that are involved in the translation of mRNAs into proteins.\n\nIn summary, Hsp70 and Hsp110 can help to stabilize mRNAs by preventing their degradation by RNase enzymes and by recruiting other proteins that are involved in the translation of mRNAs into proteins.",
    "llama-7b_fact_raw": "1. Hsp70 and Hsp110 are heat shock proteins that play roles in the regulation of mRNA stability.\n2. Hsp70 functions as a molecular chaperone that helps to fold and stabilize proteins.\n3. Hsp70 binds to and stabilizes mRNAs, inhibiting the activity of ribonuclease enzymes that degrade RNA.\n4. Hsp110 also stabilizes mRNAs by binding to them and preventing degradation by RNase enzymes.\n5. Hsp110 assists in recruiting other proteins involved in the translation of mRNAs into proteins.",
    "llama-7b_fact": [
      "Hsp70 and Hsp110 are heat shock proteins that play roles in the regulation of mRNA stability.",
      "Hsp70 functions as a molecular chaperone that helps to fold and stabilize proteins.",
      "Hsp70 binds to and stabilizes mRNAs, inhibiting the activity of ribonuclease enzymes that degrade RNA.",
      "Hsp110 also stabilizes mRNAs by binding to them and preventing degradation by RNase enzymes.",
      "Hsp110 assists in recruiting other proteins involved in the translation of mRNAs into proteins."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Hsp70 and Hsp110 are heat shock proteins that play roles in protein folding and stabilization, not specifically in the regulation of mRNA stability.\n2. TRUE\n3. FALSE [correction]: Hsp70 does not typically bind to and stabilize mRNAs; it primarily assists in the folding of newly synthesized proteins and the refolding of misfolded proteins.\n4. FALSE [correction]: Hsp110 is known to function as a molecular chaperone like Hsp70, aiding in protein folding and preventing aggregation, rather than stabilizing mRNAs.\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "You MUST give a detailed answer to the following question: Which deiodinases are present in skeletal  muscle?",
    "llama-7b_response": "Deiodinases are enzymes that play a crucial role in regulating the activity of the thyroid hormones, triiodothyronine (T3) and thyroxine (T4). In skeletal muscle, three types of deiodinases have been identified: type 1 (D1), type 2 (D2), and type 3 (D3).\n\nType 1 deiodinase (D1) is also known as the thyroid hormone sulfotransferase and is responsible for converting T4 to the active form of T3, triiodothyronine (T3). D1 is primarily localized in the endoplasmic reticulum (ER) of skeletal muscle cells and plays a crucial role in regulating the activity of the thyroid hormones.\n\nType 2 deiodinase (D2) is also known as the type 2 iodothyronine deiodinase and is responsible for converting T4 to the inactive form of T3, reverse triiodothyronine (rT3). D2 is primarily localized in the cytosol of skeletal muscle cells and plays a crucial role in regulating the activity of the thyroid hormones.\n\nType 3 deiodinase (D3) is also known as the type 3 iodothyronine deiodinase and is responsible for converting T4 to the active form of T3, triiodothyronine (T3). D3 is primarily localized in the mitochondria of skeletal muscle cells and plays a crucial role in regulating the activity of the thyroid hormones.\n\nIn summary, the three types of deiodinases (D1, D2, and D3) are present in skeletal muscle and play a crucial role in regulating the activity of the thyroid hormones. D1 is primarily localized in the endoplasmic reticulum (ER) of skeletal muscle cells and is responsible for converting T4 to the active form of T3, triiodothyronine (T3). D2 is primarily localized in the cytosol of skeletal muscle cells and is responsible for converting T4 to the inactive form of T3, reverse triiodothyronine (",
    "llama-7b_fact_raw": "1. Three types of deiodinases identified in skeletal muscle are type 1 (D1), type 2 (D2), and type 3 (D3).\n2. Type 1 deiodinase (D1) in skeletal muscle is responsible for converting thyroxine (T4) to the active form of triiodothyronine (T3).\n3. Type 1 deiodinase (D1) is primarily localized in the endoplasmic reticulum (ER) of skeletal muscle cells.\n4. Type 2 deiodinase (D2) in skeletal muscle is responsible for converting thyroxine (T4) to the inactive form of triiodothyronine (reverse T3 or rT3).\n5. Type 3 deiodinase (D3) in skeletal muscle is responsible for converting thyroxine (T4) to the active form of triiodothyronine (T3) and is primarily localized in the mitochondria of skeletal muscle cells.",
    "llama-7b_fact": [
      "Three types of deiodinases identified in skeletal muscle are type 1 (D1), type 2 (D2), and type 3 (D3).",
      "Type 1 deiodinase (D1) in skeletal muscle is responsible for converting thyroxine (T4) to the active form of triiodothyronine (T3).",
      "Type 1 deiodinase (D1) is primarily localized in the endoplasmic reticulum (ER) of skeletal muscle cells.",
      "Type 2 deiodinase (D2) in skeletal muscle is responsible for converting thyroxine (T4) to the inactive form of triiodothyronine (reverse T3 or rT3).",
      "Type 3 deiodinase (D3) in skeletal muscle is responsible for converting thyroxine (T4) to the active form of triiodothyronine (T3) and is primarily localized in the mitochondria of skeletal muscle cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Type 1 deiodinase (D1) is primarily localized in the plasma membrane and in the cytosol of cells, not specifically in the endoplasmic reticulum (ER) of skeletal muscle cells.\n4. FALSE [correction]: Type 2 deiodinase (D2) in skeletal muscle is responsible for converting thyroxine (T4) to the active form of triiodothyronine (T3), not the inactive form (reverse T3 or rT3).\n5. FALSE [correction]: Type 3 deiodinase (D3) in skeletal muscle is responsible for inactivating thyroid hormones by converting thyroxine (T4) to reverse T3 (rT3) and triiodothyronine (T3) to diiodothyronine (T2). The localization of D3 in mitochondria of skeletal muscle cells is not commonly emphasized, and D3 is generally found in the plasma membrane and cytosol.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 534,
    "user_query": "You MUST give a detailed answer to the following question: List inflammatory caspase proteins?",
    "llama-7b_response": "There are several inflammatory caspase proteins, including:\n\n1. Caspase-1: also known as the interleukin-1 beta converting enzyme (ICE), caspase-1 is involved in the processing and activation of the pro-inflammatory cytokine interleukin-1 beta (IL-1β).\n2. Caspase-4: also known as the apoptosis-inducing factor (AIF), caspase-4 is involved in the execution phase of programmed cell death (apoptosis).\n3. Caspase-5: also known as the Fas-associated death domain protein (FADD), caspase-5 is involved in the activation of the pro-apoptotic protein Fas (CD95).\n4. Caspase-6: also known as the Apaf-1 protein, caspase-6 is involved in the activation of the pro-apoptotic protein apoptosis-inducing factor (AIF).\n5. Caspase-8: also known as the Fas-associated death domain protein (FADD), caspase-8 is involved in the activation of the pro-apoptotic protein Fas (CD95).\n6. Caspase-9: also known as the Apaf-1 protein, caspase-9 is involved in the activation of the pro-apoptotic protein apoptosis-inducing factor (AIF).\n7. Caspase-11: also known as the interleukin-1 beta converting enzyme (ICE), caspase-11 is involved in the processing and activation of the pro-inflammatory cytokine interleukin-1 beta (IL-1β).\n8. Caspase-12: also known as the interleukin-1 beta converting enzyme (ICE), caspase-12 is involved in the processing and activation of the pro-inflammatory cytokine interleukin-1 beta (IL-1β).\n9. Caspase-13: also known as the Apaf-1 protein, caspase-13 is involved in the activation of the pro-apoptotic protein apoptosis-inducing factor (AIF).\n10. Caspase",
    "llama-7b_fact_raw": "1. Caspase-1 is involved in the processing and activation of the pro-inflammatory cytokine interleukin-1 beta (IL-1β).\n2. Caspase-4 is involved in the execution phase of programmed cell death (apoptosis).\n3. Caspase-5 is involved in the activation of the pro-apoptotic protein Fas (CD95).\n4. Caspase-8 is involved in the activation of the pro-apoptotic protein Fas (CD95).\n5. Caspase-11 is involved in the processing and activation of the pro-inflammatory cytokine interleukin-1 beta (IL-1β).\n\nNote: The answer contains inaccuracies regarding the functions and aliases of certain caspases. For example, caspase-4 is not known as the apoptosis-inducing factor (AIF), and caspase-5 is not known as the Fas-associated death domain protein (FADD). These are errors in the provided answer. However, the statements above have been corrected to reflect the known functions of the caspases mentioned.",
    "llama-7b_fact": [
      "Caspase-1 is involved in the processing and activation of the pro-inflammatory cytokine interleukin-1 beta (IL-1β).",
      "Caspase-4 is involved in the execution phase of programmed cell death (apoptosis).",
      "Caspase-5 is involved in the activation of the pro-apoptotic protein Fas (CD95).",
      "Caspase-8 is involved in the activation of the pro-apoptotic protein Fas (CD95).",
      "Caspase-11 is involved in the processing and activation of the pro-inflammatory cytokine interleukin-1 beta (IL-1β).",
      "te: The answer contains inaccuracies regarding the functions and aliases of certain caspases. For example, caspase-4 is not known as the apoptosis-inducing factor (AIF), and caspase-5 is not known as the Fas-associated death domain protein (FADD). These are errors in the provided answer. However, the statements above have been corrected to reflect the known functions of the caspases mentioned."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Caspase-4 is involved in the innate immune response, particularly in the non-canonical inflammasome pathway leading to the release of pro-inflammatory cytokines like IL-1β, not directly in the execution phase of apoptosis.\n3. FALSE [correction]: Caspase-5, like caspase-1, is involved in the inflammatory response and the processing of pro-inflammatory cytokines. It is not directly involved in the activation of the pro-apoptotic protein Fas (CD95).\n4. TRUE\n5. TRUE\n6. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 579,
    "user_query": "You MUST give a detailed answer to the following question: Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-7b_response": "Yes, there is a link between the Aurora B kinase and the Polycomb protein Ring1B.\n\nAurora B is a serine/threonine kinase that plays a crucial role in the regulation of mitosis, the process of cell division. It is involved in the formation of spindle poles, the structures that guide the separation of chromosomes during cell division. Ring1B is a member of the Polycomb family of proteins, which are involved in the regulation of gene expression.\n\nStudies have shown that Aurora B and Ring1B interact with each other and that this interaction is important for the regulation of gene expression during mitosis. Specifically, Aurora B phosphorylates Ring1B, which leads to the degradation of Ring1B and the repression of target genes. Conversely, the degradation of Ring1B by the proteasome also leads to the activation of Aurora B kinase activity.\n\nTherefore, the interaction between Aurora B and Ring1B plays a crucial role in the regulation of gene expression during mitosis and is an important mechanism for the control of cell division.",
    "llama-7b_fact_raw": "1. Aurora B is a serine/threonine kinase that is involved in the regulation of mitosis.\n2. Aurora B kinase is involved in the formation of spindle poles during cell division.\n3. Ring1B is a member of the Polycomb family of proteins, which regulate gene expression.\n4. Aurora B and Ring1B interact with each other, and this interaction is important for gene expression regulation during mitosis.\n5. Aurora B phosphorylates Ring1B, leading to Ring1B's degradation and the repression of target genes.",
    "llama-7b_fact": [
      "Aurora B is a serine/threonine kinase that is involved in the regulation of mitosis.",
      "Aurora B kinase is involved in the formation of spindle poles during cell division.",
      "Ring1B is a member of the Polycomb family of proteins, which regulate gene expression.",
      "Aurora B and Ring1B interact with each other, and this interaction is important for gene expression regulation during mitosis.",
      "Aurora B phosphorylates Ring1B, leading to Ring1B's degradation and the repression of target genes."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Aurora B kinase is not involved in the formation of spindle poles during cell division; instead, it is involved in the correct attachment of microtubules to kinetochores, chromosome condensation, and cytokinesis.\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 597,
    "user_query": "You MUST give a detailed answer to the following question: What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-7b_response": "The most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates include the following:\n\n* At the donor splice site, the most frequent motif is the \"GT-AG\" dinucleotide, which is required for the binding of the U1 small nuclear ribonucleoprotein (snRNP) complex.\n* At the acceptor splice site, the most frequent motif is the \"AG-GT\" dinucleotide, which is required for the binding of the U2 small nuclear ribonucleoprotein (snRNP) complex.\n* Other non-canonical sequence motifs that have been observed at the donor and acceptor splice sites in vertebrates include the \"AT-AC\" motif at the donor splice site and the \"GT-AG\" motif at the acceptor splice site.\n\nIt is worth noting that the specific non-canonical sequence motifs that are present at the donor and acceptor splice sites can vary between different species, and can even vary between different tissues within the same individual.",
    "llama-7b_fact_raw": "1. The \"GT-AG\" dinucleotide is the most frequent motif at the donor splice site in vertebrates.\n2. The \"AG-GT\" dinucleotide is the most frequent motif at the acceptor splice site in vertebrates.\n3. The \"AT-AC\" motif is a non-canonical sequence observed at the donor splice site in vertebrates.\n4. The \"GT-AG\" motif is also observed at the acceptor splice site in vertebrates as a non-canonical sequence.\n5. Non-canonical sequence motifs at the donor and acceptor splice sites can vary between different species and tissues.",
    "llama-7b_fact": [
      "The \"GT-AG\" dinucleotide is the most frequent motif at the donor splice site in vertebrates.",
      "The \"AG-GT\" dinucleotide is the most frequent motif at the acceptor splice site in vertebrates.",
      "The \"AT-AC\" motif is a non-canonical sequence observed at the donor splice site in vertebrates.",
      "The \"GT-AG\" motif is also observed at the acceptor splice site in vertebrates as a non-canonical sequence.",
      "Non-canonical sequence motifs at the donor and acceptor splice sites can vary between different species and tissues."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The \"AG-GT\" dinucleotide is not the most frequent motif at the acceptor splice site in vertebrates. The correct motif is \"AG\" at the 3' end of the intron.\n3. TRUE\n4. FALSE [correction]: The \"GT-AG\" motif is not observed at the acceptor splice site as a non-canonical sequence. The canonical sequence at the acceptor splice site is \"AG\" at the 3' end of the intron.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 629,
    "user_query": "You MUST give a detailed answer to the following question: Which event results in the acetylation of S6K1?",
    "llama-7b_response": "The event that results in the acetylation of S6K1 is the binding of an acetyl-coenzyme A (acetyl-CoA) molecule to the lysine residue on the amino-terminal domain of S6K1.\n\nS6K1 is a serine/threonine kinase that plays a key role in regulating cell growth and metabolism. It is activated in response to various stimuli, including growth factors, insulin, and energy stress, and it phosphorylates and activates a number of downstream targets, including 4E-BP1 and eukaryotic initiation factor 4E (eIF4E), to regulate protein synthesis.\n\nAcetylation is a post-translational modification that alters the activity of a protein by changing its conformation or interactions with other proteins. In the case of S6K1, acetylation leads to the inhibition of its kinase activity and the promotion of its protein-binding partners, such as 4E-BP1 and eIF4E.\n\nThe acetylation of S6K1 is catalyzed by histone acetyltransferases (HATs), which add an acetyl group to the lysine residue on the target protein. In the case of S6K1, the HAT that acetylates it is p300, a transcriptional co-activator that is recruited to the promoter region of target genes by other transcription factors.\n\nTherefore, the binding of acetyl-CoA to the lysine residue on the amino-terminal domain of S6K1, followed by the acetylation of this residue by p300, results in the inhibition of S6K1's kinase activity and the promotion of its protein-binding partners, leading to the regulation of cell growth and metabolism.",
    "llama-7b_fact_raw": "1. Acetylation of S6K1 occurs when an acetyl-coenzyme A (acetyl-CoA) molecule binds to the lysine residue on the amino-terminal domain of S6K1.\n2. S6K1 is a serine/threonine kinase involved in regulating cell growth and metabolism.\n3. S6K1 phosphorylates and activates downstream targets such as 4E-BP1 and eukaryotic initiation factor 4E (eIF4E) to regulate protein synthesis.\n4. Acetylation of S6K1 leads to the inhibition of its kinase activity.\n5. The histone acetyltransferase (HAT) p300 catalyzes the acetylation of S6K1.",
    "llama-7b_fact": [
      "Acetylation of S6K1 occurs when an acetyl-coenzyme A (acetyl-CoA) molecule binds to the lysine residue on the amino-terminal domain of S6K1.",
      "S6K1 is a serine/threonine kinase involved in regulating cell growth and metabolism.",
      "S6K1 phosphorylates and activates downstream targets such as 4E-BP1 and eukaryotic initiation factor 4E (eIF4E) to regulate protein synthesis.",
      "Acetylation of S6K1 leads to the inhibition of its kinase activity.",
      "The histone acetyltransferase (HAT) p300 catalyzes the acetylation of S6K1."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: The specific site and domain of acetylation for S6K1 are not commonly known details and would require specific biochemical literature to confirm.\n2. TRUE: S6K1, or ribosomal protein S6 kinase beta-1, is indeed a serine/threonine kinase that plays a role in cell growth and metabolism, among other functions.\n3. TRUE: S6K1 is known to phosphorylate substrates such as 4E-BP1 and eukaryotic initiation factor 4E (eIF4E), which are involved in the regulation of protein synthesis.\n4. UNKNOWN: The effect of acetylation on S6K1's kinase activity is a specific biochemical detail that would require literature support to confirm as true or false.\n5. UNKNOWN: The specific enzymes that catalyze the acetylation of S6K1, such as whether p300 is responsible for this modification, would require validation from scientific literature.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 632,
    "user_query": "You MUST give a detailed answer to the following question: What is the cause of episodic ataxia type 6?",
    "llama-7b_response": "Episode",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 646,
    "user_query": "You MUST give a detailed answer to the following question: Are chromomethylases present in animal genomes?",
    "llama-7b_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that add methyl groups to DNA, and they play an important role in regulating gene expression. These enzymes are found in many organisms, including animals, and they are involved in a variety of biological processes, including DNA replication, transcription, and repair. In animals, chromomethylases are typically found in the form of DNA methyltransferases, which are enzymes that add methyl groups to cytosine residues in DNA. These methyl groups can have a variety of effects on gene expression, including silencing genes or preventing them from being expressed.",
    "llama-7b_fact_raw": "1. Chromomethylases are present in animal genomes.\n2. Chromomethylases are enzymes that add methyl groups to DNA.\n3. These enzymes play a role in regulating gene expression in animals.\n4. DNA methyltransferases are a form of chromomethylases found in animals.\n5. DNA methyltransferases add methyl groups to cytosine residues in DNA.",
    "llama-7b_fact": [
      "Chromomethylases are present in animal genomes.",
      "Chromomethylases are enzymes that add methyl groups to DNA.",
      "These enzymes play a role in regulating gene expression in animals.",
      "DNA methyltransferases are a form of chromomethylases found in animals.",
      "DNA methyltransferases add methyl groups to cytosine residues in DNA."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Chromomethylases are not typically present in animal genomes; they are more commonly associated with plants.\n2. TRUE\n3. FALSE [correction]: Since chromomethylases are not typically found in animals, they do not play a role in regulating gene expression in animals. However, the broader class of enzymes that add methyl groups to DNA, including DNA methyltransferases, do play such a role in animals.\n4. FALSE [correction]: DNA methyltransferases are not a form of chromomethylases. They are distinct enzymes that are found in animals and add methyl groups to DNA.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 650,
    "user_query": "You MUST give a detailed answer to the following question: List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-7b_response": "There are several packages available in R/Bioconductor for transcription factor binding site (TFBS) analysis. Here are some of the most commonly used packages:\n\n1. ChIPS: The ChIP-Seq Package for R (ChIPS) is a comprehensive package for analyzing ChIP-Seq data. It provides tools for mapping reads to the reference genome, calling peaks, and identifying binding sites.\n2. DRIVE: The DRIVE package is a suite of tools for analyzing ChIP-Seq and other types of genomic data. It provides tools for calling peaks, identifying binding sites, and visualizing enrichment.\n3. GROMACS: The GROMACS package is a suite of tools for analyzing ChIP-Seq and other types of genomic data. It provides tools for calling peaks, identifying binding sites, and visualizing enrichment.\n4. PeakAnalyzer: The PeakAnalyzer package is a suite of tools for analyzing ChIP-Seq and other types of genomic data. It provides tools for calling peaks, identifying binding sites, and visualizing enrichment.\n5. PeakSeq: The PeakSeq package is a suite of tools for analyzing ChIP-Seq and other types of genomic data. It provides tools for calling peaks, identifying binding sites, and visualizing enrichment.\n6. REDIRECT: The REDIRECT package is a suite of tools for analyzing ChIP-Seq and other types of genomic data. It provides tools for calling peaks, identifying binding sites, and visualizing enrichment.\n7. SICER: The SICER package is a suite of tools for analyzing ChIP-Seq and other types of genomic data. It provides tools for calling peaks, identifying binding sites, and visualizing enrichment.\n\nThese are just a few examples of the many packages available for TFBS analysis in R/Bioconductor. The choice of package will depend on the specific needs of the analysis and the type of data being analyzed.",
    "llama-7b_fact_raw": "1. ChIPS is a package in R/Bioconductor for analyzing ChIP-Seq data.\n2. DRIVE is a package in R/Bioconductor that includes tools for analyzing genomic data such as ChIP-Seq.\n3. GROMACS is incorrectly listed as a package for TFBS analysis in R/Bioconductor; it is actually a molecular dynamics simulation package.\n4. PeakAnalyzer is a package in R/Bioconductor for analyzing genomic data including ChIP-Seq.\n5. SICER is a package in R/Bioconductor that provides tools for ChIP-Seq data analysis.",
    "llama-7b_fact": [
      "ChIPS is a package in R/Bioconductor for analyzing ChIP-Seq data.",
      "DRIVE is a package in R/Bioconductor that includes tools for analyzing genomic data such as ChIP-Seq.",
      "GROMACS is incorrectly listed as a package for TFBS analysis in R/Bioconductor; it is actually a molecular dynamics simulation package.",
      "PeakAnalyzer is a package in R/Bioconductor for analyzing genomic data including ChIP-Seq.",
      "SICER is a package in R/Bioconductor that provides tools for ChIP-Seq data analysis."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: ChIPpeakAnno is a package in R/Bioconductor for analyzing ChIP-Seq data, not ChIPS.\n2. UNKNOWN: Without specific information about the DRIVE package in R/Bioconductor, it is not possible to confirm its existence or its tools for analyzing genomic data such as ChIP-Seq.\n3. TRUE: GROMACS is indeed a molecular dynamics simulation package and not a package for TFBS (Transcription Factor Binding Sites) analysis in R/Bioconductor.\n4. FALSE [correction]: PeakAnalyzer is not a package in R/Bioconductor; it is a standalone tool for analyzing ChIP-Seq data.\n5. TRUE: SICER is a package in R/Bioconductor that provides tools for ChIP-Seq data analysis.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 721,
    "user_query": "You MUST give a detailed answer to the following question: List clinical trials for prevention of sarcopenia",
    "llama-7b_response": "Certainly, here are some clinical trials for the prevention of sarcopenia:\n\n1. Sarcopenia Prevention Trial (SPT): This is a multicenter, randomized, double-blind, placebo-controlled trial that aims to evaluate the efficacy and safety of a combination of resistance training and protein supplementation in preventing sarcopenia in older adults. The trial is currently recruiting participants and is expected to be completed in 2023.\n2. Resistance Training and Sarcopenia Prevention (RISP): This is a multicenter, randomized, double-blind, placebo-controlled trial that aims to evaluate the efficacy and safety of resistance training with or without protein supplementation in preventing sarcopenia in older adults. The trial is currently recruiting participants and is expected to be completed in 2023.\n3. Sarcopenia Prevention with Resistance Training (SPRT): This is a multicenter, randomized, double-blind, placebo-controlled trial that aims to evaluate the efficacy and safety of resistance training with or without protein supplementation in preventing sarcopenia in older adults. The trial is currently recruiting participants and is expected to be completed in 2023.\n4. Sarcopenia Prevention with Progressive Resistance Exercise (SPREE): This is a multicenter, randomized, double-blind, placebo-controlled trial that aims to evaluate the efficacy and safety of progressive resistance exercise with or without protein supplementation in preventing sarcopenia in older adults. The trial is currently recruiting participants and is expected to be completed in 2023.\n5. Sarcopenia Prevention with Progressive Resistance Exercise and Nutritional Supplementation (SPRENS): This is a multicenter, randomized, double-blind, placebo-controlled trial that aims to evaluate the efficacy and safety of progressive resistance exercise with or without protein supplementation in preventing sarcopenia in older adults. The trial is currently recruiting participants and is expected to be completed in 2023.\n\nThese are just a few examples of clinical",
    "llama-7b_fact_raw": "1. The Sarcopenia Prevention Trial (SPT) is a multicenter, randomized, double-blind, placebo-controlled trial.\n2. The Resistance Training and Sarcopenia Prevention (RISP) trial is expected to be completed in 2023.\n3. The Sarcopenia Prevention with Resistance Training (SPRT) trial is currently recruiting participants.\n4. The Sarcopenia Prevention with Progressive Resistance Exercise (SPREE) trial evaluates the efficacy and safety of progressive resistance exercise in preventing sarcopenia.\n5. The Sarcopenia Prevention with Progressive Resistance Exercise and Nutritional Supplementation (SPRENS) trial includes nutritional supplementation as part of the intervention.",
    "llama-7b_fact": [
      "The Sarcopenia Prevention Trial (SPT) is a multicenter, randomized, double-blind, placebo-controlled trial.",
      "The Resistance Training and Sarcopenia Prevention (RISP) trial is expected to be completed in 2023.",
      "The Sarcopenia Prevention with Resistance Training (SPRT) trial is currently recruiting participants.",
      "The Sarcopenia Prevention with Progressive Resistance Exercise (SPREE) trial evaluates the efficacy and safety of progressive resistance exercise in preventing sarcopenia.",
      "The Sarcopenia Prevention with Progressive Resistance Exercise and Nutritional Supplementation (SPRENS) trial includes nutritional supplementation as part of the intervention."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the trials mentioned, it is not possible to determine the truthfulness of these statements. They could be hypothetical, real, or part of a fictional context. Further information would be required to assess each statement.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "You MUST give a detailed answer to the following question: Which is the database of molecular recognition features in membrane proteins?",
    "llama-7b_response": "The database of molecular recognition features in membrane proteins is called the Membrane Protein Data Bank (MPDB). It is a part of the Protein Data Bank (PDB), which is a database of three-dimensional structural data for proteins. The MPDB contains structural data for membrane proteins, including transmembrane helices, ion channels, and other types of membrane-associated proteins. The data in the MPDB is collected from a variety of sources, including X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and electron microscopy. The MPDB provides a valuable resource for researchers studying the structure and function of membrane proteins, and can be used to identify and study molecular recognition features in these proteins.",
    "llama-7b_fact_raw": "1. The Membrane Protein Data Bank (MPDB) is a database of molecular recognition features in membrane proteins.\n2. The MPDB is part of the Protein Data Bank (PDB).\n3. The MPDB contains structural data for various membrane proteins, including transmembrane helices and ion channels.\n4. Data in the MPDB is collected from sources such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and electron microscopy.\n5. The MPDB serves as a resource for researchers to study the structure and function of membrane proteins.",
    "llama-7b_fact": [
      "The Membrane Protein Data Bank (MPDB) is a database of molecular recognition features in membrane proteins.",
      "The MPDB is part of the Protein Data Bank (PDB).",
      "The MPDB contains structural data for various membrane proteins, including transmembrane helices and ion channels.",
      "Data in the MPDB is collected from sources such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and electron microscopy.",
      "The MPDB serves as a resource for researchers to study the structure and function of membrane proteins."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Membrane Protein Data Bank (MPDB) is not a database of molecular recognition features in membrane proteins. The correct name for a database that stores information on membrane proteins is the Protein Data Bank (PDB), which includes a subset of data specific to membrane proteins.\n2. FALSE [correction]: The MPDB is not a part of the Protein Data Bank (PDB). The MPDB does not exist as a separate entity; rather, membrane protein data is included within the PDB.\n3. TRUE: The Protein Data Bank contains structural data for various proteins, including membrane proteins such as transmembrane helices and ion channels.\n4. TRUE: Data in the PDB, which includes membrane protein data, is collected from sources such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and electron microscopy.\n5. TRUE: The PDB, which includes data on membrane proteins, serves as a resource for researchers to study the structure and function of all types of proteins, including membrane proteins.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 745,
    "user_query": "You MUST give a detailed answer to the following question: Is rivaroxaban metabolized in kidneys?",
    "llama-7b_response": "Yes, rivaroxaban is metabolized in the kidneys.\n\nRivaroxaban is a direct factor Xa inhibitor that is primarily metabolized by the liver via cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9. However, the kidneys also play a role in the elimination of rivaroxaban from the body.\n\nRivaroxaban and its metabolites are primarily excreted in the urine. The metabolism of rivaroxaban results in the formation of several active and inactive metabolites, including O-desmethyl rivaroxaban and N-desmethyl rivaroxaban. These metabolites are also excreted in the urine.\n\nIn patients with renal impairment, the elimination of rivaroxaban and its metabolites may be affected. In patients with severe renal impairment (creatinine clearance <30 mL/min), the elimination half-life of rivaroxaban is prolonged, and the dose of rivaroxaban may need to be adjusted.\n\nIn summary, while the primary metabolism of rivaroxaban occurs in the liver, the kidneys also play a role in the elimination of rivaroxaban and its metabolites. The elimination of rivaroxaban and its metabolites may be affected in patients with renal impairment, and the dose of rivaroxaban may need to be adjusted in these patients.",
    "llama-7b_fact_raw": "1. Rivaroxaban is primarily metabolized by the liver via cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9.\n2. The kidneys play a role in the elimination of rivaroxaban from the body.\n3. Rivaroxaban and its metabolites are primarily excreted in the urine.\n4. Metabolites of rivaroxaban include O-desmethyl rivaroxaban and N-desmethyl rivaroxaban.\n5. In patients with severe renal impairment (creatinine clearance <30 mL/min), the elimination half-life of rivaroxaban is prolonged.",
    "llama-7b_fact": [
      "Rivaroxaban is primarily metabolized by the liver via cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9.",
      "The kidneys play a role in the elimination of rivaroxaban from the body.",
      "Rivaroxaban and its metabolites are primarily excreted in the urine.",
      "Metabolites of rivaroxaban include O-desmethyl rivaroxaban and N-desmethyl rivaroxaban.",
      "In patients with severe renal impairment (creatinine clearance <30 mL/min), the elimination half-life of rivaroxaban is prolonged."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Rivaroxaban and its metabolites are primarily excreted in the urine and feces.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "You MUST give a detailed answer to the following question: Which genes are regulated by TRalpha2  in the heart?",
    "llama-7b_response": "Transforming growth factor beta (TGF-beta) is a family of structurally related cytokines that play a crucial role in the regulation of cell growth, differentiation, and apoptosis. TGF-beta signaling is mediated by the binding of TGF-beta to its specific receptors, which then activate intracellular signaling pathways. TGF-beta receptor type I (TbetaRI) and TGF-beta receptor type II (TbetaRII) are the two main receptors for TGF-beta in mammalian cells.\n\nTransforming growth factor beta receptor type II (TbetaRII) is a transmembrane receptor that binds TGF-beta and activates downstream signaling pathways. TbetaRII is expressed in various tissues, including the heart, where it plays a crucial role in the regulation of cardiac development and homeostasis.\n\nTransforming growth factor beta receptor type I (TbetaRI) is a transmembrane receptor that binds TGF-beta and activates downstream signaling pathways. TbetaRI is expressed in various tissues, including the heart, where it plays a crucial role in the regulation of cardiac development and homeostasis.\n\nTransforming growth factor beta receptor type II (TbetaRII) and Transforming growth factor beta receptor type I (TbetaRI) are the two main receptors for TGF-beta in the heart. TGF-beta signaling through TbetaRII and TbetaRI regulates various genes in the heart, including those involved in cardiac development, remodeling, and homeostasis.\n\nIn summary, TGF-beta signaling through TbetaRII and TbetaRI regulates various genes in the heart, including those involved in cardiac development, remodeling, and homeostasis.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 786,
    "user_query": "You MUST give a detailed answer to the following question: List available biomedical question answering systems.",
    "llama-7b_response": "There are several biomedical question answering systems available, including:\n\n1. Clinical Question Answering (CRAQ) system: This system is designed to answer clinical questions posed in natural language. It uses a combination of machine learning and natural language processing techniques to extract relevant information from unstructured text.\n2. BioASQ: This system is a series of bio-medical question answering challenges that are organized by the European Bioinformatics Institute (EMBL-EBI). The challenges are designed to test the ability of machine learning algorithms to answer biomedical questions posed in natural language.\n3. Biocreative: This system is a series of biomedical question answering challenges that were organized by the National Center for Biomedical Ontology (NCBO). The challenges were designed to test the ability of machine learning algorithms to answer biomedical questions posed in natural language.\n4. Biomedical Question Answering (Bio-QA) system: This system is designed to answer biomedical questions posed in natural language. It uses a combination of machine learning and natural language processing techniques to extract relevant information from unstructured text.\n5. Biomedical Text Analysis and Question Answering (Bio-TAQA) system: This system is designed to analyze biomedical text and answer questions posed in natural language. It uses a combination of machine learning and natural language processing techniques to extract relevant information from unstructured text.\n\nThese are just a few examples of the many biomedical question answering systems that are available. Each system has its own strengths and weaknesses, and may be better suited to certain types of questions than others.",
    "llama-7b_fact_raw": "1. The Clinical Question Answering (CRAQ) system is designed to answer clinical questions using machine learning and natural language processing.\n2. BioASQ is a series of biomedical question answering challenges organized by the European Bioinformatics Institute (EMBL-EBI).\n3. Biocreative is a series of biomedical question answering challenges organized by the National Center for Biomedical Ontology (NCBO).\n4. The Biomedical Question Answering (Bio-QA) system is designed to answer biomedical questions using machine learning and natural language processing.\n5. The Biomedical Text Analysis and Question Answering (Bio-TAQA) system is designed to analyze biomedical text and answer questions using machine learning and natural language processing.",
    "llama-7b_fact": [
      "The Clinical Question Answering (CRAQ) system is designed to answer clinical questions using machine learning and natural language processing.",
      "BioASQ is a series of biomedical question answering challenges organized by the European Bioinformatics Institute (EMBL-EBI).",
      "Biocreative is a series of biomedical question answering challenges organized by the National Center for Biomedical Ontology (NCBO).",
      "The Biomedical Question Answering (Bio-QA) system is designed to answer biomedical questions using machine learning and natural language processing.",
      "The Biomedical Text Analysis and Question Answering (Bio-TAQA) system is designed to analyze biomedical text and answer questions using machine learning and natural language processing."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: The statement could be true, but without specific information about a system named \"Clinical Question Answering (CRAQ),\" it is not possible to verify the accuracy of this statement.\n2. TRUE: BioASQ is indeed a series of biomedical question answering challenges, but it is organized by a team of researchers from various institutions, not specifically by the European Bioinformatics Institute (EMBL-EBI).\n3. FALSE [correction]: Biocreative is a series of biomedical text mining challenges, including question answering, but it is not organized by the National Center for Biomedical Ontology (NCBO). It is an international community-wide effort.\n4. UNKNOWN: Similar to statement 1, the statement could be true, but without specific information about a system named \"Biomedical Question Answering (Bio-QA),\" it is not possible to verify the accuracy of this statement.\n5. UNKNOWN: Similar to statements 1 and 4, the statement could be true, but without specific information about a system named \"Biomedical Text Analysis and Question Answering (Bio-TAQA),\" it is not possible to verify the accuracy of this statement.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 794,
    "user_query": "You MUST give a detailed answer to the following question: Which trancription factor activates the betalain pathway?",
    "llama-7b_response": "The transcription factor that activates the betalain pathway has not yet been identified. The betalain pathway is a secondary metabolic pathway that is involved in the biosynthesis of betalain pigments, which are responsible for the red, purple, and yellow colors of certain plant species. The pathway involves the sequential action of several enzymes, including betalain synthase, betalain reductase, and betalain peroxidase, which convert various precursor compounds into betalain pigments. While the genes encoding these enzymes have been identified, the transcription factors that activate their expression have not been fully characterized. Further research is needed to elucidate the molecular mechanisms underlying the regulation of betalain biosynthesis.",
    "llama-7b_fact_raw": "1. The transcription factor that activates the betalain pathway has not yet been identified.\n2. The betalain pathway is involved in the biosynthesis of betalain pigments.\n3. Betalain pigments are responsible for the red, purple, and yellow colors of certain plant species.\n4. The betalain pathway includes enzymes such as betalain synthase, betalain reductase, and betalain peroxidase.\n5. The genes encoding the enzymes for the betalain pathway have been identified.",
    "llama-7b_fact": [
      "The transcription factor that activates the betalain pathway has not yet been identified.",
      "The betalain pathway is involved in the biosynthesis of betalain pigments.",
      "Betalain pigments are responsible for the red, purple, and yellow colors of certain plant species.",
      "The betalain pathway includes enzymes such as betalain synthase, betalain reductase, and betalain peroxidase.",
      "The genes encoding the enzymes for the betalain pathway have been identified."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The betalain pathway includes enzymes such as tyrosinase, DOPA 4,5-dioxygenase (DODA), and cyclo-DOPA 5-O-glucosyltransferase, but not \"betalain synthase, betalain reductase, and betalain peroxidase\" as these are not recognized enzymes in the pathway.\n5. TRUE",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 883,
    "user_query": "You MUST give a detailed answer to the following question: Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-7b_response": "There are several technologies that can be used for the enrichment of phosphorylated peptides in quantitative phosphoproteomic analyses. Some of the most commonly used methods include:\n\n1. TiO2 beads: These beads are coated with a layer of titanium dioxide, which can selectively bind to phosphorylated peptides. The beads are then used to separate the phosphorylated peptides from the rest of the peptides in the sample.\n2. IMAC (Immobilized Metal Affinity Chromatography): This method uses a metal ion, such as nickel or gold, to selectively bind to phosphorylated peptides. The metal ion is immobilized on a column, and the phosphorylated peptides are then eluted from the column.\n3. SULFO-TAG: This method uses a reagent called SULFO-TAG, which can be added to the sample to selectively label phosphorylated peptides. The labeled peptides are then captured on a column, and the unlabeled peptides are washed away.\n4. Strep-tag: This method uses a reagent called Strep-tag, which can be added to the sample to selectively label phosphorylated peptides. The labeled peptides are then captured on a column, and the unlabeled peptides are washed away.",
    "llama-7b_fact_raw": "1. TiO2 beads are used for the enrichment of phosphorylated peptides and are coated with titanium dioxide.\n2. Immobilized Metal Affinity Chromatography (IMAC) uses metal ions like nickel or gold to bind to phosphorylated peptides.\n3. SULFO-TAG is a reagent used to selectively label phosphorylated peptides in quantitative phosphoproteomic analyses.\n4. Strep-tag is a reagent used to selectively label phosphorylated peptides for enrichment purposes.",
    "llama-7b_fact": [
      "TiO2 beads are used for the enrichment of phosphorylated peptides and are coated with titanium dioxide.",
      "Immobilized Metal Affinity Chromatography (IMAC) uses metal ions like nickel or gold to bind to phosphorylated peptides.",
      "SULFO-TAG is a reagent used to selectively label phosphorylated peptides in quantitative phosphoproteomic analyses.",
      "Strep-tag is a reagent used to selectively label phosphorylated peptides for enrichment purposes."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: SULFO-TAG is not a reagent used to selectively label phosphorylated peptides in quantitative phosphoproteomic analyses. It is a label used in electrochemiluminescence assays for the detection of proteins, peptides, and other molecules.\n4. FALSE [correction]: Strep-tag is an affinity tag used for the purification of proteins, not for the selective labeling of phosphorylated peptides for enrichment purposes.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 901,
    "user_query": "You MUST give a detailed answer to the following question: Which disorder is rated by Palmini classification?",
    "llama-7b_response": "The Palmini classification is a system used to rate the severity of various neurological and psychiatric disorders. It is not a specific disorder, but rather a way of categorizing the symptoms and severity of a wide range of conditions.\n\nThe Palmini classification is based on the work of Italian neurologist Giuseppe Palmini, who developed a system for rating the severity of parkinsonism, which is a group of disorders characterized by movement disorders such as tremors, rigidity, and bradykinesia.\n\nThe Palmini classification is typically used to rate the severity of parkinsonism, but it can also be used to rate the severity of other neurological and psychiatric disorders, such as Huntington's disease, essential tremor, and schizophrenia.\n\nIn the Palmini classification, the severity of a disorder is rated on a scale of 1 to 4, with 1 indicating mild symptoms and 4 indicating severe and disabling symptoms. The specific symptoms that are rated depend on the disorder being evaluated, but generally include motor symptoms, non-motor symptoms, and functional impairment.\n\nOverall, the Palmini classification is a useful tool for clinicians and researchers to objectively evaluate the severity of various neurological and psychiatric disorders and to track the progress of patients over time.",
    "llama-7b_fact_raw": "1. The Palmini classification is used to rate the severity of various neurological and psychiatric disorders.\n2. Giuseppe Palmini, an Italian neurologist, developed the system for rating the severity of parkinsonism.\n3. The Palmini classification is typically used to rate the severity of parkinsonism.\n4. The Palmini classification can also be applied to other disorders such as Huntington's disease, essential tremor, and schizophrenia.\n5. In the Palmini classification, the severity of a disorder is rated on a scale of 1 to 4, with 1 being mild symptoms and 4 being severe and disabling symptoms.",
    "llama-7b_fact": [
      "The Palmini classification is used to rate the severity of various neurological and psychiatric disorders.",
      "Giuseppe Palmini, an Italian neurologist, developed the system for rating the severity of parkinsonism.",
      "The Palmini classification is typically used to rate the severity of parkinsonism.",
      "The Palmini classification can also be applied to other disorders such as Huntington's disease, essential tremor, and schizophrenia.",
      "In the Palmini classification, the severity of a disorder is rated on a scale of 1 to 4, with 1 being mild symptoms and 4 being severe and disabling symptoms."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Palmini classification is not used to rate the severity of various neurological and psychiatric disorders. It is actually used for classifying the outcomes of epilepsy surgery.\n2. FALSE [correction]: Giuseppe Palmini is not known for developing a system for rating the severity of parkinsonism. The Hoehn and Yahr scale is commonly used for parkinsonism, and the Palmini classification refers to a system used in epilepsy surgery.\n3. FALSE [correction]: The Palmini classification is not typically used to rate the severity of parkinsonism; it is used in the context of epilepsy surgery.\n4. FALSE [correction]: The Palmini classification is specifically associated with epilepsy surgery outcomes and not typically applied to other disorders such as Huntington's disease, essential tremor, and schizophrenia.\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 905,
    "user_query": "You MUST give a detailed answer to the following question: Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-7b_response": "Yes, viruses have been implicated in the etiology of human subacute thyroiditis. Subacute thyroiditis, also known as De Quervain's thyroiditis, is an inflammatory condition of the thyroid gland that typically occurs after a viral infection. The exact mechanism by which viruses cause subacute thyroiditis is not fully understood, but it is thought to involve direct viral infection of thyroid cells, as well as the production of pro-inflammatory cytokines and chemokines by infected cells.\n\nSeveral viruses have been implicated in the etiology of subacute thyroiditis, including:\n\n1. Parvovirus B19: Parvovirus B19 is a single-stranded DNA virus that causes erythema infectiosum, also known as fifth disease, in children. It has also been associated with subacute thyroiditis in adults.\n2. Coxsackievirus: Coxsackieviruses are a group of enteroviruses that can cause a variety of illnesses, including hand, foot, and mouth disease and myocarditis. They have also been implicated in the etiology of subacute thyroiditis.\n3. Enteroviruses: Enteroviruses are a group of RNA viruses that can cause a variety of illnesses, including poliovirus, coxsackievirus, and echovirus. They have also been implicated in the etiology of subacute thyroiditis.\n\nThe clinical presentation of subacute thyroiditis typically includes pain in the neck, painful swelling of the thyroid gland, and an elevated thyroid-stimulating hormone (TSH) level. The pain and swelling typically resolve within a few months, and the TSH level returns to normal. However, in some cases, subacute thyroiditis can lead to permanent thyroid dysfunction, such as hypothyroidism or hyperthyroidism.\n\nIn summary, viruses are involved in the etiology of human subacute thyroiditis. Parvovirus B19, Coxsackievirus, enteroviruses, and other viruses can cause subacute thyroiditi",
    "llama-7b_fact_raw": "1. Viruses have been implicated in the etiology of human subacute thyroiditis, also known as De Quervain's thyroiditis.\n2. Subacute thyroiditis typically occurs after a viral infection.\n3. Parvovirus B19, which causes erythema infectiosum in children, has been associated with subacute thyroiditis in adults.\n4. Coxsackieviruses, which can cause hand, foot, and mouth disease and myocarditis, have been implicated in the etiology of subacute thyroiditis.\n5. Enteroviruses, which include poliovirus, coxsackievirus, and echovirus, have also been implicated in the etiology of subacute thyroiditis.",
    "llama-7b_fact": [
      "Viruses have been implicated in the etiology of human subacute thyroiditis, also known as De Quervain's thyroiditis.",
      "Subacute thyroiditis typically occurs after a viral infection.",
      "Parvovirus B19, which causes erythema infectiosum in children, has been associated with subacute thyroiditis in adults.",
      "Coxsackieviruses, which can cause hand, foot, and mouth disease and myocarditis, have been implicated in the etiology of subacute thyroiditis.",
      "Enteroviruses, which include poliovirus, coxsackievirus, and echovirus, have also been implicated in the etiology of subacute thyroiditis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nViruses are indeed known to be associated with the etiology of subacute thyroiditis, also known as De Quervain's thyroiditis. Subacute thyroiditis often follows a viral infection. Parvovirus B19 is known for causing erythema infectiosum (also known as fifth disease) in children and has been associated with subacute thyroiditis in adults. Coxsackieviruses, which can lead to conditions such as hand, foot, and mouth disease and myocarditis, have been implicated in the development of subacute thyroiditis. Enteroviruses, a group that includes poliovirus, coxsackievirus, and echovirus, have also been implicated in the etiology of this condition.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "You MUST give a detailed answer to the following question: Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-7b_response": "Yes, STAT3 is involved in EIF2AK2-dependent suppression of autophagy.\n\nSTAT3 is a transcription factor that plays a crucial role in regulating immune and inflammatory responses, as well as cell survival and proliferation. Recent studies have shown that STAT3 can also regulate autophagy, a cellular process involved in the degradation of damaged organelles and proteins.\n\nEIF2AK2, also known as eukaryotic initiation factor 2 alpha kinase 2, is a key regulator of autophagy. It has been shown to play a role in the suppression of autophagy by inhibiting the activity of the Unc-51-like autophagy activating kinase (Ulk1).\n\nThere is evidence to suggest that STAT3 can interact with and regulate the activity of EIF2AK2. For example, studies have shown that STAT3 can bind to the promoter region of the EIF2AK2 gene and enhance its transcription. Additionally, STAT3 has been shown to interact with and inhibit the activity of Ulk1, which is a key regulator of autophagy.\n\nTogether, these findings suggest that STAT3 is involved in EIF2AK2-dependent suppression of autophagy. Specifically, STAT3 can interact with and regulate the activity of EIF2AK2, which in turn inhibits the activity of Ulk1 and suppresses autophagy.",
    "llama-7b_fact_raw": "1. STAT3 is a transcription factor that regulates immune and inflammatory responses, as well as cell survival and proliferation.\n2. STAT3 has been shown to regulate autophagy, a cellular process involved in the degradation of damaged organelles and proteins.\n3. EIF2AK2, also known as eukaryotic initiation factor 2 alpha kinase 2, is a key regulator of autophagy.\n4. STAT3 can bind to the promoter region of the EIF2AK2 gene and enhance its transcription.\n5. STAT3 has been shown to interact with and inhibit the activity of Unc-51-like autophagy activating kinase (Ulk1), a key regulator of autophagy.",
    "llama-7b_fact": [
      "STAT3 is a transcription factor that regulates immune and inflammatory responses, as well as cell survival and proliferation.",
      "STAT3 has been shown to regulate autophagy, a cellular process involved in the degradation of damaged organelles and proteins.",
      "EIF2AK2, also known as eukaryotic initiation factor 2 alpha kinase 2, is a key regulator of autophagy.",
      "STAT3 can bind to the promoter region of the EIF2AK2 gene and enhance its transcription.",
      "STAT3 has been shown to interact with and inhibit the activity of Unc-51-like autophagy activating kinase (Ulk1), a key regulator of autophagy."
    ],
    "llama-7b_judge_raw": "1. TRUE: STAT3 is indeed a transcription factor that plays a role in various cellular processes, including immune and inflammatory responses, as well as cell survival and proliferation.\n2. TRUE: STAT3 has been implicated in the regulation of autophagy, although its exact role in this process can be complex and context-dependent.\n3. FALSE [correction]: EIF2AK2, also known as PKR (Protein Kinase R), is primarily known for its role in the antiviral response and the regulation of protein synthesis by phosphorylating eIF2α (eukaryotic initiation factor 2 alpha), not as a key regulator of autophagy.\n4. UNKNOWN: Without specific evidence from scientific literature, it is difficult to confirm whether STAT3 can bind to the promoter region of the EIF2AK2 gene and enhance its transcription.\n5. UNKNOWN: The interaction between STAT3 and Ulk1 and the effect of STAT3 on Ulk1 activity would require specific scientific evidence to confirm, which is not provided in the context of these statements.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 973,
    "user_query": "You MUST give a detailed answer to the following question: Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-7b_response": "The Theatre software tool is a genomic analysis tool that is used to visualize and analyze large-scale genomic data sets. It is designed to handle high-throughput sequencing data, such as that generated by next-generation sequencing (NGS) technologies.\n\nTheatre provides a range of features for analyzing genomic data, including:\n\n1. Data management: Theatre allows users to manage and organize their genomic data, including the ability to import and export data in a variety of formats.\n2. Data visualization: Theatre provides a range of visualization tools for analyzing genomic data, including heatmaps, bar charts, and scatter plots. These tools can be used to identify patterns and trends in the data.\n3. Genome annotation: Theatre can be used to annotate genomic data, including the identification of genes, regulatory elements, and other features of the genome.\n4. Variant analysis: Theatre can be used to identify and analyze variants in the genome, including single nucleotide variants (SNVs), insertions/deletions (indels), and copy number variations (CNVs).\n5. Integration with other tools: Theatre can be integrated with other genomic analysis tools and databases, allowing users to leverage the power of these tools in combination with Theatre's visualization and analysis capabilities.\n\nOverall, Theatre is a powerful tool for genomic analysis that can be used to identify patterns and trends in large-scale genomic data sets, and to gain insights into the structure and function of the genome.",
    "llama-7b_fact_raw": "1. The Theatre software tool is used for visualizing and analyzing large-scale genomic data sets.\n2. Theatre is designed to handle high-throughput sequencing data from next-generation sequencing (NGS) technologies.\n3. Theatre allows users to manage and organize their genomic data, including importing and exporting data in various formats.\n4. Theatre provides visualization tools such as heatmaps, bar charts, and scatter plots for genomic data analysis.\n5. Theatre can be used to annotate genomic data, including the identification of genes and regulatory elements.",
    "llama-7b_fact": [
      "The Theatre software tool is used for visualizing and analyzing large-scale genomic data sets.",
      "Theatre is designed to handle high-throughput sequencing data from next-generation sequencing (NGS) technologies.",
      "Theatre allows users to manage and organize their genomic data, including importing and exporting data in various formats.",
      "Theatre provides visualization tools such as heatmaps, bar charts, and scatter plots for genomic data analysis.",
      "Theatre can be used to annotate genomic data, including the identification of genes and regulatory elements."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without additional context or a known reference to a software tool named \"Theatre\" specifically designed for genomic data, it's not possible to determine the truth of this statement.\n2. UNKNOWN: Similarly, without more information about the \"Theatre\" software tool, it's not possible to confirm whether it is designed to handle data from NGS technologies.\n3. UNKNOWN: The ability to manage and organize genomic data, including importing and exporting in various formats, is a feature of many genomic data analysis tools, but it's unclear if this is true for \"Theatre\" without further context.\n4. UNKNOWN: While visualization tools such as heatmaps, bar charts, and scatter plots are common in genomic data analysis software, it's not possible to verify if \"Theatre\" provides these without more information.\n5. UNKNOWN: Annotation of genomic data is a feature of many bioinformatics tools, but without specific information about \"Theatre,\" it's not possible to confirm this statement.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "You MUST give a detailed answer to the following question: Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-7b_response": "The Smith-Waterman algorithm is a widely used algorithm for the alignment of two sequences. The execution time (complexity) of the Smith-Waterman algorithm depends on several factors, including the length of the sequences being aligned, the similarity between the sequences, and the algorithm implementation.\n\nIn general, the Smith-Waterman algorithm has a time complexity of O(n^2), where n is the length of the shorter of the two sequences. This means that the algorithm will take O(n^2) time to align two sequences of length n.\n\nHowever, the actual execution time of the Smith-Waterman algorithm can vary depending on the specific implementation and the characteristics of the sequences being aligned. For example, if the sequences have a high degree of similarity, the algorithm may be able to find a match more quickly, resulting in a shorter execution time. Conversely, if the sequences have a low degree of similarity, the algorithm may need to search through a larger portion of the sequences to find a match, resulting in a longer execution time.\n\nIn addition to the time complexity, the Smith-Waterman algorithm also has a space complexity of O(n), which means that it requires O(n) memory to store the sequences being aligned.\n\nOverall, the Smith-Waterman algorithm is a powerful and widely used algorithm for the alignment of two sequences, but its execution time can vary depending on the specific implementation and the characteristics of the sequences being aligned.",
    "llama-7b_fact_raw": "1. The Smith-Waterman algorithm is used for the alignment of two sequences.\n2. The time complexity of the Smith-Waterman algorithm is generally O(n^2), where n is the length of the shorter sequence.\n3. The execution time of the Smith-Waterman algorithm can vary based on the similarity between the sequences.\n4. The space complexity of the Smith-Waterman algorithm is O(n), where n is the length of the sequences being aligned.",
    "llama-7b_fact": [
      "The Smith-Waterman algorithm is used for the alignment of two sequences.",
      "The time complexity of the Smith-Waterman algorithm is generally O(n^2), where n is the length of the shorter sequence.",
      "The execution time of the Smith-Waterman algorithm can vary based on the similarity between the sequences.",
      "The space complexity of the Smith-Waterman algorithm is O(n), where n is the length of the sequences being aligned."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The execution time of the Smith-Waterman algorithm is determined by the lengths of the two sequences being aligned, not by the similarity between the sequences. The time complexity remains O(n^2) regardless of sequence similarity.\n4. FALSE [correction]: The space complexity of the Smith-Waterman algorithm is also O(n^2), where n is the length of the sequences being aligned, because it requires constructing a matrix where the dimensions are based on the lengths of both sequences.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1004,
    "user_query": "You MUST give a detailed answer to the following question: Which SLC family is FLVCR1 a member of?",
    "llama-7b_response": "FLVCR1, also known as folliculin, is a protein that belongs to the SLC35A1 family of solute carrier transporters. The SLC35A1 gene encodes a protein that is involved in the transport of small molecules, such as amino acids, across cell membranes. The SLC35A1 gene is located on chromosome 1q21.3 and is composed of 17 exons. The protein encoded by the SLC35A1 gene, folliculin, plays a role in the regulation of cell growth, differentiation, and survival. Mutations in the SLC35A1 gene have been implicated in the development of several human cancers, including kidney cancer and thyroid cancer.",
    "llama-7b_fact_raw": "1. FLVCR1 is also known as folliculin.\n2. FLVCR1 belongs to the SLC35A1 family of solute carrier transporters.\n3. The SLC35A1 gene is located on chromosome 1q21.3.\n4. The SLC35A1 gene is composed of 17 exons.\n5. Mutations in the SLC35A1 gene have been implicated in the development of human cancers, including kidney cancer and thyroid cancer.",
    "llama-7b_fact": [
      "FLVCR1 is also known as folliculin.",
      "FLVCR1 belongs to the SLC35A1 family of solute carrier transporters.",
      "The SLC35A1 gene is located on chromosome 1q21.3.",
      "The SLC35A1 gene is composed of 17 exons.",
      "Mutations in the SLC35A1 gene have been implicated in the development of human cancers, including kidney cancer and thyroid cancer."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: FLVCR1 is not known as folliculin; it is a heme transporter. Folliculin is associated with the gene FLCN.\n2. FALSE [correction]: FLVCR1 does not belong to the SLC35A1 family of solute carrier transporters. It is part of the SLC49 family.\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: Mutations in the SLC35A1 gene have been implicated in Congenital Disorder of Glycosylation, not specifically in the development of human cancers like kidney cancer and thyroid cancer. It is important to note that while mutations in genes can be associated with cancer, the statement incorrectly identifies SLC35A1 as being implicated in kidney and thyroid cancers.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "You MUST give a detailed answer to the following question: List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-7b_response": "GATA-1 (GATA binding protein 1) is a transcription factor that plays a crucial role in regulating the expression of genes involved in various cellular processes, including differentiation, proliferation, and apoptosis. GATA-1 interacts with a variety of proteins to regulate its target genes.\n\nTo identify GATA-1 interacting partners, a biotinylation tagging approach was used. In this approach, a biotinylation tag is added to GATA-1, and then the interacting proteins are captured by streptavidin beads. The interacting proteins can then be identified by mass spectrometry.\n\nHere are some of the GATA-1 interacting partners that have been identified using the biotinylation tagging approach:\n\n1. TBP (TATA box binding protein): TBP is a general transcription factor that binds to the TATA box element in the promoter region of genes. GATA-1 and TBP form a complex that binds to the promoter region of GATA-1 target genes.\n2. NCoR (nuclear receptor corepressor): NCoR is a corepressor that interacts with histone deacetylases to repress transcription. GATA-1 and NCoR form a complex that represses transcription from GATA-1 target genes.\n3. HDAC1 (histone deacetylase 1): HDAC1 is a histone deacetylase that interacts with NCoR to repress transcription. GATA-1 and HDAC1 form a complex that represses transcription from GATA-1 target genes.\n4. HDAC3 (histone deacetylase 3): HDAC3 is a histone deacetylase that interacts with GATA-1 to repress transcription. GATA-1 and HDAC3 form a complex that represses transcription from GATA-1 target genes.\n5. HDAC4 (histone deacetylase 4): HDAC4 is a histone deacetylase that interacts with GATA-1 to repress transcription. GATA-1 and HDAC4 form a complex that represses transcription from GATA",
    "llama-7b_fact_raw": "1. GATA-1 interacts with TBP (TATA box binding protein) to form a complex that binds to the promoter region of GATA-1 target genes.\n2. GATA-1 forms a complex with NCoR (nuclear receptor corepressor) that represses transcription from GATA-1 target genes.\n3. GATA-1 and HDAC1 (histone deacetylase 1) form a complex that represses transcription from GATA-1 target genes.\n4. GATA-1 interacts with HDAC3 (histone deacetylase 3) to form a complex that represses transcription.\n5. HDAC4 (histone deacetylase 4) interacts with GATA-1 to form a complex that represses transcription from GATA-1 target genes.",
    "llama-7b_fact": [
      "GATA-1 interacts with TBP (TATA box binding protein) to form a complex that binds to the promoter region of GATA-1 target genes.",
      "GATA-1 forms a complex with NCoR (nuclear receptor corepressor) that represses transcription from GATA-1 target genes.",
      "GATA-1 and HDAC1 (histone deacetylase 1) form a complex that represses transcription from GATA-1 target genes.",
      "GATA-1 interacts with HDAC3 (histone deacetylase 3) to form a complex that represses transcription.",
      "HDAC4 (histone deacetylase 4) interacts with GATA-1 to form a complex that represses transcription from GATA-1 target genes."
    ],
    "llama-7b_judge_raw": "1. TRUE: GATA-1 is known to interact with various transcription factors, including TBP, to regulate the transcription of its target genes.\n2. TRUE: GATA-1 can form a complex with NCoR to repress transcription from its target genes. This is part of the mechanism by which GATA-1 can act as both an activator and a repressor of transcription.\n3. TRUE: GATA-1 has been shown to interact with HDAC1 to form a complex that represses transcription from GATA-1 target genes. This is part of the transcriptional repression mechanism.\n4. TRUE: GATA-1 can interact with HDAC3 to form a complex that represses transcription, as part of its role in regulating gene expression.\n5. UNKNOWN: The interaction between GATA-1 and HDAC4 specifically in the context of forming a complex that represses transcription from GATA-1 target genes is not well-established in the literature as of my knowledge cutoff date. Without specific evidence, the truth of this statement cannot be determined.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1072,
    "user_query": "You MUST give a detailed answer to the following question: What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-7b_response": "TAF10 is a transcriptional co-activator that interacts with the GATA1 transcription factor, which is a key regulator of hematopoiesis and immune cell development. The interaction between TAF10 and GATA1 can lead to the activation of target genes involved in hematopoiesis and immune cell differentiation.\n\nIn particular, GATA1 binds to specific DNA sequences known as GATA boxes, which are found in the promoter regions of genes involved in hematopoiesis and immune cell development. When TAF10 interacts with GATA1, it helps to stabilize the GATA1-DNA complex and enhances the recruitment of other transcriptional co-activators, such as p300 and Brd4, to the GATA1-bound promoter. This leads to the formation of a transcriptional complex that is able to activate gene transcription and promote the differentiation of hematopoietic stem cells into mature immune cells.\n\nOverall, the interaction between TAF10 and GATA1 plays a crucial role in regulating hematopoiesis and immune cell development, and dysregulation of this interaction has been implicated in various hematological disorders and immune deficiency diseases.",
    "llama-7b_fact_raw": "1. TAF10 is a transcriptional co-activator that interacts with the GATA1 transcription factor.\n2. GATA1 is a key regulator of hematopoiesis and immune cell development.\n3. GATA1 binds to specific DNA sequences known as GATA boxes in the promoter regions of genes involved in hematopoiesis and immune cell development.\n4. The interaction between TAF10 and GATA1 helps to stabilize the GATA1-DNA complex and enhances the recruitment of other transcriptional co-activators.\n5. Dysregulation of the interaction between TAF10 and GATA1 has been implicated in various hematological disorders and immune deficiency diseases.",
    "llama-7b_fact": [
      "TAF10 is a transcriptional co-activator that interacts with the GATA1 transcription factor.",
      "GATA1 is a key regulator of hematopoiesis and immune cell development.",
      "GATA1 binds to specific DNA sequences known as GATA boxes in the promoter regions of genes involved in hematopoiesis and immune cell development.",
      "The interaction between TAF10 and GATA1 helps to stabilize the GATA1-DNA complex and enhances the recruitment of other transcriptional co-activators.",
      "Dysregulation of the interaction between TAF10 and GATA1 has been implicated in various hematological disorders and immune deficiency diseases."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with known information about TAF10 and GATA1, their roles in hematopoiesis, and the implications of their dysregulation. However, it is important to note that the specifics of these interactions and their implications in disease can be complex and may require more detailed scientific evidence to fully validate.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "You MUST give a detailed answer to the following question: Are there any Decision support systems for chronic pain management ?",
    "llama-7b_response": "Yes, there are decision support systems for chronic pain management. These systems are designed to help healthcare providers and patients make informed decisions about the management of chronic pain.\n\nOne example of a decision support system for chronic pain management is the Pain Management Decision Support System (PM-DSS). PM-DSS is a web-based tool that provides clinicians with evidence-based recommendations for the management of chronic pain. The system includes a database of clinical guidelines, patient education materials, and other resources to support clinical decision-making.\n\nAnother example of a decision support system for chronic pain management is the Chronic Pain Management Decision Support System (CPMDSS). CPMDSS is a mobile app that provides patients with personalized recommendations for the management of chronic pain. The app includes a symptom checker, medication reminders, and other resources to support self-management of chronic pain.\n\nOverall, decision support systems for chronic pain management can help healthcare providers and patients make informed decisions about the management of chronic pain by providing evidence-based recommendations and personalized support.",
    "llama-7b_fact_raw": "1. Decision support systems exist to aid in the management of chronic pain.\n2. The Pain Management Decision Support System (PM-DSS) is a web-based tool for chronic pain management.\n3. PM-DSS provides clinicians with evidence-based recommendations for managing chronic pain.\n4. The Chronic Pain Management Decision Support System (CPMDSS) is a mobile app designed to help patients manage chronic pain.\n5. CPMDSS offers features like a symptom checker and medication reminders to support patients in self-managing their chronic pain.",
    "llama-7b_fact": [
      "Decision support systems exist to aid in the management of chronic pain.",
      "The Pain Management Decision Support System (PM-DSS) is a web-based tool for chronic pain management.",
      "PM-DSS provides clinicians with evidence-based recommendations for managing chronic pain.",
      "The Chronic Pain Management Decision Support System (CPMDSS) is a mobile app designed to help patients manage chronic pain.",
      "CPMDSS offers features like a symptom checker and medication reminders to support patients in self-managing their chronic pain."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the Chronic Pain Management Decision Support System (CPMDSS), it is not possible to confirm the details provided in statements 4 and 5. If CPMDSS is a real system with those features, then those statements would be true, but without context or source information, their accuracy cannot be determined.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "You MUST give a detailed answer to the following question: Which is the subcellular localization of the protein angiogenin?",
    "llama-7b_response": "Angiogenin is a protein that plays a role in the process of angiogenesis, which is the formation of new blood vessels from pre-existing ones. The subcellular localization of angiogenin can vary depending on the cell type and the stage of the angiogenic process.\n\nIn general, angiogenin is found in the cytosol of cells, meaning it is present in the fluid inside the cell. However, during the early stages of angiogenesis, angiogenin can be found in the nucleus of endothelial cells, which are cells that line the inside of blood vessels.\n\nOnce angiogenesis is complete and new blood vessels have formed, angiogenin can be found in the extracellular space, which is the space outside of cells. It is thought that angiogenin may play a role in maintaining the integrity of newly formed blood vessels.\n\nOverall, the subcellular localization of angiogenin can vary depending on the cell type and the stage of the angiogenic process. It is present in the cytosol of cells during the early stages of angiogenesis and in the extracellular space once angiogenesis is complete.",
    "llama-7b_fact_raw": "1. Angiogenin plays a role in angiogenesis, the formation of new blood vessels from pre-existing ones.\n2. Angiogenin is generally found in the cytosol of cells.\n3. In the early stages of angiogenesis, angiogenin can be located in the nucleus of endothelial cells.\n4. After the completion of angiogenesis, angiogenin can be found in the extracellular space.\n5. Angiogenin may contribute to maintaining the integrity of newly formed blood vessels.",
    "llama-7b_fact": [
      "Angiogenin plays a role in angiogenesis, the formation of new blood vessels from pre-existing ones.",
      "Angiogenin is generally found in the cytosol of cells.",
      "In the early stages of angiogenesis, angiogenin can be located in the nucleus of endothelial cells.",
      "After the completion of angiogenesis, angiogenin can be found in the extracellular space.",
      "Angiogenin may contribute to maintaining the integrity of newly formed blood vessels."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "You MUST give a detailed answer to the following question: How does ranolazine affect kinase signaling activation in the heart?",
    "llama-7b_response": "Ranolazine is a medication that is used to treat chronic angina, a type of chest pain that occurs when the blood flow to the muscles of the heart is reduced. It works by blocking the voltage-gated potassium channels in the heart, which helps to reduce the electrical activity in the heart and reduce the demand for oxygen in the muscles of the heart.\n\nIn terms of kinase signaling activation in the heart, ranolazine has been shown to inhibit the activity of several kinases, including AKT, ERK, and p38 MAPK. These kinases are involved in a variety of cellular processes, including cell survival, proliferation, and differentiation. By inhibiting the activity of these kinases, ranolazine may help to reduce the demand for oxygen in the muscles of the heart and reduce the frequency and severity of angina attacks.\n\nIt is worth noting that the exact mechanism by which ranolazine affects kinase signaling in the heart is not fully understood, and further research is needed to fully understand the effects of this medication on kinase signaling in the heart.",
    "llama-7b_fact_raw": "1. Ranolazine is used to treat chronic angina.\n2. Ranolazine works by blocking voltage-gated potassium channels in the heart.\n3. Blocking these channels helps to reduce the electrical activity in the heart.\n4. Ranolazine inhibits the activity of several kinases, including AKT, ERK, and p38 MAPK.\n5. These kinases are involved in cellular processes such as cell survival, proliferation, and differentiation.",
    "llama-7b_fact": [
      "Ranolazine is used to treat chronic angina.",
      "Ranolazine works by blocking voltage-gated potassium channels in the heart.",
      "Blocking these channels helps to reduce the electrical activity in the heart.",
      "Ranolazine inhibits the activity of several kinases, including AKT, ERK, and p38 MAPK.",
      "These kinases are involved in cellular processes such as cell survival, proliferation, and differentiation."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Ranolazine works by inhibiting the late phase of the inward sodium current in the heart, not by blocking voltage-gated potassium channels.\n3. TRUE (Given the correction in statement 2, this statement is true in the context that reducing sodium influx can reduce electrical activity, but it is not directly related to potassium channels as initially stated.)\n4. FALSE [correction]: Ranolazine is not known to inhibit kinases like AKT, ERK, and p38 MAPK; it primarily affects sodium channels in the heart.\n5. TRUE (This statement is generally true about these kinases, but it is not related to the mechanism of action of ranolazine.)",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1225,
    "user_query": "You MUST give a detailed answer to the following question: Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-7b_response": "Yes, the regulation of the VSR endonuclease is independent of the growth phase of bacteria.\n\nThe VSR endonuclease is a site-specific endonuclease that is involved in the integration of viral DNA into the bacterial genome. It has been shown to be regulated by a variety of factors, including the growth phase of the bacteria. For example, it has been shown that the activity of the VSR endonuclease is increased during the exponential phase of growth, and decreased during the stationary phase.\n\nHowever, it has also been shown that the regulation of the VSR endonuclease is independent of the growth phase of the bacteria. For example, it has been shown that the activity of the VSR endonuclease can be regulated by factors such as the concentration of Mg2+, the pH of the environment, and the presence of certain inhibitors. These factors can all affect the activity of the VSR endonuclease, regardless of the growth phase of the bacteria.\n\nTherefore, while the regulation of the VSR endonuclease may be influenced by the growth phase of the bacteria to some extent, it is not solely dependent on the growth phase and can be regulated by a variety of other factors as well.",
    "llama-7b_fact_raw": "1. The VSR endonuclease is a site-specific endonuclease involved in the integration of viral DNA into the bacterial genome.\n2. The activity of the VSR endonuclease is increased during the exponential phase of bacterial growth.\n3. The activity of the VSR endonuclease is decreased during the stationary phase of bacterial growth.\n4. The regulation of the VSR endonuclease can be affected by the concentration of Mg2+.\n5. The pH of the environment and the presence of certain inhibitors can regulate the activity of the VSR endonuclease.",
    "llama-7b_fact": [
      "The VSR endonuclease is a site-specific endonuclease involved in the integration of viral DNA into the bacterial genome.",
      "The activity of the VSR endonuclease is increased during the exponential phase of bacterial growth.",
      "The activity of the VSR endonuclease is decreased during the stationary phase of bacterial growth.",
      "The regulation of the VSR endonuclease can be affected by the concentration of Mg2+.",
      "The pH of the environment and the presence of certain inhibitors can regulate the activity of the VSR endonuclease."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The VSR endonuclease is not involved in the integration of viral DNA into the bacterial genome. VSR (Very Short Patch Repair) endonuclease is involved in DNA mismatch repair, specifically repairing T:G mismatches to C:G in bacteria.\n2. UNKNOWN: The statement about the activity of the VSR endonuclease increasing during the exponential phase of bacterial growth is not universally established and can vary depending on the organism and specific conditions.\n3. UNKNOWN: Similar to statement 2, the activity of the VSR endonuclease decreasing during the stationary phase of bacterial growth is not universally established and can vary.\n4. TRUE: The activity of many endonucleases, including VSR endonuclease, can be affected by the concentration of divalent cations like Mg2+.\n5. TRUE: The activity of endonucleases, in general, can be influenced by environmental factors such as pH and the presence of certain inhibitors.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1233,
    "user_query": "You MUST give a detailed answer to the following question: What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-7b_response": "There are several computational tools available for the prediction of beta-barrel transmembrane proteins. Here are some of the most commonly used methods:\n\n1. TMHMM: TMHMM (Transmembrane Helices of Microbial Heme-containing proteins) is a widely used method for predicting transmembrane helices in proteins. It uses a hidden Markov model (HMM) to predict the location of transmembrane helices in proteins. TMHMM can also be used to predict beta-barrel proteins.\n2. beta-Barrel Predictor: The beta-Barrel Predictor is a web server that uses a machine learning approach to predict beta-barrel proteins. It uses a support vector machine (SVM) to classify proteins as beta-barrels or non-beta-barrels. The beta-Barrel Predictor has a high accuracy for predicting beta-barrel proteins.\n3. PSIPRED: PSIPRED (Protein Secondary Structure Prediction by Hidden Markov Models) is a web server that uses HMMs to predict the secondary structure of proteins. PSIPRED can be used to predict beta-barrel proteins by identifying the beta-strands that make up the beta-barrel.\n4. SCOP (Structural Classification of Proteins): SCOP (Structural Classification of Proteins) is a database and web server that classifies proteins based on their structural similarity. SCOP can be used to predict beta-barrel proteins by identifying proteins that have a beta-barrel structure.\n5. I-Tasser: I-Tasser is a web server that uses a combination of machine learning and bioinformatics methods to predict the structure and function of proteins. I-Tasser can be used to predict beta-barrel proteins by identifying the beta-strands that make up the beta-barrel.\n\nIn summary, there are several computational tools available for the prediction of beta-barrel transmembrane proteins, including TMHMM, beta-Barrel Predictor, PSIPRED, SCOP, and I-Tasser. These tools use different methods, such as HMMs, machine learning, and structural classification, to predict beta-",
    "llama-7b_fact_raw": "1. TMHMM is a method that predicts transmembrane helices in proteins using a hidden Markov model.\n2. The beta-Barrel Predictor is a web server that uses a support vector machine to classify proteins as beta-barrels or non-beta-barrels.\n3. PSIPRED is a web server that predicts the secondary structure of proteins using hidden Markov models and can be used to predict beta-barrel proteins.\n4. SCOP is a database that classifies proteins based on structural similarity and can be used to identify proteins with a beta-barrel structure.\n5. I-Tasser is a web server that predicts the structure and function of proteins using machine learning and bioinformatics methods, including the prediction of beta-barrel proteins.",
    "llama-7b_fact": [
      "TMHMM is a method that predicts transmembrane helices in proteins using a hidden Markov model.",
      "The beta-Barrel Predictor is a web server that uses a support vector machine to classify proteins as beta-barrels or non-beta-barrels.",
      "PSIPRED is a web server that predicts the secondary structure of proteins using hidden Markov models and can be used to predict beta-barrel proteins.",
      "SCOP is a database that classifies proteins based on structural similarity and can be used to identify proteins with a beta-barrel structure.",
      "I-Tasser is a web server that predicts the structure and function of proteins using machine learning and bioinformatics methods, including the prediction of beta-barrel proteins."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: PSIPRED is a web server that predicts the secondary structure of proteins using neural networks, not hidden Markov models, and it is not specifically used to predict beta-barrel proteins.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1251,
    "user_query": "You MUST give a detailed answer to the following question: Galassi classification is used for which disorder?",
    "llama-7b_response": "Galassi classification is used to classify congenital muscular dystrophies (CMDs), which are a group of inherited muscle disorders characterized by progressive muscle weakness and degeneration. The classification system was developed by Galassi et al. in 1998 and is based on clinical, genetic, and pathological features. There are three main categories of CMDs: Becker muscular dystrophy (BMD), Limb-girdle muscular dystrophy (LGMD), and Distal muscular dystrophy (DMD). Within each category, there are further subcategories based on specific genetic mutations and patterns of muscle involvement.",
    "llama-7b_fact_raw": "1. Galassi classification is used to classify congenital muscular dystrophies (CMDs).\n2. Congenital muscular dystrophies are characterized by progressive muscle weakness and degeneration.\n3. The Galassi classification system was developed in 1998.\n4. The Galassi classification system includes clinical, genetic, and pathological features.\n5. Becker muscular dystrophy (BMD), Limb-girdle muscular dystrophy (LGMD), and Distal muscular dystrophy (DMD) are the three main categories of CMDs in the Galassi classification.",
    "llama-7b_fact": [
      "Galassi classification is used to classify congenital muscular dystrophies (CMDs).",
      "Congenital muscular dystrophies are characterized by progressive muscle weakness and degeneration.",
      "The Galassi classification system was developed in 1998.",
      "The Galassi classification system includes clinical, genetic, and pathological features.",
      "Becker muscular dystrophy (BMD), Limb-girdle muscular dystrophy (LGMD), and Distal muscular dystrophy (DMD) are the three main categories of CMDs in the Galassi classification."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Galassi classification is used to classify congenital malformations of the brain, not congenital muscular dystrophies (CMDs).\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: Becker muscular dystrophy (BMD), Limb-girdle muscular dystrophy (LGMD), and Distal muscular dystrophy (DMD) are not categories of CMDs in the Galassi classification, as the Galassi classification is not for CMDs. These are different types of muscular dystrophies but not classified under Galassi.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1304,
    "user_query": "You MUST give a detailed answer to the following question: List common features of Shapiro syndrome",
    "llama-7b_response": "Shapiro syndrome is a rare genetic disorder that affects the body's ability to process amino acids, which are the building blocks of proteins. It is caused by a deficiency in the enzyme ornithine transcarbamylase (OTC), which is necessary for the breakdown of ornithine, an amino acid.\n\nHere are some common features of Shapiro syndrome:\n\n1. Hyperammonemia: This is a condition in which there is an abnormally high level of ammonia in the blood. Ammonia is a byproduct of the breakdown of ornithine, and it can build up to toxic levels in people with Shapiro syndrome.\n2. Liver dysfunction: The liver is responsible for breaking down ammonia and other toxins, so it is often affected in people with Shapiro syndrome. The liver may become enlarged and may not function properly, leading to a buildup of toxins in the blood.\n3. Intellectual disability: Intellectual disability is a common feature of Shapiro syndrome. This can range from mild to severe and may affect a person's ability to learn, communicate, and take care of themselves.\n4. Developmental delays: Children with Shapiro syndrome may experience delays in their physical and cognitive development. This can include delays in walking, talking, and other milestones.\n5. Behavioral problems: People with Shapiro syndrome may experience behavioral problems, such as aggression, irritability, and difficulty with social interactions.\n6. Eye abnormalities: Some people with Shapiro syndrome may have abnormalities in their eyes, such as cataracts, glaucoma, or nystagmus (involuntary movement of the eyes).\n7. Muscle weakness: Muscle weakness is a common feature of Shapiro syndrome, and it can affect the muscles in the arms, legs, and face. This can lead to difficulty with movement and coordination.\n8. Skin abnormalities: Some people with Shapiro syndrome may have skin abnormalities, such as acanthosis nigricans (a skin condition characterized by dark, thick, and velvety skin) or x",
    "llama-7b_fact_raw": "1. Shapiro syndrome is a rare genetic disorder that affects the body's ability to process amino acids.\n2. It is caused by a deficiency in the enzyme ornithine transcarbamylase (OTC).\n3. Hyperammonemia, characterized by an abnormally high level of ammonia in the blood, is a common feature of Shapiro syndrome.\n4. Liver dysfunction, which may include an enlarged liver and impaired function, is often affected in people with Shapiro syndrome.\n5. Intellectual disability ranging from mild to severe is a common feature of Shapiro syndrome.",
    "llama-7b_fact": [
      "Shapiro syndrome is a rare genetic disorder that affects the body's ability to process amino acids.",
      "It is caused by a deficiency in the enzyme ornithine transcarbamylase (OTC).",
      "Hyperammonemia, characterized by an abnormally high level of ammonia in the blood, is a common feature of Shapiro syndrome.",
      "Liver dysfunction, which may include an enlarged liver and impaired function, is often affected in people with Shapiro syndrome.",
      "Intellectual disability ranging from mild to severe is a common feature of Shapiro syndrome."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Shapiro syndrome is not a genetic disorder affecting amino acid processing; it is a rare neurological condition characterized by recurrent episodes of hypothermia, sweating, and agenesis of the corpus callosum.\n2. FALSE [correction]: Shapiro syndrome is not caused by a deficiency in the enzyme ornithine transcarbamylase (OTC); OTC deficiency is associated with a different condition called ornithine transcarbamylase deficiency, which is a urea cycle disorder.\n3. FALSE [correction]: Hyperammonemia is not a common feature of Shapiro syndrome; it is associated with urea cycle disorders like OTC deficiency. Shapiro syndrome does not typically involve ammonia levels.\n4. FALSE [correction]: Liver dysfunction is not typically associated with Shapiro syndrome. Shapiro syndrome primarily affects the nervous system.\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1320,
    "user_query": "You MUST give a detailed answer to the following question: Which disease is linked to mutations within BRAG1?",
    "llama-7b_response": "BRAG1, also known as BRCA1-associated RING domain protein 1, is a protein that plays a role in the repair of damaged DNA. Mutations in the BRAG1 gene have been linked to the development of several types of cancer, including breast, ovarian, and prostate cancer.\n\nSpecifically, mutations in the BRAG1 gene have been found to be associated with an increased risk of developing hereditary breast and ovarian cancer syndrome (HBOC), which is a genetic disorder that increases the risk of developing breast and ovarian cancer. HBOC is caused by mutations in either the BRCA1 or BRCA2 genes, which are involved in the repair of damaged DNA.\n\nIn addition to HBOC, mutations in the BRAG1 gene have also been linked to the development of other types of cancer, including prostate cancer. Prostate cancer is the second leading cause of death from cancer among men in the United States.\n\nOverall, mutations in the BRAG1 gene have been found to be associated with an increased risk of developing several types of cancer, including breast, ovarian, and prostate cancer.",
    "llama-7b_fact_raw": "1. Mutations in the BRAG1 gene have been linked to the development of several types of cancer, including breast, ovarian, and prostate cancer.\n2. Mutations in the BRAG1 gene are associated with an increased risk of developing hereditary breast and ovarian cancer syndrome (HBOC).\n3. HBOC is a genetic disorder that increases the risk of developing breast and ovarian cancer.\n4. HBOC is caused by mutations in either the BRCA1 or BRCA2 genes.\n5. Prostate cancer is the second leading cause of death from cancer among men in the United States.",
    "llama-7b_fact": [
      "Mutations in the BRAG1 gene have been linked to the development of several types of cancer, including breast, ovarian, and prostate cancer.",
      "Mutations in the BRAG1 gene are associated with an increased risk of developing hereditary breast and ovarian cancer syndrome (HBOC).",
      "HBOC is a genetic disorder that increases the risk of developing breast and ovarian cancer.",
      "HBOC is caused by mutations in either the BRCA1 or BRCA2 genes.",
      "Prostate cancer is the second leading cause of death from cancer among men in the United States."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Mutations in the BRCA1 gene, not BRAG1, have been linked to the development of several types of cancer, including breast, ovarian, and prostate cancer.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Prostate cancer is the second most common cancer among men in the United States, but it is not the second leading cause of death from cancer among men. Lung cancer is the leading cause of cancer death among men.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1362,
    "user_query": "You MUST give a detailed answer to the following question: Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-7b_response": "​",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1374,
    "user_query": "You MUST give a detailed answer to the following question: Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-7b_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a process by which bacteria, such as Bacillus subtilis, undergo genetic changes in response to environmental stress, such as a lack of nutrients. This process allows the bacteria to adapt and survive in the face of adverse conditions.\n\nThere are several mechanisms that underlie adaptive mutagenesis in B. subtilis:\n\n1. Mutator mutations: These are mutations that increase the frequency of mutations in the bacterial genome. The mutator phenotype is conferred by mutations in the mutS and mutL genes, which are involved in DNA mismatch repair. B. subtilis strains with a mutator phenotype have a higher frequency of spontaneous mutations and are more likely to undergo adaptive mutagenesis.\n2. Transposon mutagenesis: Transposons are mobile genetic elements that can insert themselves into the genome of B. subtilis. When transposons insert themselves into the genome, they can disrupt the function of nearby genes, leading to mutations. Transposon mutagenesis is a major mechanism of adaptive mutagenesis in B. subtilis.\n3. DNA damage response: B. subtilis responds to DNA damage by activating the DNA damage checkpoint, which delays cell division until the damage is repaired. If the damage is not repaired, the cell can undergo programmed cell death, or apoptosis, which can lead to the selection of cells with mutations that allow them to survive in the presence of DNA damage.\n4. Genetic recombination: Genetic recombination, or the exchange of genetic material between bacterial cells, can lead to the integration of new genetic elements into the genome, which can result in mutations. Genetic recombination is particularly important in B. subtilis during competence, a state in which the bacteria are able to take up extracellular DNA and use it as a source of genetic information.\n\nOverall, these mechanisms allow B. subtilis to undergo adaptive mutagenesis and evolve genetic changes that allow it to survive in the face of environmental stress.",
    "llama-7b_fact_raw": "1. Adaptive mutagenesis in Bacillus subtilis is a response to environmental stress such as a lack of nutrients.\n2. Mutator mutations in B. subtilis, which increase the frequency of mutations, are conferred by mutations in the mutS and mutL genes involved in DNA mismatch repair.\n3. Transposon mutagenesis in B. subtilis involves mobile genetic elements inserting into the genome, potentially disrupting gene function and leading to mutations.\n4. The DNA damage response in B. subtilis activates a checkpoint that delays cell division until damage is repaired, and can lead to programmed cell death if the damage is irreparable.\n5. Genetic recombination in B. subtilis, especially during competence, can result in the integration of new genetic elements into the genome, causing mutations.",
    "llama-7b_fact": [
      "Adaptive mutagenesis in Bacillus subtilis is a response to environmental stress such as a lack of nutrients.",
      "Mutator mutations in B. subtilis, which increase the frequency of mutations, are conferred by mutations in the mutS and mutL genes involved in DNA mismatch repair.",
      "Transposon mutagenesis in B. subtilis involves mobile genetic elements inserting into the genome, potentially disrupting gene function and leading to mutations.",
      "The DNA damage response in B. subtilis activates a checkpoint that delays cell division until damage is repaired, and can lead to programmed cell death if the damage is irreparable.",
      "Genetic recombination in B. subtilis, especially during competence, can result in the integration of new genetic elements into the genome, causing mutations."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Genetic recombination in B. subtilis, especially during competence, can result in the integration of new genetic elements into the genome, but this process itself is not considered to cause mutations. Instead, it is a natural process that can introduce genetic diversity.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1399,
    "user_query": "You MUST give a detailed answer to the following question: What causes erucism?",
    "llama-7b_response": "Erucism, also known as goitrogenic hypothyroidism, is a condition caused by a deficiency of iodine in the diet, which leads to an enlargement of the thyroid gland (goiter) and an underactive thyroid gland (hypothyroidism).\n\nThe thyroid gland is located in the neck and is responsible for producing hormones that regulate metabolism, growth and development, and body temperature. Iodine is an essential nutrient that the thyroid gland needs to produce these hormones.\n\nWhen there is a deficiency of iodine in the diet, the thyroid gland tries to compensate by producing more thyroid hormones. However, this can lead to an enlargement of the thyroid gland (goiter) and an underactive thyroid gland (hypothyroidism). This condition is known as erucism.\n\nErucism can also be caused by consuming foods that contain goitrogens, which are compounds that interfere with the absorption of iodine in the body. These foods include cruciferous vegetables such as broccoli, cauliflower, cabbage, and Brussels sprouts.\n\nIn summary, erucism is caused by a deficiency of iodine in the diet, which leads to an enlargement of the thyroid gland (goiter) and an underactive thyroid gland (hypothyroidism). It can also be caused by consuming foods that contain goitrogens, which interfere with the absorption of iodine in the body.",
    "llama-7b_fact_raw": "1. Erucism is a condition caused by a deficiency of iodine in the diet.\n2. A deficiency of iodine can lead to an enlargement of the thyroid gland, known as a goiter.\n3. Iodine deficiency can also result in an underactive thyroid gland, a condition known as hypothyroidism.\n4. The thyroid gland is responsible for producing hormones that regulate metabolism, growth and development, and body temperature.\n5. Consuming foods that contain goitrogens, such as cruciferous vegetables, can interfere with the absorption of iodine and contribute to erucism.",
    "llama-7b_fact": [
      "Erucism is a condition caused by a deficiency of iodine in the diet.",
      "A deficiency of iodine can lead to an enlargement of the thyroid gland, known as a goiter.",
      "Iodine deficiency can also result in an underactive thyroid gland, a condition known as hypothyroidism.",
      "The thyroid gland is responsible for producing hormones that regulate metabolism, growth and development, and body temperature.",
      "Consuming foods that contain goitrogens, such as cruciferous vegetables, can interfere with the absorption of iodine and contribute to erucism."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Erucism is not a condition caused by a deficiency of iodine. Erucism is a type of poisoning that occurs when someone comes into contact with the caterpillar or moth of the genus Erebus. The term for a condition caused by a deficiency of iodine is iodine deficiency disorder.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Consuming foods that contain goitrogens, such as cruciferous vegetables, can interfere with the function of the thyroid gland, but they contribute to goiter, not erucism. Goitrogens can inhibit the uptake of iodine into the thyroid gland, potentially leading to an enlargement of the gland if consumed in large amounts without sufficient iodine intake.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1413,
    "user_query": "You MUST give a detailed answer to the following question: What are the indications for hydrochlorothiazide?",
    "llama-7b_response": "Hydrochlorothiazide is a thiazide diuretic medication that is used to treat hypertension (high blood pressure) and edema (swelling) caused by various conditions, such as heart failure, liver disease, and kidney disease. It works by increasing the production of urine, which helps to remove excess fluid from the body. Hydrochlorothiazide is also used to treat hypokalemia (low potassium levels in the blood), which can occur as a side effect of certain diuretics or as a result of certain medical conditions. In addition, hydrochlorothiazide may be used to treat other conditions as determined by a healthcare provider.",
    "llama-7b_fact_raw": "1. Hydrochlorothiazide is used to treat hypertension (high blood pressure).\n2. Hydrochlorothiazide is used to treat edema (swelling) caused by conditions such as heart failure, liver disease, and kidney disease.\n3. Hydrochlorothiazide works by increasing the production of urine to remove excess fluid from the body.\n4. Hydrochlorothiazide is used to treat hypokalemia (low potassium levels in the blood).\n5. Hydrochlorothiazide may be prescribed for other conditions as determined by a healthcare provider.",
    "llama-7b_fact": [
      "Hydrochlorothiazide is used to treat hypertension (high blood pressure).",
      "Hydrochlorothiazide is used to treat edema (swelling) caused by conditions such as heart failure, liver disease, and kidney disease.",
      "Hydrochlorothiazide works by increasing the production of urine to remove excess fluid from the body.",
      "Hydrochlorothiazide is used to treat hypokalemia (low potassium levels in the blood).",
      "Hydrochlorothiazide may be prescribed for other conditions as determined by a healthcare provider."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Hydrochlorothiazide can actually cause hypokalemia (low potassium levels in the blood) as a side effect, rather than treat it.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1447,
    "user_query": "You MUST give a detailed answer to the following question: Has silicon been used in treatment of  incontinence ?",
    "llama-7b_response": "Yes, silicone has been used in the treatment of stress urinary incontinence (SUI) in women. Silicone is a synthetic substance that is often used in medical devices and implants because of its durability and biocompatibility.\n\nSilicone implants for SUI are designed to be placed in the vagina and act as a \"sling\" to support the urethra and prevent urine leakage. These implants are typically made of a soft, pliable silicone material that can be adjusted to fit the individual patient's anatomy.\n\nSilicone implants for SUI have been shown to be effective in reducing urine leakage and improving quality of life in women with SUI. However, like any medical device, there are potential risks and complications associated with their use, including infection, bleeding, and implant migration. It is important for patients to discuss the risks and benefits of silicone implants for SUI with their healthcare provider before making a decision about treatment.",
    "llama-7b_fact_raw": "1. Silicone has been used in the treatment of stress urinary incontinence (SUI) in women.\n2. Silicone is used in medical devices and implants due to its durability and biocompatibility.\n3. Silicone implants for SUI are designed to support the urethra and prevent urine leakage.\n4. Silicone implants for SUI are made of a soft, pliable material that can be adjusted to fit the patient's anatomy.\n5. Silicone implants for SUI have been shown to be effective in reducing urine leakage and improving quality of life in women with SUI.",
    "llama-7b_fact": [
      "Silicone has been used in the treatment of stress urinary incontinence (SUI) in women.",
      "Silicone is used in medical devices and implants due to its durability and biocompatibility.",
      "Silicone implants for SUI are designed to support the urethra and prevent urine leakage.",
      "Silicone implants for SUI are made of a soft, pliable material that can be adjusted to fit the patient's anatomy.",
      "Silicone implants for SUI have been shown to be effective in reducing urine leakage and improving quality of life in women with SUI."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nSilicone is indeed used in the treatment of stress urinary incontinence (SUI) in women, particularly in the form of urethral bulking agents or other types of implants designed to support the urethra. Its properties such as durability and biocompatibility make it suitable for medical devices and implants. Silicone implants for SUI are designed to be soft and pliable to conform to the patient's anatomy, and they have been shown to be effective in reducing urine leakage and improving the quality of life for women with SUI.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "You MUST give a detailed answer to the following question: What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-7b_response": "The association between the moon cycle and rupture risk of intracranial aneurysms is a topic of ongoing research and debate. Some studies have suggested that there may be a correlation between the phases of the moon and the occurrence of intracranial aneurysm ruptures, while others have found no such association.\n\nIt is thought that the moon's gravitational pull may have an effect on the blood flow in the brain, which could potentially influence the rupture risk of an intracranial aneurysm. However, the exact mechanism by which this might occur is not well understood.\n\nSeveral studies have investigated the relationship between the moon cycle and intracranial aneurysm ruptures, with mixed results. Some studies have found that the risk of rupture may be higher during certain phases of the moon, such as the full moon or the new moon, while others have found no such association.\n\nFor example, a study published in the journal Neurology in 2012 found that the risk of intracranial aneurysm rupture was significantly higher during the full moon phase compared to other phases of the moon. However, another study published in the same journal in 2016 found no such association.\n\nIt is worth noting that these studies have limitations, such as small sample sizes and potential confounding factors, and more research is needed to determine the true association between the moon cycle and intracranial aneurysm ruptures.\n\nIn summary, the association between the moon cycle and rupture risk of intracranial aneurysms is a topic of ongoing research and debate. While some studies have suggested that there may be a correlation between the phases of the moon and the occurrence of intracranial aneurysm ruptures, others have found no such association. Further research is needed to better understand this relationship.",
    "llama-7b_fact_raw": "1. Some studies have suggested a correlation between the phases of the moon and the occurrence of intracranial aneurysm ruptures.\n2. Other studies have found no association between the moon cycle and the risk of intracranial aneurysm ruptures.\n3. A study published in the journal Neurology in 2012 found a significantly higher risk of intracranial aneurysm rupture during the full moon phase.\n4. Another study published in the journal Neurology in 2016 found no association between the moon cycle and intracranial aneurysm ruptures.\n5. The exact mechanism by which the moon's gravitational pull might affect the blood flow in the brain and influence aneurysm rupture risk is not well understood.",
    "llama-7b_fact": [
      "Some studies have suggested a correlation between the phases of the moon and the occurrence of intracranial aneurysm ruptures.",
      "Other studies have found no association between the moon cycle and the risk of intracranial aneurysm ruptures.",
      "A study published in the journal Neurology in 2012 found a significantly higher risk of intracranial aneurysm rupture during the full moon phase.",
      "Another study published in the journal Neurology in 2016 found no association between the moon cycle and intracranial aneurysm ruptures.",
      "The exact mechanism by which the moon's gravitational pull might affect the blood flow in the brain and influence aneurysm rupture risk is not well understood."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "You MUST give a detailed answer to the following question: Does HuR protein regulate the splicing process?",
    "llama-7b_response": "Yes, HuR (ELAVL1) protein has been shown to regulate the splicing process.\n\nHuR is a RNA-binding protein that plays a crucial role in the regulation of gene expression at the post-transcriptional level. One of the key functions of HuR is to bind to unspliced or partially spliced pre-mRNAs and to promote their splicing by recruiting splicing factors and modulating their activity.\n\nHuR has been shown to interact with a variety of splicing factors, including SF2/ASF, SC35, and hnRNPA/B, and to regulate the splicing of a wide range of genes. For example, HuR has been shown to play a role in the splicing of tumor suppressor genes, such as p53 and retinoblastoma, as well as in the splicing of genes involved in cell proliferation, differentiation, and apoptosis.\n\nFurthermore, HuR has also been shown to regulate the splicing of microRNAs (miRNAs), which are small non-coding RNAs that play a crucial role in post-transcriptional gene regulation. HuR has been shown to bind to miRNA precursors and to promote their splicing, leading to the production of mature miRNAs that can regulate the expression of target genes.\n\nOverall, HuR is a key regulator of the splicing process and plays a crucial role in the regulation of gene expression at the post-transcriptional level.",
    "llama-7b_fact_raw": "1. HuR (ELAVL1) protein regulates the splicing process.\n2. HuR is a RNA-binding protein that influences gene expression at the post-transcriptional level.\n3. HuR promotes the splicing of pre-mRNAs by recruiting splicing factors and modulating their activity.\n4. HuR interacts with splicing factors such as SF2/ASF, SC35, and hnRNPA/B.\n5. HuR is involved in the splicing of genes related to tumor suppression, cell proliferation, differentiation, and apoptosis.",
    "llama-7b_fact": [
      "HuR (ELAVL1) protein regulates the splicing process.",
      "HuR is a RNA-binding protein that influences gene expression at the post-transcriptional level.",
      "HuR promotes the splicing of pre-mRNAs by recruiting splicing factors and modulating their activity.",
      "HuR interacts with splicing factors such as SF2/ASF, SC35, and hnRNPA/B.",
      "HuR is involved in the splicing of genes related to tumor suppression, cell proliferation, differentiation, and apoptosis."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: HuR (ELAVL1) protein is primarily known for regulating mRNA stability and translation, not the splicing process.\n2. TRUE\n3. FALSE [correction]: While HuR is involved in various aspects of mRNA metabolism, its primary role is not promoting the splicing of pre-mRNAs. It is mainly known for affecting mRNA stability and translation.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "You MUST give a detailed answer to the following question: Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-7b_response": "The prothymosin alpha c-terminal peptide is a small protein fragment that is derived from the larger prothymosin alpha protein. The known functions of the prothymosin alpha c-terminal peptide include:\n\n1. Regulation of gene expression: The prothymosin alpha c-terminal peptide has been shown to regulate the expression of certain genes, including genes involved in immune function and inflammation.\n2. Modulation of immune responses: The prothymosin alpha c-terminal peptide has been shown to modulate immune responses, including the activation of T cells and the production of cytokines.\n3. Anti-inflammatory effects: The prothymosin alpha c-terminal peptide has been shown to have anti-inflammatory effects, including the inhibition of the production of certain pro-inflammatory cytokines.\n4. Neuroprotective effects: The prothymosin alpha c-terminal peptide has been shown to have neuroprotective effects, including the protection of neurons against oxidative stress and the promotion of neuronal survival.\n5. Anti-cancer effects: The prothymosin alpha c-terminal peptide has been shown to have anti-cancer effects, including the inhibition of cancer cell growth and the promotion of cancer cell death.\n\nOverall, the prothymosin alpha c-terminal peptide appears to have a wide range of potential therapeutic applications, including the treatment of inflammatory disorders, neurodegenerative diseases, and cancer. However, further research is needed to fully understand the mechanisms by which the prothymosin alpha c-terminal peptide exerts its effects and to determine its safety and efficacy as a therapeutic agent.",
    "llama-7b_fact_raw": "1. The prothymosin alpha c-terminal peptide regulates the expression of certain genes, including those involved in immune function and inflammation.\n2. The prothymosin alpha c-terminal peptide modulates immune responses, including the activation of T cells and the production of cytokines.\n3. The prothymosin alpha c-terminal peptide has anti-inflammatory effects, including the inhibition of the production of certain pro-inflammatory cytokines.\n4. The prothymosin alpha c-terminal peptide has neuroprotective effects, such as protecting neurons against oxidative stress and promoting neuronal survival.\n5. The prothymosin alpha c-terminal peptide has anti-cancer effects, including inhibiting cancer cell growth and promoting cancer cell death.",
    "llama-7b_fact": [
      "The prothymosin alpha c-terminal peptide regulates the expression of certain genes, including those involved in immune function and inflammation.",
      "The prothymosin alpha c-terminal peptide modulates immune responses, including the activation of T cells and the production of cytokines.",
      "The prothymosin alpha c-terminal peptide has anti-inflammatory effects, including the inhibition of the production of certain pro-inflammatory cytokines.",
      "The prothymosin alpha c-terminal peptide has neuroprotective effects, such as protecting neurons against oxidative stress and promoting neuronal survival.",
      "The prothymosin alpha c-terminal peptide has anti-cancer effects, including inhibiting cancer cell growth and promoting cancer cell death."
    ],
    "llama-7b_judge_raw": "1. TRUE: Prothymosin alpha is known to be involved in the regulation of gene expression and has been implicated in various cellular processes, including those related to immune function and inflammation.\n2. TRUE: Prothymosin alpha has been reported to modulate immune responses, which can include the activation of T cells and the production of cytokines.\n3. TRUE: Prothymosin alpha has been shown to have anti-inflammatory effects, which may involve the inhibition of pro-inflammatory cytokines.\n4. TRUE: There is evidence suggesting that prothymosin alpha has neuroprotective effects, including the protection of neurons against oxidative stress and the promotion of neuronal survival.\n5. TRUE: Prothymosin alpha has been studied for its potential anti-cancer effects, which include inhibiting the growth of cancer cells and promoting apoptosis or cancer cell death.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "You MUST give a detailed answer to the following question: Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-7b_response": "The peptide that plays a pivotal role in human cystatin C fibrillization is the C-terminal domain (CTD) of cystatin C.\n\nCystatin C is a cysteine protease inhibitor that plays a role in regulating various cellular processes, including protein folding, trafficking, and degradation. It is also involved in the regulation of the actin cytoskeleton and the maintenance of cellular homeostasis.\n\nFibrillization of cystatin C is a process in which the protein undergoes a series of structural changes that result in the formation of amyloid fibrils. These fibrils can accumulate in various tissues and organs, leading to a range of pathological conditions, including neurodegeneration, cardiovascular disease, and kidney dysfunction.\n\nThe CTD of cystatin C has been shown to play a pivotal role in the fibrillization process. The CTD is a highly conserved region of cystatin C that is involved in the regulation of various cellular processes, including protein folding, trafficking, and degradation. It is also involved in the regulation of the actin cytoskeleton and the maintenance of cellular homeostasis.\n\nStudies have shown that the CTD of cystatin C undergoes a series of structural changes during the fibrillization process, leading to the formation of amyloid fibrils. These fibrils can accumulate in various tissues and organs, leading to a range of pathological conditions, including neurodegeneration, cardiovascular disease, and kidney dysfunction.\n\nIn summary, the CTD of cystatin C plays a pivotal role in the fibrillization of cystatin C, which can lead to a range of pathological conditions. Understanding the mechanisms underlying cystatin C fibrillization is important for the development of therapeutic strategies to prevent or treat these conditions.",
    "llama-7b_fact_raw": "1. The C-terminal domain (CTD) of cystatin C plays a pivotal role in human cystatin C fibrillization.\n2. Cystatin C is a cysteine protease inhibitor involved in regulating protein folding, trafficking, and degradation.\n3. Fibrillization of cystatin C results in the formation of amyloid fibrils.\n4. Accumulation of amyloid fibrils from cystatin C can lead to pathological conditions such as neurodegeneration, cardiovascular disease, and kidney dysfunction.\n5. The CTD of cystatin C is a highly conserved region involved in the regulation of the actin cytoskeleton and maintenance of cellular homeostasis.",
    "llama-7b_fact": [
      "The C-terminal domain (CTD) of cystatin C plays a pivotal role in human cystatin C fibrillization.",
      "Cystatin C is a cysteine protease inhibitor involved in regulating protein folding, trafficking, and degradation.",
      "Fibrillization of cystatin C results in the formation of amyloid fibrils.",
      "Accumulation of amyloid fibrils from cystatin C can lead to pathological conditions such as neurodegeneration, cardiovascular disease, and kidney dysfunction.",
      "The CTD of cystatin C is a highly conserved region involved in the regulation of the actin cytoskeleton and maintenance of cellular homeostasis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The C-terminal domain (CTD) of cystatin C is not involved in the regulation of the actin cytoskeleton and maintenance of cellular homeostasis. Instead, it is important for its inhibitory activity and stability, and changes in the CTD can lead to increased fibrillization and associated diseases.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1574,
    "user_query": "You MUST give a detailed answer to the following question: Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-7b_response": "Yes, the concentration of protein HIF-1α (hypoxia-inducible factor 1 alpha) can increase after the administration of the cytoprotective prodrug amifostine (ethyol).\n\nHIF-1α is a transcription factor that plays a crucial role in the response of cells to hypoxia (low oxygen levels). It regulates the expression of genes involved in various cellular processes, including angiogenesis, metabolism, and cell survival.\n\nAmifostine (ethyol) is a cytoprotective prodrug that is administered to protect cells against the toxic effects of chemotherapy and radiation therapy. It is a water-soluble compound that is converted to a more stable form in cells, which can then be transported across the cell membrane and into the cytoplasm. Once inside the cell, amifostine can react with and detoxify reactive oxygen species (ROS) and other reactive nitrogen species (RNS) that are generated during chemotherapy and radiation therapy.\n\nThe effect of amifostine on the concentration of HIF-1α has been studied in various cell lines and in vivo models. In some studies, amifostine has been shown to increase the concentration of HIF-1α in response to hypoxia. This increase in HIF-1α can lead to the upregulation of genes involved in angiogenesis, metabolism, and cell survival, which can contribute to the cytoprotective effects of amifostine.\n\nIn summary, the concentration of protein HIF-1α can increase after the administration of the cytoprotective prodrug amifostine (ethyol) in response to hypoxia. This increase in HIF-1α can contribute to the cytoprotective effects of amifostine and may play a role in its ability to protect cells against the toxic effects of chemotherapy and radiation therapy.",
    "llama-7b_fact_raw": "1. The concentration of protein HIF-1α can increase after the administration of the cytoprotective prodrug amifostine (ethyol).\n2. HIF-1α is a transcription factor that is involved in the cellular response to hypoxia.\n3. Amifostine is used to protect cells against the toxic effects of chemotherapy and radiation therapy.\n4. Amifostine is a water-soluble compound that, once inside the cell, can detoxify reactive oxygen species (ROS) and reactive nitrogen species (RNS).\n5. Studies have shown that amifostine can increase the concentration of HIF-1α in response to hypoxia in various cell lines and in vivo models.",
    "llama-7b_fact": [
      "The concentration of protein HIF-1α can increase after the administration of the cytoprotective prodrug amifostine (ethyol).",
      "HIF-1α is a transcription factor that is involved in the cellular response to hypoxia.",
      "Amifostine is used to protect cells against the toxic effects of chemotherapy and radiation therapy.",
      "Amifostine is a water-soluble compound that, once inside the cell, can detoxify reactive oxygen species (ROS) and reactive nitrogen species (RNS).",
      "Studies have shown that amifostine can increase the concentration of HIF-1α in response to hypoxia in various cell lines and in vivo models."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAll statements provided are consistent with known information about HIF-1α, amifostine, and their roles in cellular responses to stress such as hypoxia and treatments like chemotherapy and radiation therapy. However, it is important to note that the specific details of scientific research, such as the effects of amifostine on HIF-1α concentration in various studies, can be complex and context-dependent. Therefore, while the statement is generally true, the exact outcomes can vary based on experimental conditions and models used.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1588,
    "user_query": "You MUST give a detailed answer to the following question: Which histone marks are deposited by Set7?",
    "llama-7b_response": "Set7 is a histone lysine methyltransferase that adds a methyl group to histone H3 at lysine 27 (H3K27) to repress transcription. In addition to H3K27, Set7 can also add methyl groups to histone H3 at lysine 36 (H3K36) and histone H4 at lysine 20 (H4K20) to repress transcription. These histone marks are often referred to as \"Set7 marks\" or \"Set7-specific marks.\"",
    "llama-7b_fact_raw": "1. Set7 is a histone lysine methyltransferase.\n2. Set7 adds a methyl group to histone H3 at lysine 27 (H3K27).\n3. The methylation of H3K27 by Set7 is associated with repression of transcription.\n4. Set7 can also methylate histone H3 at lysine 36 (H3K36).\n5. Set7 is capable of methylating histone H4 at lysine 20 (H4K20).",
    "llama-7b_fact": [
      "Set7 is a histone lysine methyltransferase.",
      "Set7 adds a methyl group to histone H3 at lysine 27 (H3K27).",
      "The methylation of H3K27 by Set7 is associated with repression of transcription.",
      "Set7 can also methylate histone H3 at lysine 36 (H3K36).",
      "Set7 is capable of methylating histone H4 at lysine 20 (H4K20)."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Set7 specifically adds a methyl group to histone H3 at lysine 4 (H3K4), not lysine 27 (H3K27).\n3. FALSE [correction]: The methylation of H3K27 is generally associated with repression of transcription, but Set7 does not methylate H3K27; it methylates H3K4, which is associated with the activation of transcription.\n4. FALSE [correction]: Set7 specifically methylates lysine 4 on histone H3 (H3K4) and does not methylate histone H3 at lysine 36 (H3K36).\n5. FALSE [correction]: Set7 specifically methylates lysine 4 on histone H3 (H3K4) and is not known to methylate histone H4 at lysine 20 (H4K20).",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1620,
    "user_query": "You MUST give a detailed answer to the following question: How many disulfide bridges has the protein hepcidin got?",
    "llama-7b_response": "Hepcidin is a protein that plays a crucial role in the regulation of iron metabolism in the body. It is composed of two polypeptide chains, which are linked together by disulfide bridges. The exact number of disulfide bridges in hepcidin can vary depending on the species and the specific isoform of the protein. However, it is generally accepted that hepcidin contains between 4 and 6 disulfide bridges.",
    "llama-7b_fact_raw": "1. Hepcidin is a protein involved in the regulation of iron metabolism.\n2. Hepcidin is composed of two polypeptide chains.\n3. These polypeptide chains are linked together by disulfide bridges.\n4. The number of disulfide bridges in hepcidin can vary depending on the species.\n5. Hepcidin generally contains between 4 and 6 disulfide bridges.",
    "llama-7b_fact": [
      "Hepcidin is a protein involved in the regulation of iron metabolism.",
      "Hepcidin is composed of two polypeptide chains.",
      "These polypeptide chains are linked together by disulfide bridges.",
      "The number of disulfide bridges in hepcidin can vary depending on the species.",
      "Hepcidin generally contains between 4 and 6 disulfide bridges."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Hepcidin is composed of a single polypeptide chain.\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: Hepcidin generally contains 4 disulfide bridges.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1643,
    "user_query": "You MUST give a detailed answer to the following question: What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-7b_response": "The localization of the protein encoded by the gene DNAJC11 is not well understood. DNAJC11 is a member of the DNAJ (HSP40) family of chaperone proteins, which are involved in the folding, assembly, and transport of other proteins within the cell. While some members of the DNAJ family have been shown to localize to specific subcellular compartments, such as the endoplasmic reticulum or the mitochondria, the localization of DNAJC11 has not been extensively studied.\n\nIt is possible that DNAJC11 localizes to multiple subcellular compartments or that its localization is regulated in a tissue-specific or cell-specific manner. Further research is needed to determine the precise localization of DNAJC11 and the role it plays in the cell.",
    "llama-7b_fact_raw": "1. DNAJC11 is a member of the DNAJ (HSP40) family of chaperone proteins.\n2. Proteins in the DNAJ family are involved in the folding, assembly, and transport of other proteins within the cell.\n3. Some members of the DNAJ family localize to specific subcellular compartments such as the endoplasmic reticulum or the mitochondria.\n4. The precise localization of DNAJC11 has not been extensively studied.\n5. Further research is needed to determine the precise localization of DNAJC11.",
    "llama-7b_fact": [
      "DNAJC11 is a member of the DNAJ (HSP40) family of chaperone proteins.",
      "Proteins in the DNAJ family are involved in the folding, assembly, and transport of other proteins within the cell.",
      "Some members of the DNAJ family localize to specific subcellular compartments such as the endoplasmic reticulum or the mitochondria.",
      "The precise localization of DNAJC11 has not been extensively studied.",
      "Further research is needed to determine the precise localization of DNAJC11."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements are consistent with general knowledge about the DNAJ (HSP40) family of chaperone proteins. However, without specific information about DNAJC11's localization, statements 4 and 5 cannot be confirmed as true or false and are therefore marked as UNKNOWN.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1655,
    "user_query": "You MUST give a detailed answer to the following question: Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-7b_response": "Ultraconserved elements (UCEs) are regions of the genome that are highly conserved across evolutionary time and are believed to be functionally important. UCEs are defined as regions of at least 200 nucleotides in length that are at least 100 times more conserved than the average genomic sequence.\n\nCopy number variants (CNVs) are variations in the number of copies of a particular genomic region. CNVs can arise through a variety of mechanisms, including duplications, deletions, and translocations.\n\nIt is possible that UCEs could be affected by CNVs, as CNVs can alter the copy number of UCEs and potentially affect their function. However, there is currently limited information on the relationship between UCEs and CNVs. Some studies have suggested that UCEs may be more likely to be affected by CNVs than other regions of the genome, but this has not been widely confirmed.\n\nIn summary, while it is possible that UCEs could be affected by CNVs, the relationship between UCEs and CNVs is not well understood and more research is needed to determine the extent to which UCEs are depleted among CNVs.",
    "llama-7b_fact_raw": "1. Ultraconserved elements (UCEs) are regions of the genome that are highly conserved across evolutionary time.\n2. UCEs are defined as regions of at least 200 nucleotides in length.\n3. UCEs are at least 100 times more conserved than the average genomic sequence.\n4. Copy number variants (CNVs) are variations in the number of copies of a particular genomic region.\n5. CNVs can arise through mechanisms such as duplications, deletions, and translocations.",
    "llama-7b_fact": [
      "Ultraconserved elements (UCEs) are regions of the genome that are highly conserved across evolutionary time.",
      "UCEs are defined as regions of at least 200 nucleotides in length.",
      "UCEs are at least 100 times more conserved than the average genomic sequence.",
      "Copy number variants (CNVs) are variations in the number of copies of a particular genomic region.",
      "CNVs can arise through mechanisms such as duplications, deletions, and translocations."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Ultraconserved elements (UCEs) are typically defined as regions of at least 200 base pairs in length that are identical in humans, rats, and mice.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "You MUST give a detailed answer to the following question: Which is the substrate of the haspin kinase during mitosis?",
    "llama-7b_response": "The haspin kinase is a serine/threonine kinase that plays a critical role in mitosis, the process by which cells divide and produce daughter cells. During mitosis, the haspin kinase is activated and phosphorylates a number of proteins, including tubulin, which is a key component of the mitotic spindle.\n\nThe substrate of the haspin kinase during mitosis is not a specific molecule or compound, but rather a wide range of proteins and other molecules that are phosphorylated by the enzyme. These include proteins involved in the regulation of cell division, such as cyclin-dependent kinases (CDKs), as well as proteins involved in the formation and maintenance of the mitotic spindle, such as tubulin.\n\nThe specific substrates of the haspin kinase during mitosis can vary depending on the stage of the cell cycle and the cell's needs. For example, during interphase, when the cell is not dividing, the haspin kinase may phosphorylate proteins involved in the regulation of gene expression and other cellular processes. During mitosis, however, the haspin kinase is primarily focused on phosphorylating proteins involved in the formation and maintenance of the mitotic spindle.\n\nOverall, the substrate of the haspin kinase during mitosis is a wide range of proteins and other molecules that are phosphorylated by the enzyme, and the specific substrates can vary depending on the stage of the cell cycle.",
    "llama-7b_fact_raw": "1. The haspin kinase is a serine/threonine kinase.\n2. Haspin kinase plays a critical role in mitosis.\n3. During mitosis, haspin kinase phosphorylates a number of proteins, including tubulin.\n4. Tubulin is a key component of the mitotic spindle.\n5. The substrates of haspin kinase can vary depending on the stage of the cell cycle.",
    "llama-7b_fact": [
      "The haspin kinase is a serine/threonine kinase.",
      "Haspin kinase plays a critical role in mitosis.",
      "During mitosis, haspin kinase phosphorylates a number of proteins, including tubulin.",
      "Tubulin is a key component of the mitotic spindle.",
      "The substrates of haspin kinase can vary depending on the stage of the cell cycle."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: During mitosis, haspin kinase is known to phosphorylate histone H3 at threonine 3 (H3T3ph), not tubulin.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "You MUST give a detailed answer to the following question: What is the mechanism of viroid replication?",
    "llama-7b_response": "Viroids are small infectious non-coding RNAs that replicate in the cytoplasm of host cells without the need for a complementary DNA template. The mechanism of viroid replication is different from that of viruses, which require a complementary DNA template to replicate.\n\nViroid replication begins when a viroid particle enters a host cell. The viroid particle is then endocytosed into the host cell and transported to the endoplasmic reticulum (ER). In the ER, the viroid particle is degraded into smaller fragments, which are then transported to the cis-Golgi apparatus.\n\nIn the cis-Golgi apparatus, the viroid fragments are reassembled into intact viroid particles. The reassembled viroid particles are then transported to the plasma membrane of the host cell, where they are released into the extracellular environment.\n\nOnce in the extracellular environment, the viroid particles can infect other host cells. The mechanism of viroid replication is not well understood, and further research is needed to fully understand the process.",
    "llama-7b_fact_raw": "1. Viroids are small infectious non-coding RNAs that replicate in the cytoplasm of host cells.\n2. Viroids replicate without the need for a complementary DNA template.\n3. The replication process of viroids begins with the entry of a viroid particle into a host cell.\n4. Viroid particles are transported to the endoplasmic reticulum and the cis-Golgi apparatus during replication.\n5. Reassembled viroid particles are released into the extracellular environment where they can infect other host cells.",
    "llama-7b_fact": [
      "Viroids are small infectious non-coding RNAs that replicate in the cytoplasm of host cells.",
      "Viroids replicate without the need for a complementary DNA template.",
      "The replication process of viroids begins with the entry of a viroid particle into a host cell.",
      "Viroid particles are transported to the endoplasmic reticulum and the cis-Golgi apparatus during replication.",
      "Reassembled viroid particles are released into the extracellular environment where they can infect other host cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Viroids typically replicate in the nucleus or chloroplast of host cells, not the endoplasmic reticulum or the cis-Golgi apparatus.\n5. FALSE [correction]: Viroids do not form particles; they are naked RNA and do not get released into the extracellular environment like viruses. Instead, they spread to other cells through cell-to-cell contact or mechanical means.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1723,
    "user_query": "You MUST give a detailed answer to the following question: Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-7b_response": "Fibronectin is a protein that is present in the extracellular matrix of many tissues and plays a role in cell-matrix interactions. It has been suggested that fibronectin may be a potential serum biomarker for Duchenne muscular dystrophy (DMD), a genetic disorder that causes progressive muscle degeneration and weakness.\n\nStudies have shown that fibronectin levels are increased in the serum of patients with DMD compared to healthy controls. This increase in fibronectin levels has been observed in both muscle biopsies and serum samples from patients with DMD.\n\nFurthermore, studies have also shown that fibronectin levels are increased in the serum of patients with other forms of muscular dystrophy, such as Becker muscular dystrophy (BMD) and limb-girdle muscular dystrophy (LGMD), which suggests that fibronectin may be a general marker for muscular dystrophy.\n\nHowever, it is worth noting that the relationship between fibronectin levels and muscular dystrophy is complex and not fully understood. Other factors, such as inflammation and fibrosis, may also contribute to the increase in fibronectin levels in the serum of patients with muscular dystrophy.\n\nIn conclusion, while fibronectin has been suggested as a potential serum biomarker for Duchenne muscular dystrophy, further research is needed to fully understand the relationship between fibronectin and muscular dystrophy.",
    "llama-7b_fact_raw": "1. Fibronectin is a protein present in the extracellular matrix of many tissues.\n2. Fibronectin may be a potential serum biomarker for Duchenne muscular dystrophy (DMD).\n3. Studies have indicated that fibronectin levels are increased in the serum of patients with DMD compared to healthy controls.\n4. Increased fibronectin levels have been observed in muscle biopsies and serum samples from patients with DMD.\n5. Fibronectin levels are also increased in the serum of patients with other forms of muscular dystrophy, such as Becker muscular dystrophy (BMD) and limb-girdle muscular dystrophy (LGMD).",
    "llama-7b_fact": [
      "Fibronectin is a protein present in the extracellular matrix of many tissues.",
      "Fibronectin may be a potential serum biomarker for Duchenne muscular dystrophy (DMD).",
      "Studies have indicated that fibronectin levels are increased in the serum of patients with DMD compared to healthy controls.",
      "Increased fibronectin levels have been observed in muscle biopsies and serum samples from patients with DMD.",
      "Fibronectin levels are also increased in the serum of patients with other forms of muscular dystrophy, such as Becker muscular dystrophy (BMD) and limb-girdle muscular dystrophy (LGMD)."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nFibronectin is indeed a protein present in the extracellular matrix, and it has been studied as a potential biomarker for various diseases, including Duchenne muscular dystrophy. Studies have shown that fibronectin levels can be elevated in the serum of patients with DMD and other forms of muscular dystrophy, which is consistent with the statements provided.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "You MUST give a detailed answer to the following question: Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-7b_response": "The DeepBlue epigenomic data server contains data from several major epigenome projects, including:\n\n1. The Encyclopedia of DNA Elements (ENCODE) project, which aims to identify and characterize all functional elements in the human genome, including regulatory elements such as enhancers and silencers.\n2. The Roadmap Epigenomics Project, which aims to create a comprehensive resource of epigenomic data for a variety of human tissues and cell types.\n3. The Epigenome Roadmap Project, which aims to create a comprehensive resource of epigenomic data for a variety of model organisms, including mouse and human.\n4. The 1000 Genomes Project, which aims to create a comprehensive resource of genomic data for a variety of human populations, including data on DNA methylation and other epigenetic marks.\n\nThese projects have generated a large amount of data on DNA methylation, histone modifications, and other epigenetic marks, which is available through the DeepBlue epigenomic data server.",
    "llama-7b_fact_raw": "1. The DeepBlue epigenomic data server contains data from the Encyclopedia of DNA Elements (ENCODE) project.\n2. The Roadmap Epigenomics Project's data is included in the DeepBlue epigenomic data server.\n3. Data from the Epigenome Roadmap Project for model organisms is available on the DeepBlue epigenomic data server.\n4. The DeepBlue epigenomic data server includes data from the 1000 Genomes Project.\n5. The DeepBlue epigenomic data server provides access to data on DNA methylation, histone modifications, and other epigenetic marks.",
    "llama-7b_fact": [
      "The DeepBlue epigenomic data server contains data from the Encyclopedia of DNA Elements (ENCODE) project.",
      "The Roadmap Epigenomics Project's data is included in the DeepBlue epigenomic data server.",
      "Data from the Epigenome Roadmap Project for model organisms is available on the DeepBlue epigenomic data server.",
      "The DeepBlue epigenomic data server includes data from the 1000 Genomes Project.",
      "The DeepBlue epigenomic data server provides access to data on DNA methylation, histone modifications, and other epigenetic marks."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The Roadmap Epigenomics Project focuses on human data, not model organisms.\n4. FALSE [correction]: The 1000 Genomes Project is a separate project focused on human genetic variation and is not specifically an epigenomic data server like DeepBlue.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1792,
    "user_query": "You MUST give a detailed answer to the following question: Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-7b_response": "One tool that employs self-organizing maps (SOMs) for analyzing synonymous codon usage is the program CodonOptimizer.\n\nCodonOptimizer is a bioinformatics tool that uses SOMs to analyze synonymous codon usage and identify optimal codon usage patterns for a given gene or set of genes. SOMs are a type of artificial neural network that can be used to map high-dimensional input data onto a lower-dimensional map, allowing for the visualization and analysis of complex patterns and relationships.\n\nIn the case of CodonOptimizer, the tool uses SOMs to analyze the codon usage patterns of a given gene or set of genes and identify patterns of codon usage that are optimal for a given host organism. The tool can then use this information to generate optimized codon usage tables that can be used to improve the efficiency and accuracy of gene expression in the host organism.\n\nOverall, CodonOptimizer is a useful tool for analyzing synonymous codon usage and identifying optimal codon usage patterns for a given gene or set of genes. Its use of SOMs allows for the visualization and analysis of complex patterns and relationships in the data, and can help to improve the efficiency and accuracy of gene expression in the host organism.",
    "llama-7b_fact_raw": "1. CodonOptimizer is a bioinformatics tool that employs self-organizing maps (SOMs) for analyzing synonymous codon usage.\n2. Self-organizing maps are a type of artificial neural network used in CodonOptimizer.\n3. CodonOptimizer uses SOMs to identify optimal codon usage patterns for a given gene or set of genes.\n4. CodonOptimizer can generate optimized codon usage tables to improve gene expression efficiency and accuracy in a host organism.\n5. The tool helps in the visualization and analysis of complex patterns and relationships in codon usage data.",
    "llama-7b_fact": [
      "CodonOptimizer is a bioinformatics tool that employs self-organizing maps (SOMs) for analyzing synonymous codon usage.",
      "Self-organizing maps are a type of artificial neural network used in CodonOptimizer.",
      "CodonOptimizer uses SOMs to identify optimal codon usage patterns for a given gene or set of genes.",
      "CodonOptimizer can generate optimized codon usage tables to improve gene expression efficiency and accuracy in a host organism.",
      "The tool helps in the visualization and analysis of complex patterns and relationships in codon usage data."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nThe statements about CodonOptimizer are specific to a particular bioinformatics tool, and without additional context or information about this specific tool, it's difficult to verify the accuracy of statements 1, 3, and 4. However, statement 2 is a general statement about self-organizing maps (SOMs) being a type of artificial neural network, which is true. Statement 5 is also generally true for tools that analyze codon usage, as they often help in visualization and analysis of complex patterns in the data.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1793,
    "user_query": "You MUST give a detailed answer to the following question: What is MINDY-1?",
    "llama-7b_response": "I'm sorry, but I am not familiar with any technology or device called \"MINDY-1.\" Can you provide more context or information about what you are referring to?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1810,
    "user_query": "You MUST give a detailed answer to the following question: Which software package is available for the analysis of conserved genomic loci?",
    "llama-7b_response": "There are several software packages available for the analysis of conserved genomic loci. Some of the most commonly used ones include:\n\n1. BLAST: BLAST (Basic Local Alignment Search Tool) is a widely used software tool for comparing nucleotide or protein sequences to a reference database. It can be used to identify regions of the genome that are highly conserved across different species.\n2. MEGA: MEGA (Molecular Evolutionary Genetics Analysis) is a software package for the analysis of molecular evolution. It can be used to perform phylogenetic analysis, identify conserved regions of the genome, and perform other molecular evolutionary analyses.\n3. PHYLIP: PHYLIP (Phylogeny Inference Package) is a software package for the analysis of phylogenetic trees. It can be used to construct phylogenetic trees based on conserved genomic loci and to perform other phylogenetic analyses.\n4. GENEious: GENEious is a software package for the analysis of gene expression data. It can be used to identify conserved regions of the genome that are associated with gene expression, and to perform other analyses of gene expression data.\n\nThese are just a few examples of the many software packages that are available for the analysis of conserved genomic loci. The choice of software package will depend on the specific goals of the analysis and the type of data that is available.",
    "llama-7b_fact_raw": "1. BLAST (Basic Local Alignment Search Tool) is used for comparing nucleotide or protein sequences to a reference database.\n2. MEGA (Molecular Evolutionary Genetics Analysis) is a software package for the analysis of molecular evolution.\n3. PHYLIP (Phylogeny Inference Package) is a software package for the analysis of phylogenetic trees.\n4. GENEious is a software package for the analysis of gene expression data.\n5. BLAST, MEGA, PHYLIP, and GENEious can be used to identify regions of the genome that are highly conserved across different species.",
    "llama-7b_fact": [
      "BLAST (Basic Local Alignment Search Tool) is used for comparing nucleotide or protein sequences to a reference database.",
      "MEGA (Molecular Evolutionary Genetics Analysis) is a software package for the analysis of molecular evolution.",
      "PHYLIP (Phylogeny Inference Package) is a software package for the analysis of phylogenetic trees.",
      "GENEious is a software package for the analysis of gene expression data.",
      "BLAST, MEGA, PHYLIP, and GENEious can be used to identify regions of the genome that are highly conserved across different species."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: GENEious is a software package for bioinformatics, including sequence alignment, molecular cloning, phylogenetics, and sequence analysis, but not specifically for the analysis of gene expression data.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1860,
    "user_query": "You MUST give a detailed answer to the following question: Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-7b_response": "Sure, here are three diseases associated with the PIEZO2 gene:\n\n1. Hereditary hemorrhagic telangiectasia (HHT): HHT is a genetic disorder that affects blood vessels, causing them to be abnormally fragile and prone to bleeding. The PIEZO2 gene has been implicated in the development of HHT, and mutations in this gene can increase the risk of developing the condition.\n2. Ehlers-Danlos syndrome (EDS): EDS is a group of genetic disorders that affect the connective tissues in the body, including the skin, joints, and blood vessels. The PIEZO2 gene has been implicated in the development of EDS, and mutations in this gene can increase the risk of developing the condition.\n3. Stickler syndrome: Stickler syndrome is a genetic disorder that affects the connective tissues in the body, including the eyes, joints, and bones. The PIEZO2 gene has been implicated in the development of Stickler syndrome, and mutations in this gene can increase the risk of developing the condition.",
    "llama-7b_fact_raw": "1. Hereditary hemorrhagic telangiectasia (HHT) is associated with the PIEZO2 gene.\n2. Ehlers-Danlos syndrome (EDS) is associated with the PIEZO2 gene.\n3. Stickler syndrome is associated with the PIEZO2 gene.",
    "llama-7b_fact": [
      "Hereditary hemorrhagic telangiectasia (HHT) is associated with the PIEZO2 gene.",
      "Ehlers-Danlos syndrome (EDS) is associated with the PIEZO2 gene.",
      "Stickler syndrome is associated with the PIEZO2 gene."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Hereditary hemorrhagic telangiectasia (HHT) is associated with several genes, including ENG, ACVRL1, and SMAD4, but not specifically with the PIEZO2 gene.\n2. FALSE [correction]: Ehlers-Danlos syndrome (EDS) is associated with several genes related to collagen synthesis, such as COL5A1, COL5A2, and COL3A1, among others, but not specifically with the PIEZO2 gene.\n3. FALSE [correction]: Stickler syndrome is associated with genes that affect collagen formation, such as COL2A1, COL11A1, and COL11A2, but not specifically with the PIEZO2 gene.",
    "llama-7b_judge": [
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1867,
    "user_query": "You MUST give a detailed answer to the following question: What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-7b_response": "ERAP1 and ERAP2 are two members of the ER-associated degradation (ERAD) pathway, which is responsible for the recognition and removal of misfolded or damaged proteins from the endoplasmic reticulum (ER) in eukaryotic cells. The dimerization of ERAP1 and ERAP2 is an important step in the ERAD pathway, as it allows the two proteins to form a stable complex that can recognize and bind to misfolded proteins.\n\nThe ERAP1-ERAP2 dimerization promotes the recognition of misfolded proteins in several ways:\n\n1. Enhanced binding affinity: The dimerization of ERAP1 and ERAP2 leads to an increase in the binding affinity of the two proteins for misfolded proteins, allowing them to recognize and bind to a wider range of misfolded proteins.\n2. Increased specificity: The dimerization of ERAP1 and ERAP2 leads to an increase in the specificity of the ERAD pathway, as the two proteins can recognize and bind to a wider range of misfolded proteins.\n3. Improved efficiency: The dimerization of ERAP1 and ERAP2 leads to an increase in the efficiency of the ERAD pathway, as the two proteins can recognize and bind to a wider range of misfolded proteins.\n\nOverall, the ERAP1-ERAP2 dimerization is an important step in the ERAD pathway, as it allows the two proteins to form a stable complex that can recognize and bind to a wider range of misfolded proteins, improving the efficiency and specificity of the pathway.",
    "llama-7b_fact_raw": "1. ERAP1 and ERAP2 are members of the ER-associated degradation (ERAD) pathway.\n2. The ERAD pathway is responsible for the recognition and removal of misfolded or damaged proteins from the endoplasmic reticulum in eukaryotic cells.\n3. Dimerization of ERAP1 and ERAP2 forms a stable complex.\n4. The dimerization of ERAP1 and ERAP2 increases the binding affinity for misfolded proteins.\n5. The dimerization of ERAP1 and ERAP2 enhances the specificity and efficiency of the ERAD pathway.",
    "llama-7b_fact": [
      "ERAP1 and ERAP2 are members of the ER-associated degradation (ERAD) pathway.",
      "The ERAD pathway is responsible for the recognition and removal of misfolded or damaged proteins from the endoplasmic reticulum in eukaryotic cells.",
      "Dimerization of ERAP1 and ERAP2 forms a stable complex.",
      "The dimerization of ERAP1 and ERAP2 increases the binding affinity for misfolded proteins.",
      "The dimerization of ERAP1 and ERAP2 enhances the specificity and efficiency of the ERAD pathway."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: ERAP1 and ERAP2 are not members of the ER-associated degradation (ERAD) pathway. They are aminopeptidases involved in trimming peptides for presentation by MHC class I molecules.\n2. TRUE: The ERAD pathway is indeed responsible for the recognition and removal of misfolded or damaged proteins from the endoplasmic reticulum in eukaryotic cells.\n3. UNKNOWN: The statement about the dimerization of ERAP1 and ERAP2 forming a stable complex is specific and would require scientific evidence to confirm or refute.\n4. UNKNOWN: The effect of dimerization of ERAP1 and ERAP2 on the binding affinity for misfolded proteins is a detailed biochemical property that would need to be verified by scientific research.\n5. UNKNOWN: The statement regarding the enhancement of specificity and efficiency of the ERAD pathway due to the dimerization of ERAP1 and ERAP2 is also specific and would require scientific evidence to support it.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1890,
    "user_query": "You MUST give a detailed answer to the following question: What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-7b_response": "R-spondin 1 and noggin are both proteins that play important roles in the development and maintenance of various tissues, including the gallbladder.\n\nR-spondin 1 is a member of the R-spondin family of proteins, which are secreted by cells and bind to specific receptors on the surface of other cells to regulate various physiological processes. In the case of the gallbladder, R-spondin 1 has been shown to play a role in the development and maturation of the epithelial cells that line the gallbladder. Specifically, R-spondin 1 has been shown to promote the proliferation and differentiation of these cells, which is important for the normal development of the gallbladder.\n\nNoggin, on the other hand, is a protein that is known to inhibit the activity of bone morphogenetic proteins (BMPs), which are signaling molecules that play a role in the development and maintenance of various tissues. In the gallbladder, noggin has been shown to inhibit the activity of BMPs, which may help to maintain the normal structure and function of the epithelial cells that line the gallbladder.\n\nIn summary, R-spondin 1 and noggin play important roles in the development and maintenance of the gallbladder. R-spondin 1 promotes the proliferation and differentiation of the epithelial cells that line the gallbladder, while noggin inhibits the activity of BMPs, which may help to maintain the normal structure and function of these cells.",
    "llama-7b_fact_raw": "1. R-spondin 1 is involved in the development and maturation of epithelial cells that line the gallbladder.\n2. R-spondin 1 promotes the proliferation and differentiation of gallbladder epithelial cells.\n3. Noggin is a protein that inhibits the activity of bone morphogenetic proteins (BMPs).\n4. Noggin's inhibition of BMPs may help maintain the normal structure and function of epithelial cells in the gallbladder.",
    "llama-7b_fact": [
      "R-spondin 1 is involved in the development and maturation of epithelial cells that line the gallbladder.",
      "R-spondin 1 promotes the proliferation and differentiation of gallbladder epithelial cells.",
      "Noggin is a protein that inhibits the activity of bone morphogenetic proteins (BMPs).",
      "Noggin's inhibition of BMPs may help maintain the normal structure and function of epithelial cells in the gallbladder."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "You MUST give a detailed answer to the following question: Does NADPH oxidase 5 require any subunit for function?",
    "llama-7b_response": "Yes, NADPH oxidase 5 (NOX5) requires multiple subunits for its function. NOX5 is a member of the NADPH oxidase family, which is a group of enzymes that generate reactive oxygen species (ROS) from NADPH.\n\nNOX5 is composed of two structural subunits, p22phox and p40phox, and three accessory subunits, gp91phox, p67phox, and p47phox. The p22phox and p40phox subunits are required for the enzymatic activity of NOX5, while the gp91phox, p67phox, and p47phox subunits play important roles in the regulation and localization of NOX5.\n\nThe gp91phox subunit is involved in the recruitment of NOX5 to the plasma membrane, while the p67phox and p47phox subunits are required for the assembly of NOX5 into a functional enzyme complex. The p47phox subunit also plays a role in the regulation of NOX5 activity by interacting with the p22phox and p40phox subunits.\n\nThe absence of any of these subunits results in a loss of NOX5 activity, indicating that these subunits are required for the function of NOX5. Therefore, the answer to the question is \"Yes, NADPH oxidase 5 requires multiple subunits for its function.\"",
    "llama-7b_fact_raw": "1. NADPH oxidase 5 (NOX5) requires multiple subunits for its function.\n2. NOX5 is composed of two structural subunits, p22phox and p40phox.\n3. NOX5 has three accessory subunits: gp91phox, p67phox, and p47phox.\n4. The gp91phox subunit is involved in the recruitment of NOX5 to the plasma membrane.\n5. The absence of any of the subunits p22phox, p40phox, gp91phox, p67phox, or p47phox results in a loss of NOX5 activity.",
    "llama-7b_fact": [
      "NADPH oxidase 5 (NOX5) requires multiple subunits for its function.",
      "NOX5 is composed of two structural subunits, p22phox and p40phox.",
      "NOX5 has three accessory subunits: gp91phox, p67phox, and p47phox.",
      "The gp91phox subunit is involved in the recruitment of NOX5 to the plasma membrane.",
      "The absence of any of the subunits p22phox, p40phox, gp91phox, p67phox, or p47phox results in a loss of NOX5 activity."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) is unique among NOX isoforms because it does not require p22phox or other subunits for its function; it is a calcium-dependent enzyme that functions independently.\n2. FALSE [correction]: NOX5 does not require p22phox and p40phox as structural subunits; it is a single polypeptide enzyme.\n3. FALSE [correction]: The accessory subunits gp91phox, p67phox, and p47phox are associated with NOX2, not NOX5.\n4. FALSE [correction]: The gp91phox subunit is associated with NOX2 and not involved in the recruitment of NOX5 to the plasma membrane.\n5. FALSE [correction]: The absence of subunits p22phox, p40phox, gp91phox, p67phox, or p47phox does not affect NOX5 activity since NOX5 does not require these subunits to function.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1944,
    "user_query": "You MUST give a detailed answer to the following question: What is the connection between furin and hepcidin?",
    "llama-7b_response": "Furin and hepcidin are two different proteins that have distinct functions in the body.\n\nFurin is an enzyme that plays a role in the post-translational modification of other proteins. Specifically, it cleaves specific peptide bonds in other proteins, resulting in the formation of new peptides or proteins with different functions. Furin has been implicated in a variety of biological processes, including cell growth and differentiation, angiogenesis, and inflammation.\n\nHepcidin, on the other hand, is a hormone that plays a key role in regulating iron metabolism in the body. It is produced by hepatocytes in the liver and is released into the bloodstream, where it binds to iron and inhibits the absorption of iron from the gut. Hepcidin also regulates the storage of iron in various tissues, such as the liver and spleen.\n\nThe connection between furin and hepcidin is that both proteins are involved in iron metabolism. Furin has been shown to play a role in the regulation of hepcidin expression and activity. For example, studies have shown that furin can cleave a specific peptide within the hepcidin mRNA, leading to the production of a shorter, less active form of hepcidin. Conversely, hepcidin has been shown to inhibit the activity of furin, suggesting that the two proteins may interact in a feedback loop to regulate iron metabolism.\n\nOverall, while furin and hepcidin are two distinct proteins, they are both involved in the regulation of iron metabolism and have important roles in maintaining iron homeostasis in the body.",
    "llama-7b_fact_raw": "1. Furin is an enzyme that plays a role in the post-translational modification of proteins by cleaving specific peptide bonds.\n2. Hepcidin is a hormone produced by hepatocytes in the liver that regulates iron metabolism.\n3. Hepcidin binds to iron and inhibits the absorption of iron from the gut.\n4. Furin has been shown to play a role in the regulation of hepcidin expression and activity.\n5. Studies have indicated that furin can cleave a specific peptide within the hepcidin mRNA, leading to the production of a shorter, less active form of hepcidin.",
    "llama-7b_fact": [
      "Furin is an enzyme that plays a role in the post-translational modification of proteins by cleaving specific peptide bonds.",
      "Hepcidin is a hormone produced by hepatocytes in the liver that regulates iron metabolism.",
      "Hepcidin binds to iron and inhibits the absorption of iron from the gut.",
      "Furin has been shown to play a role in the regulation of hepcidin expression and activity.",
      "Studies have indicated that furin can cleave a specific peptide within the hepcidin mRNA, leading to the production of a shorter, less active form of hepcidin."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Hepcidin does not bind to iron directly; it regulates iron metabolism by binding to the iron exporter ferroportin, causing its internalization and degradation, which in turn inhibits the absorption of iron from the gut.\n4. TRUE\n5. FALSE [correction]: Furin is known to cleave specific peptide bonds in proteins, not within mRNA. The statement about furin cleaving hepcidin mRNA is incorrect; furin's role would involve the processing of the hepcidin precursor protein, not its mRNA.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1956,
    "user_query": "You MUST give a detailed answer to the following question: Which is the largest metabolic gene cluster in yeast?",
    "llama-7b_response": "The largest metabolic gene cluster in yeast is the pentose phosphate pathway (PPP). The PPP is a metabolic pathway that converts glucose, glyceraldehyde-3-phosphate (G3P), and pyruvate into ribose-5-phosphate and glyceraldehyde-3-phosphate, which are used in the synthesis of nucleic acids and other biomolecules. The PPP is composed of a series of enzymes that work together to convert glucose into ribose-5-phosphate and glyceraldehyde-3-phosphate. The PPP is one of the largest metabolic pathways in yeast, and it plays a crucial role in the synthesis of nucleic acids and other biomolecules.\n\nThe PPP is composed of several genes that are located on different chromosomes in the yeast genome. The genes that encode the enzymes of the PPP are clustered together in a region of the yeast genome that is known as the \"PPP region.\" The PPP region is one of the largest metabolic gene clusters in yeast, and it contains many genes that are involved in the synthesis of nucleic acids and other biomolecules.\n\nThe PPP region is composed of several genes that are involved in the synthesis of nucleic acids and other biomolecules. The genes that encode the enzymes of the PPP are clustered together in a region of the yeast genome that is known as the \"PPP region.\" The PPP region is one of the largest metabolic gene clusters in yeast, and it contains many genes that are involved in the synthesis of nucleic acids and other biomolecules.\n\nThe PPP region is composed of several genes that are involved in the synthesis of nucleic acids and other biomolecules. The genes that encode the enzymes of the PPP are clustered together in a region of the yeast genome that is known as the \"PPP region.\" The PPP region is one of the largest metabolic gene clusters in yeast, and it contains many genes that are involved in the synthesis of nucleic acids and other bi",
    "llama-7b_fact_raw": "1. The largest metabolic gene cluster in yeast is the pentose phosphate pathway (PPP).\n2. The PPP converts glucose, glyceraldehyde-3-phosphate (G3P), and pyruvate into ribose-5-phosphate and glyceraldehyde-3-phosphate.\n3. The PPP is involved in the synthesis of nucleic acids and other biomolecules.\n4. The genes encoding the enzymes of the PPP are clustered together in a region of the yeast genome known as the \"PPP region.\"\n5. The PPP region contains many genes that are involved in the synthesis of nucleic acids and other biomolecules.",
    "llama-7b_fact": [
      "The largest metabolic gene cluster in yeast is the pentose phosphate pathway (PPP).",
      "The PPP converts glucose, glyceraldehyde-3-phosphate (G3P), and pyruvate into ribose-5-phosphate and glyceraldehyde-3-phosphate.",
      "The PPP is involved in the synthesis of nucleic acids and other biomolecules.",
      "The genes encoding the enzymes of the PPP are clustered together in a region of the yeast genome known as the \"PPP region.\"",
      "The PPP region contains many genes that are involved in the synthesis of nucleic acids and other biomolecules."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The largest metabolic gene cluster in yeast is not necessarily the pentose phosphate pathway (PPP). The term \"largest\" is vague without specific context, and metabolic gene clusters can vary in size depending on the organism and the specific genes included.\n2. FALSE [correction]: The PPP converts glucose-6-phosphate into ribose-5-phosphate and NADPH; glyceraldehyde-3-phosphate and pyruvate are not direct products of the PPP.\n3. TRUE\n4. FALSE [correction]: In yeast, genes encoding enzymes for a specific metabolic pathway are not typically clustered together in a specific region named after that pathway. Gene organization can be more scattered in eukaryotic genomes like that of yeast.\n5. FALSE [correction]: While the PPP is involved in the synthesis of nucleic acids and other biomolecules, there is no specific \"PPP region\" in the yeast genome that contains many genes involved in these processes. The statement is based on a misunderstanding of yeast genome organization.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1967,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of LIMT lncRNA?",
    "llama-7b_response": "The LIMT lncRNA (long non-coding RNA) is a non-coding RNA molecule that has been implicated in various biological processes, including cell differentiation, proliferation, and apoptosis. However, the precise role of LIMT lncRNA in these processes is not yet fully understood.\n\nRecent studies have suggested that LIMT lncRNA may play a role in regulating gene expression at the transcriptional level. For example, LIMT lncRNA has been shown to interact with transcription factors and modulate their activity, leading to changes in the expression of downstream target genes.\n\nAdditionally, LIMT lncRNA has been implicated in the regulation of cell proliferation and apoptosis. For example, overexpression of LIMT lncRNA has been shown to promote cell proliferation and inhibit apoptosis, while knockdown of LIMT lncRNA has been shown to inhibit cell proliferation and promote apoptosis.\n\nDespite these findings, the precise mechanisms by which LIMT lncRNA regulates gene expression and cellular processes are not yet fully understood. Further research is needed to elucidate the role of LIMT lncRNA in various biological processes and to determine its potential as a therapeutic target for various diseases.",
    "llama-7b_fact_raw": "1. LIMT lncRNA is a long non-coding RNA molecule.\n2. LIMT lncRNA has been implicated in cell differentiation, proliferation, and apoptosis.\n3. LIMT lncRNA may regulate gene expression at the transcriptional level.\n4. Overexpression of LIMT lncRNA has been shown to promote cell proliferation and inhibit apoptosis.\n5. Knockdown of LIMT lncRNA has been shown to inhibit cell proliferation and promote apoptosis.",
    "llama-7b_fact": [
      "LIMT lncRNA is a long non-coding RNA molecule.",
      "LIMT lncRNA has been implicated in cell differentiation, proliferation, and apoptosis.",
      "LIMT lncRNA may regulate gene expression at the transcriptional level.",
      "Overexpression of LIMT lncRNA has been shown to promote cell proliferation and inhibit apoptosis.",
      "Knockdown of LIMT lncRNA has been shown to inhibit cell proliferation and promote apoptosis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Overexpression of LIMT lncRNA has been shown to inhibit cell proliferation and promote apoptosis.\n5. FALSE [correction]: Knockdown of LIMT lncRNA has been shown to promote cell proliferation and inhibit apoptosis.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1984,
    "user_query": "You MUST give a detailed answer to the following question: Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-7b_response": "The R/Bioconductor package used for performing SNP enrichment analysis is called \"GREAT\".",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2015,
    "user_query": "You MUST give a detailed answer to the following question: Which are the key players on radial glial specification to ependymal cells?",
    "llama-7b_response": "Radial glial cells are a type of glial cell that play a crucial role in the development of the central nervous system, including the formation of the ependymal cells that line the ventricles of the brain. The process of radial glial specification to ependymal cells involves several key players and signaling pathways.\n\nOne of the key players in the specification of radial glial cells to ependymal cells is the Sonic hedgehog (Shh) signaling pathway. Shh is a protein that is expressed in the ventricular zone of the developing brain, where radial glial cells arise. Shh signaling promotes the proliferation and differentiation of radial glial cells into ependymal cells.\n\nAnother key player in the specification of radial glial cells to ependymal cells is the Bone Morphogenetic Protein (BMP) signaling pathway. BMP signaling inhibits the proliferation of radial glial cells and promotes their differentiation into ependymal cells.\n\nIn addition to Shh and BMP signaling, other signaling pathways, such as Wnt and Notch, also play a role in the specification of radial glial cells to ependymal cells. For example, Wnt signaling promotes the proliferation of radial glial cells, while Notch signaling inhibits their proliferation and promotes their differentiation into ependymal cells.\n\nOverall, the specification of radial glial cells to ependymal cells involves a complex interplay between several key players, including Shh, BMP, Wnt, and Notch signaling pathways. These signaling pathways work together to regulate the proliferation and differentiation of radial glial cells, ultimately leading to the formation of ependymal cells that line the ventricles of the brain.",
    "llama-7b_fact_raw": "1. Radial glial cells are involved in the development of the central nervous system and the formation of ependymal cells.\n2. The Sonic hedgehog (Shh) signaling pathway is a key player in the specification of radial glial cells to ependymal cells.\n3. Bone Morphogenetic Protein (BMP) signaling pathway inhibits the proliferation of radial glial cells and promotes their differentiation into ependymal cells.\n4. Wnt signaling promotes the proliferation of radial glial cells.\n5. Notch signaling inhibits the proliferation of radial glial cells and promotes their differentiation into ependymal cells.",
    "llama-7b_fact": [
      "Radial glial cells are involved in the development of the central nervous system and the formation of ependymal cells.",
      "The Sonic hedgehog (Shh) signaling pathway is a key player in the specification of radial glial cells to ependymal cells.",
      "Bone Morphogenetic Protein (BMP) signaling pathway inhibits the proliferation of radial glial cells and promotes their differentiation into ependymal cells.",
      "Wnt signaling promotes the proliferation of radial glial cells.",
      "Notch signaling inhibits the proliferation of radial glial cells and promotes their differentiation into ependymal cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Notch signaling promotes the proliferation of radial glial cells and maintains their undifferentiated state, rather than inhibiting their proliferation.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2065,
    "user_query": "You MUST give a detailed answer to the following question: How are triple negative gliomas characterized?",
    "llama-7b_response": "Triple-negative breast cancer (TNBC) is a type of breast cancer that does not express estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). TNBC accounts for approximately 15-20% of all breast cancers and is more aggressive and difficult to treat than other types of breast cancer.\n\nTNBC is characterized by the absence of three key receptors on the surface of cancer cells: estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). The absence of these receptors makes TNBC resistant to hormonal therapies and targeted therapies that are commonly used to treat other types of breast cancer.\n\nTNBC is also characterized by the presence of certain genetic mutations, such as mutations in the BRCA1 and BRCA2 genes, which increase the risk of developing TNBC. Additionally, TNBC is often characterized by the presence of a specific pattern of gene expression, known as the basal-like subtype, which is associated with a particularly aggressive form of the disease.\n\nTNBC is typically diagnosed through a combination of imaging tests, such as mammography and ultrasound, and biopsy. Once diagnosed, TNBC is typically treated with a combination of chemotherapy, targeted therapies, and radiation therapy.",
    "llama-7b_fact_raw": "1. Triple-negative breast cancer (TNBC) does not express estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2).\n2. TNBC accounts for approximately 15-20% of all breast cancers.\n3. TNBC is more aggressive and difficult to treat than other types of breast cancer.\n4. Certain genetic mutations, such as mutations in the BRCA1 and BRCA2 genes, are associated with an increased risk of developing TNBC.\n5. The basal-like subtype is a specific pattern of gene expression associated with TNBC and is linked to a particularly aggressive form of the disease.",
    "llama-7b_fact": [
      "Triple-negative breast cancer (TNBC) does not express estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2).",
      "TNBC accounts for approximately 15-20% of all breast cancers.",
      "TNBC is more aggressive and difficult to treat than other types of breast cancer.",
      "Certain genetic mutations, such as mutations in the BRCA1 and BRCA2 genes, are associated with an increased risk of developing TNBC.",
      "The basal-like subtype is a specific pattern of gene expression associated with TNBC and is linked to a particularly aggressive form of the disease."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "You MUST give a detailed answer to the following question: What is TOPAZ1?",
    "llama-7b_response": "TOPAZ1 is a cryptographic algorithm used for encrypting and decrypting data. It is a stream cipher that uses a linear feedback shift register (LFSR) to generate a pseudorandom sequence of bits, which are then used to encrypt or decrypt the data. TOPAZ1 was developed by the National Security Agency (NSA) and is considered to be a strong encryption algorithm. It is often used in conjunction with other encryption algorithms to provide additional security.",
    "llama-7b_fact_raw": "1. TOPAZ1 is a cryptographic algorithm designed for encrypting and decrypting data.\n2. TOPAZ1 is a stream cipher.\n3. TOPAZ1 uses a linear feedback shift register (LFSR) to generate a pseudorandom sequence of bits.\n4. The National Security Agency (NSA) developed TOPAZ1.\n5. TOPAZ1 is considered to be a strong encryption algorithm.",
    "llama-7b_fact": [
      "TOPAZ1 is a cryptographic algorithm designed for encrypting and decrypting data.",
      "TOPAZ1 is a stream cipher.",
      "TOPAZ1 uses a linear feedback shift register (LFSR) to generate a pseudorandom sequence of bits.",
      "The National Security Agency (NSA) developed TOPAZ1.",
      "TOPAZ1 is considered to be a strong encryption algorithm."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation: Without specific information about a cryptographic algorithm named TOPAZ1, it is not possible to determine the truth of these statements. TOPAZ1 is not a widely recognized or standard cryptographic algorithm in the public domain as of my knowledge cutoff date. It could be a proprietary or classified system, or it might not exist at all. Therefore, without additional context or information, the truthfulness of these statements cannot be ascertained.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "You MUST give a detailed answer to the following question: Which gene controls the expression of GATA-1 isoforms?",
    "llama-7b_response": "The gene that controls the expression of GATA-1 isoforms is called GATA-1. GATA-1 is a transcription factor, which means it is a protein that regulates the expression of other genes by binding to specific DNA sequences. GATA-1 isoforms are different versions of the GATA-1 protein that result from alternative splicing, which is the removal or addition of non-coding regions to the mRNA transcript of the GATA-1 gene. The different isoforms can have different functions and may be expressed in different tissues or under different conditions.",
    "llama-7b_fact_raw": "1. The GATA-1 gene controls the expression of GATA-1 isoforms.\n2. GATA-1 is a transcription factor.\n3. GATA-1 regulates the expression of other genes by binding to specific DNA sequences.\n4. GATA-1 isoforms are produced through alternative splicing of the mRNA transcript of the GATA-1 gene.\n5. Different GATA-1 isoforms may have different functions and expression patterns in various tissues or conditions.",
    "llama-7b_fact": [
      "The GATA-1 gene controls the expression of GATA-1 isoforms.",
      "GATA-1 is a transcription factor.",
      "GATA-1 regulates the expression of other genes by binding to specific DNA sequences.",
      "GATA-1 isoforms are produced through alternative splicing of the mRNA transcript of the GATA-1 gene.",
      "Different GATA-1 isoforms may have different functions and expression patterns in various tissues or conditions."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "You MUST give a detailed answer to the following question: What is MIRA-seq?",
    "llama-7b_response": "MIRA-seq is a sequencing-based method for measuring the abundance of RNA molecules in a biological sample. It stands for \"multi-index RNA amplification sequencing\" and was developed by researchers at the Broad Institute of MIT and Harvard.\n\nThe MIRA-seq method is based on the principle of multiple displacement amplification (MDA), which is a technique used to increase the copy number of a specific RNA molecule in a sample. In MIRA-seq, MDA is used in combination with sequencing to measure the abundance of RNA molecules in a sample.\n\nThe MIRA-seq protocol involves the following steps:\n\n1. RNA isolation: The starting material for MIRA-seq is a biological sample containing RNA molecules. The sample is first isolated and purified to remove any contaminants.\n2. RNA fragmentation: The RNA molecules in the sample are fragmented into smaller pieces to make them more accessible to the MDA reaction.\n3. Multiple displacement amplification: MDA is used to increase the copy number of a specific RNA molecule in the sample. This is achieved by using a DNA polymerase enzyme to make multiple copies of the RNA molecule.\n4. Library preparation: The amplified RNA molecules are then used to prepare a library for sequencing. This involves fragmenting the RNA molecules further and attaching them to sequencing adapters.\n5. Sequencing: The prepared library is then sequenced using a high-throughput sequencing technology such as Illumina or PacBio.\n6. Data analysis: The sequencing data is analyzed to determine the abundance of each RNA molecule in the sample. This is typically done using a bioinformatics pipeline that involves mapping the sequencing reads to a reference genome, and then counting the number of reads that map to each RNA molecule.\n\nMIRA-seq has several advantages over other sequencing-based methods for measuring RNA abundance, including high sensitivity, specificity, and accuracy. It is particularly well-suited for measuring the abundance of low-abundance RNA molecules, as well as RNA molecules that are difficult to detect using other methods. MIRA-seq ha",
    "llama-7b_fact_raw": "1. MIRA-seq stands for \"multi-index RNA amplification sequencing.\"\n2. MIRA-seq was developed by researchers at the Broad Institute of MIT and Harvard.\n3. The method is based on multiple displacement amplification (MDA) to increase the copy number of specific RNA molecules.\n4. MIRA-seq involves steps such as RNA isolation, RNA fragmentation, multiple displacement amplification, library preparation, sequencing, and data analysis.\n5. MIRA-seq is used for measuring the abundance of RNA molecules in a biological sample.",
    "llama-7b_fact": [
      "MIRA-seq stands for \"multi-index RNA amplification sequencing.\"",
      "MIRA-seq was developed by researchers at the Broad Institute of MIT and Harvard.",
      "The method is based on multiple displacement amplification (MDA) to increase the copy number of specific RNA molecules.",
      "MIRA-seq involves steps such as RNA isolation, RNA fragmentation, multiple displacement amplification, library preparation, sequencing, and data analysis.",
      "MIRA-seq is used for measuring the abundance of RNA molecules in a biological sample."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: MIRA-seq stands for \"methylation-based integrated read analysis sequencing.\"\n2. UNKNOWN\n3. FALSE [correction]: MIRA-seq is based on capturing methylated DNA fragments rather than amplifying RNA molecules.\n4. UNKNOWN (While the steps listed are common in various sequencing protocols, without specific context it's unclear if all these steps are part of the MIRA-seq protocol.)\n5. FALSE [correction]: MIRA-seq is used for analyzing DNA methylation patterns, not for measuring the abundance of RNA molecules.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2108,
    "user_query": "You MUST give a detailed answer to the following question: What is the indication of ARCALYST?",
    "llama-7b_response": "ARCALYST (rilonacept) is a biologic medication that is used to treat cryopyrin-associated periodic syndromes (CAPS), such as Muckle-Wells syndrome (MWS) and neonatal-onset multisystem inflammatory disease (NOMID). CAPS are a group of rare autoinflammatory disorders that are characterized by recurrent episodes of inflammation, fever, and joint pain.\n\nARCALYST works by binding to a specific protein called interleukin-1 beta (IL-1β), which is a key mediator of inflammation in these disorders. By binding to IL-1β, ARCALYST helps to prevent the formation of active IL-1β, which can reduce the frequency and severity of inflammatory episodes in patients with CAPS.\n\nARCALYST is administered as an injection under the skin (subcutaneously) once a month. It is typically used in combination with other medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids, to manage symptoms of CAPS. The efficacy and safety of ARCALYST have been studied in several clinical trials, and it has been shown to be effective in reducing the frequency and severity of inflammatory episodes in patients with CAPS.",
    "llama-7b_fact_raw": "1. ARCALYST (rilonacept) is used to treat cryopyrin-associated periodic syndromes (CAPS).\n2. CAPS are characterized by recurrent episodes of inflammation, fever, and joint pain.\n3. ARCALYST works by binding to interleukin-1 beta (IL-1β), a protein involved in inflammation.\n4. ARCALYST is administered subcutaneously once a month.\n5. ARCALYST has been shown to be effective in reducing the frequency and severity of inflammatory episodes in patients with CAPS through clinical trials.",
    "llama-7b_fact": [
      "ARCALYST (rilonacept) is used to treat cryopyrin-associated periodic syndromes (CAPS).",
      "CAPS are characterized by recurrent episodes of inflammation, fever, and joint pain.",
      "ARCALYST works by binding to interleukin-1 beta (IL-1β), a protein involved in inflammation.",
      "ARCALYST is administered subcutaneously once a month.",
      "ARCALYST has been shown to be effective in reducing the frequency and severity of inflammatory episodes in patients with CAPS through clinical trials."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: ARCALYST is administered subcutaneously, but the dosing frequency can vary. It is often initially administered weekly, not just once a month.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "You MUST give a detailed answer to the following question: List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-7b_response": "Robertsonian translocation is a type of chromosomal rearrangement that involves the fusion of two acrocentric chromosomes. The human acrocentric chromosomes involved in Robertsonian translocation are chromosomes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2237,
    "user_query": "You MUST give a detailed answer to the following question: Which R package could be used for the identification of pediatric brain tumors?",
    "llama-7b_response": "There are several R packages that could be used for the identification of pediatric brain tumors, including:\n\n1. R/Bioconductor packages: The R/Bioconductor packages are a collection of tools for the analysis of high-throughput genomic data, including packages for the identification of pediatric brain tumors. Some examples of R/Bioconductor packages that could be used for this purpose include edgeR, DESeq2, and limma.\n2. R/Bioinformatics packages: The R/Bioinformatics packages are a collection of tools for the analysis of biological data, including packages for the identification of pediatric brain tumors. Some examples of R/Bioinformatics packages that could be used for this purpose include GROMACS, VMD, and PyMOL.\n3. R/Computational Biology packages: The R/Computational Biology packages are a collection of tools for the analysis of biological data, including packages for the identification of pediatric brain tumors. Some examples of R/Computational Biology packages that could be used for this purpose include GROMACS, VMD, and PyMOL.\n4. R/Machine Learning packages: The R/Machine Learning packages are a collection of tools for the analysis of biological data, including packages for the identification of pediatric brain tumors. Some examples of R/Machine Learning packages that could be used for this purpose include scikit-learn, TensorFlow, and Keras.\n5. R/Data Science packages: The R/Data Science packages are a collection of tools for the analysis of biological data, including packages for the identification of pediatric brain tumors. Some examples of R/Data Science packages that could be used for this purpose include scikit-learn, TensorFlow, and Keras.",
    "llama-7b_fact_raw": "1. R/Bioconductor packages are used for the analysis of high-throughput genomic data and include tools for the identification of pediatric brain tumors.\n2. EdgeR, DESeq2, and limma are examples of R/Bioconductor packages that could be used for identifying pediatric brain tumors.\n3. GROMACS and VMD are mentioned as R/Bioinformatics packages that could be used for the identification of pediatric brain tumors.\n4. PyMOL is listed as an R/Bioinformatics package that could be used for the identification of pediatric brain tumors.\n5. Scikit-learn, TensorFlow, and Keras are R/Machine Learning packages that could be used for the analysis of biological data, including the identification of pediatric brain tumors.",
    "llama-7b_fact": [
      "R/Bioconductor packages are used for the analysis of high-throughput genomic data and include tools for the identification of pediatric brain tumors.",
      "EdgeR, DESeq2, and limma are examples of R/Bioconductor packages that could be used for identifying pediatric brain tumors.",
      "GROMACS and VMD are mentioned as R/Bioinformatics packages that could be used for the identification of pediatric brain tumors.",
      "PyMOL is listed as an R/Bioinformatics package that could be used for the identification of pediatric brain tumors.",
      "Scikit-learn, TensorFlow, and Keras are R/Machine Learning packages that could be used for the analysis of biological data, including the identification of pediatric brain tumors."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: GROMACS and VMD are not R/Bioinformatics packages; they are software for molecular dynamics simulations and visualization, respectively.\n4. FALSE [correction]: PyMOL is not an R/Bioinformatics package; it is a molecular visualization system.\n5. FALSE [correction]: Scikit-learn, TensorFlow, and Keras are not R/Machine Learning packages; they are Python libraries used for machine learning tasks.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2246,
    "user_query": "You MUST give a detailed answer to the following question: Is NEMO a zinc finger protein?",
    "llama-7b_response": "No, NEMO (NF-κB essential modulator) is not a zinc finger protein.\n\nZinc finger proteins are a class of transcription factors that contain zinc ions in their structure, which allows them to bind specifically to DNA sequences. Zinc finger proteins are known for their ability to recognize and bind to specific DNA sequences, which can then be used to regulate gene expression.\n\nNEMO, on the other hand, is a protein that plays a critical role in the regulation of the NF-κB signaling pathway. NF-κB is a transcription factor that regulates the expression of genes involved in immune and inflammatory responses. NEMO is a key regulator of the NF-κB signaling pathway, and it acts as a kinase that phosphorylates and activates IκBα, leading to its degradation and the activation of NF-κB.\n\nWhile NEMO does not contain zinc ions in its structure, it is an important regulator of the NF-κB signaling pathway and plays a critical role in the regulation of immune and inflammatory responses.",
    "llama-7b_fact_raw": "1. NEMO (NF-κB essential modulator) is not a zinc finger protein.\n2. Zinc finger proteins contain zinc ions in their structure.\n3. Zinc finger proteins bind specifically to DNA sequences to regulate gene expression.\n4. NEMO plays a critical role in the regulation of the NF-κB signaling pathway.\n5. NF-κB is a transcription factor that regulates genes involved in immune and inflammatory responses.",
    "llama-7b_fact": [
      "NEMO (NF-κB essential modulator) is not a zinc finger protein.",
      "Zinc finger proteins contain zinc ions in their structure.",
      "Zinc finger proteins bind specifically to DNA sequences to regulate gene expression.",
      "NEMO plays a critical role in the regulation of the NF-κB signaling pathway.",
      "NF-κB is a transcription factor that regulates genes involved in immune and inflammatory responses."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "You MUST give a detailed answer to the following question: Does TFIIS affect nucleosome positioning?",
    "llama-7b_response": "Yes, TFIIS does affect nucleosome positioning. TFIIS is a general transcription factor that plays a crucial role in the initiation of RNA polymerase II transcription by unwinding the DNA double helix and positioning the RNA polymerase II holoenzyme at the transcription start site (TSS).\n\nDuring transcription, TFIIS interacts with the RNA polymerase II holoenzyme and helps to position the holoenzyme at the correct location on the DNA template. TFIIS also interacts with other transcription factors and cofactors, such as TFIIE and TFIIB, to facilitate the recruitment of these factors to the TSS.\n\nIn addition to its role in positioning the RNA polymerase II holoenzyme, TFIIS also plays a role in regulating nucleosome positioning. Nucleosomes are the basic units of chromatin, and they consist of DNA wrapped around a core of histone proteins. The positioning of nucleosomes on the DNA template can affect the accessibility of the DNA template to the RNA polymerase II holoenzyme and other transcription factors.\n\nTFIIS has been shown to interact with histone proteins and to affect the positioning of nucleosomes on the DNA template. For example, TFIIS has been shown to displace nucleosomes from the TSS and to promote the formation of a nucleosome-free region around the TSS. This nucleosome-free region is thought to facilitate the recruitment of the RNA polymerase II holoenzyme to the TSS and to promote the initiation of transcription.\n\nIn summary, TFIIS plays a crucial role in the initiation of RNA polymerase II transcription by positioning the RNA polymerase II holoenzyme at the correct location on the DNA template. TFIIS also plays a role in regulating nucleosome positioning, and has been shown to affect the positioning of nucleosomes around the TSS, promoting the formation of a nucleosome-free region that facilitates the initiation of transcription.",
    "llama-7b_fact_raw": "1. TFIIS is a general transcription factor that plays a role in the initiation of RNA polymerase II transcription.\n2. TFIIS helps to position the RNA polymerase II holoenzyme at the transcription start site (TSS).\n3. TFIIS interacts with other transcription factors and cofactors, such as TFIIE and TFIIB.\n4. TFIIS has been shown to interact with histone proteins.\n5. TFIIS can displace nucleosomes from the TSS and promote the formation of a nucleosome-free region around the TSS.",
    "llama-7b_fact": [
      "TFIIS is a general transcription factor that plays a role in the initiation of RNA polymerase II transcription.",
      "TFIIS helps to position the RNA polymerase II holoenzyme at the transcription start site (TSS).",
      "TFIIS interacts with other transcription factors and cofactors, such as TFIIE and TFIIB.",
      "TFIIS has been shown to interact with histone proteins.",
      "TFIIS can displace nucleosomes from the TSS and promote the formation of a nucleosome-free region around the TSS."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: TFIIS is not a general transcription factor; it is a transcription elongation factor that plays a role in the process of elongation during RNA polymerase II transcription.\n2. FALSE [correction]: TFIIS does not position the RNA polymerase II holoenzyme at the transcription start site (TSS); this is the role of general transcription factors such as TFIID.\n3. TRUE: TFIIS can interact with other transcription factors and cofactors, although the specific interactions with TFIIE and TFIIB are not as well-characterized as its role in elongation.\n4. UNKNOWN: The statement is vague as it does not specify the nature of the interaction between TFIIS and histone proteins. While TFIIS is involved in transcription elongation, direct interactions with histones are not typically highlighted in its known functions.\n5. FALSE [correction]: TFIIS does not displace nucleosomes from the TSS. The formation of a nucleosome-free region is typically associated with the action of other factors such as chromatin remodelers and not directly with TFIIS.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2262,
    "user_query": "You MUST give a detailed answer to the following question: Do origins of replication close to yeast centromeres fire early or late?",
    "llama-7b_response": "The question of whether origins of replication that are close to yeast centromeres fire early or late is a topic of ongoing research and debate in the field of genetics and molecular biology.\n\nIn general, origins of replication are regions on chromosomes where DNA replication begins. In eukaryotic cells, such as yeast, there are multiple origins of replication that are distributed along the length of each chromosome.\n\nIn yeast, the centromere is a specialized region of the chromosome that plays a crucial role in the proper separation of sister chromatids during cell division. It is thought that the proximity of origins of replication to centromeres may play a role in the regulation of DNA replication and the proper segregation of genetic material during cell division.\n\nSome studies have suggested that origins of replication that are close to yeast centromeres may fire earlier than origins that are further away from centromeres. This is based on the observation that origins that are closer to centromeres tend to initiate DNA replication earlier in the cell cycle than origins that are further away.\n\nOther studies, however, have suggested that the timing of DNA replication at origins of replication that are close to yeast centromeres may not be significantly different from origins that are further away.\n\nOverall, the question of whether origins of replication that are close to yeast centromeres fire early or late is a complex and active area of research, and the answer may depend on a variety of factors, including the specific strain of yeast being studied and the conditions under which the cells are grown.",
    "llama-7b_fact_raw": "1. Origins of replication are regions on chromosomes where DNA replication begins.\n2. In eukaryotic cells, such as yeast, there are multiple origins of replication distributed along the length of each chromosome.\n3. The centromere is a specialized region of the chromosome that is crucial for the proper separation of sister chromatids during cell division in yeast.\n4. Some studies suggest that origins of replication close to yeast centromeres may fire earlier than those further away.\n5. The timing of DNA replication at origins of replication close to yeast centromeres is a subject of ongoing research and debate.",
    "llama-7b_fact": [
      "Origins of replication are regions on chromosomes where DNA replication begins.",
      "In eukaryotic cells, such as yeast, there are multiple origins of replication distributed along the length of each chromosome.",
      "The centromere is a specialized region of the chromosome that is crucial for the proper separation of sister chromatids during cell division in yeast.",
      "Some studies suggest that origins of replication close to yeast centromeres may fire earlier than those further away.",
      "The timing of DNA replication at origins of replication close to yeast centromeres is a subject of ongoing research and debate."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "You MUST give a detailed answer to the following question: Which are the properties of mammalian GA-sequences?",
    "llama-7b_response": "Mammalian GA-sequences are a type of non-coding RNA that have been identified in a wide range of mammalian tissues, including the brain, heart, liver, and skeletal muscle. They are characterized by a specific sequence motif, known as the GA-motif, which consists of two guanine (G) nucleotides followed by one adenine (A) nucleotide.\n\nIn addition to the GA-motif, mammalian GA-sequences have several other properties that distinguish them from other types of non-coding RNA. For example, they are typically longer in length than other non-coding RNAs, with lengths ranging from several hundred to several thousand nucleotides. They are also highly conserved across different mammalian species, which suggests that they play important functional roles in the cell.\n\nFurthermore, mammalian GA-sequences have been shown to be involved in a variety of biological processes, including regulation of gene expression, RNA splicing, and ribosome biogenesis. They have also been implicated in the development of certain diseases, such as cancer and neurodegenerative disorders.\n\nOverall, the properties of mammalian GA-sequences suggest that they are an important class of non-coding RNA that plays crucial roles in various biological processes and may be involved in the development of certain diseases. Further research is needed to fully understand the functions of these RNAs and their potential as therapeutic targets.",
    "llama-7b_fact_raw": "1. Mammalian GA-sequences are a type of non-coding RNA found in various mammalian tissues such as the brain, heart, liver, and skeletal muscle.\n2. The GA-motif in mammalian GA-sequences consists of two guanine nucleotides followed by one adenine nucleotide.\n3. Mammalian GA-sequences are typically longer than other non-coding RNAs, with lengths ranging from several hundred to several thousand nucleotides.\n4. These sequences are highly conserved across different mammalian species.\n5. Mammalian GA-sequences are involved in biological processes including regulation of gene expression, RNA splicing, and ribosome biogenesis, and have been implicated in diseases like cancer and neurodegenerative disorders.",
    "llama-7b_fact": [
      "Mammalian GA-sequences are a type of non-coding RNA found in various mammalian tissues such as the brain, heart, liver, and skeletal muscle.",
      "The GA-motif in mammalian GA-sequences consists of two guanine nucleotides followed by one adenine nucleotide.",
      "Mammalian GA-sequences are typically longer than other non-coding RNAs, with lengths ranging from several hundred to several thousand nucleotides.",
      "These sequences are highly conserved across different mammalian species.",
      "Mammalian GA-sequences are involved in biological processes including regulation of gene expression, RNA splicing, and ribosome biogenesis, and have been implicated in diseases like cancer and neurodegenerative disorders."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: The GA-motif in mammalian GA-sequences typically consists of a repetitive sequence of guanine (G) and adenine (A) nucleotides, not just two guanines followed by one adenine.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about mammalian GA-sequences are highly specific and would require specialized knowledge in molecular biology or genetics to confirm. Without the specific context or a reference to the scientific literature, it is not possible to accurately determine the truthfulness of these statements. The correction provided for statement 2 is based on the general understanding that GA-sequences refer to repetitive sequences of guanine and adenine nucleotides, but without specific context, the details about these sequences cannot be confirmed.",
    "llama-7b_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2291,
    "user_query": "You MUST give a detailed answer to the following question: How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-7b_response": "The number of Groucho-related genes (GRG) contained in the mouse genome is currently unknown. Groucho is a transcriptional repressor that belongs to the Groucho family of proteins, which also includes Groucho-related proteins (Gro) and Groucho-like proteins (Gro-like). The Groucho family of proteins is involved in various cellular processes, including transcriptional regulation, development, and cell-cycle progression.\n\nThe mouse genome contains a total of approximately 20,000 protein-coding genes, and it is likely that some of these genes are members of the Groucho family. However, it is not possible to determine the exact number of Groucho-related genes in the mouse genome without a comprehensive study of the Groucho family in the mouse genome.\n\nTherefore, the answer to the question of how many Groucho-related genes are contained in the mouse genome is \"unknown.\" Further research is needed to determine the exact number of Groucho-related genes in the mouse genome.",
    "llama-7b_fact_raw": "1. The number of Groucho-related genes (GRG) in the mouse genome is currently unknown.\n2. Groucho is a transcriptional repressor.\n3. The Groucho family of proteins includes Groucho-related proteins (Gro) and Groucho-like proteins (Gro-like).\n4. The Groucho family of proteins is involved in transcriptional regulation, development, and cell-cycle progression.\n5. The mouse genome contains a total of approximately 20,000 protein-coding genes.",
    "llama-7b_fact": [
      "The number of Groucho-related genes (GRG) in the mouse genome is currently unknown.",
      "Groucho is a transcriptional repressor.",
      "The Groucho family of proteins includes Groucho-related proteins (Gro) and Groucho-like proteins (Gro-like).",
      "The Groucho family of proteins is involved in transcriptional regulation, development, and cell-cycle progression.",
      "The mouse genome contains a total of approximately 20,000 protein-coding genes."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "You MUST give a detailed answer to the following question: Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-7b_response": "The RNA polymerase II subunit that carries RNA cleavage activity is the C-terminal domain (CTD) of the largest subunit of RNA polymerase II. The CTD is a repeated sequence of approximately 20 amino acids that is located at the carboxy-terminal end of the largest subunit of RNA polymerase II. The CTD contains a serine residue that can be phosphorylated by the enzyme RNA polymerase II kinase, leading to the formation of a phosphoserine residue. This phosphoserine residue can then interact with the exonuclease activity of the RNase III enzyme, leading to the cleavage of RNA transcripts. The CTD is therefore an important component of the RNA cleavage activity of RNA polymerase II.",
    "llama-7b_fact_raw": "1. The C-terminal domain (CTD) of the largest subunit of RNA polymerase II carries RNA cleavage activity.\n2. The CTD is a repeated sequence of approximately 20 amino acids.\n3. The CTD is located at the carboxy-terminal end of the largest subunit of RNA polymerase II.\n4. A serine residue in the CTD can be phosphorylated by RNA polymerase II kinase.\n5. The phosphorylated serine residue in the CTD can interact with RNase III enzyme, leading to RNA transcript cleavage.",
    "llama-7b_fact": [
      "The C-terminal domain (CTD) of the largest subunit of RNA polymerase II carries RNA cleavage activity.",
      "The CTD is a repeated sequence of approximately 20 amino acids.",
      "The CTD is located at the carboxy-terminal end of the largest subunit of RNA polymerase II.",
      "A serine residue in the CTD can be phosphorylated by RNA polymerase II kinase.",
      "The phosphorylated serine residue in the CTD can interact with RNase III enzyme, leading to RNA transcript cleavage."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The C-terminal domain (CTD) of the largest subunit of RNA polymerase II does not carry RNA cleavage activity. It is involved in the processing of the pre-mRNA and the coordination of RNA processing with transcription.\n2. FALSE [correction]: The CTD is a repeated sequence of seven amino acids (tyrosine-serine-proline-threonine-serine-proline-serine) in humans, which can be repeated up to 52 times.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The phosphorylated serine residue in the CTD does not interact with RNase III enzyme for RNA transcript cleavage. Instead, it is involved in the recruitment of various factors necessary for RNA processing, such as capping, splicing, and polyadenylation.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2321,
    "user_query": "You MUST give a detailed answer to the following question: What is the genetic basis of Ohdo syndrome?",
    "llama-7b_response": "Ohdo syndrome is a rare genetic disorder that affects multiple systems in the body, including the skeletal, muscular, and cardiovascular systems. The genetic basis of Ohdo syndrome has been identified as a mutation in the COL11A1 gene.\n\nThe COL11A1 gene provides instructions for making a protein called type XI collagen, which is a component of the extracellular matrix, a complex network of proteins and other molecules that provides structural support to cells. Mutations in the COL11A1 gene lead to a deficiency of type XI collagen, which can cause the symptoms of Ohdo syndrome.\n\nThe COL11A1 gene is located on the long (q) arm of chromosome 12 at position 12q13.2. The mutation that causes Ohdo syndrome can occur in any of the three exons of the COL11A1 gene, but the most common mutation is a deletion of part of exon 3. This deletion results in a premature stop codon and a truncated form of the type XI collagen protein that is unable to perform its normal functions.\n\nThe symptoms of Ohdo syndrome result from the effects of the mutated type XI collagen protein on multiple systems in the body. For example, the mutated protein may affect the development and function of bones and muscles, leading to skeletal abnormalities and muscle weakness. It may also affect the function of the heart and blood vessels, leading to cardiovascular problems.\n\nIn summary, the genetic basis of Ohdo syndrome is a mutation in the COL11A1 gene that leads to a deficiency of type XI collagen and the symptoms of the disorder. The mutation can occur in any of the three exons of the COL11A1 gene, but the most common mutation is a deletion of part of exon 3. The symptoms of Ohdo syndrome result from the effects of the mutated type XI collagen protein on multiple systems in the body.",
    "llama-7b_fact_raw": "1. Ohdo syndrome is a genetic disorder caused by a mutation in the COL11A1 gene.\n2. The COL11A1 gene is responsible for making type XI collagen.\n3. Type XI collagen is a component of the extracellular matrix that provides structural support to cells.\n4. The COL11A1 gene is located on the long (q) arm of chromosome 12 at position 12q13.2.\n5. The most common mutation in the COL11A1 gene associated with Ohdo syndrome is a deletion of part of exon 3, leading to a premature stop codon.",
    "llama-7b_fact": [
      "Ohdo syndrome is a genetic disorder caused by a mutation in the COL11A1 gene.",
      "The COL11A1 gene is responsible for making type XI collagen.",
      "Type XI collagen is a component of the extracellular matrix that provides structural support to cells.",
      "The COL11A1 gene is located on the long (q) arm of chromosome 12 at position 12q13.2.",
      "The most common mutation in the COL11A1 gene associated with Ohdo syndrome is a deletion of part of exon 3, leading to a premature stop codon."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Ohdo syndrome is a genetic disorder, but it is not typically caused by a mutation in the COL11A1 gene. It is often associated with mutations in the MED12 gene or other genes.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The most common mutation in the COL11A1 gene associated with Ohdo syndrome is not specified here, and Ohdo syndrome is not typically associated with mutations in the COL11A1 gene. Mutations in the MED12 gene are more commonly associated with Ohdo syndrome.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2360,
    "user_query": "You MUST give a detailed answer to the following question: Describe swirl sign in intracerebral hemorrhage.",
    "llama-7b_response": "A swirl sign in intracerebral hemorrhage is a characteristic imaging finding on computed tomography (CT) or magnetic resonance imaging (MRI) scans of the brain. It is a sign of intracerebral hemorrhage, which is a type of stroke caused by bleeding in the brain.\n\nThe swirl sign is characterized by a swirling pattern of blood within the affected hemisphere of the brain. This pattern is caused by the movement of blood within the hemorrhage, which can cause the blood to flow in a circular pattern. The swirl sign is typically seen on CT or MRI scans of the brain, and it can be a useful tool for diagnosing intracerebral hemorrhage.\n\nThe swirl sign is not specific to intracerebral hemorrhage, and it can also be seen in other conditions that cause bleeding in the brain, such as subarachnoid hemorrhage, which is a type of stroke caused by bleeding in the subarachnoid space around the brain. However, the presence of the swirl sign in combination with other symptoms and imaging findings is highly suggestive of intracerebral hemorrhage.\n\nIn summary, the swirl sign is a characteristic imaging finding in intracerebral hemorrhage, and it is caused by the movement of blood within the hemorrhage. It is typically seen on CT or MRI scans of the brain and can be a useful tool for diagnosing intracerebral hemorrhage.",
    "llama-7b_fact_raw": "1. The swirl sign is an imaging finding on computed tomography (CT) or magnetic resonance imaging (MRI) scans of the brain.\n2. It indicates the presence of intracerebral hemorrhage, which is a type of stroke caused by bleeding in the brain.\n3. The swirl sign is characterized by a swirling pattern of blood within the affected hemisphere of the brain.\n4. The swirl sign can also be seen in conditions other than intracerebral hemorrhage, such as subarachnoid hemorrhage.\n5. The presence of the swirl sign, along with other symptoms and imaging findings, is highly suggestive of intracerebral hemorrhage.",
    "llama-7b_fact": [
      "The swirl sign is an imaging finding on computed tomography (CT) or magnetic resonance imaging (MRI) scans of the brain.",
      "It indicates the presence of intracerebral hemorrhage, which is a type of stroke caused by bleeding in the brain.",
      "The swirl sign is characterized by a swirling pattern of blood within the affected hemisphere of the brain.",
      "The swirl sign can also be seen in conditions other than intracerebral hemorrhage, such as subarachnoid hemorrhage.",
      "The presence of the swirl sign, along with other symptoms and imaging findings, is highly suggestive of intracerebral hemorrhage."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The swirl sign is specifically associated with intracerebral hemorrhage and not typically used to describe findings in subarachnoid hemorrhage.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "You MUST give a detailed answer to the following question: What induces Arabidopsis ROF1 expression?",
    "llama-7b_response": "Arabidopsis ROF1 is a transcription factor that plays a crucial role in the response of plants to various stresses, including drought, salt, and temperature stress. ROF1 expression is regulated by a variety of factors, including abiotic and biotic stresses, hormones, and signaling molecules.\n\nOne of the key inducers of ROF1 expression is abscisic acid (ABA), a phytohormone that plays a central role in the response of plants to drought stress. ABA binds to and activates several ABA receptors, including the ABSCISIC ACID INSENSITIVE3 (ABI3) and ABSCISIC ACID INSENSITIVE2 (ABI2) proteins, which in turn activate downstream signaling pathways that lead to the expression of ROF1 and other drought-responsive genes.\n\nAnother inducer of ROF1 expression is salicylic acid (SA), a plant hormone that plays a key role in the response to pathogens and other biotic stresses. Like ABA, SA activates the ABI3 and ABI2 receptors, leading to the expression of ROF1 and other defense genes.\n\nROF1 expression can also be induced by various stress-related signaling molecules, such as jasmonic acid (JA) and ethylene. JA, for example, is a signaling molecule that plays a central role in the response to pathogens and other biotic stresses, and it has been shown to induce ROF1 expression in Arabidopsis thaliana.\n\nIn summary, ROF1 expression is induced by a variety of factors, including abiotic and biotic stresses, hormones, and signaling molecules. These inducers activate downstream signaling pathways that lead to the expression of ROF1 and other drought-responsive genes.",
    "llama-7b_fact_raw": "1. Arabidopsis ROF1 is a transcription factor involved in plant responses to stresses such as drought, salt, and temperature.\n2. Abscisic acid (ABA) is a phytohormone that induces ROF1 expression in response to drought stress.\n3. The ABSCISIC ACID INSENSITIVE3 (ABI3) and ABSCISIC ACID INSENSITIVE2 (ABI2) proteins are ABA receptors that activate signaling pathways leading to ROF1 expression.\n4. Salicylic acid (SA) is a plant hormone that induces ROF1 expression in response to pathogens and other biotic stresses.\n5. Jasmonic acid (JA) is a signaling molecule that induces ROF1 expression in Arabidopsis thaliana in response to biotic stresses.",
    "llama-7b_fact": [
      "Arabidopsis ROF1 is a transcription factor involved in plant responses to stresses such as drought, salt, and temperature.",
      "Abscisic acid (ABA) is a phytohormone that induces ROF1 expression in response to drought stress.",
      "The ABSCISIC ACID INSENSITIVE3 (ABI3) and ABSCISIC ACID INSENSITIVE2 (ABI2) proteins are ABA receptors that activate signaling pathways leading to ROF1 expression.",
      "Salicylic acid (SA) is a plant hormone that induces ROF1 expression in response to pathogens and other biotic stresses.",
      "Jasmonic acid (JA) is a signaling molecule that induces ROF1 expression in Arabidopsis thaliana in response to biotic stresses."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The ABSCISIC ACID INSENSITIVE3 (ABI3) and ABSCISIC ACID INSENSITIVE2 (ABI2) proteins are not ABA receptors; they are part of the ABA signaling pathway. The ABA receptors are the PYRABACTIN RESISTANCE1 (PYR1)/PYR1-LIKE (PYL)/REGULATORY COMPONENT OF ABA RECEPTOR (RCAR) proteins.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "You MUST give a detailed answer to the following question: What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-7b_response": "Hereditary renal amyloidosis is a condition caused by the accumulation of abnormal protein deposits in the kidneys. The most common protein that causes hereditary renal amyloidosis is called transthyretin (TTR). TTR is a plasma protein that is normally involved in transporting thyroid hormones and retinol (vitamin A) throughout the body. In hereditary renal amyloidosis, mutations in the TTR gene lead to the production of abnormal TTR protein that accumulates in the kidneys, causing damage and eventually leading to kidney failure.",
    "llama-7b_fact_raw": "1. Hereditary renal amyloidosis is caused by the accumulation of abnormal protein deposits in the kidneys.\n2. Transthyretin (TTR) is the most common protein that causes hereditary renal amyloidosis.\n3. TTR is a plasma protein involved in transporting thyroid hormones and retinol (vitamin A).\n4. Mutations in the TTR gene can lead to the production of abnormal TTR protein.\n5. The accumulation of abnormal TTR protein in the kidneys can cause damage and lead to kidney failure.",
    "llama-7b_fact": [
      "Hereditary renal amyloidosis is caused by the accumulation of abnormal protein deposits in the kidneys.",
      "Transthyretin (TTR) is the most common protein that causes hereditary renal amyloidosis.",
      "TTR is a plasma protein involved in transporting thyroid hormones and retinol (vitamin A).",
      "Mutations in the TTR gene can lead to the production of abnormal TTR protein.",
      "The accumulation of abnormal TTR protein in the kidneys can cause damage and lead to kidney failure."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The most common protein that causes hereditary renal amyloidosis is not transthyretin (TTR), but rather the protein fibrinogen, apolipoprotein A-I, or lysozyme. Transthyretin is more commonly associated with familial amyloid polyneuropathy (FAP).\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2407,
    "user_query": "You MUST give a detailed answer to the following question: Has the proteome of mice hippocampus been analysed?",
    "llama-7b_response": "Yes, the proteome of mice hippocampus has been analyzed. The proteome is the complete set of proteins expressed by an organism or a cell at a particular time or under specific conditions. The hippocampus is a critical brain region involved in learning, memory, and emotional regulation, and its proteome has been extensively studied in various experimental models, including mice.\n\nSeveral large-scale proteomic studies have been conducted to identify and characterize the proteins expressed in the mouse hippocampus. These studies have used a variety of techniques, including two-dimensional gel electrophoresis, mass spectrometry, and bioinformatics analysis, to identify and quantify thousands of proteins in the hippocampus.\n\nFor example, a study published in the journal Molecular and Cellular Proteomics in 2006 used two-dimensional gel electrophoresis and mass spectrometry to identify and quantify over 1,000 proteins in the mouse hippocampus. Another study published in the journal Proteomics in 2008 used a similar approach to identify and quantify over 2,000 proteins in the hippocampus of mice.\n\nThese studies have provided a wealth of information about the proteins expressed in the mouse hippocampus and have helped to elucidate the molecular mechanisms underlying learning, memory, and other cognitive processes. They have also identified potential biomarkers and targets for the treatment of neurological disorders, such as Alzheimer's disease and epilepsy.",
    "llama-7b_fact_raw": "1. The proteome of mice hippocampus has been analyzed.\n2. The hippocampus is involved in learning, memory, and emotional regulation.\n3. Large-scale proteomic studies have identified and characterized proteins expressed in the mouse hippocampus.\n4. A study published in Molecular and Cellular Proteomics in 2006 identified and quantified over 1,000 proteins in the mouse hippocampus.\n5. Another study published in the journal Proteomics in 2008 identified and quantified over 2,000 proteins in the hippocampus of mice.",
    "llama-7b_fact": [
      "The proteome of mice hippocampus has been analyzed.",
      "The hippocampus is involved in learning, memory, and emotional regulation.",
      "Large-scale proteomic studies have identified and characterized proteins expressed in the mouse hippocampus.",
      "A study published in Molecular and Cellular Proteomics in 2006 identified and quantified over 1,000 proteins in the mouse hippocampus.",
      "Another study published in the journal Proteomics in 2008 identified and quantified over 2,000 proteins in the hippocampus of mice."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements are generally true as the proteome of the mouse hippocampus has been analyzed, the hippocampus is indeed involved in learning, memory, and emotional regulation, and large-scale proteomic studies have characterized proteins in the mouse hippocampus. However, without specific references to the studies mentioned in statements 4 and 5, the exact numbers of proteins identified and quantified cannot be verified, so the truth of these statements remains unknown.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2409,
    "user_query": "You MUST give a detailed answer to the following question: Are mouse chromosomes acrocentric?",
    "llama-7b_response": "Yes, mouse chromosomes are acrocentric. Acrocentric chromosomes are a type of chromosome that have their centromeres (the point at which the two arms of the chromosome are attached) located towards the ends of the chromosome, rather than in the middle. This is in contrast to metacentric chromosomes, which have their centromeres in the middle of the chromosome.\n\nMouse chromosomes are numbered from 1 to 20, with the exception of the X and Y chromosomes, which are designated as chromosome 17 and chromosome 18, respectively. The centromeres of mouse chromosomes are located at different positions along the length of the chromosomes. For example, the centromere of chromosome 1 is located near the middle of the chromosome, while the centromere of chromosome 19 is located towards the end of the chromosome.\n\nOverall, the arrangement of the centromeres on mouse chromosomes is consistent with the classification of acrocentric chromosomes.",
    "llama-7b_fact_raw": "1. Mouse chromosomes are acrocentric.\n2. Acrocentric chromosomes have their centromeres located towards the ends of the chromosome.\n3. Metacentric chromosomes have their centromeres in the middle of the chromosome.\n4. Mouse chromosomes are numbered from 1 to 20, not including the X and Y chromosomes.\n5. The centromere of mouse chromosome 1 is located near the middle of the chromosome.",
    "llama-7b_fact": [
      "Mouse chromosomes are acrocentric.",
      "Acrocentric chromosomes have their centromeres located towards the ends of the chromosome.",
      "Metacentric chromosomes have their centromeres in the middle of the chromosome.",
      "Mouse chromosomes are numbered from 1 to 20, not including the X and Y chromosomes.",
      "The centromere of mouse chromosome 1 is located near the middle of the chromosome."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Mouse chromosomes are numbered from 1 to 19, not including the X and Y chromosomes.\n5. FALSE [correction]: The centromere of mouse chromosome 1 is not located near the middle; it is acrocentric, meaning the centromere is located towards one end of the chromosome.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2417,
    "user_query": "You MUST give a detailed answer to the following question: Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-7b_response": "There are several small interfering RNA (siRNA) based drugs that are currently in clinical trials for the treatment of pancreatic cancer. One such drug is AT-1212, which is being developed by Alnylam Pharmaceuticals. AT-1212 is an RNA interference (RNAi) therapeutic that uses a single-stranded RNA molecule to silence the expression of a specific gene that is believed to play a role in the development and progression of pancreatic cancer.\n\nAnother siRNA-based drug that is being studied for the treatment of pancreatic cancer is ON-01910, which is being developed by OncoNeb. ON-01910 is an RNAi therapeutic that uses a double-stranded RNA molecule to silence the expression of a specific gene that is believed to play a role in the development and progression of pancreatic cancer.\n\nBoth AT-1212 and ON-01910 are still in the early stages of clinical development and have not yet been approved for use in the treatment of pancreatic cancer. However, they have shown promising results in preclinical studies and are being closely watched by the medical community as potential new treatments for this deadly disease.",
    "llama-7b_fact_raw": "1. AT-1212 is an siRNA-based drug in clinical trials for the treatment of pancreatic cancer.\n2. Alnylam Pharmaceuticals is developing AT-1212.\n3. AT-1212 uses a single-stranded RNA molecule to silence the expression of a specific gene related to pancreatic cancer.\n4. ON-01910 is another siRNA-based drug in clinical trials for the treatment of pancreatic cancer.\n5. ON-01910 is being developed by OncoNeb and uses a double-stranded RNA molecule to target a specific gene associated with pancreatic cancer.",
    "llama-7b_fact": [
      "AT-1212 is an siRNA-based drug in clinical trials for the treatment of pancreatic cancer.",
      "Alnylam Pharmaceuticals is developing AT-1212.",
      "AT-1212 uses a single-stranded RNA molecule to silence the expression of a specific gene related to pancreatic cancer.",
      "ON-01910 is another siRNA-based drug in clinical trials for the treatment of pancreatic cancer.",
      "ON-01910 is being developed by OncoNeb and uses a double-stranded RNA molecule to target a specific gene associated with pancreatic cancer."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: AT-1212, if it is an siRNA-based drug, would use a double-stranded RNA molecule to silence the expression of a specific gene, as siRNA is typically double-stranded, not single-stranded.\n4. UNKNOWN\n5. UNKNOWN\n\nNote: The correctness of statements 1, 2, 4, and 5 cannot be determined without specific information about the drugs mentioned, which is not provided in the context. The correction for statement 3 is based on the general knowledge that siRNA (small interfering RNA) molecules are typically double-stranded.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "You MUST give a detailed answer to the following question: What is the HPG pore?",
    "llama-7b_response": "I'm sorry, but I am not familiar with the term \"HPG pore.\" Could you please provide more context or information about what you are referring to?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2472,
    "user_query": "You MUST give a detailed answer to the following question: What is the 959 Nematode Genomes initiative?",
    "llama-7b_response": "The 959 Nematode Genomes initiative is a large-scale project aimed at sequencing and analyzing the genomes of 959 species of roundworms, also known as nematodes. Nematodes are a diverse group of organisms that include parasitic worms, plant-feeding nematodes, and free-living soil-dwelling nematodes.\n\nThe goal of the 959 Nematode Genomes initiative is to create a comprehensive resource of nematode genomes that will provide insights into the evolution, ecology, and biology of these organisms. By sequencing and analyzing the genomes of a wide range of nematode species, researchers hope to gain a better understanding of the genetic basis of nematode traits, such as their ability to cause disease in humans and animals, their interactions with other organisms, and their role in nutrient cycling in soil.\n\nThe 959 Nematode Genomes initiative is a collaborative effort between researchers from around the world, and is supported by a number of funding agencies and organizations. The sequencing and analysis of the nematode genomes is being carried out using a combination of next-generation sequencing technologies and bioinformatics tools.\n\nOverall, the 959 Nematode Genomes initiative has the potential to provide significant insights into the biology and evolution of nematodes, and could have implications for a wide range of fields, including medicine, agriculture, and ecology.",
    "llama-7b_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of roundworms.\n2. Nematodes include parasitic worms, plant-feeding nematodes, and free-living soil-dwelling nematodes.\n3. The initiative's goal is to provide insights into the evolution, ecology, and biology of nematodes.\n4. Researchers involved in the initiative are looking to understand the genetic basis of nematode traits.\n5. The initiative is a collaborative effort supported by various funding agencies and organizations.",
    "llama-7b_fact": [
      "The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of roundworms.",
      "Nematodes include parasitic worms, plant-feeding nematodes, and free-living soil-dwelling nematodes.",
      "The initiative's goal is to provide insights into the evolution, ecology, and biology of nematodes.",
      "Researchers involved in the initiative are looking to understand the genetic basis of nematode traits.",
      "The initiative is a collaborative effort supported by various funding agencies and organizations."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the typical goals and scope of a large-scale genomics initiative like the 959 Nematode Genomes project, which would aim to sequence a variety of nematode species to gain insights into their biology and evolution. The collaborative nature of such initiatives is also common, often involving multiple funding sources and organizations.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "You MUST give a detailed answer to the following question: Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-7b_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data. Some of the most popular ones include:\n\n1. NIPTAnalytics: This package provides tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.\n2. NIPT-R: This package provides a range of tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.\n3. NIPTAnalytics: This package provides tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.\n4. NIPT-R: This package provides a range of tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.\n5. NIPTAnalytics: This package provides tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.\n6. NIPT-R: This package provides a range of tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.\n7. NIPTAnalytics: This package provides tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.\n8. NIPT-R: This package provides a range of tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.\n9. NIPTAnalytics: This package provides tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.\n10. NIPT-R: This package provides a range of tools for analyzing NIPT data, including tools for imputation, quality control, and statistical analysis.",
    "llama-7b_fact_raw": "1. NIPTAnalytics is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.\n2. NIPT-R is another R package developed for analyzing NIPT data.\n3. Both NIPTAnalytics and NIPT-R packages include tools for imputation.\n4. Both NIPTAnalytics and NIPT-R packages include tools for quality control.\n5. Both NIPTAnalytics and NIPT-R packages include tools for statistical analysis.",
    "llama-7b_fact": [
      "NIPTAnalytics is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "NIPT-R is another R package developed for analyzing NIPT data.",
      "Both NIPTAnalytics and NIPT-R packages include tools for imputation.",
      "Both NIPTAnalytics and NIPT-R packages include tools for quality control.",
      "Both NIPTAnalytics and NIPT-R packages include tools for statistical analysis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the features of the NIPTAnalytics and NIPT-R R packages, it is not possible to accurately confirm the presence of tools for imputation, quality control, or statistical analysis in these packages.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "You MUST give a detailed answer to the following question: Describe Achenbach’s syndrome.",
    "llama-7b_response": "Achenbach's syndrome, also known as Achenbach's sign or Achenbach's test, is a physical examination maneuver used to assess the integrity of the cervical spinal nerve roots. It is named after the German neurologist Friedrich Achenbach, who first described the syndrome in 1891.\n\nThe maneuver involves applying pressure to the skin overlying the cervical spine, typically at the C6-C7 or C7-T1 levels, while the patient is asked to turn their head to the opposite side. If the nerve root is intact, the patient will experience pain, paresthesia (abnormal sensations such as tingling or numbness), or weakness in the arm or hand on the affected side. If the nerve root is compressed or damaged, these symptoms will be elicited.\n\nAchenbach's syndrome is often used as a diagnostic tool for conditions that affect the cervical spine, such as cervical disc herniation, cervical spinal stenosis, or cervical radiculopathy. It can also be used to evaluate the effectiveness of treatments for these conditions, such as surgery or physical therapy. However, it should be noted that Achenbach's syndrome is not a definitive diagnostic test and should be used in conjunction with other diagnostic tests and clinical examination findings.",
    "llama-7b_fact_raw": "1. Achenbach's syndrome is a physical examination maneuver used to assess the integrity of the cervical spinal nerve roots.\n2. Friedrich Achenbach, a German neurologist, first described the syndrome in 1891.\n3. The maneuver involves applying pressure to the skin overlying the cervical spine at the C6-C7 or C7-T1 levels while the patient turns their head to the opposite side.\n4. Achenbach's syndrome can elicit pain, paresthesia, or weakness in the arm or hand if the nerve root is intact.\n5. The syndrome is used as a diagnostic tool for conditions affecting the cervical spine, such as cervical disc herniation, cervical spinal stenosis, or cervical radiculopathy.",
    "llama-7b_fact": [
      "Achenbach's syndrome is a physical examination maneuver used to assess the integrity of the cervical spinal nerve roots.",
      "Friedrich Achenbach, a German neurologist, first described the syndrome in 1891.",
      "The maneuver involves applying pressure to the skin overlying the cervical spine at the C6-C7 or C7-T1 levels while the patient turns their head to the opposite side.",
      "Achenbach's syndrome can elicit pain, paresthesia, or weakness in the arm or hand if the nerve root is intact.",
      "The syndrome is used as a diagnostic tool for conditions affecting the cervical spine, such as cervical disc herniation, cervical spinal stenosis, or cervical radiculopathy."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is not a physical examination maneuver; it is a rare condition characterized by sudden, unexplained bruising on the hand or fingers.\n2. FALSE [correction]: Friedrich Achenbach was a German physician, but he is not known for describing a neurological syndrome in 1891; Achenbach's syndrome was first described in the 20th century and is not associated with a neurologist of that name.\n3. FALSE [correction]: Since Achenbach's syndrome is not a physical examination maneuver, this description of a maneuver involving pressure to the cervical spine is incorrect and does not pertain to Achenbach's syndrome.\n4. FALSE [correction]: Achenbach's syndrome involves spontaneous bruising and does not elicit pain, paresthesia, or weakness in the arm or hand due to nerve root integrity; these symptoms are more consistent with nerve root compression or irritation.\n5. FALSE [correction]: Achenbach's syndrome is not used as a diagnostic tool for conditions affecting the cervical spine. It is a condition in itself, typically benign and self-limiting, and not related to cervical spine pathology.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2581,
    "user_query": "You MUST give a detailed answer to the following question: Which algorithm is used for detection of long repeat expansions?",
    "llama-7b_response": "There are several algorithms that can be used for the detection of long repeat expansions, but one of the most commonly used algorithms is the \"sliding window\" approach.\n\nIn this approach, a sliding window is used to scan the DNA sequence for the presence of the repeat expansion. The window is moved along the DNA sequence one nucleotide at a time, and for each nucleotide in the window, the number of repeats is counted. If the number of repeats exceeds a certain threshold, then the repeat expansion is detected.\n\nAnother algorithm that can be used for the detection of long repeat expansions is the \"dynamic programming\" approach. In this approach, a matrix is used to keep track of the number of repeats at each position in the DNA sequence. The matrix is initialized with zeros, and then the number of repeats is incremented for each nucleotide in the window. If the number of repeats exceeds a certain threshold, then the repeat expansion is detected.\n\nBoth of these algorithms have their own advantages and disadvantages, and the choice of algorithm will depend on the specific requirements of the application.",
    "llama-7b_fact_raw": "1. The \"sliding window\" approach is an algorithm used for the detection of long repeat expansions.\n2. In the \"sliding window\" approach, the DNA sequence is scanned one nucleotide at a time.\n3. The \"sliding window\" approach involves counting the number of repeats for each nucleotide in the window.\n4. The \"dynamic programming\" approach is another algorithm used for the detection of long repeat expansions.\n5. The \"dynamic programming\" approach uses a matrix to track the number of repeats at each position in the DNA sequence.",
    "llama-7b_fact": [
      "The \"sliding window\" approach is an algorithm used for the detection of long repeat expansions.",
      "In the \"sliding window\" approach, the DNA sequence is scanned one nucleotide at a time.",
      "The \"sliding window\" approach involves counting the number of repeats for each nucleotide in the window.",
      "The \"dynamic programming\" approach is another algorithm used for the detection of long repeat expansions.",
      "The \"dynamic programming\" approach uses a matrix to track the number of repeats at each position in the DNA sequence."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: In the \"sliding window\" approach, the DNA sequence is scanned with a window of a fixed size that slides along the sequence, not just one nucleotide at a time.\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2582,
    "user_query": "You MUST give a detailed answer to the following question: Which brain tumors does neuroligin-3 promote?",
    "llama-7b_response": "Neuroligin-3 is a protein that plays a role in the development and function of the nervous system. It has been shown to promote the growth of certain types of brain tumors, specifically gliomas.\n\nGliomas are a type of brain tumor that arise from glial cells, which are supportive cells in the brain. There are several subtypes of gliomas, including astrocytomas, oligodendrogliomas, and ependymomas. Neuroligin-3 has been found to promote the growth of astrocytomas and oligodendrogliomas, which are two of the most common types of gliomas.\n\nNeuroligin-3 works by promoting the survival and proliferation of glioma cells. It does this by interacting with N-methyl-D-aspartate (NMDA) receptors on the surface of glioma cells. Activation of NMDA receptors can lead to an increase in intracellular calcium levels, which can promote the growth and survival of glioma cells. By interacting with NMDA receptors, neuroligin-3 can enhance the activity of these receptors and promote the growth of glioma cells.\n\nIt is worth noting that the role of neuroligin-3 in gliomas is complex and not fully understood. Further research is needed to fully understand the mechanisms by which neuroligin-3 promotes the growth of gliomas.",
    "llama-7b_fact_raw": "1. Neuroligin-3 is a protein that plays a role in the development and function of the nervous system.\n2. Neuroligin-3 promotes the growth of certain types of brain tumors, specifically gliomas.\n3. Gliomas are brain tumors that arise from glial cells.\n4. Neuroligin-3 has been found to promote the growth of astrocytomas and oligodendrogliomas, which are subtypes of gliomas.\n5. Neuroligin-3 interacts with N-methyl-D-aspartate (NMDA) receptors on glioma cells, which can lead to increased intracellular calcium levels and promote glioma cell growth and survival.",
    "llama-7b_fact": [
      "Neuroligin-3 is a protein that plays a role in the development and function of the nervous system.",
      "Neuroligin-3 promotes the growth of certain types of brain tumors, specifically gliomas.",
      "Gliomas are brain tumors that arise from glial cells.",
      "Neuroligin-3 has been found to promote the growth of astrocytomas and oligodendrogliomas, which are subtypes of gliomas.",
      "Neuroligin-3 interacts with N-methyl-D-aspartate (NMDA) receptors on glioma cells, which can lead to increased intracellular calcium levels and promote glioma cell growth and survival."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2586,
    "user_query": "You MUST give a detailed answer to the following question: What is the approximate size of gas vesicles?",
    "llama-7b_response": "Gas vacuoles, also known as gas vesicles, are small, gas-filled organelles found in some bacteria and archaea. Their size can vary depending on the species and environmental conditions, but they are typically on the order of 1-100 nm in diameter. In some cases, gas vacuoles can reach up to several micrometers in size, but this is relatively rare. It's worth noting that the size of gas vacuoles can be influenced by factors such as nutrient availability, temperature, and pH, which can affect their growth and development.",
    "llama-7b_fact_raw": "1. Gas vesicles are found in some bacteria and archaea.\n2. The typical diameter of gas vesicles is on the order of 1-100 nm.\n3. In some cases, gas vesicles can reach up to several micrometers in size.\n4. The size of gas vesicles can be influenced by nutrient availability, temperature, and pH.",
    "llama-7b_fact": [
      "Gas vesicles are found in some bacteria and archaea.",
      "The typical diameter of gas vesicles is on the order of 1-100 nm.",
      "In some cases, gas vesicles can reach up to several micrometers in size.",
      "The size of gas vesicles can be influenced by nutrient availability, temperature, and pH."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The typical diameter of gas vesicles is on the order of 45-200 nm.\n3. TRUE\n4. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "You MUST give a detailed answer to the following question: List BET proteins.",
    "llama-7b_response": "BET (Bromodomain and Extra-terminal domain) proteins are a family of epigenetic regulators that play a crucial role in the regulation of gene expression. BET proteins are characterized by the presence of two distinct domains: the bromodomain, which recognizes acetylated lysine residues, and the extra-terminal (ET) domain, which is involved in protein-protein interactions and transcriptional regulation.\n\nHere is a non-exhaustive list of BET proteins:\n\n1. BRD2 (Bromodomain-containing protein 2)\n2. BRD3 (Bromodomain-containing protein 3)\n3. BRD4 (Bromodomain-containing protein 4)\n4. BAP1 (Bromodomain-associated protein 1)\n5. BAP3 (Bromodomain-associated protein 3)\n6. BAP2 (Bromodomain-associated protein 2)\n7. BAP4 (Bromodomain-associated protein 4)\n8. BAP5 (Bromodomain-associated protein 5)\n9. BAP6 (Bromodomain-associated protein 6)\n10. BAP7 (Bromodomain-associated protein 7)\n11. BAP8 (Bromodomain-associated protein 8)\n12. BAP9 (Bromodomain-associated protein 9)\n13. BAP10 (Bromodomain-associated protein 10)\n14. BAP11 (Bromodomain-associated protein 11)\n15. BAP12 (Bromodomain-associated protein 12)\n16. BAP13 (Bromodomain-associated protein 13)\n17. BAP14 (Bromodomain-associated protein 14)\n18. BAP15 (Bromodomain-associated protein 15)\n19. BAP16 (Bromodomain-associated protein 16)\n20.",
    "llama-7b_fact_raw": "1. BET proteins are a family of epigenetic regulators involved in the regulation of gene expression.\n2. BET proteins have a bromodomain that recognizes acetylated lysine residues.\n3. BET proteins have an extra-terminal (ET) domain involved in protein-protein interactions and transcriptional regulation.\n4. BRD2 is a member of the BET protein family.\n5. BRD4 is a member of the BET protein family.",
    "llama-7b_fact": [
      "BET proteins are a family of epigenetic regulators involved in the regulation of gene expression.",
      "BET proteins have a bromodomain that recognizes acetylated lysine residues.",
      "BET proteins have an extra-terminal (ET) domain involved in protein-protein interactions and transcriptional regulation.",
      "BRD2 is a member of the BET protein family.",
      "BRD4 is a member of the BET protein family."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "You MUST give a detailed answer to the following question: Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-7b_response": "There are several algorithms that have been developed for the prediction of protein subcellular localization using deep learning, including:\n\n1. Convolutional Neural Networks (CNNs): These are a type of deep learning algorithm that have been used to predict protein subcellular localization by analyzing the amino acid sequence of the protein.\n2. Recurrent Neural Networks (RNNs): These are a type of deep learning algorithm that have been used to predict protein subcellular localization by analyzing the amino acid sequence of the protein and taking into account the context in which the protein is found in the cell.\n3. Autoencoders: These are a type of deep learning algorithm that have been used to predict protein subcellular localization by learning to reconstruct the protein from its amino acid sequence, and then using this reconstruction to predict the subcellular location of the protein.\n4. Generative Adversarial Networks (GANs): These are a type of deep learning algorithm that have been used to predict protein subcellular localization by training two neural networks, one generative and one discriminative, to predict the subcellular location of the protein.\n5. Transformers: These are a type of deep learning algorithm that have been used to predict protein subcellular localization by using a self-attention mechanism to analyze the amino acid sequence of the protein and take into account the context in which the protein is found in the cell.",
    "llama-7b_fact_raw": "1. Convolutional Neural Networks (CNNs) have been used to predict protein subcellular localization by analyzing amino acid sequences.\n2. Recurrent Neural Networks (RNNs) have been used to predict protein subcellular localization by considering the context of proteins in cells.\n3. Autoencoders have been used to predict protein subcellular localization by reconstructing proteins from their amino acid sequences.\n4. Generative Adversarial Networks (GANs) have been used to predict protein subcellular localization by training generative and discriminative neural networks.\n5. Transformers have been used to predict protein subcellular localization by using self-attention mechanisms to analyze amino acid sequences.",
    "llama-7b_fact": [
      "Convolutional Neural Networks (CNNs) have been used to predict protein subcellular localization by analyzing amino acid sequences.",
      "Recurrent Neural Networks (RNNs) have been used to predict protein subcellular localization by considering the context of proteins in cells.",
      "Autoencoders have been used to predict protein subcellular localization by reconstructing proteins from their amino acid sequences.",
      "Generative Adversarial Networks (GANs) have been used to predict protein subcellular localization by training generative and discriminative neural networks.",
      "Transformers have been used to predict protein subcellular localization by using self-attention mechanisms to analyze amino acid sequences."
    ],
    "llama-7b_judge_raw": "1. TRUE: Convolutional Neural Networks (CNNs) have been used in bioinformatics for various tasks, including the prediction of protein subcellular localization by analyzing amino acid sequences.\n2. TRUE: Recurrent Neural Networks (RNNs) are suitable for sequential data and have been used to predict protein subcellular localization by considering the sequential context of amino acids in proteins.\n3. UNKNOWN: While autoencoders are used for unsupervised learning tasks such as dimensionality reduction and feature learning, which could indirectly help with the prediction of protein subcellular localization, it is not clear from the statement whether they have been used directly for this purpose.\n4. UNKNOWN: Generative Adversarial Networks (GANs) are typically used for generating data that is similar to a given distribution. While they could theoretically be applied to the task of predicting protein subcellular localization, the statement does not provide enough information to confirm their use in this context.\n5. TRUE: Transformers, which utilize self-attention mechanisms, have been applied to biological sequence data and could be used to predict protein subcellular localization by analyzing amino acid sequences.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "You MUST give a detailed answer to the following question: What is MULTOVL?",
    "llama-7b_response": "I'm sorry, but I am not familiar with the term \"MULTOVL.\" Without more context or information, it is difficult for me to provide a detailed answer. Could you please provide more information or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2660,
    "user_query": "You MUST give a detailed answer to the following question: Can GDF15 be a biomarker for metformin treatment?",
    "llama-7b_response": "GDF15 (Growth Differentiation Factor 15) is a protein that has been studied as a potential biomarker for various conditions, including aging, cancer, and cardiovascular disease. However, its role as a biomarker for metformin treatment has not been well established.\n\nGDF15 is known to be involved in the regulation of glucose metabolism and insulin sensitivity. Some studies have suggested that GDF15 levels may be elevated in individuals with type 2 diabetes, and that metformin treatment may decrease GDF15 levels. However, other studies have found conflicting results, and the relationship between GDF15 and metformin treatment is not yet fully understood.\n\nTherefore, while GDF15 has been studied as a potential biomarker for metformin treatment, its role in this regard is not yet well established. Further research is needed to clarify the relationship between GDF15 and metformin treatment, and to determine whether GDF15 can be used as a reliable biomarker for metformin efficacy.",
    "llama-7b_fact_raw": "1. GDF15 (Growth Differentiation Factor 15) is a protein that has been studied as a potential biomarker for aging, cancer, and cardiovascular disease.\n2. GDF15 is involved in the regulation of glucose metabolism and insulin sensitivity.\n3. Some studies have suggested that GDF15 levels may be elevated in individuals with type 2 diabetes.\n4. Metformin treatment may decrease GDF15 levels according to some studies.\n5. The role of GDF15 as a biomarker for metformin treatment is not yet well established.",
    "llama-7b_fact": [
      "GDF15 (Growth Differentiation Factor 15) is a protein that has been studied as a potential biomarker for aging, cancer, and cardiovascular disease.",
      "GDF15 is involved in the regulation of glucose metabolism and insulin sensitivity.",
      "Some studies have suggested that GDF15 levels may be elevated in individuals with type 2 diabetes.",
      "Metformin treatment may decrease GDF15 levels according to some studies.",
      "The role of GDF15 as a biomarker for metformin treatment is not yet well established."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Metformin treatment has been associated with increased GDF15 levels according to some studies.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "You MUST give a detailed answer to the following question: Is recursive splicing more common in short introns?",
    "llama-7b_response": "Recursive splicing is more common in short introns.\n\nRecursive splicing occurs when an intron is spliced out of an RNA transcript multiple times, resulting in multiple copies of the intron being present in the final transcript. This phenomenon is more likely to occur in short introns because they are more likely to be spliced out of the transcript multiple times due to their smaller size.\n\nShort introns are more likely to be spliced out of the transcript because they are more likely to interfere with the correct splicing of the coding exons. This is because short introns are more likely to be located in the vicinity of coding exons, which increases the likelihood of the intron being spliced out of the transcript.\n\nIn addition, short introns are more likely to be spliced out of the transcript because they are more likely to contain regulatory elements that can affect the splicing of the coding exons. For example, short introns may contain splicing enhancers or silencers that can affect the splicing of the coding exons, leading to the intron being spliced out of the transcript.\n\nOverall, short introns are more likely to be spliced out of the transcript, which increases the likelihood of recursive splicing occurring. This is because short introns are more likely to be located in the vicinity of coding exons and contain regulatory elements that can affect the splicing of the coding exons.",
    "llama-7b_fact_raw": "1. Recursive splicing is more common in short introns.\n2. Short introns are more likely to be spliced out of an RNA transcript multiple times.\n3. Short introns are more likely to interfere with the correct splicing of the coding exons due to their proximity.\n4. Short introns may contain regulatory elements such as splicing enhancers or silencers that can affect the splicing of the coding exons.\n5. The presence of regulatory elements in short introns can lead to them being spliced out of the transcript.",
    "llama-7b_fact": [
      "Recursive splicing is more common in short introns.",
      "Short introns are more likely to be spliced out of an RNA transcript multiple times.",
      "Short introns are more likely to interfere with the correct splicing of the coding exons due to their proximity.",
      "Short introns may contain regulatory elements such as splicing enhancers or silencers that can affect the splicing of the coding exons.",
      "The presence of regulatory elements in short introns can lead to them being spliced out of the transcript."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Recursive splicing is more common in long introns.\n2. FALSE [correction]: Short introns are typically spliced out of an RNA transcript only once, as they are usually recognized and processed efficiently by the splicing machinery.\n3. UNKNOWN: The statement is speculative and would require specific context or evidence to determine its accuracy.\n4. TRUE: Short introns can indeed contain regulatory elements such as splicing enhancers or silencers that affect the splicing of coding exons.\n5. FALSE [correction]: The presence of regulatory elements in short introns can influence the splicing process, but it does not necessarily lead to the introns being spliced out of the transcript. Regulatory elements can enhance or repress splicing, but they do not dictate the removal of the intron itself.",
    "llama-7b_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 2679,
    "user_query": "You MUST give a detailed answer to the following question: What is the TALE-iD method used for?",
    "llama-7b_response": "The TALE-iD (Transcription Activator-Like Effector-based IDentification) method is a bioinformatics tool used for the identification of transcription factor binding sites (TFBS) in DNA sequences.\n\nTranscription factors (TFs) are proteins that regulate gene expression by binding to specific sequences in the promoter or enhancer regions of target genes. The binding of TFs to these sequences plays a crucial role in the regulation of gene expression, and the identification of TFBS is an important step in understanding gene regulation.\n\nThe TALE-iD method is based on the use of Transcription Activator-Like Effector (TALE) proteins, which are DNA-binding proteins that can be programmed to recognize specific DNA sequences. TALE-iD uses TALE proteins to identify TFBS in a given DNA sequence by measuring the binding affinity of TALE proteins for different regions of the DNA sequence.\n\nThe TALE-iD method works by designing TALE proteins that recognize specific TFBS, and then using these TALE proteins to bind to the DNA sequence of interest. The binding affinity of the TALE proteins for different regions of the DNA sequence is then measured, and the regions with the highest binding affinity are identified as TFBS.\n\nThe TALE-iD method has several advantages over other methods for the identification of TFBS, including its high specificity and sensitivity, as well as its ability to identify TFBS in complex genomic regions. The method has been used to identify TFBS in a variety of organisms, including bacteria, yeast, and mammals, and has been applied to a wide range of research areas, including gene regulation, epigenetics, and drug discovery.\n\nOverall, the TALE-iD method is a powerful tool for the identification of TFBS in DNA sequences, and has the potential to contribute to our understanding of gene regulation and the development of new therapeutics.",
    "llama-7b_fact_raw": "1. The TALE-iD method is used for the identification of transcription factor binding sites in DNA sequences.\n2. Transcription factors regulate gene expression by binding to specific sequences in the promoter or enhancer regions of target genes.\n3. The TALE-iD method uses Transcription Activator-Like Effector proteins to recognize specific DNA sequences.\n4. TALE-iD measures the binding affinity of TALE proteins for different regions of the DNA sequence to identify TFBS.\n5. The TALE-iD method has been used to identify TFBS in organisms such as bacteria, yeast, and mammals.",
    "llama-7b_fact": [
      "The TALE-iD method is used for the identification of transcription factor binding sites in DNA sequences.",
      "Transcription factors regulate gene expression by binding to specific sequences in the promoter or enhancer regions of target genes.",
      "The TALE-iD method uses Transcription Activator-Like Effector proteins to recognize specific DNA sequences.",
      "TALE-iD measures the binding affinity of TALE proteins for different regions of the DNA sequence to identify TFBS.",
      "The TALE-iD method has been used to identify TFBS in organisms such as bacteria, yeast, and mammals."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2747,
    "user_query": "You MUST give a detailed answer to the following question: Which Lisp framework has been developed for image processing?",
    "llama-7b_response": "There are several Lisp frameworks that have been developed for image processing, including:\n\n1. Common Lisp Object System (CLOS)\n2. Lisp Image Processing System (LIPS)\n3. Lisp Machine Image Processing System (LMIPS)\n4. Common Lisp Image Processing (CLIP)\n5. Lisp Machine Image Processing (LMIP)\n\nIt is worth noting that these frameworks are not specific to image processing and can be used for a variety of tasks, including natural language processing, data analysis, and more.",
    "llama-7b_fact_raw": "1. The Common Lisp Object System (CLOS) is a Lisp framework that has been developed for image processing.\n2. The Lisp Image Processing System (LIPS) is a Lisp framework that has been developed for image processing.\n3. The Lisp Machine Image Processing System (LMIPS) is a Lisp framework that has been developed for image processing.\n4. Common Lisp Image Processing (CLIP) is a Lisp framework that has been developed for image processing.\n5. Lisp Machine Image Processing (LMIP) is a Lisp framework that has been developed for image processing.",
    "llama-7b_fact": [
      "The Common Lisp Object System (CLOS) is a Lisp framework that has been developed for image processing.",
      "The Lisp Image Processing System (LIPS) is a Lisp framework that has been developed for image processing.",
      "The Lisp Machine Image Processing System (LMIPS) is a Lisp framework that has been developed for image processing.",
      "Common Lisp Image Processing (CLIP) is a Lisp framework that has been developed for image processing.",
      "Lisp Machine Image Processing (LMIP) is a Lisp framework that has been developed for image processing."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Common Lisp Object System (CLOS) is not specifically developed for image processing; it is a powerful object-oriented programming system integrated into Common Lisp.\n2. UNKNOWN: There is no widely recognized Lisp framework specifically named \"Lisp Image Processing System (LIPS)\" for image processing. It's possible that it could be a specific, less-known or proprietary system, but without more context, its existence cannot be confirmed.\n3. UNKNOWN: Similar to statement 2, there is no widely recognized Lisp framework named \"Lisp Machine Image Processing System (LMIPS).\" It could be a specific system not widely known, but without additional context, its existence cannot be confirmed.\n4. UNKNOWN: \"Common Lisp Image Processing (CLIP)\" could refer to a specific image processing library or framework in Common Lisp, but without more context or specific references, it's not possible to confirm its existence or purpose.\n5. UNKNOWN: As with the previous statements, \"Lisp Machine Image Processing (LMIP)\" is not a widely recognized framework. It could be a specific, less-known system, but without further information, its existence and purpose cannot be confirmed.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "You MUST give a detailed answer to the following question: How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-7b_response": "There are approximately 5,000 genes in the genome of Saccharomyces cerevisiae, also known as baker's yeast. It is believed that the majority of these genes are the result of an ancient whole genome duplication event that occurred approximately 100 million years ago. This event resulted in the duplication of the ancestral yeast genome, leading to the formation of two identical copies of each gene. Over time, many of these duplicate genes have become functionally distinct or have lost their original function, leading to the diversification of the S. cerevisiae genome.",
    "llama-7b_fact_raw": "1. The genome of Saccharomyces cerevisiae contains approximately 5,000 genes.\n2. The majority of the genes in Saccharomyces cerevisiae are believed to be the result of an ancient whole genome duplication event.\n3. The ancient whole genome duplication event in Saccharomyces cerevisiae occurred approximately 100 million years ago.\n4. The whole genome duplication event resulted in two identical copies of each gene in the ancestral yeast genome.\n5. Over time, many of the duplicate genes in Saccharomyces cerevisiae have become functionally distinct or lost their original function.",
    "llama-7b_fact": [
      "The genome of Saccharomyces cerevisiae contains approximately 5,000 genes.",
      "The majority of the genes in Saccharomyces cerevisiae are believed to be the result of an ancient whole genome duplication event.",
      "The ancient whole genome duplication event in Saccharomyces cerevisiae occurred approximately 100 million years ago.",
      "The whole genome duplication event resulted in two identical copies of each gene in the ancestral yeast genome.",
      "Over time, many of the duplicate genes in Saccharomyces cerevisiae have become functionally distinct or lost their original function."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The genome of Saccharomyces cerevisiae contains approximately 6,000 genes.\n2. TRUE\n3. FALSE [correction]: The ancient whole genome duplication event in Saccharomyces cerevisiae is believed to have occurred approximately 100 to 150 million years ago, but the exact timing is still a subject of scientific research and debate.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2763,
    "user_query": "You MUST give a detailed answer to the following question: Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-7b_response": "Estrogen-related receptor β (Esrrb) is a member of the nuclear receptor superfamily of transcription factors. It is a ligand-activated transcription factor that plays a role in the regulation of gene expression in response to estrogen and other steroid hormones.\n\nEsrrb is known to be bound by a variety of compounds, including steroid hormones such as estrogen and androgens, as well as non-steroidal compounds such as tamoxifen and raloxifene. These compounds act as ligands for Esrrb, binding to specific domains on the receptor and activating its transcriptional activity.\n\nEsrrb is expressed in a variety of tissues, including the breast, where it plays a role in the regulation of gene expression in response to estrogen. It has been shown to be involved in the development and progression of breast cancer, and may be a target for the development of new therapeutic strategies for the treatment of this disease.\n\nIn summary, Esrrb is bound by a variety of compounds, including steroid hormones and non-steroidal compounds, and plays a role in the regulation of gene expression in response to estrogen and other steroid hormones. It is expressed in a variety of tissues, including the breast, and may be a target for the development of new therapeutic strategies for the treatment of breast cancer.",
    "llama-7b_fact_raw": "1. Estrogen-related receptor β (Esrrb) is a member of the nuclear receptor superfamily of transcription factors.\n2. Esrrb is a ligand-activated transcription factor that regulates gene expression in response to estrogen and other steroid hormones.\n3. Compounds that bind to Esrrb include steroid hormones such as estrogen and androgens, as well as non-steroidal compounds like tamoxifen and raloxifene.\n4. Esrrb is expressed in various tissues, including the breast.\n5. Esrrb is involved in the development and progression of breast cancer and may be a target for new therapeutic strategies.",
    "llama-7b_fact": [
      "Estrogen-related receptor β (Esrrb) is a member of the nuclear receptor superfamily of transcription factors.",
      "Esrrb is a ligand-activated transcription factor that regulates gene expression in response to estrogen and other steroid hormones.",
      "Compounds that bind to Esrrb include steroid hormones such as estrogen and androgens, as well as non-steroidal compounds like tamoxifen and raloxifene.",
      "Esrrb is expressed in various tissues, including the breast.",
      "Esrrb is involved in the development and progression of breast cancer and may be a target for new therapeutic strategies."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Estrogen-related receptor β (Esrrb) is an orphan nuclear receptor, meaning it is not known to be activated by any naturally occurring ligands such as estrogen or other steroid hormones.\n3. FALSE [correction]: Since Esrrb is an orphan receptor, it is not known to bind to steroid hormones such as estrogen and androgens. However, it may be modulated by synthetic compounds, but the statement as given is incorrect.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2842,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of ZCCHC17?",
    "llama-7b_response": "ZCCHC17, also known as zinc finger CCCH-type zinc finger protein 17, is a protein that plays a crucial role in various cellular processes. The exact function of ZCCHC17 is not fully understood, but it is believed to be involved in the regulation of gene expression.\n\nZCCHC17 is a zinc finger protein, which means it contains multiple zinc ions bound to amino acid side chains in its structure. These zinc ions play a crucial role in the protein's ability to bind to DNA and other molecules. ZCCHC17 contains several zinc finger domains, which allow it to recognize specific DNA sequences and bind to them.\n\nOne of the main functions of ZCCHC17 is to act as a transcription factor, which means it can bind to specific DNA sequences and regulate the expression of genes. Studies have shown that ZCCHC17 can bind to promoter regions of genes and enhance their transcription. This suggests that ZCCHC17 may play a role in the regulation of gene expression in a variety of cells and tissues.\n\nIn addition to its role in transcription, ZCCHC17 has also been implicated in other cellular processes. For example, studies have shown that ZCCHC17 can interact with other proteins and modulate their activity. This suggests that ZCCHC17 may play a role in the regulation of signaling pathways and other cellular processes.\n\nOverall, while the exact function of ZCCHC17 is not fully understood, it is clear that it plays a crucial role in various cellular processes. Further research is needed to fully elucidate the role of ZCCHC17 in the regulation of gene expression and other cellular processes.",
    "llama-7b_fact_raw": "1. ZCCHC17 is also known as zinc finger CCCH-type zinc finger protein 17.\n2. ZCCHC17 is believed to be involved in the regulation of gene expression.\n3. ZCCHC17 is a zinc finger protein, which means it contains multiple zinc ions bound to amino acid side chains in its structure.\n4. ZCCHC17 can act as a transcription factor by binding to specific DNA sequences and regulating the expression of genes.\n5. ZCCHC17 has been shown to interact with other proteins and modulate their activity.",
    "llama-7b_fact": [
      "ZCCHC17 is also known as zinc finger CCCH-type zinc finger protein 17.",
      "ZCCHC17 is believed to be involved in the regulation of gene expression.",
      "ZCCHC17 is a zinc finger protein, which means it contains multiple zinc ions bound to amino acid side chains in its structure.",
      "ZCCHC17 can act as a transcription factor by binding to specific DNA sequences and regulating the expression of genes.",
      "ZCCHC17 has been shown to interact with other proteins and modulate their activity."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: ZCCHC17 is a zinc finger protein, which means it contains zinc ion(s) bound to its structure, but not necessarily multiple zinc ions bound to amino acid side chains. Zinc finger domains typically coordinate zinc ions to stabilize their structure.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2861,
    "user_query": "You MUST give a detailed answer to the following question: Which proteins form the nuclear pore basket in human cells?",
    "llama-7b_response": "The nuclear pore basket, also known as the nuclear pore complex (NPC), is a large protein structure that forms a selective barrier between the nucleus and the cytoplasm of eukaryotic cells. The NPC is composed of multiple copies of a large number of different proteins, and the exact composition of these proteins can vary between different organisms and even between different cell types within the same organism.\n\nIn human cells, the NPC is composed of a number of different proteins, including:\n\n1. Nup107-160: These proteins make up the outer ring of the NPC and are responsible for forming the selective barrier between the nucleus and the cytoplasm.\n2. Nup153: This protein forms part of the inner ring of the NPC and is involved in the transport of molecules through the pore.\n3. Nup214: This protein is involved in the assembly of the NPC and is required for its proper function.\n4. Nup93: This protein forms part of the inner ring of the NPC and is involved in the transport of molecules through the pore.\n5. Nup188: This protein is involved in the assembly of the NPC and is required for its proper function.\n\nThese are just a few examples of the proteins that make up the nuclear pore basket in human cells. There are many other proteins that are also involved in the formation and function of the NPC, and the exact composition of the NPC can vary depending on the cell type and the organism.",
    "llama-7b_fact_raw": "1. Nup107-160 proteins make up the outer ring of the nuclear pore complex (NPC) in human cells.\n2. Nup153 is a protein that forms part of the inner ring of the NPC in human cells.\n3. Nup214 is a protein involved in the assembly of the NPC in human cells.\n4. Nup93 is a protein that forms part of the inner ring of the NPC in human cells.\n5. Nup188 is a protein involved in the assembly of the NPC in human cells.",
    "llama-7b_fact": [
      "Nup107-160 proteins make up the outer ring of the nuclear pore complex (NPC) in human cells.",
      "Nup153 is a protein that forms part of the inner ring of the NPC in human cells.",
      "Nup214 is a protein involved in the assembly of the NPC in human cells.",
      "Nup93 is a protein that forms part of the inner ring of the NPC in human cells.",
      "Nup188 is a protein involved in the assembly of the NPC in human cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Nup153 is a protein that is associated with the nuclear basket of the NPC in human cells, not the inner ring.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "You MUST give a detailed answer to the following question: What type of topoisomerase inhibitor is gepotidacin?",
    "llama-7b_response": "Gepotidacin is a topoisomerase II inhibitor.",
    "llama-7b_fact_raw": "1. Gepotidacin is an inhibitor of topoisomerase II.",
    "llama-7b_fact": [
      "Gepotidacin is an inhibitor of topoisomerase II."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Gepotidacin is an inhibitor of bacterial type II topoisomerases, specifically targeting DNA gyrase (topoisomerase II) and topoisomerase IV, not just topoisomerase II.",
    "llama-7b_judge": [
      "false"
    ]
  },
  {
    "id": 2943,
    "user_query": "You MUST give a detailed answer to the following question: Describe Canvas SPW",
    "llama-7b_response": "I'm sorry, but I'm not sure what you mean by \"Canvas SPW.\" Could you please provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2960,
    "user_query": "You MUST give a detailed answer to the following question: List STING agonists.",
    "llama-7b_response": "STING (Stimulator of Interferon Genes) is a protein that plays a crucial role in the innate immune response to viral infections. STING agonists are compounds or agents that stimulate the activity of STING and enhance the immune response against viral infections. Here are some examples of STING agonists:\n\n1. Cyclic di-GMP (c-di-GMP): c-di-GMP is a bacterial second messenger that regulates various cellular processes, including virulence and host-pathogen interactions. STING agonists such as c-di-GMP have been shown to enhance the immune response against viral infections by activating STING.\n2. Cyclic dinucleotides: Cyclic dinucleotides are a class of small molecules that mimic c-di-GMP. They have been shown to activate STING and enhance the immune response against viral infections.\n3. Cyclic di-GMP mimetics: Cyclic di-GMP mimetics are synthetic compounds that mimic the activity of c-di-GMP. They have been shown to activate STING and enhance the immune response against viral infections.\n4. CpG oligonucleotides: CpG oligonucleotides are synthetic nucleic acids that contain unmethylated CpG dinucleotides. They have been shown to activate STING and enhance the immune response against viral infections.\n5. Poly I:C: Poly I:C is a synthetic analog of double-stranded RNA. It has been shown to activate STING and enhance the immune response against viral infections.\n\nThese are just a few examples of STING agonists. There are many other compounds and agents that have been shown to activate STING and enhance the immune response against viral infections.",
    "llama-7b_fact_raw": "1. Cyclic di-GMP (c-di-GMP) is a bacterial second messenger that can activate STING.\n2. Cyclic dinucleotides are a class of small molecules that can activate STING.\n3. Cyclic di-GMP mimetics are synthetic compounds designed to mimic the activity of c-di-GMP and can activate STING.\n4. CpG oligonucleotides are synthetic nucleic acids containing unmethylated CpG dinucleotides that can activate STING.\n5. Poly I:C is a synthetic analog of double-stranded RNA that can activate STING.",
    "llama-7b_fact": [
      "Cyclic di-GMP (c-di-GMP) is a bacterial second messenger that can activate STING.",
      "Cyclic dinucleotides are a class of small molecules that can activate STING.",
      "Cyclic di-GMP mimetics are synthetic compounds designed to mimic the activity of c-di-GMP and can activate STING.",
      "CpG oligonucleotides are synthetic nucleic acids containing unmethylated CpG dinucleotides that can activate STING.",
      "Poly I:C is a synthetic analog of double-stranded RNA that can activate STING."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Cyclic di-GMP (c-di-GMP) is a bacterial second messenger, but it does not activate STING. It is involved in bacterial intracellular signaling.\n2. TRUE: Cyclic dinucleotides, such as cyclic di-AMP (c-di-AMP) and cyclic GMP-AMP (cGAMP), are a class of small molecules that can activate STING (Stimulator of Interferon Genes).\n3. TRUE: Cyclic di-GMP mimetics are synthetic compounds designed to mimic the activity of c-di-GMP, and some of these mimetics are designed to activate STING.\n4. FALSE [correction]: CpG oligonucleotides are synthetic nucleic acids containing unmethylated CpG dinucleotides that can activate Toll-like receptor 9 (TLR9), not STING.\n5. FALSE [correction]: Poly I:C is a synthetic analog of double-stranded RNA that can activate TLR3 and other pattern recognition receptors, but it is not known to directly activate STING.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2964,
    "user_query": "You MUST give a detailed answer to the following question: Describe SLIC-CAGE",
    "llama-7b_response": "SLIC-CAGE is an acronym that stands for \"Slice-based Layer-wise Integrated Channel Attention and Graph Convolutional Encoder.\" It is a deep learning model that is used for natural language processing (NLP) tasks, such as text classification and sentiment analysis.\n\nThe SLIC-CAGE model is composed of several layers, each of which performs a specific task. The first layer in the model is called the \"Slice-based Layer-wise Integrated Channel Attention\" layer. This layer uses attention mechanisms to focus on different parts of the input text when making predictions.\n\nThe next layer in the SLIC-CAGE model is called the \"Graph Convolutional Encoder.\" This layer uses graph convolutional networks (GCNs) to process the input text as a graph, where each node in the graph represents a word or a subword in the text, and the edges between the nodes represent the relationships between the words.\n\nThe final layer in the SLIC-CAGE model is a classification layer, which uses a softmax function to produce a probability distribution over the possible classes or labels that the input text could belong to.\n\nOverall, the SLIC-CAGE model is a powerful tool for NLP tasks, as it is able to process text as both a sequence of words and as a graph, and it can use attention mechanisms to focus on important parts of the input text when making predictions.",
    "llama-7b_fact_raw": "1. SLIC-CAGE stands for \"Slice-based Layer-wise Integrated Channel Attention and Graph Convolutional Encoder.\"\n2. The SLIC-CAGE model is used for natural language processing tasks such as text classification and sentiment analysis.\n3. The \"Slice-based Layer-wise Integrated Channel Attention\" layer in SLIC-CAGE uses attention mechanisms to focus on different parts of the input text.\n4. The \"Graph Convolutional Encoder\" layer in SLIC-CAGE processes the input text as a graph, with nodes representing words or subwords and edges representing relationships between words.\n5. The final layer of the SLIC-CAGE model uses a softmax function to produce a probability distribution over possible classes or labels for the input text.",
    "llama-7b_fact": [
      "SLIC-CAGE stands for \"Slice-based Layer-wise Integrated Channel Attention and Graph Convolutional Encoder.\"",
      "The SLIC-CAGE model is used for natural language processing tasks such as text classification and sentiment analysis.",
      "The \"Slice-based Layer-wise Integrated Channel Attention\" layer in SLIC-CAGE uses attention mechanisms to focus on different parts of the input text.",
      "The \"Graph Convolutional Encoder\" layer in SLIC-CAGE processes the input text as a graph, with nodes representing words or subwords and edges representing relationships between words.",
      "The final layer of the SLIC-CAGE model uses a softmax function to produce a probability distribution over possible classes or labels for the input text."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: SLIC-CAGE stands for \"Slice-based Layer-wise Integrated Convolutional Attention and Graph Convolutional Encoder.\"\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "You MUST give a detailed answer to the following question: What are the roles of LEM-3?",
    "llama-7b_response": "LEM-3 (Lymphoid Enhancer-Binding Factor 3) is a transcription factor that plays a crucial role in the development and function of the immune system. It is a member of the LEF/TCF (Lymphoid Enhancer-Binding Factor/Transcriptional Coactivator with PDZ-binding motif) family of proteins, which are involved in the regulation of gene expression.\n\nThe main roles of LEM-3 in the immune system are:\n\n1. Regulation of B cell development: LEM-3 is essential for the development of B cells, which are a type of immune cell that produces antibodies to protect against infections. It regulates the expression of genes involved in B cell development and activation.\n2. Regulation of T cell development: LEM-3 also plays a role in the development of T cells, which are a type of immune cell that helps coordinate the immune response. It regulates the expression of genes involved in T cell development and activation.\n3. Regulation of immune response: LEM-3 is involved in the regulation of the immune response to infections and inflammation. It regulates the expression of genes involved in the production of immune cells, the activation of immune responses, and the regulation of inflammation.\n4. Regulation of stem cell function: LEM-3 is also involved in the regulation of stem cell function. It regulates the self-renewal and differentiation of hematopoietic stem cells, which are stem cells that give rise to immune cells.\n\nIn summary, LEM-3 plays a crucial role in the development and function of the immune system by regulating the expression of genes involved in B cell, T cell, and immune response development, as well as stem cell function.",
    "llama-7b_fact_raw": "1. LEM-3 (Lymphoid Enhancer-Binding Factor 3) is a transcription factor involved in the development and function of the immune system.\n2. LEM-3 is a member of the LEF/TCF family of proteins, which regulate gene expression.\n3. LEM-3 is essential for the development of B cells, a type of immune cell that produces antibodies.\n4. LEM-3 plays a role in the development of T cells, a type of immune cell that helps coordinate the immune response.\n5. LEM-3 regulates the self-renewal and differentiation of hematopoietic stem cells, which give rise to immune cells.",
    "llama-7b_fact": [
      "LEM-3 (Lymphoid Enhancer-Binding Factor 3) is a transcription factor involved in the development and function of the immune system.",
      "LEM-3 is a member of the LEF/TCF family of proteins, which regulate gene expression.",
      "LEM-3 is essential for the development of B cells, a type of immune cell that produces antibodies.",
      "LEM-3 plays a role in the development of T cells, a type of immune cell that helps coordinate the immune response.",
      "LEM-3 regulates the self-renewal and differentiation of hematopoietic stem cells, which give rise to immune cells."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: LEM-3 (Lymphoid Enhancer-Binding Factor 3) does not exist. The correct transcription factor is LEF-1 (Lymphoid Enhancer-Binding Factor 1).\n2. TRUE (assuming the reference to LEM-3 was intended to be LEF-1)\n3. UNKNOWN (the specific role of LEF-1 in B cell development is complex and context-dependent, but it is involved in the immune system)\n4. TRUE (LEF-1 is involved in T cell development and function)\n5. UNKNOWN (LEF-1 is known to be involved in the regulation of gene expression in the immune system, but the specific role in the self-renewal and differentiation of hematopoietic stem cells would require more specific information)",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "You MUST give a detailed answer to the following question: List the releases of tmVar",
    "llama-7b_response": "I'm sorry, but I cannot provide a detailed answer to your question as it is not clear what you are asking. Could you please provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3018,
    "user_query": "You MUST give a detailed answer to the following question: Which is the database of somatic mutations in normal cells?",
    "llama-7b_response": "The database of somatic mutations in normal cells is called the Cancer Genome Atlas (TCGA). It is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), both part of the National Institutes of Health (NIH). The TCGA project aims to comprehensively characterize the genomic changes that occur in various types of cancer, with the goal of improving our understanding of cancer biology and identifying potential targets for cancer treatment.\n\nThe TCGA project has generated a vast amount of data on somatic mutations in normal cells, including whole-exome sequencing (WES) and whole-genome sequencing (WGS) data for a large number of cancer tissue samples. This data is publicly available and can be accessed through the TCGA Data Portal, which provides a range of tools and resources for analyzing and interpreting the data.\n\nThe TCGA data has been used to identify recurrent somatic mutations in various types of cancer, as well as to study the genomic changes that occur during cancer development and progression. The data has also been used to identify potential therapeutic targets and to develop new cancer treatments. Overall, the TCGA project has made significant contributions to our understanding of cancer genomics and has the potential to improve the diagnosis, treatment, and prevention of cancer.",
    "llama-7b_fact_raw": "1. The Cancer Genome Atlas (TCGA) is a database of somatic mutations in normal cells.\n2. The TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).\n3. The TCGA project aims to characterize genomic changes in various types of cancer.\n4. The TCGA Data Portal provides access to data including whole-exome sequencing (WES) and whole-genome sequencing (WGS) for cancer tissue samples.\n5. The TCGA data has been used to identify recurrent somatic mutations in different types of cancer and to develop new cancer treatments.",
    "llama-7b_fact": [
      "The Cancer Genome Atlas (TCGA) is a database of somatic mutations in normal cells.",
      "The TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).",
      "The TCGA project aims to characterize genomic changes in various types of cancer.",
      "The TCGA Data Portal provides access to data including whole-exome sequencing (WES) and whole-genome sequencing (WGS) for cancer tissue samples.",
      "The TCGA data has been used to identify recurrent somatic mutations in different types of cancer and to develop new cancer treatments."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Cancer Genome Atlas (TCGA) is a database of somatic mutations in cancer cells, not normal cells.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3037,
    "user_query": "You MUST give a detailed answer to the following question: Are there graph kernel libraries available implemented in JAVA?",
    "llama-7b_response": "Yes, there are several graph kernel libraries available implemented in Java. Some of the popular ones include:\n\n1. Jena: Jena is a Java framework for building Semantic Web and Linked Data applications. It provides a set of libraries for working with RDF and OWL ontologies, as well as a SPARQL query engine. Jena also has support for graph kernels through the use of the Sesame library.\n2. Sesame: Sesame is a Java library for working with RDF and OWL ontologies. It provides a SPARQL query engine and support for graph kernels through the use of the Jena framework.\n3. Apache Jena: Apache Jena is a Java framework for building Semantic Web and Linked Data applications. It provides a set of libraries for working with RDF and OWL ontologies, as well as a SPARQL query engine. Jena also has support for graph kernels through the use of the Sesame library.\n4. OpenCog: OpenCog is a Java-based platform for building intelligent applications. It provides a set of libraries for working with knowledge graphs and has support for graph kernels through the use of the Sesame library.\n\nThese are just a few examples of the many graph kernel libraries available implemented in Java.",
    "llama-7b_fact_raw": "1. Jena is a Java framework for building Semantic Web and Linked Data applications.\n2. Sesame is a Java library that provides a SPARQL query engine and support for graph kernels.\n3. Apache Jena provides libraries for working with RDF and OWL ontologies.\n4. OpenCog is a Java-based platform that includes support for graph kernels.\n5. Both Jena and Sesame libraries have support for graph kernels.",
    "llama-7b_fact": [
      "Jena is a Java framework for building Semantic Web and Linked Data applications.",
      "Sesame is a Java library that provides a SPARQL query engine and support for graph kernels.",
      "Apache Jena provides libraries for working with RDF and OWL ontologies.",
      "OpenCog is a Java-based platform that includes support for graph kernels.",
      "Both Jena and Sesame libraries have support for graph kernels."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Sesame, now known as RDF4J, is a Java framework that provides an API for handling RDF data and includes a SPARQL query engine, but it does not specifically provide support for graph kernels.\n3. TRUE\n4. FALSE [correction]: OpenCog is not a Java-based platform; it is an open-source software project aimed at directly confronting the AGI challenge, using a framework that includes components designed to embody various cognitive processes, but it is primarily written in C++, Scheme, and Python.\n5. FALSE [correction]: While Jena provides libraries for working with RDF, and Sesame (RDF4J) provides an API for handling RDF data and a SPARQL query engine, neither specifically advertises support for graph kernels as part of their core features.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3045,
    "user_query": "You MUST give a detailed answer to the following question: List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-7b_response": "Sure, here are the four advances integrated into the SHERLOCKv2 platform:\n\n1. Machine learning algorithms: SHERLOCKv2 uses machine learning algorithms to analyze and interpret medical images, such as X-rays, CT scans, and MRI scans. These algorithms can detect and diagnose a wide range of medical conditions, including cancer, cardiovascular disease, and neurological disorders.\n2. Artificial intelligence: SHERLOCKv2 is an example of artificial intelligence (AI) in healthcare. AI refers to the ability of computers and machines to perform tasks that typically require human intelligence, such as learning, problem-solving, and decision-making. In the case of SHERLOCKv2, AI is used to analyze medical images and provide accurate diagnoses.\n3. Computer vision: SHERLOCKv2 uses computer vision technology to analyze medical images. Computer vision is the ability of computers and machines to interpret and understand visual information, such as images and videos. In the case of SHERLOCKv2, computer vision is used to analyze X-rays, CT scans, and MRI scans to detect and diagnose medical conditions.\n4. Deep learning: SHERLOCKv2 uses deep learning, a type of machine learning algorithm, to analyze medical images. Deep learning is a subset of machine learning that involves training artificial neural networks to learn from large amounts of data. In the case of SHERLOCKv2, deep learning is used to analyze medical images and provide accurate diagnoses.",
    "llama-7b_fact_raw": "1. SHERLOCKv2 uses machine learning algorithms to analyze and interpret medical images.\n2. SHERLOCKv2 incorporates artificial intelligence to perform tasks such as learning, problem-solving, and decision-making in healthcare.\n3. SHERLOCKv2 employs computer vision technology to interpret and understand visual information from medical images.\n4. SHERLOCKv2 utilizes deep learning, a subset of machine learning, to train artificial neural networks for analyzing medical images.",
    "llama-7b_fact": [
      "SHERLOCKv2 uses machine learning algorithms to analyze and interpret medical images.",
      "SHERLOCKv2 incorporates artificial intelligence to perform tasks such as learning, problem-solving, and decision-making in healthcare.",
      "SHERLOCKv2 employs computer vision technology to interpret and understand visual information from medical images.",
      "SHERLOCKv2 utilizes deep learning, a subset of machine learning, to train artificial neural networks for analyzing medical images."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout additional context or information about SHERLOCKv2, it is not possible to determine the accuracy of these statements. SHERLOCKv2 could be a hypothetical or proprietary system not widely known or documented as of my knowledge cutoff date.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3078,
    "user_query": "You MUST give a detailed answer to the following question: Describe the bartender algorithm",
    "llama-7b_response": "The bartender algorithm is a heuristic algorithm used in the traveling salesman problem (TSP) to find near-optimal solutions to the problem. The algorithm is based on the idea of having a bartender who serves drinks to a group of customers, where the goal is to minimize the total distance traveled by the bartender while serving all the customers.\n\nThe algorithm works as follows:\n\n1. Start with an initial solution, which is a tour that visits all the cities in the TSP problem.\n2. For each city in the tour, calculate the distance between the city and all other cities in the tour.\n3. Select the city with the highest distance from the other cities as the next city to be visited.\n4. Repeat steps 2 and 3 until all cities have been visited.\n\nThe bartender algorithm is a local search algorithm, which means that it only considers the immediate neighborhood of the current solution when making decisions. This makes the algorithm computationally efficient, but it may not find the optimal solution to the TSP problem.\n\nThe bartender algorithm has been shown to be effective in solving small to medium-sized TSP problems, and it is often used as a baseline algorithm for comparing the performance of other TSP-solving algorithms.",
    "llama-7b_fact_raw": "1. The bartender algorithm is used in the traveling salesman problem to find near-optimal solutions.\n2. The goal of the bartender algorithm is to minimize the total distance traveled while serving all customers.\n3. The algorithm starts with an initial tour that visits all the cities in the TSP problem.\n4. The bartender algorithm is a local search algorithm.\n5. The bartender algorithm is considered computationally efficient.",
    "llama-7b_fact": [
      "The bartender algorithm is used in the traveling salesman problem to find near-optimal solutions.",
      "The goal of the bartender algorithm is to minimize the total distance traveled while serving all customers.",
      "The algorithm starts with an initial tour that visits all the cities in the TSP problem.",
      "The bartender algorithm is a local search algorithm.",
      "The bartender algorithm is considered computationally efficient."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The correct term is the \"barter algorithm,\" not the \"bartender algorithm.\" The barter algorithm is used in the traveling salesman problem to find near-optimal solutions.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "You MUST give a detailed answer to the following question: Which web-based pedigree editors are available?",
    "llama-7b_response": "There are several web-based pedigree editors available, including:\n\n1. Geni: Geni is a popular web-based genealogy platform that allows users to create and manage their family trees online. It offers a range of features, including the ability to collaborate with others on your tree, add photos and stories, and connect with other users who are researching the same ancestors.\n2. MyHeritage: MyHeritage is a comprehensive genealogy platform that offers a range of features, including a web-based pedigree editor. Users can create and manage their family trees, add photos and documents, and connect with other users who are researching the same ancestors.\n3. Ancestry: Ancestry is a popular genealogy platform that offers a range of features, including a web-based pedigree editor. Users can create and manage their family trees, add photos and documents, and connect with other users who are researching the same ancestors.\n4. WeRelate: WeRelate is a web-based genealogy platform that allows users to create and manage their family trees online. It offers a range of features, including the ability to collaborate with others on your tree, add photos and stories, and connect with other users who are researching the same ancestors.\n5. WikiTree: WikiTree is a collaborative genealogy platform that allows users to create and manage their family trees online. It offers a range of features, including the ability to collaborate with others on your tree, add photos and stories, and connect with other users who are researching the same ancestors.\n\nThese are just a few examples of the many web-based pedigree editors available. Each platform offers different features and benefits, so it's worth exploring a few to find the one that best suits your needs.",
    "llama-7b_fact_raw": "1. Geni is a web-based genealogy platform that allows users to create and manage their family trees online.\n2. MyHeritage offers a web-based pedigree editor as part of its genealogy platform.\n3. Ancestry provides a web-based pedigree editor for users to create and manage family trees.\n4. WeRelate is a web-based genealogy platform that includes features for creating and managing family trees.\n5. WikiTree is a collaborative genealogy platform with a web-based system for users to create and manage their family trees.",
    "llama-7b_fact": [
      "Geni is a web-based genealogy platform that allows users to create and manage their family trees online.",
      "MyHeritage offers a web-based pedigree editor as part of its genealogy platform.",
      "Ancestry provides a web-based pedigree editor for users to create and manage family trees.",
      "WeRelate is a web-based genealogy platform that includes features for creating and managing family trees.",
      "WikiTree is a collaborative genealogy platform with a web-based system for users to create and manage their family trees."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "You MUST give a detailed answer to the following question: Which curated databases exist for spider-venom toxins?",
    "llama-7b_response": "There are several curated databases that exist for spider venom toxins. Here are some of the most notable ones:\n\n1. Spider Toxin Database (STD): The Spider Toxin Database is a comprehensive resource for spider venom toxins. It provides information on the chemical structure, biological activity, and pharmacological effects of spider venom toxins. The database includes information on toxins from a wide range of spider species, including venomous and non-venomous spiders.\n2. Australian Spider Venom Database (ASVD): The Australian Spider Venom Database is a comprehensive resource for spider venom toxins from Australian spiders. It provides information on the chemical structure, biological activity, and pharmacological effects of spider venom toxins. The database includes information on toxins from a wide range of spider species, including venomous and non-venomous spiders.\n3. World Spider Catalog (WSC): The World Spider Catalog is a comprehensive resource for spider species, including information on their venom toxins. It provides information on the chemical structure, biological activity, and pharmacological effects of spider venom toxins. The database includes information on toxins from a wide range of spider species, including venomous and non-venomous spiders.\n4. Spider Venom Database (SVDB): The Spider Venom Database is a comprehensive resource for spider venom toxins. It provides information on the chemical structure, biological activity, and pharmacological effects of spider venom toxins. The database includes information on toxins from a wide range of spider species, including venomous and non-venomous spiders.\n\nThese databases are valuable resources for researchers studying spider venom toxins, and they provide a wealth of information on the chemical structure, biological activity, and pharmacological effects of spider venom toxins.",
    "llama-7b_fact_raw": "1. The Spider Toxin Database (STD) is a resource that provides information on the chemical structure, biological activity, and pharmacological effects of spider venom toxins.\n2. The Australian Spider Venom Database (ASVD) focuses on spider venom toxins from Australian spiders.\n3. The World Spider Catalog (WSC) includes information on spider species and their venom toxins.\n4. The Spider Venom Database (SVDB) is a resource that provides information on spider venom toxins, including their chemical structure, biological activity, and pharmacological effects.\n5. The databases mentioned include information on toxins from both venomous and non-venomous spider species.",
    "llama-7b_fact": [
      "The Spider Toxin Database (STD) is a resource that provides information on the chemical structure, biological activity, and pharmacological effects of spider venom toxins.",
      "The Australian Spider Venom Database (ASVD) focuses on spider venom toxins from Australian spiders.",
      "The World Spider Catalog (WSC) includes information on spider species and their venom toxins.",
      "The Spider Venom Database (SVDB) is a resource that provides information on spider venom toxins, including their chemical structure, biological activity, and pharmacological effects.",
      "The databases mentioned include information on toxins from both venomous and non-venomous spider species."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The World Spider Catalog (WSC) includes information on spider species, but it does not specifically focus on their venom toxins.\n4. UNKNOWN (Without additional context, it's unclear whether the Spider Venom Database (SVDB) is a real database or has the same or different content from the Spider Toxin Database (STD).)\n5. FALSE [correction]: Typically, databases focusing on spider venom toxins would include information primarily on venomous spider species, as non-venomous spiders do not produce venom toxins.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3111,
    "user_query": "You MUST give a detailed answer to the following question: Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-7b_response": "Axitinib is a medication that is used to treat certain types of cancer, including pancreatic cancer. It is a type of drug called a tyrosine kinase inhibitor, which works by blocking the action of certain proteins that help cancer cells grow and divide.\n\nThere have been several studies that have looked at the use of axitinib in patients with pancreatic cancer. While some of these studies have suggested that axitinib may be able to slow the growth of the cancer and improve survival, the results have been mixed and more research is needed to confirm these findings.\n\nFor example, one study published in the Journal of Clinical Oncology in 2017 found that patients with advanced pancreatic cancer who received axitinib had a longer survival rate compared to those who received standard chemotherapy. However, another study published in the Journal of the National Cancer Institute in 2018 found that axitinib did not improve overall survival in patients with advanced pancreatic cancer.\n\nIt's also worth noting that the use of axitinib in pancreatic cancer is still considered experimental and is not yet widely used as a standard treatment option. More research is needed to fully understand the benefits and risks of using this medication in patients with pancreatic cancer.",
    "llama-7b_fact_raw": "1. Axitinib is used to treat certain types of cancer, including pancreatic cancer.\n2. Axitinib is a tyrosine kinase inhibitor that blocks the action of proteins that help cancer cells grow and divide.\n3. Some studies suggest that axitinib may slow the growth of pancreatic cancer and improve survival, but results are mixed.\n4. A study published in the Journal of Clinical Oncology in 2017 found that axitinib provided a longer survival rate for patients with advanced pancreatic cancer compared to standard chemotherapy.\n5. A study published in the Journal of the National Cancer Institute in 2018 found that axitinib did not improve overall survival in patients with advanced pancreatic cancer.",
    "llama-7b_fact": [
      "Axitinib is used to treat certain types of cancer, including pancreatic cancer.",
      "Axitinib is a tyrosine kinase inhibitor that blocks the action of proteins that help cancer cells grow and divide.",
      "Some studies suggest that axitinib may slow the growth of pancreatic cancer and improve survival, but results are mixed.",
      "A study published in the Journal of Clinical Oncology in 2017 found that axitinib provided a longer survival rate for patients with advanced pancreatic cancer compared to standard chemotherapy.",
      "A study published in the Journal of the National Cancer Institute in 2018 found that axitinib did not improve overall survival in patients with advanced pancreatic cancer."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Axitinib is used to treat advanced renal cell carcinoma (kidney cancer) and not specifically indicated for pancreatic cancer.\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: There is no evidence provided that such a study exists, and axitinib is not typically used for the treatment of pancreatic cancer.\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3113,
    "user_query": "You MUST give a detailed answer to the following question: Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-7b_response": "MLP (Myosin-Light-Chain-Phosphatase) is a protein that plays a crucial role in regulating the dynamics of F-actin, a component of the cytoskeleton. The cytoskeleton is a network of proteins that provides structural support to cells and helps them maintain their shape. F-actin is a key component of the cytoskeleton, and its dynamics are tightly regulated by a variety of proteins.\n\nOne way in which MLP regulates F-actin dynamics is through its interaction with the Arp2/3 complex. The Arp2/3 complex is a protein complex that is responsible for nucleating the formation of new F-actin filaments. MLP interacts with the Arp2/3 complex and helps to regulate its activity, which in turn affects the dynamics of F-actin.\n\nAnother way in which MLP regulates F-actin dynamics is through its interaction with myosin motors. Myosin motors are proteins that move along F-actin filaments and use their energy to generate force. MLP interacts with myosin motors and helps to regulate their activity, which in turn affects the dynamics of F-actin.\n\nOverall, MLP regulates F-actin dynamics through its interactions with the Arp2/3 complex and myosin motors. These interactions help to regulate the formation and breakdown of F-actin filaments, which in turn affects the overall dynamics of the cytoskeleton.",
    "llama-7b_fact_raw": "1. MLP (Myosin-Light-Chain-Phosphatase) regulates the dynamics of F-actin, a component of the cytoskeleton.\n2. The Arp2/3 complex is responsible for nucleating the formation of new F-actin filaments.\n3. MLP interacts with the Arp2/3 complex to regulate its activity and affect F-actin dynamics.\n4. Myosin motors move along F-actin filaments and generate force.\n5. MLP interacts with myosin motors to help regulate their activity, influencing F-actin dynamics.",
    "llama-7b_fact": [
      "MLP (Myosin-Light-Chain-Phosphatase) regulates the dynamics of F-actin, a component of the cytoskeleton.",
      "The Arp2/3 complex is responsible for nucleating the formation of new F-actin filaments.",
      "MLP interacts with the Arp2/3 complex to regulate its activity and affect F-actin dynamics.",
      "Myosin motors move along F-actin filaments and generate force.",
      "MLP interacts with myosin motors to help regulate their activity, influencing F-actin dynamics."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Myosin-Light-Chain-Phosphatase (MLCP) regulates the phosphorylation state of the regulatory light chain of myosin II, not the dynamics of F-actin directly.\n2. TRUE\n3. UNKNOWN: Without specific context or additional information, it is not clear whether MLP interacts with the Arp2/3 complex. This is not a commonly known interaction in the field of cell biology.\n4. TRUE\n5. UNKNOWN: While MLCP does regulate the activity of myosin II by dephosphorylating the regulatory light chain, the statement about direct interaction with myosin motors to help regulate their activity is not specific enough without further context. MLCP's primary known function is to regulate myosin II activity indirectly through dephosphorylation, which can influence F-actin dynamics, but the exact nature of \"interaction\" is not clear from the statement.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "You MUST give a detailed answer to the following question: How many pseudokinases are there in the human kinome?",
    "llama-7b_response": "There are 53 pseudokinases in the human kinome.",
    "llama-7b_fact_raw": "1. There are 53 pseudokinases in the human kinome.",
    "llama-7b_fact": [
      "There are 53 pseudokinases in the human kinome."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The exact number of pseudokinases in the human kinome can vary according to different scientific sources and discoveries. As of my last update, there is no universally agreed-upon number of 53 pseudokinases in the human kinome. The number of pseudokinases identified in the human genome has been reported to be around 10% of the approximately 500-520 known human kinases, which would suggest a number closer to 50-52. However, ongoing research may continue to refine this number.",
    "llama-7b_judge": [
      "false"
    ]
  },
  {
    "id": 3139,
    "user_query": "You MUST give a detailed answer to the following question: List 3 apoE mimetics.",
    "llama-7b_response": "ApoE (apolipoprotein E) is a protein that plays an important role in the transport and metabolism of lipids in the blood. It is a major protein component of high-density lipoproteins (HDL), which are known as the \"good cholesterol\" because they help to remove cholesterol from the bloodstream and prevent it from building up in the arteries.\n\nThere are three main forms of apoE: apoE2, apoE3, and apoE4. ApoE2 and apoE3 are considered \"beneficial\" forms of the protein because they are associated with a lower risk of cardiovascular disease. ApoE4, on the other hand, is considered \"detrimental\" because it is associated with an increased risk of cardiovascular disease and Alzheimer's disease.\n\nOne way to mimic the beneficial effects of apoE is to increase the levels of HDL cholesterol in the blood. This can be done through a healthy diet and regular exercise, as well as through the use of certain medications. Another way to mimic the beneficial effects of apoE is to consume foods or supplements that contain compounds that are similar to apoE. These compounds are known as apoE mimetics.\n\nHere are three examples of apoE mimetics:\n\n1. Omega-3 fatty acids: Omega-3 fatty acids, such as EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), are essential fatty acids that are important for heart health. They have been shown to increase HDL cholesterol levels and reduce the risk of cardiovascular disease. Omega-3 fatty acids can be found in fatty fish, such as salmon and sardines, as well as in supplements.\n2. Resveratrol: Resveratrol is a compound that is found in certain plants, including grapes, berries, and peanuts. It has been shown to have a number of health benefits, including reducing inflammation and improving cardiovascular health. Resveratrol has also been shown to increase HDL cholesterol levels and reduce the risk of cardiovasc",
    "llama-7b_fact_raw": "1. ApoE (apolipoprotein E) is a protein that plays a role in the transport and metabolism of lipids in the blood.\n2. ApoE is a major protein component of high-density lipoproteins (HDL).\n3. There are three main forms of apoE: apoE2, apoE3, and apoE4.\n4. ApoE2 and apoE3 are associated with a lower risk of cardiovascular disease.\n5. ApoE4 is associated with an increased risk of cardiovascular disease and Alzheimer's disease.",
    "llama-7b_fact": [
      "ApoE (apolipoprotein E) is a protein that plays a role in the transport and metabolism of lipids in the blood.",
      "ApoE is a major protein component of high-density lipoproteins (HDL).",
      "There are three main forms of apoE: apoE2, apoE3, and apoE4.",
      "ApoE2 and apoE3 are associated with a lower risk of cardiovascular disease.",
      "ApoE4 is associated with an increased risk of cardiovascular disease and Alzheimer's disease."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: ApoE is a major protein component of very low-density lipoproteins (VLDL) and chylomicrons, not high-density lipoproteins (HDL).\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3140,
    "user_query": "You MUST give a detailed answer to the following question: What are there sex differences in SAMHD1 activity?",
    "llama-7b_response": "Sex differences in SAMHD1 activity have not been extensively studied, but there is some evidence to suggest that there may be differences in SAMHD1 activity between males and females.\n\nSAMHD1 is an important regulator of the HIV-1 life cycle, as it has been shown to inhibit HIV-1 replication by depleting the intracellular pool of deoxynucleoside triphosphates (dNTPs), which are required for HIV-1 reverse transcription. SAMHD1 is primarily expressed in immune cells, such as CD4+ T cells and macrophages, and its activity is thought to be regulated by post-translational modifications, such as phosphorylation and ubiquitination.\n\nA study published in 2018 found that SAMHD1 activity was higher in female compared to male mice, which was associated with higher levels of HIV-1 replication in female mice. However, it is worth noting that this study used a mouse model of HIV-1 infection, and the results may not be directly applicable to humans.\n\nAnother study published in 2020 found that SAMHD1 activity was lower in CD4+ T cells from HIV-1-infected women compared to HIV-1-infected men, which was associated with higher levels of HIV-1 replication in women. However, this study also used a mouse model of HIV-1 infection, and the results may not be directly applicable to humans.\n\nOverall, while there is some evidence to suggest that there may be differences in SAMHD1 activity between males and females, further research is needed to fully understand the role of SAMHD1 in HIV-1 replication and to determine if there are sex differences in SAMHD1 activity in humans.",
    "llama-7b_fact_raw": "1. SAMHD1 is known to inhibit HIV-1 replication by depleting the intracellular pool of deoxynucleoside triphosphates (dNTPs).\n2. SAMHD1 is primarily expressed in immune cells, including CD4+ T cells and macrophages.\n3. A study published in 2018 found that SAMHD1 activity was higher in female mice compared to male mice.\n4. The same 2018 study associated higher SAMHD1 activity in female mice with higher levels of HIV-1 replication in these mice.\n5. A 2020 study found that SAMHD1 activity was lower in CD4+ T cells from HIV-1-infected women compared to HIV-1-infected men.",
    "llama-7b_fact": [
      "SAMHD1 is known to inhibit HIV-1 replication by depleting the intracellular pool of deoxynucleoside triphosphates (dNTPs).",
      "SAMHD1 is primarily expressed in immune cells, including CD4+ T cells and macrophages.",
      "A study published in 2018 found that SAMHD1 activity was higher in female mice compared to male mice.",
      "The same 2018 study associated higher SAMHD1 activity in female mice with higher levels of HIV-1 replication in these mice.",
      "A 2020 study found that SAMHD1 activity was lower in CD4+ T cells from HIV-1-infected women compared to HIV-1-infected men."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: Higher SAMHD1 activity would be associated with lower levels of HIV-1 replication in these mice, as SAMHD1 inhibits HIV-1 replication.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "You MUST give a detailed answer to the following question: Does RUNX2 inhibit astrocyte differentiation?",
    "llama-7b_response": "Yes, RUNX2 has been shown to inhibit astrocyte differentiation.\n\nRUNX2 is a transcription factor that plays a crucial role in the regulation of gene expression during the differentiation of various cell types, including astrocytes. Studies have shown that RUNX2 can inhibit astrocyte differentiation by suppressing the expression of genes involved in the astrocyte lineage.\n\nFor example, a study published in the journal Molecular and Cellular Biology in 2005 found that RUNX2 inhibited the differentiation of neural stem cells into astrocytes by suppressing the expression of genes involved in the astrocyte lineage. The study also found that overexpression of RUNX2 in astrocytes led to the upregulation of genes involved in the oligodendrocyte lineage, indicating that RUNX2 can also affect the differentiation of other cell types.\n\nAdditionally, a study published in the journal Glia in 2012 found that RUNX2 inhibited astrocyte differentiation by suppressing the expression of genes involved in the Wnt signaling pathway, which is a key pathway in the regulation of astrocyte development.\n\nOverall, these studies suggest that RUNX2 can inhibit astrocyte differentiation by suppressing the expression of genes involved in the astrocyte lineage and the Wnt signaling pathway.",
    "llama-7b_fact_raw": "1. RUNX2 is a transcription factor that plays a role in the regulation of gene expression during the differentiation of various cell types, including astrocytes.\n2. RUNX2 has been shown to inhibit astrocyte differentiation by suppressing the expression of genes involved in the astrocyte lineage.\n3. A study published in the journal Molecular and Cellular Biology in 2005 found that RUNX2 inhibited the differentiation of neural stem cells into astrocytes.\n4. The same study indicated that overexpression of RUNX2 led to the upregulation of genes involved in the oligodendrocyte lineage.\n5. A study published in the journal Glia in 2012 found that RUNX2 inhibited astrocyte differentiation by suppressing the expression of genes involved in the Wnt signaling pathway.",
    "llama-7b_fact": [
      "RUNX2 is a transcription factor that plays a role in the regulation of gene expression during the differentiation of various cell types, including astrocytes.",
      "RUNX2 has been shown to inhibit astrocyte differentiation by suppressing the expression of genes involved in the astrocyte lineage.",
      "A study published in the journal Molecular and Cellular Biology in 2005 found that RUNX2 inhibited the differentiation of neural stem cells into astrocytes.",
      "The same study indicated that overexpression of RUNX2 led to the upregulation of genes involved in the oligodendrocyte lineage.",
      "A study published in the journal Glia in 2012 found that RUNX2 inhibited astrocyte differentiation by suppressing the expression of genes involved in the Wnt signaling pathway."
    ],
    "llama-7b_judge_raw": "1. TRUE: RUNX2 is indeed a transcription factor known to play a role in the regulation of gene expression during the differentiation of various cell types, including osteoblasts, which are involved in bone formation. However, its role in astrocyte differentiation is not well-established, so this statement could be misleading if RUNX2 is not typically associated with astrocytes.\n2. UNKNOWN: While RUNX2 is known to be involved in the differentiation of certain cell types, the specific claim that it inhibits astrocyte differentiation by suppressing gene expression involved in the astrocyte lineage would require a specific citation to verify its accuracy.\n3. UNKNOWN: Without access to the specific study from the journal Molecular and Cellular Biology in 2005, the claim that RUNX2 inhibited the differentiation of neural stem cells into astrocytes cannot be verified.\n4. UNKNOWN: Similarly, without access to the specific study, the claim that overexpression of RUNX2 led to the upregulation of genes involved in the oligodendrocyte lineage cannot be verified.\n5. UNKNOWN: The claim that a study published in the journal Glia in 2012 found that RUNX2 inhibited astrocyte differentiation by suppressing the expression of genes involved in the Wnt signaling pathway would need to be verified with the specific study to determine its accuracy.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3209,
    "user_query": "You MUST give a detailed answer to the following question: Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-7b_response": "The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat osteoarthritis of the knee. It involves the removal of a wedge-shaped portion of the articular cartilage from the femoral condyle and the tibial plateau, along with the underlying bone. The goal of the procedure is to relieve pain and improve joint function.\n\nThe Cobb-Stainsby excision arthroplasty is typically performed on the knee joint, specifically on the femoral condyle and the tibial plateau. The procedure is typically performed arthroscopically, which means that it is done through small incisions and using specialized instruments that allow the surgeon to visualize and operate on the joint through these incisions.\n\nThe specific location of the incisions for the Cobb-Stainsby excision arthroplasty will depend on the individual patient and the surgeon's preferred approach. However, in general, the incisions are made on the front (anterior) or back (posterior) of the knee, depending on the location of the damaged cartilage. The surgeon will use these incisions to access the joint and remove the damaged cartilage and underlying bone.\n\nOverall, the Cobb-Stainsby excision arthroplasty is typically performed on the knee joint, specifically on the femoral condyle and the tibial plateau. The procedure is typically performed arthroscopically, which means that it is done through small incisions and using specialized instruments that allow the surgeon to visualize and operate on the joint through these incisions. The specific location of the incisions will depend on the individual patient and the surgeon's preferred approach.",
    "llama-7b_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat osteoarthritis of the knee.\n2. The procedure involves the removal of a wedge-shaped portion of the articular cartilage from the femoral condyle and the tibial plateau, along with the underlying bone.\n3. The goal of the Cobb-Stainsby excision arthroplasty is to relieve pain and improve joint function.\n4. The Cobb-Stainsby excision arthroplasty is typically performed arthroscopically, through small incisions using specialized instruments.\n5. The incisions for the Cobb-Stainsby excision arthroplasty are generally made on the front (anterior) or back (posterior) of the knee.",
    "llama-7b_fact": [
      "The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat osteoarthritis of the knee.",
      "The procedure involves the removal of a wedge-shaped portion of the articular cartilage from the femoral condyle and the tibial plateau, along with the underlying bone.",
      "The goal of the Cobb-Stainsby excision arthroplasty is to relieve pain and improve joint function.",
      "The Cobb-Stainsby excision arthroplasty is typically performed arthroscopically, through small incisions using specialized instruments.",
      "The incisions for the Cobb-Stainsby excision arthroplasty are generally made on the front (anterior) or back (posterior) of the knee."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat osteoarthritis of the hip, not the knee.\n2. FALSE [correction]: The procedure does not involve the removal of a wedge-shaped portion of the articular cartilage from the femoral condyle and the tibial plateau. Instead, it involves the excision of the femoral head and neck, as well as the interposition of soft tissue to prevent bone-on-bone contact in the hip.\n3. TRUE\n4. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is not typically performed arthroscopically. It is an open surgical procedure due to the nature of the excision and the interposition of soft tissue.\n5. UNKNOWN (The statement is specific to knee surgery, which is not applicable to the Cobb-Stainsby excision arthroplasty of the hip. Therefore, the location of incisions for a hip procedure is not addressed in this statement.)",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3243,
    "user_query": "You MUST give a detailed answer to the following question: Does GRHL2 over-expression lead to EMT?",
    "llama-7b_response": "Yes, GRHL2 over-expression has been shown to lead to epithelial-to-mesenchymal transition (EMT) in various cell types.\n\nEpithelial-to-mesenchymal transition (EMT) is a process by which epithelial cells lose their cell-cell adhesion and acquire a mesenchymal phenotype, characterized by the loss of cell-cell adhesion, the upregulation of mesenchymal genes, and the acquisition of a migratory and invasive phenotype.\n\nGRHL2, also known as E-cadherin repressor 2, is a transcription factor that regulates the expression of genes involved in cell-cell adhesion and epithelial differentiation. Over-expression of GRHL2 has been shown to downregulate the expression of E-cadherin, a key protein involved in cell-cell adhesion, and upregulate the expression of mesenchymal genes, leading to EMT in various cell types.\n\nFor example, in breast cancer cells, over-expression of GRHL2 has been shown to downregulate the expression of E-cadherin and upregulate the expression of mesenchymal genes, leading to EMT and increased invasiveness. Similarly, in lung cancer cells, over-expression of GRHL2 has been shown to downregulate the expression of E-cadherin and upregulate the expression of mesenchymal genes, leading to EMT and increased migration and invasion.\n\nTherefore, GRHL2 over-expression has been shown to lead to EMT in various cell types, by downregulating the expression of E-cadherin and upregulating the expression of mesenchymal genes.",
    "llama-7b_fact_raw": "1. GRHL2 over-expression leads to epithelial-to-mesenchymal transition (EMT) in various cell types.\n2. EMT is characterized by the loss of cell-cell adhesion and the acquisition of a mesenchymal phenotype.\n3. GRHL2, also known as Grainyhead-like 2 or E-cadherin repressor 2, is a transcription factor that regulates genes involved in cell-cell adhesion and epithelial differentiation.\n4. Over-expression of GRHL2 downregulates the expression of E-cadherin, a key protein in cell-cell adhesion.\n5. In breast cancer cells, over-expression of GRHL2 leads to EMT and increased invasiveness.",
    "llama-7b_fact": [
      "GRHL2 over-expression leads to epithelial-to-mesenchymal transition (EMT) in various cell types.",
      "EMT is characterized by the loss of cell-cell adhesion and the acquisition of a mesenchymal phenotype.",
      "GRHL2, also known as Grainyhead-like 2 or E-cadherin repressor 2, is a transcription factor that regulates genes involved in cell-cell adhesion and epithelial differentiation.",
      "Over-expression of GRHL2 downregulates the expression of E-cadherin, a key protein in cell-cell adhesion.",
      "In breast cancer cells, over-expression of GRHL2 leads to EMT and increased invasiveness."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: GRHL2, also known as Grainyhead-like 2, is a transcription factor that regulates genes involved in cell-cell adhesion and epithelial differentiation, but it is not known as E-cadherin repressor 2.\n4. FALSE [correction]: Over-expression of GRHL2 typically upregulates the expression of E-cadherin, not downregulates it, as GRHL2 is generally associated with the maintenance of the epithelial phenotype.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3254,
    "user_query": "You MUST give a detailed answer to the following question: Which T-UCRs have been implicated in lung cancer?",
    "llama-7b_response": "There are several T-UCRs that have been implicated in lung cancer. These include:\n\n1. TNF-alpha (Tumor Necrosis Factor-alpha): TNF-alpha is a pro-inflammatory cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n2. Interleukin-1 beta (IL-1 beta): IL-1 beta is another pro-inflammatory cytokine that has been implicated in the development of lung cancer.\n3. Interleukin-6 (IL-6): IL-6 is a cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n4. Interleukin-8 (IL-8): IL-8 is a cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n5. Interleukin-12 (IL-12): IL-12 is a cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n6. Interleukin-18 (IL-18): IL-18 is a cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n7. Interleukin-23 (IL-23): IL-23 is a cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n8. Interleukin-27 (IL-27): IL-27 is a cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n9. Interleukin-35 (IL-35): IL-35 is a cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n10. Interleukin-36 (IL-36): IL-36 is a cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n11. Interleukin-38 (IL-38): IL-38 is a cytokine that has been implicated in the development of several types of cancer, including lung cancer.\n12. Interleukin-40",
    "llama-7b_fact_raw": "1. TNF-alpha (Tumor Necrosis Factor-alpha) has been implicated in the development of lung cancer.\n2. Interleukin-1 beta (IL-1 beta) has been implicated in the development of lung cancer.\n3. Interleukin-6 (IL-6) has been implicated in the development of lung cancer.\n4. Interleukin-8 (IL-8) has been implicated in the development of lung cancer.\n5. Interleukin-12 (IL-12) has been implicated in the development of lung cancer.",
    "llama-7b_fact": [
      "TNF-alpha (Tumor Necrosis Factor-alpha) has been implicated in the development of lung cancer.",
      "Interleukin-1 beta (IL-1 beta) has been implicated in the development of lung cancer.",
      "Interleukin-6 (IL-6) has been implicated in the development of lung cancer.",
      "Interleukin-8 (IL-8) has been implicated in the development of lung cancer.",
      "Interleukin-12 (IL-12) has been implicated in the development of lung cancer."
    ],
    "llama-7b_judge_raw": "1. TRUE: TNF-alpha has been implicated in the development of various types of cancer, including lung cancer, due to its role in inflammation and cell proliferation.\n2. TRUE: IL-1 beta is known to be involved in inflammatory processes and has been implicated in tumor growth and progression, including lung cancer.\n3. TRUE: IL-6 is a cytokine that can promote tumor growth and has been associated with the development and progression of lung cancer.\n4. TRUE: IL-8 is involved in angiogenesis and inflammation, and its expression has been correlated with lung cancer progression.\n5. FALSE [correction]: IL-12 is generally considered to have anti-tumor activity and is involved in the stimulation of the immune response against cancer cells. It is not typically implicated in the development of lung cancer but rather is investigated for its potential therapeutic effects against cancer.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3268,
    "user_query": "You MUST give a detailed answer to the following question: What is known about the orphan receptor GPR151?",
    "llama-7b_response": "GPR151, also known as G protein-coupled receptor 151, is an orphan receptor that belongs to the G protein-coupled receptor (GPCR) family. GPCRs are a large family of transmembrane proteins that play a crucial role in various physiological processes, including signal transduction, cellular communication, and the regulation of various physiological responses.\n\nGPR151 is primarily expressed in the brain, particularly in the hippocampus and cerebral cortex, and has been implicated in various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. However, the precise function of GPR151 and its role in these disorders is not well understood.\n\nSeveral studies have suggested that GPR151 may play a role in the regulation of neurotransmitter release, particularly dopamine and serotonin, in the brain. For example, GPR151 has been shown to modulate the activity of dopamine D2 receptors, which are important regulators of dopamine release in the brain. Additionally, GPR151 has been implicated in the regulation of glutamate release, which is the primary excitatory neurotransmitter in the brain.\n\nFurther research is needed to fully understand the function of GPR151 and its potential as a therapeutic target for various neurological and psychiatric disorders.",
    "llama-7b_fact_raw": "1. GPR151 is known as G protein-coupled receptor 151.\n2. GPR151 belongs to the G protein-coupled receptor (GPCR) family.\n3. GPR151 is primarily expressed in the brain, particularly in the hippocampus and cerebral cortex.\n4. GPR151 has been implicated in neurological and psychiatric disorders such as Alzheimer's disease, Parkinson's disease, and schizophrenia.\n5. Studies suggest that GPR151 may play a role in the regulation of neurotransmitter release, including dopamine and serotonin.",
    "llama-7b_fact": [
      "GPR151 is known as G protein-coupled receptor 151.",
      "GPR151 belongs to the G protein-coupled receptor (GPCR) family.",
      "GPR151 is primarily expressed in the brain, particularly in the hippocampus and cerebral cortex.",
      "GPR151 has been implicated in neurological and psychiatric disorders such as Alzheimer's disease, Parkinson's disease, and schizophrenia.",
      "Studies suggest that GPR151 may play a role in the regulation of neurotransmitter release, including dopamine and serotonin."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "You MUST give a detailed answer to the following question: List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-7b_response": "The Fluzone intradermal quadrivalent vaccine contains attenuated live viruses of four strains of influenza:\n\n1. A/Michigan/45/2015 (H1N1)pdm09-like virus\n2. A/Texas/50/2012 (H3N2) virus\n3. B/Massachusetts/2/2012-like virus (B/Yamagata lineage)\n4. B/Phuket/3073/2013-like virus (B/Victoria lineage)",
    "llama-7b_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus of the A/Michigan/45/2015 (H1N1)pdm09-like strain.\n2. The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus of the A/Texas/50/2012 (H3N2) strain.\n3. The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus of the B/Massachusetts/2/2012-like strain (B/Yamagata lineage).\n4. The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus of the B/Phuket/3073/2013-like strain (B/Victoria lineage).",
    "llama-7b_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus of the A/Michigan/45/2015 (H1N1)pdm09-like strain.",
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus of the A/Texas/50/2012 (H3N2) strain.",
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus of the B/Massachusetts/2/2012-like strain (B/Yamagata lineage).",
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated live virus of the B/Phuket/3073/2013-like strain (B/Victoria lineage)."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine does not contain an attenuated live virus; it contains inactivated (killed) viruses of the strains mentioned for that particular flu season.\n2. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine does not contain an attenuated live virus; it contains inactivated viruses. The specific strains included in the vaccine can vary by flu season, but they are inactivated.\n3. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine does not contain an attenuated live virus; it contains inactivated viruses. The B/Massachusetts/2/2012-like strain (B/Yamagata lineage) may be included in the vaccine, but as an inactivated virus.\n4. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine does not contain an attenuated live virus; it contains inactivated viruses. The B/Phuket/3073/2013-like strain (B/Victoria lineage) may be included in the vaccine, but as an inactivated virus.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3345,
    "user_query": "You MUST give a detailed answer to the following question: Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-7b_response": "The TNFR2 gene, also known as the tumor necrosis factor receptor 2 gene, is located on chromosome 6p21.3 and encodes for a protein that is a key component of the tumor necrosis factor (TNF) receptor superfamily. TNF is a cytokine that plays a central role in the immune system and is involved in the regulation of inflammation, cell growth, and apoptosis (programmed cell death).\n\nSystemic lupus erythematosus (SLE) is an autoimmune disorder that is characterized by the production of autoantibodies and the formation of immune complexes that deposit in various tissues and organs, leading to inflammation, tissue damage, and organ dysfunction. The exact cause of SLE is not fully understood, but it is believed to involve a combination of genetic and environmental factors.\n\nStudies have identified several genetic variants that are associated with an increased risk of developing SLE. One of these variants is a single-nucleotide polymorphism (SNP) located in the promoter region of the TNFR2 gene. This SNP, known as rs763780, has been found to be associated with an increased risk of developing SLE in several studies.\n\nIn summary, the TNFR2 gene is genetically associated with SLE, and a specific SNP located in the promoter region of the gene, rs763780, has been found to be associated with an increased risk of developing the disease.",
    "llama-7b_fact_raw": "1. The TNFR2 gene is located on chromosome 6p21.3.\n2. The TNFR2 gene encodes for a protein that is part of the tumor necrosis factor (TNF) receptor superfamily.\n3. Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by the production of autoantibodies and immune complex deposition.\n4. A single-nucleotide polymorphism (SNP) in the promoter region of the TNFR2 gene, known as rs763780, is associated with an increased risk of developing SLE.\n5. TNF, the cytokine for which the TNFR2 gene encodes a receptor, is involved in the regulation of inflammation, cell growth, and apoptosis.",
    "llama-7b_fact": [
      "The TNFR2 gene is located on chromosome 6p21.3.",
      "The TNFR2 gene encodes for a protein that is part of the tumor necrosis factor (TNF) receptor superfamily.",
      "Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by the production of autoantibodies and immune complex deposition.",
      "A single-nucleotide polymorphism (SNP) in the promoter region of the TNFR2 gene, known as rs763780, is associated with an increased risk of developing SLE.",
      "TNF, the cytokine for which the TNFR2 gene encodes a receptor, is involved in the regulation of inflammation, cell growth, and apoptosis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3353,
    "user_query": "You MUST give a detailed answer to the following question: Is there a vaccine for peanut allergy?",
    "llama-7b_response": "Yes, there is a vaccine for peanut allergy.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3365,
    "user_query": "You MUST give a detailed answer to the following question: What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-7b_response": "The mouse Fxy gene is located on the X chromosome, which is one of the two sex chromosomes in mammals. In mammals, females have two X chromosomes (XX) and males have one X and one Y chromosome (XY). The X chromosome is known to contain a higher number of genes than the Y chromosome, and many of these genes are involved in the development and function of the female reproductive system.\n\nThe position of the Fxy gene on the X chromosome is particularly interesting because it is located in a region that contains several other genes involved in spermatogenesis, the process by which sperm are produced. This suggests that the Fxy gene may play a role in spermatogenesis, either directly or by regulating the expression of other genes in the region.\n\nFurthermore, the Fxy gene is located in a region of the X chromosome that is known to be subject to X-chromosome inactivation, a process by which one of the two X chromosomes in females is randomly silenced in each cell. This process is thought to help balance the expression of genes on the X chromosome and prevent the accumulation of excessive amounts of X-linked genes. It is possible that the Fxy gene is subject to X-chromosome inactivation, which could have implications for its expression and function in different tissues and cell types.\n\nOverall, the chromosomal position of the Fxy gene on the X chromosome and its proximity to other genes involved in spermatogenesis and X-chromosome inactivation make it a particularly interesting gene for further study.",
    "llama-7b_fact_raw": "1. The mouse Fxy gene is located on the X chromosome.\n2. In mammals, females have two X chromosomes, while males have one X and one Y chromosome.\n3. The X chromosome contains a higher number of genes than the Y chromosome.\n4. The Fxy gene is located in a region of the X chromosome that contains several other genes involved in spermatogenesis.\n5. The region of the X chromosome where the Fxy gene is located is subject to X-chromosome inactivation.",
    "llama-7b_fact": [
      "The mouse Fxy gene is located on the X chromosome.",
      "In mammals, females have two X chromosomes, while males have one X and one Y chromosome.",
      "The X chromosome contains a higher number of genes than the Y chromosome.",
      "The Fxy gene is located in a region of the X chromosome that contains several other genes involved in spermatogenesis.",
      "The region of the X chromosome where the Fxy gene is located is subject to X-chromosome inactivation."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about the specific gene Fxy and its location, involvement in spermatogenesis, and whether it is subject to X-chromosome inactivation are not standard knowledge and would require specific genetic research or literature to confirm. Without that specific information, the truth of statements 1, 4, and 5 cannot be determined.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3397,
    "user_query": "You MUST give a detailed answer to the following question: What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-7b_response": "Methiumpropyl-EDTA sequencing (MPE-seq) is a method used to sequence RNA molecules. The method is based on the fact that RNA molecules can bind to Methiumpropyl-EDTA (MPE) molecules with high affinity and specificity.\n\nThe MPE-seq method involves the following steps:\n\n1. The RNA molecules of interest are incubated with MPE molecules.\n2. The RNA-MPE complexes are then separated from the unbound RNA and MPE molecules using a technique such as chromatography or gel electrophoresis.\n3. The RNA-MPE complexes are then denatured to separate the RNA from the MPE molecules.\n4. The denatured RNA-MPE complexes are then incubated with a DNA polymerase and nucleotides.\n5. The DNA polymerase adds nucleotides to the RNA-MPE complexes, extending the RNA molecules.\n6. The extended RNA molecules are then separated from the unextended RNA and MPE molecules using a technique such as chromatography or gel electrophoresis.\n7. The extended RNA molecules are then sequenced to determine the sequence of the RNA molecules.\n\nThe basis of the MPE-seq method is that the RNA molecules bind to the MPE molecules with high affinity and specificity, allowing for the separation of the RNA molecules from the unbound RNA and MPE molecules. The method is then used to determine the sequence of the RNA molecules by sequencing the extended RNA molecules.",
    "llama-7b_fact_raw": "1. Methidiumpropyl-EDTA sequencing (MPE-seq) is a method used to sequence RNA molecules.\n2. RNA molecules can bind to Methidiumpropyl-EDTA (MPE) molecules with high affinity and specificity.\n3. The RNA-MPE complexes can be separated from unbound RNA and MPE molecules using techniques such as chromatography or gel electrophoresis.\n4. DNA polymerase is used to add nucleotides to the RNA-MPE complexes, extending the RNA molecules.\n5. The extended RNA molecules are sequenced to determine the sequence of the RNA molecules.",
    "llama-7b_fact": [
      "Methidiumpropyl-EDTA sequencing (MPE-seq) is a method used to sequence RNA molecules.",
      "RNA molecules can bind to Methidiumpropyl-EDTA (MPE) molecules with high affinity and specificity.",
      "The RNA-MPE complexes can be separated from unbound RNA and MPE molecules using techniques such as chromatography or gel electrophoresis.",
      "DNA polymerase is used to add nucleotides to the RNA-MPE complexes, extending the RNA molecules.",
      "The extended RNA molecules are sequenced to determine the sequence of the RNA molecules."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Methidiumpropyl-EDTA sequencing (MPE-seq) is a method used to sequence DNA molecules, not RNA.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: DNA polymerase is used to add nucleotides to a DNA template, not RNA-MPE complexes. In the context of sequencing, it would be used in methods like Sanger sequencing for DNA, not for extending RNA molecules.\n5. FALSE [correction]: In MPE-seq, the extended DNA molecules (not RNA) are sequenced to determine the sequence of the DNA molecules.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3400,
    "user_query": "You MUST give a detailed answer to the following question: Which programming language has been used for implementing GWAR?",
    "llama-7b_response": "I'm sorry, but I am not aware of any programming language called \"GWAR\" that has been used for implementing anything. Could you please provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3406,
    "user_query": "You MUST give a detailed answer to the following question: Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-7b_response": "Yes, xaliproden has been shown to improve the prognosis of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.\n\nXaliproden is a medication that belongs to a class of drugs called selective serotonin and norepinephrine reuptake inhibitors (SNRIs). It is thought to work by increasing the levels of certain chemicals in the brain, such as serotonin and norepinephrine, which may help to improve symptoms of ALS.\n\nSeveral studies have investigated the use of xaliproden in patients with ALS. One study, published in the journal Neurology, found that patients who took xaliproden had a slower decline in their ability to perform daily activities compared to those who did not take the medication. Another study, published in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, found that patients who took xaliproden had a longer survival time compared to those who did not take the medication.\n\nWhile these studies suggest that xaliproden may improve the prognosis of ALS, more research is needed to confirm these findings and to fully understand the potential benefits and risks of using this medication in patients with this condition.",
    "llama-7b_fact_raw": "1. Xaliproden is a medication that belongs to the class of drugs known as selective serotonin and norepinephrine reuptake inhibitors (SNRIs).\n2. Xaliproden is thought to work by increasing levels of chemicals like serotonin and norepinephrine in the brain.\n3. A study published in the journal Neurology found that ALS patients taking xaliproden had a slower decline in their ability to perform daily activities.\n4. Another study in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration found that ALS patients taking xaliproden had a longer survival time.\n5. More research is needed to confirm the findings regarding the benefits and risks of xaliproden for ALS patients.",
    "llama-7b_fact": [
      "Xaliproden is a medication that belongs to the class of drugs known as selective serotonin and norepinephrine reuptake inhibitors (SNRIs).",
      "Xaliproden is thought to work by increasing levels of chemicals like serotonin and norepinephrine in the brain.",
      "A study published in the journal Neurology found that ALS patients taking xaliproden had a slower decline in their ability to perform daily activities.",
      "Another study in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration found that ALS patients taking xaliproden had a longer survival time.",
      "More research is needed to confirm the findings regarding the benefits and risks of xaliproden for ALS patients."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Xaliproden is not classified as a selective serotonin and norepinephrine reuptake inhibitor (SNRI). It is an experimental drug that was being studied for the treatment of neurodegenerative diseases, including ALS (amyotrophic lateral sclerosis), and for cognitive impairment associated with Alzheimer's disease.\n2. UNKNOWN: Without specific information on the mechanism of action of xaliproden, it is difficult to confirm whether it works by increasing levels of serotonin and norepinephrine in the brain.\n3. UNKNOWN: Without access to the specific study published in the journal Neurology, the veracity of this statement cannot be determined.\n4. UNKNOWN: Similarly, without access to the specific study in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, the veracity of this statement cannot be determined.\n5. TRUE: This is a general statement that applies to most experimental drugs and treatments, including xaliproden, where further research is typically needed to confirm findings regarding their benefits and risks.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "You MUST give a detailed answer to the following question: In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-7b_response": "In the case of the LiPS-A3S line, the transgenes are inserted into the X chromosome.",
    "llama-7b_fact_raw": "1. The transgenes in the LiPS-A3S line are inserted into the X chromosome.",
    "llama-7b_fact": [
      "The transgenes in the LiPS-A3S line are inserted into the X chromosome."
    ],
    "llama-7b_judge_raw": "UNKNOWN\n\nWithout specific context or additional information about the \"LiPS-A3S line\" and what it pertains to (e.g., a particular study, genetic modification experiment, or a specific organism), it is not possible to determine the accuracy of the statement regarding the location of transgene insertion.",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "You MUST give a detailed answer to the following question: Which tool exist for predicting drug synergy with deep learning?",
    "llama-7b_response": "There are several tools available for predicting drug synergy using deep learning, including:\n\n1. DeepDrug: This is a deep learning-based method for predicting drug synergy and toxicity. It uses a convolutional neural network (CNN) to analyze the chemical structure of drugs and predict their potential toxicity and synergy with other drugs.\n2. DS-Net: DS-Net is a deep learning-based method for predicting drug synergy and toxicity. It uses a neural network to analyze the chemical structure of drugs and predict their potential toxicity and synergy with other drugs.\n3. ChemNet: ChemNet is a deep learning-based method for predicting drug synergy and toxicity. It uses a neural network to analyze the chemical structure of drugs and predict their potential toxicity and synergy with other drugs.\n4. DrugSyn: DrugSyn is a deep learning-based method for predicting drug synergy and toxicity. It uses a neural network to analyze the chemical structure of drugs and predict their potential toxicity and synergy with other drugs.\n\nThese are just a few examples of the many tools available for predicting drug synergy using deep learning.",
    "llama-7b_fact_raw": "1. DeepDrug is a tool that uses a convolutional neural network to predict drug synergy and toxicity.\n2. DS-Net is a deep learning-based method designed to predict drug synergy and toxicity.\n3. ChemNet is a tool that employs deep learning to analyze the chemical structure of drugs for predicting synergy and toxicity.\n4. DrugSyn utilizes a neural network for the prediction of drug synergy and toxicity.",
    "llama-7b_fact": [
      "DeepDrug is a tool that uses a convolutional neural network to predict drug synergy and toxicity.",
      "DS-Net is a deep learning-based method designed to predict drug synergy and toxicity.",
      "ChemNet is a tool that employs deep learning to analyze the chemical structure of drugs for predicting synergy and toxicity.",
      "DrugSyn utilizes a neural network for the prediction of drug synergy and toxicity."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n\nWithout specific context or additional information about \"ChemNet\" and \"DrugSyn,\" it is not possible to confirm the accuracy of statements 3 and 4. These names could refer to real tools or be hypothetical; without further details, their functions cannot be verified.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "You MUST give a detailed answer to the following question: Which cloud-based platform has been developed for comparing GWAS?",
    "llama-7b_response": "There are several cloud-based platforms that have been developed for comparing genome-wide association studies (GWAS). Some examples include:\n\n1. The National Center for Biotechnology Information's (NCBI) dbGaP (Database of Genotypes and Phenotypes): dbGaP is a public database that provides access to genotype and phenotype data from large-scale genetic studies, including GWAS.\n2. The National Institutes of Health's (NIH) National Center for Biotechnology Information's (NCBI) Gene Expression Omnibus (GEO): GEO is a public database that provides access to gene expression data from a variety of sources, including GWAS.\n3. The European Bioinformatics Institute's (EBI) ArrayExpress: ArrayExpress is a public database that provides access to gene expression data from microarray experiments, including GWAS.\n4. The Wellcome Sanger Institute's GWAS Catalog: The GWAS Catalog is a public database that provides access to summary-level data from large-scale GWAS studies.\n\nThese are just a few examples of cloud-based platforms that have been developed for comparing GWAS data. There are many others, and the choice of platform will depend on the specific needs and goals of the researcher.",
    "llama-7b_fact_raw": "1. The National Center for Biotechnology Information's dbGaP is a public database for accessing genotype and phenotype data from genetic studies, including GWAS.\n2. The National Institutes of Health's Gene Expression Omnibus is a public database that provides access to gene expression data, including from GWAS.\n3. The European Bioinformatics Institute's ArrayExpress is a public database that offers access to gene expression data from microarray experiments, including GWAS.\n4. The Wellcome Sanger Institute's GWAS Catalog is a public database that provides access to summary-level data from large-scale GWAS studies.",
    "llama-7b_fact": [
      "The National Center for Biotechnology Information's dbGaP is a public database for accessing genotype and phenotype data from genetic studies, including GWAS.",
      "The National Institutes of Health's Gene Expression Omnibus is a public database that provides access to gene expression data, including from GWAS.",
      "The European Bioinformatics Institute's ArrayExpress is a public database that offers access to gene expression data from microarray experiments, including GWAS.",
      "The Wellcome Sanger Institute's GWAS Catalog is a public database that provides access to summary-level data from large-scale GWAS studies."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The European Bioinformatics Institute's ArrayExpress is a public database that offers access to gene expression data from microarray experiments, but it does not include GWAS (Genome-Wide Association Studies) data.\n4. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3434,
    "user_query": "You MUST give a detailed answer to the following question: Can CMB305 be used against sarcomas?",
    "llama-7b_response": "CMB305 is a monoclonal antibody that targets the CD19 antigen, which is expressed on the surface of B-cells, including malignant B-cells in various B-cell malignancies such as chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).\n\nSarcomas are a diverse group of malignant tumors that arise from the mesenchymal tissues, such as bone, cartilage, fat, muscle, and connective tissue. These tumors do not express CD19 antigen on their surface, so CMB305 would not be effective against sarcomas.\n\nHowever, there are other monoclonal antibodies that target different antigens expressed on the surface of sarcoma cells, such as bevacizumab (Avastin), which targets vascular endothelial growth factor (VEGF), and pazopanib (Votrient), which targets vascular endothelial growth factor receptor (VEGFR). These antibodies may be used in combination with chemotherapy or other targeted therapies to treat sarcomas.",
    "llama-7b_fact_raw": "1. CMB305 is a monoclonal antibody that targets the CD19 antigen.\n2. CD19 antigen is expressed on the surface of B-cells, including malignant B-cells in various B-cell malignancies.\n3. Sarcomas arise from mesenchymal tissues and do not express the CD19 antigen on their surface.\n4. CMB305 would not be effective against sarcomas because they do not express CD19.\n5. Bevacizumab (Avastin) targets vascular endothelial growth factor (VEGF), and pazopanib (Votrient) targets vascular endothelial growth factor receptor (VEGFR), and these antibodies may be used to treat sarcomas.",
    "llama-7b_fact": [
      "CMB305 is a monoclonal antibody that targets the CD19 antigen.",
      "CD19 antigen is expressed on the surface of B-cells, including malignant B-cells in various B-cell malignancies.",
      "Sarcomas arise from mesenchymal tissues and do not express the CD19 antigen on their surface.",
      "CMB305 would not be effective against sarcomas because they do not express CD19.",
      "Bevacizumab (Avastin) targets vascular endothelial growth factor (VEGF), and pazopanib (Votrient) targets vascular endothelial growth factor receptor (VEGFR), and these antibodies may be used to treat sarcomas."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Bevacizumab (Avastin) is a monoclonal antibody that targets VEGF, but pazopanib (Votrient) is not an antibody; it is a small molecule tyrosine kinase inhibitor that targets VEGFR among other kinases, and these drugs may be used to treat sarcomas.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3461,
    "user_query": "You MUST give a detailed answer to the following question: What are manifestations of the Saint's Triad?",
    "llama-7b_response": "The manifestations of the Saint's Triad refer to the various ways in which the three aspects of the divine - the Father, the Son, and the Holy Spirit - are revealed or made known to humanity. These manifestations can take many different forms, depending on the religious tradition or belief system in question.\n\nIn Christianity, for example, the manifestations of the Saint's Triad can be seen in the life, teachings, death, and resurrection of Jesus Christ, who is believed to be the Son of God. The Holy Spirit is also present in the form of the Church, which is seen as the body of Christ on earth.\n\nIn Hinduism, the manifestations of the Saint's Triad can be seen in the trinity of Brahma, Vishnu, and Shiva, who are the creator, preserver, and destroyer of the universe, respectively.\n\nIn Buddhism, the manifestations of the Saint's Triad can be seen in the three jewels of Buddhism: the Buddha, the Dharma (the teachings of the Buddha), and the Sangha (the community of Buddhist practitioners).\n\nOverall, the manifestations of the Saint's Triad can be seen as the various ways in which the divine is made known to humanity, and can take many different forms depending on the religious tradition or belief system in question.",
    "llama-7b_fact_raw": "1. In Christianity, the Saint's Triad is manifested in the life, teachings, death, and resurrection of Jesus Christ.\n2. The Holy Spirit in Christianity is manifested through the Church, which is considered the body of Christ on earth.\n3. In Hinduism, the Saint's Triad is represented by the trinity of Brahma, Vishnu, and Shiva.\n4. Brahma, Vishnu, and Shiva are seen as the creator, preserver, and destroyer of the universe, respectively, in Hinduism.\n5. In Buddhism, the Saint's Triad is manifested in the three jewels: the Buddha, the Dharma, and the Sangha.",
    "llama-7b_fact": [
      "In Christianity, the Saint's Triad is manifested in the life, teachings, death, and resurrection of Jesus Christ.",
      "The Holy Spirit in Christianity is manifested through the Church, which is considered the body of Christ on earth.",
      "In Hinduism, the Saint's Triad is represented by the trinity of Brahma, Vishnu, and Shiva.",
      "Brahma, Vishnu, and Shiva are seen as the creator, preserver, and destroyer of the universe, respectively, in Hinduism.",
      "In Buddhism, the Saint's Triad is manifested in the three jewels: the Buddha, the Dharma, and the Sangha."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: In Christianity, the Holy Trinity, not the \"Saint's Triad,\" is manifested in the Father, the Son (Jesus Christ), and the Holy Spirit.\n2. TRUE\n3. FALSE [correction]: In Hinduism, the concept similar to a trinity is known as the Trimurti, not the \"Saint's Triad.\"\n4. TRUE\n5. FALSE [correction]: In Buddhism, the concept similar to a trinity is known as the Three Jewels or the Triple Gem, not the \"Saint's Triad.\"",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3470,
    "user_query": "You MUST give a detailed answer to the following question: Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-7b_response": "Yes, overexpression of LY6K has been associated with better prognosis for non-small cell lung cancer (NSCLC) patients.\n\nLY6K, also known as galectin-9, is a protein that plays a role in cell-cell and cell-matrix interactions. It has been found to be overexpressed in various types of cancer, including NSCLC.\n\nSeveral studies have investigated the prognostic significance of LY6K expression in NSCLC. One study, published in the Journal of Thoracic Oncology, analyzed the expression of LY6K and other biomarkers in a cohort of NSCLC patients and found that high LY6K expression was associated with better overall survival and disease-free survival.\n\nAnother study, published in the Journal of Clinical Oncology, analyzed the expression of LY6K and other biomarkers in a large cohort of NSCLC patients and found that high LY6K expression was associated with improved overall survival and progression-free survival.\n\nThese findings suggest that overexpression of LY6K may be a favorable prognostic factor for NSCLC patients. However, further research is needed to confirm these findings and to better understand the role of LY6K in the development and progression of NSCLC.",
    "llama-7b_fact_raw": "1. Overexpression of LY6K has been associated with better prognosis for non-small cell lung cancer (NSCLC) patients.\n2. LY6K is a protein that plays a role in cell-cell and cell-matrix interactions.\n3. A study published in the Journal of Thoracic Oncology found that high LY6K expression was associated with better overall survival and disease-free survival in NSCLC patients.\n4. Another study published in the Journal of Clinical Oncology found that high LY6K expression was associated with improved overall survival and progression-free survival in NSCLC patients.\n5. Further research is needed to confirm the findings regarding the role of LY6K in the development and progression of NSCLC.",
    "llama-7b_fact": [
      "Overexpression of LY6K has been associated with better prognosis for non-small cell lung cancer (NSCLC) patients.",
      "LY6K is a protein that plays a role in cell-cell and cell-matrix interactions.",
      "A study published in the Journal of Thoracic Oncology found that high LY6K expression was associated with better overall survival and disease-free survival in NSCLC patients.",
      "Another study published in the Journal of Clinical Oncology found that high LY6K expression was associated with improved overall survival and progression-free survival in NSCLC patients.",
      "Further research is needed to confirm the findings regarding the role of LY6K in the development and progression of NSCLC."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Overexpression of LY6K has been associated with poor prognosis for non-small cell lung cancer (NSCLC) patients.\n2. TRUE\n3. FALSE [correction]: A study published in the Journal of Thoracic Oncology found that high LY6K expression was associated with poor overall survival and disease-free survival in NSCLC patients.\n4. UNKNOWN (Without access to the specific article from the Journal of Clinical Oncology, it is not possible to confirm the accuracy of this statement.)\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3473,
    "user_query": "You MUST give a detailed answer to the following question: List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-7b_response": "Cdk targets that are dephosphorylated during cytokinesis include:\n\n1. Cyclin B1: Cyclin B1 is dephosphorylated by Cdk1 during cytokinesis, allowing it to be degraded by the ubiquitin-proteasome pathway.\n2. Plk1: Plk1 is dephosphorylated by Cdk1 during cytokinesis, allowing it to be inactivated and degraded by the proteasome.\n3. Aurora B: Aurora B is dephosphorylated by Cdk1 during cytokinesis, allowing it to be inactivated and degraded by the proteasome.\n4. Borealin: Borealin is dephosphorylated by Cdk1 during cytokinesis, allowing it to be inactivated and degraded by the proteasome.\n5. Mid1: Mid1 is dephosphorylated by Cdk1 during cytokinesis, allowing it to be inactivated and degraded by the proteasome.",
    "llama-7b_fact_raw": "1. Cyclin B1 is dephosphorylated by Cdk1 during cytokinesis.\n2. Plk1 is dephosphorylated by Cdk1 during cytokinesis.\n3. Aurora B is dephosphorylated by Cdk1 during cytokinesis.\n4. Borealin is dephosphorylated by Cdk1 during cytokinesis.\n5. Mid1 is dephosphorylated by Cdk1 during cytokinesis.",
    "llama-7b_fact": [
      "Cyclin B1 is dephosphorylated by Cdk1 during cytokinesis.",
      "Plk1 is dephosphorylated by Cdk1 during cytokinesis.",
      "Aurora B is dephosphorylated by Cdk1 during cytokinesis.",
      "Borealin is dephosphorylated by Cdk1 during cytokinesis.",
      "Mid1 is dephosphorylated by Cdk1 during cytokinesis."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Cyclin B1 is not dephosphorylated by Cdk1 during cytokinesis; rather, it is targeted for degradation during the metaphase-anaphase transition.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe specific roles and interactions of these proteins during cytokinesis can be complex and context-dependent, and without specific information from the passage, it is difficult to confirm the phosphorylation status changes of Plk1, Aurora B, Borealin, and Mid1 by Cdk1 during cytokinesis.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3508,
    "user_query": "You MUST give a detailed answer to the following question: What is Xanamem?",
    "llama-7b_response": "Xanamem is a medication that is used to treat Alzheimer's disease. It is a type of drug called a cholinesterase inhibitor, which works by increasing the levels of a chemical called acetylcholine in the brain. Acetylcholine is a neurotransmitter that is important for memory and cognitive function.\n\nXanamem is different from other cholinesterase inhibitors in that it is a prodrug, which means that it must be converted into its active form in the body before it can be effective. This conversion is catalyzed by an enzyme called butyrylcholinesterase, which is found in high levels in the brain. By inhibiting this enzyme, Xanamem is able to increase the levels of acetylcholine for a longer period of time, which can improve memory and cognitive function in people with Alzheimer's disease.\n\nXanamem is typically taken as a pill or a liquid, and the dosage and frequency of administration will depend on the individual patient and their response to the medication. Side effects of Xanamem may include nausea, diarrhea, and constipation, and it is important for patients to report any side effects to their healthcare provider.",
    "llama-7b_fact_raw": "1. Xanamem is used to treat Alzheimer's disease.\n2. Xanamem is a type of drug called a cholinesterase inhibitor.\n3. Xanamem works by increasing the levels of acetylcholine, a neurotransmitter important for memory and cognitive function.\n4. Xanamem is a prodrug that must be converted into its active form in the body by an enzyme called butyrylcholinesterase.\n5. Side effects of Xanamem may include nausea, diarrhea, and constipation.",
    "llama-7b_fact": [
      "Xanamem is used to treat Alzheimer's disease.",
      "Xanamem is a type of drug called a cholinesterase inhibitor.",
      "Xanamem works by increasing the levels of acetylcholine, a neurotransmitter important for memory and cognitive function.",
      "Xanamem is a prodrug that must be converted into its active form in the body by an enzyme called butyrylcholinesterase.",
      "Side effects of Xanamem may include nausea, diarrhea, and constipation."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without specific information on a drug named \"Xanamem,\" it is not possible to confirm its use. As of my last update, there is no widely recognized drug by that name approved for the treatment of Alzheimer's disease. Common drugs for Alzheimer's include donepezil, rivastigmine, and memantine.\n\n2. UNKNOWN: Since the existence and classification of \"Xanamem\" are not confirmed, it is not possible to accurately state whether it is a cholinesterase inhibitor.\n\n3. UNKNOWN: Without confirmation of what \"Xanamem\" is and how it works, it is not possible to determine the mechanism of action of the drug.\n\n4. UNKNOWN: The statement about \"Xanamem\" being a prodrug and its conversion in the body cannot be confirmed without specific information about the drug.\n\n5. UNKNOWN: Without confirmed information about \"Xanamem,\" it is not possible to list its side effects accurately. Side effects listed are common for cholinesterase inhibitors, but without knowing if \"Xanamem\" is indeed a drug and what its classification is, this statement cannot be verified.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-7b_response": "The Hof1-Cyk3 interaction plays a critical role in regulating the cellular response to oxidative stress in yeast. Hof1 is a ubiquitin-conjugating enzyme that adds ubiquitin molecules to proteins, marking them for degradation by the proteasome. Cyk3 is a member of the cytochrome c oxidase complex, which is responsible for generating ATP through the oxidation of molecular oxygen.\n\nDuring oxidative stress, the activity of the cytochrome c oxidase complex is inhibited, leading to the accumulation of reactive oxygen species (ROS) within the mitochondria. The Hof1-Cyk3 interaction plays a key role in sensing this increase in ROS and activating the cellular response to oxidative stress.\n\nWhen the Hof1-Cyk3 interaction is disrupted, the cellular response to oxidative stress is impaired, leading to increased sensitivity to oxidative stress and cell death. Conversely, overexpression of Hof1 or Cyk3 leads to increased resistance to oxidative stress, suggesting that the Hof1-Cyk3 interaction plays a critical role in regulating the cellular response to oxidative stress in yeast.\n\nOverall, the Hof1-Cyk3 interaction plays a crucial role in regulating the cellular response to oxidative stress in yeast by sensing the accumulation of ROS within the mitochondria and activating the cellular response to oxidative stress. Disruption of the Hof1-Cyk3 interaction leads to increased sensitivity to oxidative stress and cell death, while overexpression of Hof1 or Cyk3 leads to increased resistance to oxidative stress, suggesting that the Hof1-Cyk3 interaction plays a critical role in regulating the cellular response to oxidative stress in yeast.",
    "llama-7b_fact_raw": "1. The Hof1-Cyk3 interaction regulates the cellular response to oxidative stress in yeast.\n2. Hof1 is a ubiquitin-conjugating enzyme that marks proteins for degradation by the proteasome.\n3. Cyk3 is a member of the cytochrome c oxidase complex, which is involved in ATP generation through the oxidation of molecular oxygen.\n4. Disruption of the Hof1-Cyk3 interaction impairs the cellular response to oxidative stress, leading to increased sensitivity and cell death.\n5. Overexpression of Hof1 or Cyk3 increases resistance to oxidative stress in yeast.",
    "llama-7b_fact": [
      "The Hof1-Cyk3 interaction regulates the cellular response to oxidative stress in yeast.",
      "Hof1 is a ubiquitin-conjugating enzyme that marks proteins for degradation by the proteasome.",
      "Cyk3 is a member of the cytochrome c oxidase complex, which is involved in ATP generation through the oxidation of molecular oxygen.",
      "Disruption of the Hof1-Cyk3 interaction impairs the cellular response to oxidative stress, leading to increased sensitivity and cell death.",
      "Overexpression of Hof1 or Cyk3 increases resistance to oxidative stress in yeast."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Hof1 is not a ubiquitin-conjugating enzyme; it is a protein involved in cytokinesis in yeast.\n3. FALSE [correction]: Cyk3 is not a member of the cytochrome c oxidase complex; it is a protein involved in cell wall remodeling and cytokinesis in yeast.\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "You MUST give a detailed answer to the following question: Which T-UCRs have been implicated in gastric cancer?",
    "llama-7b_response": "There are several T-UCRs that have been implicated in gastric cancer. These include:\n\n1. TNF-alpha: TNF-alpha is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. It has been shown to promote cell proliferation, angiogenesis, and invasion in gastric cancer cells.\n2. IL-1beta: IL-1beta is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. It has been shown to promote cell proliferation, angiogenesis, and invasion in gastric cancer cells.\n3. IL-6: IL-6 is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. It has been shown to promote cell proliferation, angiogenesis, and invasion in gastric cancer cells.\n4. IL-8: IL-8 is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. It has been shown to promote cell proliferation, angiogenesis, and invasion in gastric cancer cells.\n5. IL-12: IL-12 is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. It has been shown to promote cell proliferation, angiogenesis, and invasion in gastric cancer cells.\n6. IL-18: IL-18 is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. It has been shown to promote cell proliferation, angiogenesis, and invasion in gastric cancer cells.\n7. IFN-gamma: IFN-gamma is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. It has been shown to promote cell proliferation, angiogenesis, and invasion in gastric cancer cells.\n8. TGF-beta: TGF-beta is a cytokine that has been implicated in the development of gastric cancer. It has been shown to promote cell proliferation, angiogenesis, and",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3607,
    "user_query": "You MUST give a detailed answer to the following question: What is the Lupus Severity Index (LSI)?",
    "llama-7b_response": "The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects various body systems, including the skin, joints, kidneys, heart, and lungs. The LSI was developed in the 1970s and is based on a combination of clinical and laboratory criteria.\n\nThe LSI is calculated based on the presence and severity of various SLE manifestations, such as malar rash (a butterfly-shaped rash on the cheeks), photosensitivity, discoid rash (a red, scaly rash on the skin), arthritis, nephritis (inflammation of the kidneys), and hematologic abnormalities (such as anemia or thrombocytopenia). The score ranges from 0 to 4, with higher scores indicating more severe disease.\n\nThe LSI is widely used in clinical practice and research to assess the disease activity and response to treatment in patients with SLE. It is also used to monitor the progression of the disease over time and to identify patients who may be at risk of disease flares or organ damage.\n\nIn summary, the Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects various body systems. It is based on a combination of clinical and laboratory criteria and is calculated based on the presence and severity of various SLE manifestations. The score ranges from 0 to 4, with higher scores indicating more severe disease. The LSI is widely used in clinical practice and research to assess the disease activity and response to treatment in patients with SLE and to monitor the progression of the disease over time.",
    "llama-7b_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI was developed in the 1970s.\n3. The LSI score ranges from 0 to 4, with higher scores indicating more severe disease.\n4. The LSI is based on a combination of clinical and laboratory criteria, including manifestations such as malar rash, photosensitivity, discoid rash, arthritis, nephritis, and hematologic abnormalities.\n5. The LSI is used in clinical practice and research to assess disease activity, response to treatment, and to monitor the progression of SLE.",
    "llama-7b_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI was developed in the 1970s.",
      "The LSI score ranges from 0 to 4, with higher scores indicating more severe disease.",
      "The LSI is based on a combination of clinical and laboratory criteria, including manifestations such as malar rash, photosensitivity, discoid rash, arthritis, nephritis, and hematologic abnormalities.",
      "The LSI is used in clinical practice and research to assess disease activity, response to treatment, and to monitor the progression of SLE."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: The statement about the Lupus Severity Index (LSI) being used to assess the severity of systemic lupus erythematosus (SLE) could be true, but without specific information about the LSI, it's not possible to confirm its use or existence. The more commonly known tool for assessing SLE is the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).\n\n2. UNKNOWN: Without specific information about the development of the LSI, it is not possible to confirm when it was developed. The SLEDAI, for example, was developed later than the 1970s.\n\n3. UNKNOWN: The score range for the LSI is not verifiable without specific information about the index. The SLEDAI, for instance, has a different scoring range.\n\n4. UNKNOWN: While the criteria listed are indeed associated with SLE and are used in various assessment tools, without specific information about the LSI, it is not possible to confirm that these are the exact criteria it uses.\n\n5. UNKNOWN: The use of the LSI in clinical practice and research to assess disease activity, response to treatment, and to monitor the progression of SLE cannot be confirmed without specific information about the LSI. Tools like the SLEDAI or the British Isles Lupus Assessment Group (BILAG) index are known to be used for these purposes.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "You MUST give a detailed answer to the following question: Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-7b_response": "De novo mutations are genetic changes that occur for the first time in an individual and are not inherited from the parents. ZSWIM6 is a gene that has been implicated in several human disorders, and some of these disorders may be caused by de novo mutations in this gene.\n\nOne disorder associated with de novo mutations in ZSWIM6 is autism spectrum disorder (ASD). ASD is a neurodevelopmental disorder characterized by social impairments, communication difficulties, and repetitive behaviors. Studies have identified mutations in ZSWIM6 as a risk factor for ASD, suggesting that de novo mutations in this gene may contribute to the development of this disorder.\n\nAnother disorder associated with de novo mutations in ZSWIM6 is intellectual disability (ID). ID is a condition characterized by significant impairments in cognitive abilities and adaptive skills, and it can range from mild to severe. Studies have identified mutations in ZSWIM6 as a risk factor for ID, suggesting that de novo mutations in this gene may contribute to the development of this disorder.\n\nIt's worth noting that these are just a few examples of disorders associated with de novo mutations in ZSWIM6, and further research is needed to fully understand the role of this gene in human health and disease.",
    "llama-7b_fact_raw": "1. De novo mutations in ZSWIM6 are associated with autism spectrum disorder (ASD).\n2. Autism spectrum disorder is characterized by social impairments, communication difficulties, and repetitive behaviors.\n3. Studies have identified mutations in ZSWIM6 as a risk factor for autism spectrum disorder.\n4. De novo mutations in ZSWIM6 are associated with intellectual disability (ID).\n5. Intellectual disability is characterized by significant impairments in cognitive abilities and adaptive skills.",
    "llama-7b_fact": [
      "De novo mutations in ZSWIM6 are associated with autism spectrum disorder (ASD).",
      "Autism spectrum disorder is characterized by social impairments, communication difficulties, and repetitive behaviors.",
      "Studies have identified mutations in ZSWIM6 as a risk factor for autism spectrum disorder.",
      "De novo mutations in ZSWIM6 are associated with intellectual disability (ID).",
      "Intellectual disability is characterized by significant impairments in cognitive abilities and adaptive skills."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "You MUST give a detailed answer to the following question: Which disease can be classified using the Koos Classification?",
    "llama-7b_response": "The Koos Classification is a system for classifying diseases of the foot and ankle. It was developed by Dr. Cornelis Koos, a Dutch orthopedic surgeon, and is used to categorize foot and ankle disorders based on their etiology, anatomy, and pathology.\n\nThe Koos Classification system includes several categories of foot and ankle disorders, including:\n\n1. Neuropathic foot: This category includes disorders that affect the nerves of the foot and ankle, such as neuropathy, Charcot foot, and diabetic foot ulcers.\n2. Arthritic foot: This category includes disorders that affect the joints of the foot and ankle, such as osteoarthritis, rheumatoid arthritis, and gout.\n3. Mechanical foot: This category includes disorders that affect the bones, muscles, and tendons of the foot and ankle, such as bunions, hammertoes, and Achilles tendinitis.\n4. Traumatic foot: This category includes disorders that result from trauma to the foot and ankle, such as fractures, dislocations, and crush injuries.\n5. Infectious foot: This category includes disorders that are caused by infection, such as bacterial, fungal, and viral infections.\n\nIn summary, the Koos Classification system can be used to classify a wide range of foot and ankle disorders, including neuropathic, arthritic, mechanical, traumatic, and infectious disorders.",
    "llama-7b_fact_raw": "1. The Koos Classification is a system for classifying diseases of the foot and ankle.\n2. It was developed by Dr. Cornelis Koos, a Dutch orthopedic surgeon.\n3. The Koos Classification system categorizes foot and ankle disorders based on etiology, anatomy, and pathology.\n4. Disorders such as neuropathy, Charcot foot, and diabetic foot ulcers fall under the neuropathic foot category in the Koos Classification.\n5. Conditions like osteoarthritis, rheumatoid arthritis, and gout are included in the arthritic foot category of the Koos Classification.",
    "llama-7b_fact": [
      "The Koos Classification is a system for classifying diseases of the foot and ankle.",
      "It was developed by Dr. Cornelis Koos, a Dutch orthopedic surgeon.",
      "The Koos Classification system categorizes foot and ankle disorders based on etiology, anatomy, and pathology.",
      "Disorders such as neuropathy, Charcot foot, and diabetic foot ulcers fall under the neuropathic foot category in the Koos Classification.",
      "Conditions like osteoarthritis, rheumatoid arthritis, and gout are included in the arthritic foot category of the Koos Classification."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Koos Classification is not a system for classifying diseases of the foot and ankle. The correct classification system for knee injuries is the KOOS (Knee injury and Osteoarthritis Outcome Score).\n2. FALSE [correction]: The KOOS was not developed by Dr. Cornelis Koos, but rather it was developed by a group of researchers at the Department of Orthopedics at Lund University in Sweden.\n3. FALSE [correction]: The KOOS Classification system is not for categorizing foot and ankle disorders; it is a patient-reported outcome measurement used to assess a person's opinion about their knee and associated problems.\n4. FALSE [correction]: Since the Koos Classification is not for foot and ankle disorders, neuropathy, Charcot foot, and diabetic foot ulcers would not fall under a neuropathic foot category in the Koos Classification.\n5. FALSE [correction]: Conditions like osteoarthritis, rheumatoid arthritis, and gout would not be included in an arthritic foot category of the Koos Classification, as it is not a classification system for foot and ankle disorders.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3628,
    "user_query": "You MUST give a detailed answer to the following question: What are the in vivo effects of AZD8601?",
    "llama-7b_response": "AZD8601, also known as AT-1212, is a selective and potent agonist of the AT-1 receptor, which is a subtype of the angiotensin II type 1 receptor (AT-1 receptor). The AT-1 receptor is a G protein-coupled receptor that plays a key role in the regulation of blood pressure and cardiovascular function.\n\nIn vivo studies have shown that AZD8601 has potent and selective agonist activity at the AT-1 receptor, with little to no activity at other receptors, including the AT-2 and AT-3 receptors. This selective activity makes AZD8601 a useful tool for studying the physiological and pharmacological effects of the AT-1 receptor.\n\nIn vivo studies have also shown that AZD8601 has potent and dose-dependent effects on blood pressure and cardiovascular function. For example, acute administration of AZD8601 to rats has been shown to increase mean arterial pressure, heart rate, and cardiac output, while decreasing systemic vascular resistance. These effects are thought to be mediated by the activation of the AT-1 receptor and the subsequent activation of downstream signaling pathways, including the renin-angiotensin-aldosterone system (RAAS).\n\nIn addition to its effects on blood pressure and cardiovascular function, AZD8601 has also been shown to have effects on other physiological systems. For example, acute administration of AZD8601 to rats has been shown to increase glomerular filtration rate and renal blood flow, while decreasing sodium and water retention. These effects are thought to be mediated by the activation of the AT-1 receptor and the subsequent activation of downstream signaling pathways, including the RAAS.\n\nOverall, the in vivo effects of AZD8601 are thought to be mediated by the activation of the AT-1 receptor and the subsequent activation of downstream signaling pathways, including the RAAS. These effects include the regulation of blood pressure and cardiovascular function, as well as effect",
    "llama-7b_fact_raw": "1. AZD8601 is a selective and potent agonist of the AT-1 receptor.\n2. In vivo studies have shown that AZD8601 has little to no activity at the AT-2 and AT-3 receptors.\n3. Acute administration of AZD8601 to rats increases mean arterial pressure, heart rate, and cardiac output.\n4. AZD8601 decreases systemic vascular resistance when administered acutely to rats.\n5. AZD8601 has been shown to increase glomerular filtration rate and renal blood flow, while decreasing sodium and water retention in rats.",
    "llama-7b_fact": [
      "AZD8601 is a selective and potent agonist of the AT-1 receptor.",
      "In vivo studies have shown that AZD8601 has little to no activity at the AT-2 and AT-3 receptors.",
      "Acute administration of AZD8601 to rats increases mean arterial pressure, heart rate, and cardiac output.",
      "AZD8601 decreases systemic vascular resistance when administered acutely to rats.",
      "AZD8601 has been shown to increase glomerular filtration rate and renal blood flow, while decreasing sodium and water retention in rats."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: AZD8601 is not an agonist of the AT-1 receptor; it is actually an mRNA-based therapy designed to increase the expression of VEGF-A, which is a protein involved in angiogenesis.\n2. UNKNOWN: Without specific information on AZD8601's activity at AT-2 and AT-3 receptors, it is not possible to determine the truthfulness of this statement.\n3. UNKNOWN: The effects of AZD8601 on mean arterial pressure, heart rate, and cardiac output in rats would depend on its mechanism of action, which is not typical of an AT-1 receptor agonist but rather a gene therapy approach. Therefore, without specific study results, the effects are unknown.\n4. UNKNOWN: Similar to statement 3, without specific study results on the acute administration of AZD8601 to rats, the effect on systemic vascular resistance is unknown.\n5. UNKNOWN: The effects of AZD8601 on glomerular filtration rate, renal blood flow, and sodium and water retention in rats would require specific study data to confirm, and since AZD8601 is focused on VEGF-A expression for angiogenesis, these effects are not directly related to its primary function.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "You MUST give a detailed answer to the following question: How are SAHFS created?",
    "llama-7b_response": "SAHFS (Secure Access to Healthcare Facilities and Services) are created through a process that involves several key steps:\n\n1. Identification of healthcare facilities and services: The first step in creating a SAHFS is to identify the healthcare facilities and services that are to be included in the agreement. This may involve consulting with relevant government agencies, non-governmental organizations, and other stakeholders to determine which facilities and services are most in need of support.\n2. Negotiation and signing of the agreement: Once the list of healthcare facilities and services has been established, the next step is to negotiate and sign a SAHFS agreement with the government of the country in question. This agreement should outline the terms and conditions of the support provided by the donor country, including the amount and duration of the funding, as well as any specific conditions or requirements that must be met in order to receive support.\n3. Implementation of the agreement: Once the agreement has been signed, the donor country must work with the government of the recipient country to implement the agreement. This may involve providing technical assistance and support to help the recipient country develop the necessary infrastructure and capacity to effectively manage and deliver healthcare services.\n4. Monitoring and evaluation of the agreement: It is important for both the donor country and the recipient country to monitor and evaluate the progress of the SAHFS agreement to ensure that it is being implemented effectively and that the intended outcomes are being achieved. This may involve conducting regular reviews and assessments, as well as collecting and analyzing data on the impact of the support provided.\n\nOverall, the process of creating a SAHFS involves a collaborative effort between the donor country and the recipient country, with a focus on identifying the most pressing healthcare needs and working together to develop and implement a plan to address those needs.",
    "llama-7b_fact_raw": "1. SAHFS stands for Secure Access to Healthcare Facilities and Services.\n2. The creation of a SAHFS involves identifying healthcare facilities and services that need support.\n3. A SAHFS agreement is negotiated and signed with the government of the country that requires support.\n4. The implementation of a SAHFS agreement may include providing technical assistance to the recipient country.\n5. Monitoring and evaluation are part of the process to ensure the effectiveness of a SAHFS agreement.",
    "llama-7b_fact": [
      "SAHFS stands for Secure Access to Healthcare Facilities and Services.",
      "The creation of a SAHFS involves identifying healthcare facilities and services that need support.",
      "A SAHFS agreement is negotiated and signed with the government of the country that requires support.",
      "The implementation of a SAHFS agreement may include providing technical assistance to the recipient country.",
      "Monitoring and evaluation are part of the process to ensure the effectiveness of a SAHFS agreement."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: SAHFS typically stands for \"State Animal Health/Food Safety Laboratory,\" not \"Secure Access to Healthcare Facilities and Services.\"\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe acronym SAHFS is not commonly associated with \"Secure Access to Healthcare Facilities and Services,\" and without additional context, it is not possible to verify the processes involved in creating a SAHFS agreement or its implementation, monitoring, and evaluation.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3672,
    "user_query": "You MUST give a detailed answer to the following question: What is the function of the PDZ domain in SATB1?",
    "llama-7b_response": "The PDZ domain is a protein interaction domain found in many proteins, including the transcription factor SATB1 (Special AT-rich sequence-binding protein 1). The function of the PDZ domain in SATB1 is to mediate protein-protein interactions with other proteins.\n\nThe PDZ domain in SATB1 specifically binds to other proteins that contain a PDZ-binding motif, which is a specific sequence of amino acids. The PDZ domain in SATB1 interacts with a variety of proteins, including other transcription factors, cytoskeletal proteins, and scaffolding proteins.\n\nOne of the key functions of the PDZ domain in SATB1 is to regulate the localization and activity of SATB1. By interacting with other proteins, the PDZ domain in SATB1 can target SATB1 to specific subcellular locations, such as the nucleus or the cytoplasm. Additionally, the PDZ domain in SATB1 can modulate the activity of SATB1 by recruiting other proteins that regulate its transcriptional activity.\n\nOverall, the PDZ domain in SATB1 plays a crucial role in regulating the function of SATB1 by mediating protein-protein interactions with other proteins.",
    "llama-7b_fact_raw": "1. The PDZ domain is a protein interaction domain found in SATB1.\n2. The function of the PDZ domain in SATB1 is to mediate protein-protein interactions.\n3. The PDZ domain in SATB1 binds to proteins that contain a PDZ-binding motif.\n4. The PDZ domain in SATB1 helps regulate the localization and activity of SATB1.\n5. The PDZ domain in SATB1 can target SATB1 to specific subcellular locations.",
    "llama-7b_fact": [
      "The PDZ domain is a protein interaction domain found in SATB1.",
      "The function of the PDZ domain in SATB1 is to mediate protein-protein interactions.",
      "The PDZ domain in SATB1 binds to proteins that contain a PDZ-binding motif.",
      "The PDZ domain in SATB1 helps regulate the localization and activity of SATB1.",
      "The PDZ domain in SATB1 can target SATB1 to specific subcellular locations."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The PDZ domain is a common protein interaction domain, but SATB1 does not contain a PDZ domain.\n2. TRUE (Given the context of the PDZ domain generally, this statement is true as PDZ domains mediate protein-protein interactions.)\n3. TRUE (This statement is generally true for PDZ domains; they bind to proteins that contain a PDZ-binding motif.)\n4. UNKNOWN (Without specific information on the PDZ domain in SATB1, which does not exist, the statement's applicability to SATB1 is unknown.)\n5. UNKNOWN (As SATB1 does not have a PDZ domain, the statement's applicability to SATB1 is unknown.)",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3678,
    "user_query": "You MUST give a detailed answer to the following question: What is the basis of the BLISS technique?",
    "llama-7b_response": "The BLISS technique is based on the principles of classical conditioning and operant conditioning.\n\nClassical conditioning is a learning process in which an association is made between a naturally occurring stimulus (the \"unconditioned stimulus\") and a previously neutral stimulus (the \"conditioned stimulus\"). The conditioned stimulus then elicits the same response as the unconditioned stimulus.\n\nOperant conditioning is a learning process in which behavior is modified by its consequences. Positive reinforcement increases the likelihood of the behavior occurring again, while negative reinforcement decreases the likelihood of the behavior occurring again. Punishment decreases the likelihood of the behavior occurring again.\n\nThe BLISS technique uses both classical conditioning and operant conditioning to help individuals with insomnia associate their bed and bedroom with relaxation and sleep. The technique involves the following steps:\n\n1. Bedtime routine: Establish a consistent bedtime routine that includes relaxing activities, such as reading a book or taking a warm bath, before going to bed.\n2. Bed association: Associate the bed and bedroom with relaxation and sleep by spending time in the bed and bedroom only for sleeping and sex. Avoid other activities, such as watching TV or working, in the bed and bedroom.\n3. Low stimulus environment: Create a low stimulus environment in the bed and bedroom by minimizing noise, light, and other distractions.\n4. Sleep-promoting cues: Use sleep-promoting cues, such as lavender essential oil or white noise, to signal to the brain that it is time to sleep.\n5. Sleep onset associations: Use classical conditioning to associate the bed and bedroom with sleep by associating the bed and bedroom with relaxation and sleep. This can be done by using positive reinforcement, such as giving oneself a reward (e.g., a glass of milk) when they get into bed and stay there until they fall asleep.\n\nBy using the BLISS technique, individuals with insomnia can learn to associate their bed and bedroom with relaxation and sleep, which can help them fall asleep faster and sleep more soundly.",
    "llama-7b_fact_raw": "1. The BLISS technique is based on the principles of classical conditioning and operant conditioning.\n2. Classical conditioning involves making an association between a naturally occurring stimulus and a previously neutral stimulus.\n3. Operant conditioning is a learning process where behavior is modified by its consequences, including positive reinforcement, negative reinforcement, and punishment.\n4. The BLISS technique is used to help individuals with insomnia associate their bed and bedroom with relaxation and sleep.\n5. Part of the BLISS technique involves establishing a consistent bedtime routine that includes relaxing activities before going to bed.",
    "llama-7b_fact": [
      "The BLISS technique is based on the principles of classical conditioning and operant conditioning.",
      "Classical conditioning involves making an association between a naturally occurring stimulus and a previously neutral stimulus.",
      "Operant conditioning is a learning process where behavior is modified by its consequences, including positive reinforcement, negative reinforcement, and punishment.",
      "The BLISS technique is used to help individuals with insomnia associate their bed and bedroom with relaxation and sleep.",
      "Part of the BLISS technique involves establishing a consistent bedtime routine that includes relaxing activities before going to bed."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe accuracy of statements 1, 4, and 5 depends on the specific details of the BLISS technique, which is not a widely recognized or standard term in psychology or sleep therapy as of my knowledge cutoff date. Without additional context or information about the BLISS technique, it is not possible to confirm or correct these statements.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "You MUST give a detailed answer to the following question: List 3 NK3R antagonists.",
    "llama-7b_response": "NK3 receptors are G protein-coupled receptors that play a role in the regulation of neurotransmitter release in the nervous system. They are activated by the neurokinin-3 (NK3) peptide and are involved in a variety of physiological processes, including pain perception, inflammation, and cardiovascular function.\n\nThere are several NK3 receptor antagonists that have been developed as potential therapeutic agents. Here are three examples:\n\n1. L-733060: L-733060 is a potent and selective NK3 receptor antagonist that has been used in a number of preclinical studies to investigate the role of NK3 receptors in various physiological processes. It has been shown to block the effects of the NK3 peptide on neurotransmitter release and to have analgesic and anti-inflammatory effects in animal models.\n2. AT-1212: AT-1212 is another selective NK3 receptor antagonist that has been investigated for its potential therapeutic applications. It has been shown to block the effects of the NK3 peptide on neurotransmitter release and to have analgesic and anti-inflammatory effects in animal models.\n3. SB-612125: SB-612125 is a potent and selective NK3 receptor antagonist that has been used in a number of preclinical studies to investigate the role of NK3 receptors in various physiological processes. It has been shown to block the effects of the NK3 peptide on neurotransmitter release and to have analgesic and anti-inflammatory effects in animal models.",
    "llama-7b_fact_raw": "1. L-733060 is a potent and selective NK3 receptor antagonist.\n2. AT-1212 is a selective NK3 receptor antagonist.\n3. SB-612125 is a potent and selective NK3 receptor antagonist.",
    "llama-7b_fact": [
      "L-733060 is a potent and selective NK3 receptor antagonist.",
      "AT-1212 is a selective NK3 receptor antagonist.",
      "SB-612125 is a potent and selective NK3 receptor antagonist."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nWithout specific information on the compounds L-733060, AT-1212, and SB-612125, it is not possible to verify the accuracy of these statements. The context does not provide enough details to determine the truthfulness of the claims regarding their pharmacological properties.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "You MUST give a detailed answer to the following question: Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-7b_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is known as AT-1212. It was developed by the Japanese pharmaceutical company Astellas Pharma and was initially studied for its potential use in the treatment of type 2 diabetes. AT-1212 works by binding to the ghrelin receptor (GHS-R1a) and inhibiting the activity of ghrelin, which is a hormone that is released by the stomach and plays a role in regulating hunger and appetite.\n\nAT-1212 has been studied in a number of clinical trials, including a phase 2b trial in which it was shown to be effective in reducing body weight and improving glycemic control in overweight or obese individuals with type 2 diabetes. However, the development of AT-1212 has been discontinued due to concerns about its safety profile, including an increased risk of cardiovascular events in some patients.\n\nIt's worth noting that there are other oral ghrelin receptor inverse agonists that have been developed and are currently being studied for potential use in the treatment of various conditions, including type 2 diabetes, obesity, and other metabolic disorders. However, AT-1212 was the first such drug to be profiled in healthy subjects, and it paved the way for further research in this area.",
    "llama-7b_fact_raw": "1. AT-1212 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\n2. The Japanese pharmaceutical company Astellas Pharma developed AT-1212.\n3. AT-1212 was initially studied for its potential use in the treatment of type 2 diabetes.\n4. AT-1212 has been shown to be effective in reducing body weight and improving glycemic control in overweight or obese individuals with type 2 diabetes in a phase 2b trial.\n5. The development of AT-1212 has been discontinued due to concerns about its safety profile, including an increased risk of cardiovascular events in some patients.",
    "llama-7b_fact": [
      "AT-1212 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
      "The Japanese pharmaceutical company Astellas Pharma developed AT-1212.",
      "AT-1212 was initially studied for its potential use in the treatment of type 2 diabetes.",
      "AT-1212 has been shown to be effective in reducing body weight and improving glycemic control in overweight or obese individuals with type 2 diabetes in a phase 2b trial.",
      "The development of AT-1212 has been discontinued due to concerns about its safety profile, including an increased risk of cardiovascular events in some patients."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information on AT-1212, its development, and clinical trials, it is not possible to determine the truthfulness of these statements. They would require access to detailed pharmaceutical research data or official statements from the company that developed AT-1212, which is not provided in the context.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "You MUST give a detailed answer to the following question: What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-7b_response": "Vaxchora is a vaccine that is approved for the prevention of cholera caused by the serogroup O1 in individuals 18 years of age and older. The vaccine is administered as a single-dose intramuscular injection.\n\nStudies have shown that Vaxchora provides protective efficacy against moderate to severe cholera. A randomized, double-blind, placebo-controlled trial conducted in Bangladesh found that Vaxchora was effective in preventing symptomatic cholera caused by serogroup O1. The vaccine was found to be 66% effective in preventing symptomatic cholera, with a lower bound of the 95% confidence interval of 45%.\n\nAnother randomized, double-blind, placebo-controlled trial conducted in Haiti also found that Vaxchora was effective in preventing symptomatic cholera caused by serogroup O1. The vaccine was found to be 71% effective in preventing symptomatic cholera, with a lower bound of the 95% confidence interval of 56%.\n\nThese studies suggest that Vaxchora provides protective efficacy against moderate to severe cholera caused by serogroup O1. However, it is worth noting that the efficacy of the vaccine may vary depending on factors such as the serogroup of the cholera strain, the age and immune status of the vaccine recipient, and the environment in which the vaccine is used.",
    "llama-7b_fact_raw": "1. Vaxchora is approved for the prevention of cholera caused by the serogroup O1 in individuals 18 years of age and older.\n2. Vaxchora is administered as a single-dose intramuscular injection.\n3. A study in Bangladesh found Vaxchora to be 66% effective in preventing symptomatic cholera caused by serogroup O1.\n4. The lower bound of the 95% confidence interval for the vaccine's efficacy in the Bangladesh study was 45%.\n5. A study in Haiti found Vaxchora to be 71% effective in preventing symptomatic cholera caused by serogroup O1, with a lower bound of the 95% confidence interval of 56%.",
    "llama-7b_fact": [
      "Vaxchora is approved for the prevention of cholera caused by the serogroup O1 in individuals 18 years of age and older.",
      "Vaxchora is administered as a single-dose intramuscular injection.",
      "A study in Bangladesh found Vaxchora to be 66% effective in preventing symptomatic cholera caused by serogroup O1.",
      "The lower bound of the 95% confidence interval for the vaccine's efficacy in the Bangladesh study was 45%.",
      "A study in Haiti found Vaxchora to be 71% effective in preventing symptomatic cholera caused by serogroup O1, with a lower bound of the 95% confidence interval of 56%."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Vaxchora is administered orally as a single-dose live attenuated vaccine, not as an intramuscular injection.\n3. UNKNOWN (The effectiveness percentage would need to be confirmed with the specific study data.)\n4. UNKNOWN (The specific confidence interval would need to be confirmed with the study data.)\n5. UNKNOWN (The effectiveness percentage and confidence interval would need to be confirmed with the specific study data.)",
    "llama-7b_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3716,
    "user_query": "You MUST give a detailed answer to the following question: Which was the first cholera vaccine approved in the US?",
    "llama-7b_response": "The first cholera vaccine approved in the US was Dukoral, which was approved by the US Food and Drug Administration (FDA) in 2005. Dukoral is a live, attenuated oral vaccine that is made from a strain of cholera bacteria that has been weakened through a process called attenuation. The vaccine is administered in a single dose and provides protection against cholera for up to 2 years. Dukoral is approved for use in adults and children over the age of 1 year and is recommended for use in travelers to areas where cholera is common.",
    "llama-7b_fact_raw": "1. Dukoral was the first cholera vaccine approved in the US.\n2. The US Food and Drug Administration (FDA) approved Dukoral in 2005.\n3. Dukoral is a live, attenuated oral vaccine.\n4. Dukoral provides protection against cholera for up to 2 years.\n5. Dukoral is approved for use in adults and children over the age of 1 year.",
    "llama-7b_fact": [
      "Dukoral was the first cholera vaccine approved in the US.",
      "The US Food and Drug Administration (FDA) approved Dukoral in 2005.",
      "Dukoral is a live, attenuated oral vaccine.",
      "Dukoral provides protection against cholera for up to 2 years.",
      "Dukoral is approved for use in adults and children over the age of 1 year."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Vaxchora was the first cholera vaccine approved in the US.\n2. FALSE [correction]: Dukoral has not been approved by the US Food and Drug Administration (FDA) for use in the United States; Vaxchora was approved by the FDA in 2016.\n3. FALSE [correction]: Dukoral is an inactivated oral vaccine, not a live, attenuated vaccine.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3737,
    "user_query": "You MUST give a detailed answer to the following question: Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-7b_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is the autoimmune regulator (AIRE) gene. CVID is a primary immunodeficiency disorder characterized by a reduced ability to produce immunoglobulins, which are proteins that help fight infections. The AIRE gene provides instructions for making a protein that is involved in the regulation of the immune system. Mutations in the AIRE gene can lead to reduced production of immunoglobulins and the symptoms of CVID.",
    "llama-7b_fact_raw": "1. The autoimmune regulator (AIRE) gene is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.\n2. CVID is characterized by a reduced ability to produce immunoglobulins.\n3. The AIRE gene provides instructions for making a protein involved in immune system regulation.\n4. Mutations in the AIRE gene can lead to reduced production of immunoglobulins.\n5. Symptoms of CVID are associated with mutations in the AIRE gene.",
    "llama-7b_fact": [
      "The autoimmune regulator (AIRE) gene is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.",
      "CVID is characterized by a reduced ability to produce immunoglobulins.",
      "The AIRE gene provides instructions for making a protein involved in immune system regulation.",
      "Mutations in the AIRE gene can lead to reduced production of immunoglobulins.",
      "Symptoms of CVID are associated with mutations in the AIRE gene."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The autoimmune regulator (AIRE) gene is associated with Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED), not common variable immunodeficiency (CVID). The most common genetic cause of CVID is not well-defined, as it is a complex disorder with various genetic associations.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Mutations in the AIRE gene can lead to autoimmune problems due to a failure in central immune tolerance, not directly to reduced production of immunoglobulins. Reduced production of immunoglobulins is a characteristic of CVID, but it is not typically caused by mutations in the AIRE gene.\n5. FALSE [correction]: Symptoms of CVID, which include increased susceptibility to infections due to low immunoglobulin levels, are not typically associated with mutations in the AIRE gene. Instead, AIRE gene mutations are associated with APECED, which has a different set of symptoms primarily related to autoimmune dysfunction.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3743,
    "user_query": "You MUST give a detailed answer to the following question: Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-7b_response": "The IFIT1 gene, also known as Interferon, alpha-inducible protein 18, plays a role in the immune response against viral infections. It is a type III interferon, which means it is produced by cells in response to viral infection and regulates the expression of genes involved in the antiviral response.\n\nIn the context of Systemic Lupus Erythematosus (SLE), there is some evidence to suggest that IFIT1 may play a role in the pathogenesis of the disease. SLE is an autoimmune disorder in which the immune system attacks the body's own tissues, leading to inflammation and damage to various organs and systems.\n\nOne study published in the journal Arthritis & Rheumatology in 2018 found that individuals with SLE had lower levels of IFIT1 expression in their peripheral blood mononuclear cells (PBMCs) compared to healthy controls. This suggests that IFIT1 may be involved in the regulation of the immune response in SLE and may play a role in the development of the disease.\n\nAnother study published in the journal PLoS One in 2019 found that IFIT1 was downregulated in SLE patients with active disease compared to those with inactive disease. This suggests that IFIT1 may be a potential biomarker for disease activity in SLE.\n\nOverall, while more research is needed to fully understand the role of IFIT1 in SLE, there is some evidence to suggest that it may play a role in the regulation of the immune response and may be involved in the pathogenesis of the disease.",
    "llama-7b_fact_raw": "1. The IFIT1 gene is also known as Interferon, alpha-inducible protein 18.\n2. IFIT1 is a type III interferon produced by cells in response to viral infection.\n3. Systemic Lupus Erythematosus (SLE) is an autoimmune disorder where the immune system attacks the body's own tissues.\n4. A study published in Arthritis & Rheumatology in 2018 found that individuals with SLE had lower levels of IFIT1 expression in their PBMCs compared to healthy controls.\n5. A study published in PLoS One in 2019 found that IFIT1 was downregulated in SLE patients with active disease compared to those with inactive disease.",
    "llama-7b_fact": [
      "The IFIT1 gene is also known as Interferon, alpha-inducible protein 18.",
      "IFIT1 is a type III interferon produced by cells in response to viral infection.",
      "Systemic Lupus Erythematosus (SLE) is an autoimmune disorder where the immune system attacks the body's own tissues.",
      "A study published in Arthritis & Rheumatology in 2018 found that individuals with SLE had lower levels of IFIT1 expression in their PBMCs compared to healthy controls.",
      "A study published in PLoS One in 2019 found that IFIT1 was downregulated in SLE patients with active disease compared to those with inactive disease."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The IFIT1 gene is also known as Interferon-induced protein with tetratricopeptide repeats 1, not Interferon, alpha-inducible protein 18.\n2. FALSE [correction]: IFIT1 is a type I interferon-induced protein produced by cells in response to viral infection, not a type III interferon.\n3. TRUE\n4. UNKNOWN (without access to the specific study, the statement's accuracy cannot be verified)\n5. UNKNOWN (without access to the specific study, the statement's accuracy cannot be verified)",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3752,
    "user_query": "You MUST give a detailed answer to the following question: What is the use of the Liverpool Elbow Score?",
    "llama-7b_response": "The Liverpool Elbow Score (LES) is a clinical scoring system used to assess the severity of elbow osteoarthritis. It was developed by a team of researchers at the University of Liverpool in the United Kingdom and was first published in the Journal of the American Academy of Orthopaedic Surgeons in 2010.\n\nThe LES is based on a combination of patient-reported symptoms and physical examination findings, and it has been shown to be a reliable and valid tool for assessing the severity of elbow osteoarthritis. The score ranges from 0 to 100, with higher scores indicating more severe disease.\n\nThe LES can be used in a variety of clinical settings, including primary care, orthopedic clinics, and rheumatology clinics. It can be used to monitor the progression of elbow osteoarthritis over time, to assess the effectiveness of treatment, and to identify patients who may benefit from surgical intervention.\n\nIn addition to its use in clinical practice, the LES has also been used in research studies to evaluate the effectiveness of various treatments for elbow osteoarthritis, such as medications, injections, and surgical interventions.\n\nOverall, the Liverpool Elbow Score is a useful tool for clinicians to assess the severity of elbow osteoarthritis and to guide treatment decisions.",
    "llama-7b_fact_raw": "1. The Liverpool Elbow Score (LES) is used to assess the severity of elbow osteoarthritis.\n2. The LES was developed by researchers at the University of Liverpool in the United Kingdom.\n3. The Liverpool Elbow Score was first published in the Journal of the American Academy of Orthopaedic Surgeons in 2010.\n4. The LES score ranges from 0 to 100, with higher scores indicating more severe disease.\n5. The LES can be used to monitor the progression of elbow osteoarthritis, assess the effectiveness of treatment, and identify patients who may benefit from surgical intervention.",
    "llama-7b_fact": [
      "The Liverpool Elbow Score (LES) is used to assess the severity of elbow osteoarthritis.",
      "The LES was developed by researchers at the University of Liverpool in the United Kingdom.",
      "The Liverpool Elbow Score was first published in the Journal of the American Academy of Orthopaedic Surgeons in 2010.",
      "The LES score ranges from 0 to 100, with higher scores indicating more severe disease.",
      "The LES can be used to monitor the progression of elbow osteoarthritis, assess the effectiveness of treatment, and identify patients who may benefit from surgical intervention."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Liverpool Elbow Score (LES) is used to assess outcomes in patients undergoing elbow surgery, not specifically the severity of elbow osteoarthritis.\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: The LES score ranges from 0 to 100, with higher scores indicating better elbow function, not more severe disease.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "You MUST give a detailed answer to the following question: Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-7b_response": "The 100,000 Genomes Project is a UK-based initiative that aims to sequence 100,000 whole genomes from patients with a range of diseases, including cancer. As part of this project, efforts have been made to sequence genomes of patients with sarcoma, a type of cancer that affects the soft tissues and bones.\n\nSarcomas are rare cancers, and the 100,000 Genomes Project has sequenced the genomes of over 100 patients with sarcoma. The sequencing data has been used to identify genetic mutations that are specific to sarcoma, and to develop new diagnostic tools and treatments for the disease.\n\nOne of the key findings from the 100,000 Genomes Project's efforts on sarcoma is the identification of specific genetic mutations that are common in different subtypes of sarcoma. For example, the project has identified mutations in the PIK3CA gene as being common in gastrointestinal stromal tumors (GISTs), a type of sarcoma that affects the digestive system. This information has helped clinicians to develop more targeted treatments for GISTs, and has also helped to improve the accuracy of diagnostic tests for the disease.\n\nIn addition to identifying genetic mutations, the 100,000 Genomes Project has also helped to improve our understanding of the biology of sarcoma. By sequencing the genomes of patients with sarcoma, researchers have been able to identify patterns of gene expression that are specific to different subtypes of the disease. This information has helped to develop new diagnostic tools and treatments for sarcoma, and has also helped to improve our understanding of how the disease develops and progresses.\n\nOverall, the 100,000 Genomes Project's efforts on sarcoma have made a significant contribution to our understanding of this rare and complex disease. By sequencing the genomes of patients with sarcoma, the project has identified specific genetic mutations that are common in different subtypes of the disease, and has helped to develop new diagnostic tools and treatments for sarcoma. These efforts have also helped to improve our understanding of the biology",
    "llama-7b_fact_raw": "1. The 100,000 Genomes Project is a UK-based initiative that aims to sequence 100,000 whole genomes from patients with various diseases, including cancer.\n2. The project has sequenced the genomes of over 100 patients with sarcoma.\n3. Genetic mutations specific to sarcoma have been identified through the sequencing data from the project.\n4. Mutations in the PIK3CA gene have been identified as common in gastrointestinal stromal tumors (GISTs), a subtype of sarcoma.\n5. The project has contributed to the development of new diagnostic tools and treatments for sarcoma.",
    "llama-7b_fact": [
      "The 100,000 Genomes Project is a UK-based initiative that aims to sequence 100,000 whole genomes from patients with various diseases, including cancer.",
      "The project has sequenced the genomes of over 100 patients with sarcoma.",
      "Genetic mutations specific to sarcoma have been identified through the sequencing data from the project.",
      "Mutations in the PIK3CA gene have been identified as common in gastrointestinal stromal tumors (GISTs), a subtype of sarcoma.",
      "The project has contributed to the development of new diagnostic tools and treatments for sarcoma."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The 100,000 Genomes Project has sequenced the genomes of many more than just 100 patients with sarcoma; the project's goal was to sequence 100,000 whole genomes.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3777,
    "user_query": "You MUST give a detailed answer to the following question: Does protein ALEX1 contain armadillo repeats?",
    "llama-7b_response": "Yes, protein ALEX1 contains armadillo repeats.",
    "llama-7b_fact_raw": "1. Protein ALEX1 contains armadillo repeats.",
    "llama-7b_fact": [
      "Protein ALEX1 contains armadillo repeats."
    ],
    "llama-7b_judge_raw": "UNKNOWN\n\nWithout additional context or specific scientific references, it is not possible to confirm the accuracy of the statement regarding the protein ALEX1 containing armadillo repeats. Armadillo repeats are a protein structural motif involved in protein-protein interactions, and while they are found in various proteins, without specific information about ALEX1, the statement's truth cannot be determined.",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3789,
    "user_query": "You MUST give a detailed answer to the following question: List enzymes that removes histone modifications.",
    "llama-7b_response": "There are several enzymes that remove histone modifications, including:\n\n1. Histone deacetylases (HDACs): HDACs remove acetyl groups from histone tails, leading to a more compact chromatin structure and the repression of gene expression.\n2. Histone lysine methyltransferases (KMTs): KMTs add methyl groups to histone lysine residues, leading to the repression of gene expression.\n3. Histone lysine demethylases (KDMs): KDMs remove methyl groups from histone lysine residues, leading to the activation of gene expression.\n4. Histone lysine acetyltransferases (KATs): KATs add acetyl groups to histone tails, leading to the activation of gene expression.\n5. Histone lysine methyltransferases (KMTs): KMTs add methyl groups to histone lysine residues, leading to the repression of gene expression.\n6. Histone lysine demethylases (KDMs): KDMs remove methyl groups from histone lysine residues, leading to the activation of gene expression.\n7. Histone lysine acetyltransferases (KATs): KATs add acetyl groups to histone tails, leading to the activation of gene expression.\n8. Histone lysine methyltransferases (KMTs): KMTs add methyl groups to histone lysine residues, leading to the repression of gene expression.\n9. Histone lysine demethylases (KDMs): KDMs remove methyl groups from histone lysine residues, leading to the activation of gene expression.\n10. Histone lysine acetyltransferases (KATs): KATs add acetyl groups to histone tails, leading to the activation of gene expression.\n11. Histone lysine methyltransferases (KMTs): KMTs add methyl groups to histone lysine residues, leading to the repression of gene expression.\n12. Histone lysine demethylases (KDMs): KDM",
    "llama-7b_fact_raw": "1. Histone deacetylases (HDACs) remove acetyl groups from histone tails.\n2. Histone lysine demethylases (KDMs) remove methyl groups from histone lysine residues.\n3. The removal of acetyl groups by HDACs leads to a more compact chromatin structure.\n4. The removal of methyl groups by KDMs can lead to the activation of gene expression.\n5. The addition of acetyl groups by histone lysine acetyltransferases (KATs) leads to the activation of gene expression.",
    "llama-7b_fact": [
      "Histone deacetylases (HDACs) remove acetyl groups from histone tails.",
      "Histone lysine demethylases (KDMs) remove methyl groups from histone lysine residues.",
      "The removal of acetyl groups by HDACs leads to a more compact chromatin structure.",
      "The removal of methyl groups by KDMs can lead to the activation of gene expression.",
      "The addition of acetyl groups by histone lysine acetyltransferases (KATs) leads to the activation of gene expression."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nEach of these statements is consistent with current understanding of epigenetic mechanisms. Histone modifications, such as acetylation and methylation, play a crucial role in the regulation of chromatin structure and gene expression.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "You MUST give a detailed answer to the following question: Does head ct increase brain tumor risk?",
    "llama-7b_response": "The relationship between head CT scans and brain tumor risk is complex and has been the subject of much research and debate.\n\nOn one hand, head CT scans are an important tool for diagnosing and monitoring brain tumors. They can help identify tumors at an early stage, when they are more likely to be treatable, and can also be used to monitor the effectiveness of treatment.\n\nOn the other hand, there is some evidence to suggest that repeated exposure to radiation from CT scans may increase the risk of developing a brain tumor. This is particularly true for children and young adults, whose brains are still growing and may be more sensitive to the effects of radiation.\n\nStudies have found that the risk of developing a brain tumor increases with the number of CT scans a person has undergone. However, it is worth noting that the risk is still relatively low, and most people who undergo CT scans do not go on to develop a brain tumor.\n\nIn summary, while head CT scans are an important tool for diagnosing and monitoring brain tumors, there is some evidence to suggest that repeated exposure to radiation from CT scans may increase the risk of developing a brain tumor. However, the risk is still relatively low, and most people who undergo CT scans do not go on to develop a brain tumor.",
    "llama-7b_fact_raw": "1. Head CT scans are used for diagnosing and monitoring brain tumors.\n2. There is evidence suggesting that repeated exposure to radiation from CT scans may increase the risk of developing a brain tumor.\n3. Children and young adults may be more sensitive to the effects of radiation from CT scans due to their still-growing brains.\n4. The risk of developing a brain tumor increases with the number of CT scans a person has undergone.\n5. Despite the increased risk, most people who undergo CT scans do not develop a brain tumor.",
    "llama-7b_fact": [
      "Head CT scans are used for diagnosing and monitoring brain tumors.",
      "There is evidence suggesting that repeated exposure to radiation from CT scans may increase the risk of developing a brain tumor.",
      "Children and young adults may be more sensitive to the effects of radiation from CT scans due to their still-growing brains.",
      "The risk of developing a brain tumor increases with the number of CT scans a person has undergone.",
      "Despite the increased risk, most people who undergo CT scans do not develop a brain tumor."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "You MUST give a detailed answer to the following question: Which type of pluripotency is Otx2 associated with?",
    "llama-7b_response": "Otx2 is associated with transcriptional pluripotency.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3815,
    "user_query": "You MUST give a detailed answer to the following question: How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-7b_response": "The number of DNaseI hypersensitive sites (DHS) that mark the murine beta globin locus region is not a fixed or easily quantifiable number, as the number of DHS can vary depending on the experimental conditions and the method used to identify them.\n\nDNaseI hypersensitive sites are regions of the genome that are more susceptible to DNA cleavage by the enzyme DNaseI, indicating that these regions are more accessible to the enzyme and are therefore likely to be in closer proximity to the surface of the nucleus or the nuclear membrane.\n\nThe beta globin locus region is a region of the genome that contains genes involved in the production of beta globin proteins, which are a type of hemoglobin. The beta globin locus region is located on chromosome 16 in mammals, and it contains several genes that are involved in the production of different types of beta globin proteins.\n\nThe number of DHS that mark the beta globin locus region can vary depending on the experimental conditions and the method used to identify them. For example, some studies have used DNaseI hypersensitive site mapping to identify DHS in the beta globin locus region, while other studies have used other methods, such as chromatin immunoprecipitation followed by sequencing (ChIP-seq), to identify DHS in this region.\n\nIn general, the beta globin locus region is known to contain several DHS, which are thought to play a role in the regulation of gene expression in this region. However, the exact number of DHS that mark the beta globin locus region is not a fixed or easily quantifiable number, and can vary depending on the experimental conditions and the method used to identify them.",
    "llama-7b_fact_raw": "1. DNaseI hypersensitive sites (DHS) are regions of the genome more susceptible to DNA cleavage by the enzyme DNaseI.\n2. The beta globin locus region contains genes involved in the production of beta globin proteins.\n3. The beta globin locus region is located on chromosome 16 in mammals.\n4. The number of DHS marking the beta globin locus region can vary depending on experimental conditions and identification methods.\n5. DNaseI hypersensitive site mapping and chromatin immunoprecipitation followed by sequencing (ChIP-seq) are methods used to identify DHS in the beta globin locus region.",
    "llama-7b_fact": [
      "DNaseI hypersensitive sites (DHS) are regions of the genome more susceptible to DNA cleavage by the enzyme DNaseI.",
      "The beta globin locus region contains genes involved in the production of beta globin proteins.",
      "The beta globin locus region is located on chromosome 16 in mammals.",
      "The number of DHS marking the beta globin locus region can vary depending on experimental conditions and identification methods.",
      "DNaseI hypersensitive site mapping and chromatin immunoprecipitation followed by sequencing (ChIP-seq) are methods used to identify DHS in the beta globin locus region."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The beta globin locus region is located on chromosome 11 in humans.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3822,
    "user_query": "You MUST give a detailed answer to the following question: List as many European influenza vaccines as possible.",
    "llama-7b_response": "There are several European influenza vaccines available, including:\n\n1. Fluarix: This is an inactivated influenza vaccine that is manufactured by GlaxoSmithKline (GSK). It is approved for use in adults and children aged 3 years and older.\n2. FluLaval: This is an inactivated influenza vaccine that is manufactured by Sanofi Pasteur. It is approved for use in adults and children aged 6 months and older.\n3. Fluarix Quadrivalent: This is an inactivated influenza vaccine that is manufactured by GSK. It is approved for use in adults and children aged 3 years and older.\n4. Fluarix Tetravalent: This is an inactivated influenza vaccine that is manufactured by GSK. It is approved for use in adults and children aged 3 years and older.\n5. Fluzone: This is an inactivated influenza vaccine that is manufactured by Sanofi Pasteur. It is approved for use in adults and children aged 6 months and older.\n6. Fluzone High-Dose: This is an inactivated influenza vaccine that is manufactured by Sanofi Pasteur. It is approved for use in adults aged 65 years and older.\n7. Fluad: This is an inactivated influenza vaccine that is manufactured by Novartis. It is approved for use in adults aged 65 years and older.\n8. FluMist: This is a live attenuated influenza vaccine (LAIV) that is manufactured by MedImmune. It is approved for use in healthy children and adults aged 2-49 years old who are not pregnant.\n9. Afluria: This is an inactivated influenza vaccine that is manufactured by Seqirus. It is approved for use in adults and children aged 18 years and older.\n10. Afluria Quadrivalent: This is an inactivated influenza vaccine that is manufactured by Seqirus. It is approved for use in adults and children aged 18 years and older.",
    "llama-7b_fact_raw": "1. Fluarix is an inactivated influenza vaccine manufactured by GlaxoSmithKline (GSK) for use in adults and children aged 3 years and older.\n2. FluLaval is an inactivated influenza vaccine manufactured by Sanofi Pasteur for use in adults and children aged 6 months and older.\n3. Fluzone High-Dose is an inactivated influenza vaccine manufactured by Sanofi Pasteur for use in adults aged 65 years and older.\n4. Fluad is an inactivated influenza vaccine manufactured by Novartis for use in adults aged 65 years and older.\n5. FluMist is a live attenuated influenza vaccine (LAIV) manufactured by MedImmune for use in healthy children and adults aged 2-49 years old who are not pregnant.",
    "llama-7b_fact": [
      "Fluarix is an inactivated influenza vaccine manufactured by GlaxoSmithKline (GSK) for use in adults and children aged 3 years and older.",
      "FluLaval is an inactivated influenza vaccine manufactured by Sanofi Pasteur for use in adults and children aged 6 months and older.",
      "Fluzone High-Dose is an inactivated influenza vaccine manufactured by Sanofi Pasteur for use in adults aged 65 years and older.",
      "Fluad is an inactivated influenza vaccine manufactured by Novartis for use in adults aged 65 years and older.",
      "FluMist is a live attenuated influenza vaccine (LAIV) manufactured by MedImmune for use in healthy children and adults aged 2-49 years old who are not pregnant."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: FluLaval is an inactivated influenza vaccine manufactured by GlaxoSmithKline (GSK) for use in adults and children aged 6 months and older.\n3. TRUE\n4. FALSE [correction]: Fluad is an inactivated influenza vaccine manufactured by Seqirus for use in adults aged 65 years and older.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3832,
    "user_query": "You MUST give a detailed answer to the following question: Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-7b_response": "The Paramyxovirus geneome is segmented, negative-sense RNA.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3869,
    "user_query": "You MUST give a detailed answer to the following question: Roflumilast Cream is effective for which disease?",
    "llama-7b_response": "Roflumilast cream is a medication that is used to treat a specific type of lung disease called chronic obstructive pulmonary disease (COPD). COPD is a group of lung diseases that include chronic bronchitis and emphysema. Roflumilast cream works by reducing inflammation in the lungs and improving lung function in people with COPD. It is not effective for treating any other diseases.",
    "llama-7b_fact_raw": "1. Roflumilast cream is used to treat chronic obstructive pulmonary disease (COPD).\n2. COPD is a group of lung diseases that include chronic bronchitis and emphysema.\n3. Roflumilast cream works by reducing inflammation in the lungs.\n4. Roflumilast cream is aimed at improving lung function in people with COPD.\n5. Roflumilast cream is not effective for treating diseases other than COPD.",
    "llama-7b_fact": [
      "Roflumilast cream is used to treat chronic obstructive pulmonary disease (COPD).",
      "COPD is a group of lung diseases that include chronic bronchitis and emphysema.",
      "Roflumilast cream works by reducing inflammation in the lungs.",
      "Roflumilast cream is aimed at improving lung function in people with COPD.",
      "Roflumilast cream is not effective for treating diseases other than COPD."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Roflumilast is available as a pill (oral tablet) for the treatment of chronic obstructive pulmonary disease (COPD), not as a cream.\n2. TRUE\n3. TRUE, but the statement is more accurate for the oral form of roflumilast. Roflumilast tablets work by reducing inflammation in the lungs.\n4. TRUE, but again, this statement applies to the oral tablet form of roflumilast.\n5. FALSE [correction]: Roflumilast cream may be used for skin conditions like psoriasis, but the oral form is used for COPD. It's not accurate to say that roflumilast cream is not effective for treating diseases other than COPD without specifying the form of roflumilast being discussed.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3885,
    "user_query": "You MUST give a detailed answer to the following question: Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-7b_response": "There are several tools that have been developed for identifying and visualizing ncRNA promoters. Here are some of the most commonly used ones:\n\n1. RNAhybrid: RNAhybrid is a web-based tool that uses a hybridization-based approach to identify promoter regions in ncRNAs. It can be used to identify promoters in both known and novel ncRNAs.\n2. MatInspector: MatInspector is a web-based tool that uses a machine learning approach to identify promoter regions in ncRNAs. It can be used to identify promoters in both known and novel ncRNAs.\n3. RNAprom: RNAprom is a web-based tool that uses a hybridization-based approach to identify promoter regions in ncRNAs. It can be used to identify promoters in both known and novel ncRNAs.\n4. PromoterFinder: PromoterFinder is a web-based tool that uses a hybridization-based approach to identify promoter regions in ncRNAs. It can be used to identify promoters in both known and novel ncRNAs.\n5. PROMO: PROMO is a web-based tool that uses a machine learning approach to identify promoter regions in ncRNAs. It can be used to identify promoters in both known and novel ncRNAs.\n\nThese tools can be useful for identifying and visualizing ncRNA promoters, but the specific tool used will depend on the research question and the type of ncRNA being studied.",
    "llama-7b_fact_raw": "1. RNAhybrid is a tool designed to identify promoter regions in ncRNAs using a hybridization-based approach.\n2. MatInspector utilizes a machine learning approach to identify promoter regions in ncRNAs.\n3. RNAprom is a tool that identifies promoter regions in ncRNAs through a hybridization-based approach.\n4. PromoterFinder is a web-based tool that identifies promoter regions in ncRNAs using a hybridization-based method.\n5. PROMO uses a machine learning approach to identify promoter regions in ncRNAs.",
    "llama-7b_fact": [
      "RNAhybrid is a tool designed to identify promoter regions in ncRNAs using a hybridization-based approach.",
      "MatInspector utilizes a machine learning approach to identify promoter regions in ncRNAs.",
      "RNAprom is a tool that identifies promoter regions in ncRNAs through a hybridization-based approach.",
      "PromoterFinder is a web-based tool that identifies promoter regions in ncRNAs using a hybridization-based method.",
      "PROMO uses a machine learning approach to identify promoter regions in ncRNAs."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: RNAhybrid is a tool designed to find the minimum free energy hybridization of a long and a short RNA. It is not specifically designed to identify promoter regions in ncRNAs.\n2. FALSE [correction]: MatInspector is a software tool that uses a library of matrix descriptions for transcription factor binding sites to identify potential transcription factor binding sites, not specifically to identify promoter regions in ncRNAs using a machine learning approach.\n3. TRUE\n4. UNKNOWN: Without additional context or information about a tool named \"PromoterFinder,\" it is not possible to verify the accuracy of this statement.\n5. FALSE [correction]: PROMO is a tool that predicts transcription factor binding sites in DNA sequences, not specifically using a machine learning approach to identify promoter regions in ncRNAs.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3918,
    "user_query": "You MUST give a detailed answer to the following question: List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-7b_response": "The SWIM tool is a web-based tool that uses machine learning algorithms to analyze gene expression data and identify genes that are differentially expressed in different types of cancer, including glioblastoma. The tool has identified a number of genes that are down-regulated in glioblastoma, including:\n\n1. PTEN: PTEN is a tumor suppressor gene that plays a role in regulating cell growth and division. It has been found to be down-regulated in a number of cancers, including glioblastoma.\n2. CDKN2A: CDKN2A is a tumor suppressor gene that encodes a protein that regulates cell cycle progression. It has been found to be down-regulated in a number of cancers, including glioblastoma.\n3. TP53: TP53 is a tumor suppressor gene that encodes a protein that plays a role in regulating cell growth and division. It has been found to be down-regulated in a number of cancers, including glioblastoma.\n4. CDKN1A: CDKN1A is a tumor suppressor gene that encodes a protein that regulates cell cycle progression. It has been found to be down-regulated in a number of cancers, including glioblastoma.\n5. RB1: RB1 is a tumor suppressor gene that encodes a protein that plays a role in regulating cell growth and division. It has been found to be down-regulated in a number of cancers, including glioblastoma.\n\nThese are just a few examples of the genes that SWIM tool has identified as being down-regulated in glioblastoma. The tool can also identify other genes that are differentially expressed in glioblastoma and other types of cancer.",
    "llama-7b_fact_raw": "1. The SWIM tool has identified PTEN as a gene that is down-regulated in glioblastoma.\n2. The SWIM tool has identified CDKN2A as a gene that is down-regulated in glioblastoma.\n3. The SWIM tool has identified TP53 as a gene that is down-regulated in glioblastoma.\n4. The SWIM tool has identified CDKN1A as a gene that is down-regulated in glioblastoma.\n5. The SWIM tool has identified RB1 as a gene that is down-regulated in glioblastoma.",
    "llama-7b_fact": [
      "The SWIM tool has identified PTEN as a gene that is down-regulated in glioblastoma.",
      "The SWIM tool has identified CDKN2A as a gene that is down-regulated in glioblastoma.",
      "The SWIM tool has identified TP53 as a gene that is down-regulated in glioblastoma.",
      "The SWIM tool has identified CDKN1A as a gene that is down-regulated in glioblastoma.",
      "The SWIM tool has identified RB1 as a gene that is down-regulated in glioblastoma."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without specific data or results from the SWIM tool, it is not possible to confirm whether PTEN is identified as down-regulated in glioblastoma by this tool.\n2. UNKNOWN: Without specific data or results from the SWIM tool, it is not possible to confirm whether CDKN2A is identified as down-regulated in glioblastoma by this tool.\n3. UNKNOWN: Without specific data or results from the SWIM tool, it is not possible to confirm whether TP53 is identified as down-regulated in glioblastoma by this tool.\n4. UNKNOWN: Without specific data or results from the SWIM tool, it is not possible to confirm whether CDKN1A is identified as down-regulated in glioblastoma by this tool.\n5. UNKNOWN: Without specific data or results from the SWIM tool, it is not possible to confirm whether RB1 is identified as down-regulated in glioblastoma by this tool.\n\nNote: The SWIM (SWItchMiner) tool is a bioinformatics tool used to analyze gene expression data. The statements provided do not include specific results or references to data that would allow for a determination of the truthfulness of the statements regarding gene regulation in glioblastoma. Therefore, the status of these genes as identified by the SWIM tool in the context of glioblastoma remains unknown without additional information.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "You MUST give a detailed answer to the following question: Which R packages have been developed for studying TADs?",
    "llama-7b_response": "There are several R packages that have been developed for studying TADs (Topologically Associating Domains). Here are some of the most popular ones:\n\n1. TADMatrix: This is a package for visualizing and analyzing TADs in single-cell RNA sequencing (scRNA-seq) data. It allows users to visualize and compare TADs between different cell types, and to identify TADs that are enriched for specific genes or functional annotations.\n2. TADProfiler: This is a package for analyzing TADs in bulk RNA sequencing (RNA-seq) data. It allows users to identify TADs based on gene expression data, and to compare TADs between different samples or conditions.\n3. TADTree: This is a package for visualizing and analyzing TADs in scRNA-seq data. It allows users to visualize TADs as a tree structure, and to identify TADs that are enriched for specific genes or functional annotations.\n4. TADView: This is a package for visualizing and analyzing TADs in bulk RNA sequencing (RNA-seq) data. It allows users to visualize TADs as a heatmap, and to identify TADs that are enriched for specific genes or functional annotations.\n5. TADAnalyzer: This is a package for analyzing TADs in bulk RNA sequencing (RNA-seq) data. It allows users to identify TADs based on gene expression data, and to compare TADs between different samples or conditions.\n\nThese packages provide a range of tools for studying TADs, including visualization, analysis, and comparison of TADs between different samples or conditions. They can be used to identify TADs that are enriched for specific genes or functional annotations, and to gain insights into the organization of the genome in different cell types or tissues.",
    "llama-7b_fact_raw": "1. TADMatrix is an R package designed for visualizing and analyzing Topologically Associating Domains (TADs) in single-cell RNA sequencing data.\n2. TADProfiler is an R package that allows for the analysis of TADs in bulk RNA sequencing data.\n3. TADTree is an R package that provides tools for visualizing TADs as a tree structure in single-cell RNA sequencing data.\n4. TADView is an R package that enables visualization of TADs as a heatmap in bulk RNA sequencing data.\n5. TADAnalyzer is an R package for analyzing TADs in bulk RNA sequencing data, including the identification and comparison of TADs.",
    "llama-7b_fact": [
      "TADMatrix is an R package designed for visualizing and analyzing Topologically Associating Domains (TADs) in single-cell RNA sequencing data.",
      "TADProfiler is an R package that allows for the analysis of TADs in bulk RNA sequencing data.",
      "TADTree is an R package that provides tools for visualizing TADs as a tree structure in single-cell RNA sequencing data.",
      "TADView is an R package that enables visualization of TADs as a heatmap in bulk RNA sequencing data.",
      "TADAnalyzer is an R package for analyzing TADs in bulk RNA sequencing data, including the identification and comparison of TADs."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: TADMatrix is an R package designed for visualizing and analyzing Topologically Associating Domains (TADs) in Hi-C data, not single-cell RNA sequencing data.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe corrections and assessments are based on the fact that Topologically Associating Domains (TADs) are typically studied in the context of chromatin organization using Hi-C data rather than RNA sequencing data. RNA sequencing data is used to measure gene expression, not to analyze the 3D structure of the genome where TADs are relevant. However, without specific information about the packages TADProfiler, TADTree, TADView, and TADAnalyzer, it is not possible to definitively determine the truthfulness of statements 2 through 5.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "You MUST give a detailed answer to the following question: Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-7b_response": "The bioconductor tool that has been developed for accessing bacterial regulatory networks is called \"BioNetGen\".\n\nBioNetGen is a bioconductor package that allows users to model, analyze, and simulate regulatory networks in a variety of organisms, including bacteria. It provides a range of tools for building and analyzing regulatory networks, including tools for importing and exporting data in a variety of formats, as well as tools for visualizing and analyzing the networks.\n\nOne of the key features of BioNetGen is its ability to handle large and complex regulatory networks. It can handle networks with thousands of genes and interactions, and it can also handle networks with multiple types of interactions, such as positive and negative regulation.\n\nBioNetGen is widely used in the field of systems biology and bioinformatics, and it has been applied to a variety of organisms, including bacteria. It has been used to study the regulation of gene expression in a variety of bacterial species, including Escherichia coli and Bacillus subtilis.\n\nOverall, BioNetGen is a powerful tool for accessing and analyzing bacterial regulatory networks, and it is an important resource for researchers in the field of systems biology and bioinformatics.",
    "llama-7b_fact_raw": "1. BioNetGen is a bioconductor tool developed for accessing bacterial regulatory networks.\n2. BioNetGen allows users to model, analyze, and simulate regulatory networks in a variety of organisms, including bacteria.\n3. The tool provides features for importing and exporting data in various formats and for visualizing and analyzing networks.\n4. BioNetGen can handle large and complex regulatory networks with thousands of genes and interactions.\n5. BioNetGen has been used to study gene expression regulation in bacterial species such as Escherichia coli and Bacillus subtilis.",
    "llama-7b_fact": [
      "BioNetGen is a bioconductor tool developed for accessing bacterial regulatory networks.",
      "BioNetGen allows users to model, analyze, and simulate regulatory networks in a variety of organisms, including bacteria.",
      "The tool provides features for importing and exporting data in various formats and for visualizing and analyzing networks.",
      "BioNetGen can handle large and complex regulatory networks with thousands of genes and interactions.",
      "BioNetGen has been used to study gene expression regulation in bacterial species such as Escherichia coli and Bacillus subtilis."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: BioNetGen is not a bioconductor tool; it is a software for rule-based modeling of biochemical systems, not specifically for accessing bacterial regulatory networks.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3933,
    "user_query": "You MUST give a detailed answer to the following question: What are the end products of the shikimate pathway?",
    "llama-7b_response": "​",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3936,
    "user_query": "You MUST give a detailed answer to the following question: Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-7b_response": "Yes, cabergoline is used for the treatment of Nelson's syndrome.\n\nNelson's syndrome is a rare condition that occurs in patients with a history of prolactinoma, a benign tumor of the pituitary gland that secretes high levels of the hormone prolactin. Nelson's syndrome is characterized by the development of macroprolactinoma, a type of prolactinoma that secretes large amounts of prolactin, leading to symptoms such as galactorrhea (milk production), amenorrhea (absence of menstrual periods), and erectile dysfunction.\n\nCabergoline is a dopamine agonist that is used to treat prolactinoma by lowering the levels of prolactin in the blood. It is also effective in treating Nelson's syndrome by reducing the size of the macroprolactinoma and improving symptoms such as galactorrhea, amenorrhea, and erectile dysfunction.\n\nIn addition to its use in treating Nelson's syndrome, cabergoline is also used to treat other conditions such as Parkinson's disease and hyperprolactinemia (high levels of prolactin in the blood).",
    "llama-7b_fact_raw": "1. Cabergoline is used for the treatment of Nelson's syndrome.\n2. Nelson's syndrome is a condition that occurs in patients with a history of prolactinoma.\n3. Nelson's syndrome is characterized by the development of macroprolactinoma.\n4. Cabergoline is a dopamine agonist that lowers the levels of prolactin in the blood.\n5. Cabergoline is used to treat conditions such as Parkinson's disease and hyperprolactinemia.",
    "llama-7b_fact": [
      "Cabergoline is used for the treatment of Nelson's syndrome.",
      "Nelson's syndrome is a condition that occurs in patients with a history of prolactinoma.",
      "Nelson's syndrome is characterized by the development of macroprolactinoma.",
      "Cabergoline is a dopamine agonist that lowers the levels of prolactin in the blood.",
      "Cabergoline is used to treat conditions such as Parkinson's disease and hyperprolactinemia."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Cabergoline is not typically used for the treatment of Nelson's syndrome. It is used for conditions associated with hyperprolactinemia, such as prolactinomas.\n2. FALSE [correction]: Nelson's syndrome occurs in patients with a history of Cushing's disease, not prolactinoma, who have undergone bilateral adrenalectomy.\n3. FALSE [correction]: Nelson's syndrome is characterized by the development of an ACTH-secreting pituitary adenoma after bilateral adrenalectomy in patients with Cushing's disease, not by macroprolactinoma.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3939,
    "user_query": "You MUST give a detailed answer to the following question: What is the main manifestation of Liebenberg syndrome?",
    "llama-7b_response": "Liebenberg syndrome is a rare genetic disorder caused by mutations in the PIK3CD gene, which encodes for a subunit of the phosphatidylinositol 3-kinase (PI3K) enzyme. The PI3K enzyme plays a crucial role in regulating various cellular processes, including cell growth, survival, and metabolism.\n\nThe main manifestation of Liebenberg syndrome is a combination of congenital abnormalities, including:\n\n1. Developmental delay: Children with Liebenberg syndrome may experience delays in physical and cognitive development.\n2. Microcephaly: Infants with Liebenberg syndrome may have abnormally small heads (microcephaly) due to abnormal brain development.\n3. Facial dysmorphism: Children with Liebenberg syndrome may have distinctive facial features, such as a broad forehead, widely spaced eyes, and a flattened nasal bridge.\n4. Skeletal abnormalities: Individuals with Liebenberg syndrome may have abnormalities in the development of bones and cartilage, leading to skeletal abnormalities such as short limbs, abnormal curvature of the spine (scoliosis), and joint contractures.\n5. Heart defects: Liebenberg syndrome is often associated with congenital heart defects, such as patent ductus arteriosus (PDA), atrial septal defect (ASD), and ventricular septal defect (VSD).\n6. Gastrointestinal abnormalities: Children with Liebenberg syndrome may have abnormalities in the development of the gastrointestinal tract, leading to feeding difficulties and gastrointestinal problems.\n7. Genitourinary abnormalities: Liebenberg syndrome is also associated with genitourinary abnormalities, such as hypospadias (a congenital abnormality of the urethra) and undescended testicles (cryptorchidism).\n\nOverall, Liebenberg syndrome is characterized by a combination of congenital abnormalities, including developmental delay, microcephaly, facial dysmorphism, skeletal abnormalities, heart defect",
    "llama-7b_fact_raw": "1. Liebenberg syndrome is caused by mutations in the PIK3CD gene.\n2. The PIK3CD gene encodes for a subunit of the phosphatidylinositol 3-kinase (PI3K) enzyme.\n3. Children with Liebenberg syndrome may experience developmental delays in physical and cognitive development.\n4. Infants with Liebenberg syndrome may have microcephaly due to abnormal brain development.\n5. Liebenberg syndrome is often associated with congenital heart defects, such as patent ductus arteriosus (PDA), atrial septal defect (ASD), and ventricular septal defect (VSD).",
    "llama-7b_fact": [
      "Liebenberg syndrome is caused by mutations in the PIK3CD gene.",
      "The PIK3CD gene encodes for a subunit of the phosphatidylinositol 3-kinase (PI3K) enzyme.",
      "Children with Liebenberg syndrome may experience developmental delays in physical and cognitive development.",
      "Infants with Liebenberg syndrome may have microcephaly due to abnormal brain development.",
      "Liebenberg syndrome is often associated with congenital heart defects, such as patent ductus arteriosus (PDA), atrial septal defect (ASD), and ventricular septal defect (VSD)."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Liebenberg syndrome is not caused by mutations in the PIK3CD gene. Liebenberg syndrome is a limb malformation syndrome, and its genetic cause is not well-defined. The PIK3CD gene is associated with a primary immunodeficiency disorder.\n2. TRUE\n3. UNKNOWN: Liebenberg syndrome primarily affects the development of the arms and hands, resembling a limb malformation. There is no specific information provided about cognitive development in the context of Liebenberg syndrome.\n4. UNKNOWN: Liebenberg syndrome is characterized by the abnormal development of the arms and hands, and there is no specific information provided about microcephaly or brain development in the context of Liebenberg syndrome.\n5. UNKNOWN: Liebenberg syndrome is known for limb malformations, and there is no specific information provided about its association with congenital heart defects. Without additional context, it is not possible to confirm or deny the association with the heart defects mentioned.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "You MUST give a detailed answer to the following question: List orally bioavailable MPS1 kinase inhibitors",
    "llama-7b_response": "Sure, here are some orally bioavailable MPS1 kinase inhibitors:\n\n1. AT-1212 - This is a small molecule inhibitor of MPS1 that has shown efficacy in preclinical models of cancer. It has been tested in Phase I clinical trials for the treatment of solid tumors.\n2. PF-04217903 - This is another small molecule inhibitor of MPS1 that has shown efficacy in preclinical models of cancer. It has been tested in Phase I clinical trials for the treatment of solid tumors.\n3. GSK2879552 - This is a small molecule inhibitor of MPS1 that has shown efficacy in preclinical models of cancer. It has been tested in Phase I clinical trials for the treatment of solid tumors.\n4. TAK-901 - This is a small molecule inhibitor of MPS1 that has shown efficacy in preclinical models of cancer. It has been tested in Phase I clinical trials for the treatment of solid tumors.\n5. AT-9283 - This is a small molecule inhibitor of MPS1 that has shown efficacy in preclinical models of cancer. It has been tested in Phase I clinical trials for the treatment of solid tumors.\n\nThese are just a few examples of orally bioavailable MPS1 kinase inhibitors that have been studied in clinical trials. However, it's worth noting that the development of MPS1 inhibitors as cancer therapeutics is a relatively new and active area of research, so there may be additional compounds that have not yet been tested in clinical trials.",
    "llama-7b_fact_raw": "1. AT-1212 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors.\n2. PF-04217903 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors.\n3. GSK2879552 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors.\n4. TAK-901 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors.\n5. AT-9283 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors.",
    "llama-7b_fact": [
      "AT-1212 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors.",
      "PF-04217903 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors.",
      "GSK2879552 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors.",
      "TAK-901 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors.",
      "AT-9283 is an orally bioavailable MPS1 kinase inhibitor that has been tested in Phase I clinical trials for the treatment of solid tumors."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: GSK2879552 is not an MPS1 kinase inhibitor; it is a lysine-specific demethylase 1 (LSD1) inhibitor.\n4. UNKNOWN\n5. UNKNOWN\n\nThe corrections and verifications of the statements regarding the specific inhibitors and their clinical trial phases would require access to up-to-date scientific literature or databases, which is beyond the scope of this AI's current capabilities.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4031,
    "user_query": "You MUST give a detailed answer to the following question: Was golimumab tested for diabetes?",
    "llama-7b_response": "Golimumab, also known by the trade name Simponi, is a medication that is used to treat several autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is a monoclonal antibody that works by blocking the activity of a protein called tumor necrosis factor-alpha (TNF-alpha), which is involved in the inflammatory response.\n\nAs of my knowledge cutoff date of September 2021, golimumab had not been specifically tested or approved for the treatment of diabetes. However, it is possible that there may be ongoing research or clinical trials investigating the use of golimumab for diabetes or related conditions. I would recommend consulting with a healthcare professional or conducting further research to obtain the most up-to-date information on the use of golimumab for diabetes.",
    "llama-7b_fact_raw": "1. Golimumab is used to treat autoimmune disorders such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.\n2. Golimumab is a monoclonal antibody.\n3. Golimumab works by blocking the activity of tumor necrosis factor-alpha (TNF-alpha).\n4. As of September 2021, golimumab had not been specifically tested or approved for the treatment of diabetes.",
    "llama-7b_fact": [
      "Golimumab is used to treat autoimmune disorders such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.",
      "Golimumab is a monoclonal antibody.",
      "Golimumab works by blocking the activity of tumor necrosis factor-alpha (TNF-alpha).",
      "As of September 2021, golimumab had not been specifically tested or approved for the treatment of diabetes."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 4055,
    "user_query": "You MUST give a detailed answer to the following question: Is progeria caused by an autosomal recessive gene?",
    "llama-7b_response": "Yes, progeria is caused by an autosomal recessive gene.\n\nProgeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is a rare genetic disorder that causes premature aging in children. It is caused by a mutation in the LMNA gene, which is located on chromosome 1q21. The LMNA gene provides instructions for making a protein called lamin A, which is a key component of the nuclear lamina, a structural framework that helps to maintain the shape of the nucleus in cells.\n\nIn progeria, the mutation in the LMNA gene leads to the production of a defective form of lamin A, which accumulates in the cells and causes them to age prematurely. This accumulation of defective lamin A protein is what leads to the characteristic features of progeria, such as hair loss, aged-looking skin, stiff joints, and an increased risk of heart disease and other age-related conditions.\n\nThe LMNA gene is inherited in an autosomal recessive manner, which means that a child must inherit two copies of the mutated gene (one from each parent) in order to develop progeria. If a child only inherits one copy of the mutated gene, they will be a carrier of the condition but will not show any symptoms themselves. However, if the child inherits two copies of the mutated gene, they will develop progeria.\n\nIn summary, progeria is caused by an autosomal recessive gene mutation in the LMNA gene, which leads to the production of a defective form of lamin A protein that causes premature aging in children.",
    "llama-7b_fact_raw": "1. Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is a rare genetic disorder that causes premature aging in children.\n2. The disorder is caused by a mutation in the LMNA gene, which is located on chromosome 1q21.\n3. The LMNA gene mutation leads to the production of a defective form of lamin A protein.\n4. The accumulation of defective lamin A protein in cells leads to the characteristic features of progeria.\n5. The LMNA gene is inherited in an autosomal recessive manner, meaning a child must inherit two copies of the mutated gene to develop progeria.",
    "llama-7b_fact": [
      "Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is a rare genetic disorder that causes premature aging in children.",
      "The disorder is caused by a mutation in the LMNA gene, which is located on chromosome 1q21.",
      "The LMNA gene mutation leads to the production of a defective form of lamin A protein.",
      "The accumulation of defective lamin A protein in cells leads to the characteristic features of progeria.",
      "The LMNA gene is inherited in an autosomal recessive manner, meaning a child must inherit two copies of the mutated gene to develop progeria."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The LMNA gene mutation in progeria is typically not inherited but occurs as a new (de novo) mutation. Progeria follows an autosomal dominant pattern, meaning only one copy of the mutated gene is sufficient to cause the disorder.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 4082,
    "user_query": "You MUST give a detailed answer to the following question: What are common variants at 12q14 and 12q24 associated with?",
    "llama-7b_response": "Common variants at 12q14 and 12q24 have been associated with various traits and diseases. Here are some examples:\n\n1. 12q14:\n\t* Variants at this locus have been associated with risk of type 2 diabetes, obesity, and cardiovascular disease.\n\t* One of the most well-known genes at this locus is TCF7L1, which encodes a transcription factor involved in Wnt signaling. Variants in TCF7L1 have been associated with increased risk of type 2 diabetes and obesity.\n2. 12q24:\n\t* Variants at this locus have been associated with risk of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.\n\t* One of the most well-known genes at this locus is APOE, which encodes a protein involved in lipid metabolism and transport. Variants in APOE have been associated with increased risk of Alzheimer's disease and other neurodegenerative disorders.",
    "llama-7b_fact_raw": "1. Variants at the 12q14 locus have been associated with an increased risk of type 2 diabetes.\n2. Variants at the 12q14 locus have been associated with obesity.\n3. Variants at the 12q14 locus have been associated with cardiovascular disease.\n4. Variants in the TCF7L1 gene at the 12q14 locus have been associated with an increased risk of type 2 diabetes and obesity.\n5. Variants in the APOE gene at the 12q24 locus have been associated with an increased risk of Alzheimer's disease and other neurodegenerative disorders.",
    "llama-7b_fact": [
      "Variants at the 12q14 locus have been associated with an increased risk of type 2 diabetes.",
      "Variants at the 12q14 locus have been associated with obesity.",
      "Variants at the 12q14 locus have been associated with cardiovascular disease.",
      "Variants in the TCF7L1 gene at the 12q14 locus have been associated with an increased risk of type 2 diabetes and obesity.",
      "Variants in the APOE gene at the 12q24 locus have been associated with an increased risk of Alzheimer's disease and other neurodegenerative disorders."
    ],
    "llama-7b_judge_raw": "1. TRUE: Variants at the 12q14 locus have been associated with an increased risk of type 2 diabetes in various genetic studies.\n2. TRUE: Variants at the 12q14 locus have also been associated with obesity, as this locus is known to contain genes that may influence body mass and fat distribution.\n3. UNKNOWN: While there is a well-established genetic component to cardiovascular disease, without specific evidence or studies linking the 12q14 locus to cardiovascular disease, it is difficult to determine the accuracy of this statement.\n4. FALSE [correction]: Variants in the TCF7L2 gene at the 10q25.3 locus have been associated with an increased risk of type 2 diabetes and obesity, not the TCF7L1 gene at the 12q14 locus.\n5. TRUE: Variants in the APOE gene, particularly the APOE ε4 allele, at the 19q13.32 locus have been associated with an increased risk of Alzheimer's disease and other neurodegenerative disorders, not the 12q24 locus.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "You MUST give a detailed answer to the following question: Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-7b_response": "The Roundabout (Robo) receptors are G protein-coupled receptors that are involved in various cellular processes, including cell-cell adhesion, migration, and differentiation. The ligands of the Roundabout receptors are proteins or peptides that bind to the extracellular domain of the receptor and activate its intracellular signaling pathways.\n\nThere are several known ligands of the Roundabout receptors, including:\n\n1. Robo1: Robo1 is the most well-studied ligand of the Roundabout receptors. It is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and epithelial cells. Robo1 binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion and migration.\n2. Robo2: Robo2 is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and epithelial cells. Like Robo1, Robo2 binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion and migration.\n3. Robo3: Robo3 is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and epithelial cells. Like Robo1 and Robo2, Robo3 binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion and migration.\n4. Robo4: Robo4 is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and epithelial cells. Like Robo1, Robo2, and Robo3, Robo4 binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion and migration.\n5. Robo5: Robo5 is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and epithelial cells. Like Robo1, Robo2, Robo3, and Robo4, Robo5 binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion",
    "llama-7b_fact_raw": "1. The Roundabout (Robo) receptors are G protein-coupled receptors involved in cell-cell adhesion, migration, and differentiation.\n2. Robo1 is a ligand of the Roundabout receptors and is a transmembrane protein expressed on various cell types.\n3. Robo2 is a ligand of the Roundabout receptors and is a transmembrane protein expressed on various cell types.\n4. Robo3 is a ligand of the Roundabout receptors and is a transmembrane protein expressed on various cell types.\n5. Robo4 is a ligand of the Roundabout receptors and is a transmembrane protein expressed on various cell types.",
    "llama-7b_fact": [
      "The Roundabout (Robo) receptors are G protein-coupled receptors involved in cell-cell adhesion, migration, and differentiation.",
      "Robo1 is a ligand of the Roundabout receptors and is a transmembrane protein expressed on various cell types.",
      "Robo2 is a ligand of the Roundabout receptors and is a transmembrane protein expressed on various cell types.",
      "Robo3 is a ligand of the Roundabout receptors and is a transmembrane protein expressed on various cell types.",
      "Robo4 is a ligand of the Roundabout receptors and is a transmembrane protein expressed on various cell types."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Roundabout (Robo) receptors are not G protein-coupled receptors; they are single-pass transmembrane receptors that belong to the immunoglobulin superfamily and are involved in cell-cell adhesion, migration, and axon guidance.\n2. FALSE [correction]: Robo1 is not a ligand but one of the Roundabout receptors itself. It is a transmembrane protein expressed on various cell types.\n3. FALSE [correction]: Robo2 is not a ligand but one of the Roundabout receptors itself. It is a transmembrane protein expressed on various cell types.\n4. FALSE [correction]: Robo3 is not a ligand but one of the Roundabout receptors itself. It is a transmembrane protein expressed on various cell types.\n5. FALSE [correction]: Robo4 is not a ligand but one of the Roundabout receptors itself. It is a transmembrane protein expressed on various cell types. The ligand for Robo receptors is Slit, a secreted protein that binds to Robo receptors to mediate their functions.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 4112,
    "user_query": "You MUST give a detailed answer to the following question: Is there a role for TFII-I in megakaryopoiesis?",
    "llama-7b_response": "Yes, there is a role for TFII-I in megakaryopoiesis. TFII-I is a transcription factor that plays an important role in the regulation of gene expression during the process of megakaryopoiesis.\n\nMegakaryopoiesis is the process by which megakaryocytes, which are specialized bone marrow cells that produce platelets, are formed. This process involves the proliferation and differentiation of hematopoietic stem cells into megakaryocytes.\n\nTFII-I is a key transcription factor that is involved in the regulation of gene expression during megakaryopoiesis. It binds to specific DNA sequences known as TFII-I elements, which are located upstream of genes that are specifically expressed in megakaryocytes.\n\nTFII-I has been shown to play a crucial role in the regulation of gene expression during megakaryopoiesis. For example, studies have shown that TFII-I is required for the expression of genes that are specifically expressed in megakaryocytes, such as genes that encode proteins involved in platelet production.\n\nIn addition, TFII-I has also been shown to play a role in the differentiation of hematopoietic stem cells into megakaryocytes. For example, studies have shown that TFII-I is required for the proliferation and differentiation of hematopoietic stem cells into megakaryocytes in vitro.\n\nOverall, TFII-I plays an important role in the regulation of gene expression and differentiation during megakaryopoiesis.",
    "llama-7b_fact_raw": "1. TFII-I is a transcription factor that plays a role in the regulation of gene expression during megakaryopoiesis.\n2. Megakaryopoiesis is the process of formation of megakaryocytes, which are bone marrow cells that produce platelets.\n3. TFII-I binds to specific DNA sequences known as TFII-I elements, which are located upstream of genes expressed in megakaryocytes.\n4. TFII-I is required for the expression of genes that are specifically expressed in megakaryocytes, including those involved in platelet production.\n5. TFII-I is necessary for the proliferation and differentiation of hematopoietic stem cells into megakaryocytes in vitro.",
    "llama-7b_fact": [
      "TFII-I is a transcription factor that plays a role in the regulation of gene expression during megakaryopoiesis.",
      "Megakaryopoiesis is the process of formation of megakaryocytes, which are bone marrow cells that produce platelets.",
      "TFII-I binds to specific DNA sequences known as TFII-I elements, which are located upstream of genes expressed in megakaryocytes.",
      "TFII-I is required for the expression of genes that are specifically expressed in megakaryocytes, including those involved in platelet production.",
      "TFII-I is necessary for the proliferation and differentiation of hematopoietic stem cells into megakaryocytes in vitro."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about TFII-I's role in gene regulation during megakaryopoiesis and the process of megakaryopoiesis itself are accurate. However, without specific scientific references, it's difficult to confirm the exact DNA binding sequences (TFII-I elements) and the necessity of TFII-I for the expression of specific genes in megakaryocytes or its role in the proliferation and differentiation of hematopoietic stem cells into megakaryocytes in vitro. These details would require access to specific scientific studies or literature for verification.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4145,
    "user_query": "You MUST give a detailed answer to the following question: Is atenolol metabolized by CYP2D6?",
    "llama-7b_response": "Yes, atenolol is metabolized by CYP2D6. Atenolol is a beta-blocker medication that is used to treat hypertension and angina pectoris. It works by blocking the action of certain natural substances in your body, such as norepinephrine, on the heart and blood vessels.\n\nCYP2D6 is an enzyme that is responsible for the metabolism of many medications, including atenolol. The metabolism of atenolol by CYP2D6 results in the formation of several metabolites, which are then excreted from the body.\n\nThe metabolism of atenolol by CYP2D6 can be affected by genetic variations in the CYP2D6 gene. Some people may have reduced activity of the CYP2D6 enzyme, which can result in reduced metabolism of atenolol and an increased risk of side effects. Conversely, some people may have increased activity of the CYP2D6 enzyme, which can result in increased metabolism of atenolol and a reduced effectiveness of the medication.\n\nIn summary, atenolol is metabolized by CYP2D6, and the metabolism of atenolol by CYP2D6 can be affected by genetic variations in the CYP2D6 gene.",
    "llama-7b_fact_raw": "1. Atenolol is metabolized by the enzyme CYP2D6.\n2. Atenolol is used to treat hypertension and angina pectoris.\n3. The metabolism of atenolol by CYP2D6 results in the formation of several metabolites.\n4. Genetic variations in the CYP2D6 gene can affect the metabolism of atenolol.\n5. Reduced activity of the CYP2D6 enzyme can lead to reduced metabolism of atenolol and an increased risk of side effects.",
    "llama-7b_fact": [
      "Atenolol is metabolized by the enzyme CYP2D6.",
      "Atenolol is used to treat hypertension and angina pectoris.",
      "The metabolism of atenolol by CYP2D6 results in the formation of several metabolites.",
      "Genetic variations in the CYP2D6 gene can affect the metabolism of atenolol.",
      "Reduced activity of the CYP2D6 enzyme can lead to reduced metabolism of atenolol and an increased risk of side effects."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by the liver and does not undergo significant metabolism by the enzyme CYP2D6. It is primarily excreted unchanged in urine.\n2. TRUE\n3. FALSE [correction]: Since atenolol is not significantly metabolized by CYP2D6, it does not result in the formation of several metabolites through this pathway.\n4. FALSE [correction]: Given that atenolol is not significantly metabolized by CYP2D6, genetic variations in the CYP2D6 gene would not be expected to affect the metabolism of atenolol.\n5. FALSE [correction]: Since atenolol is not significantly metabolized by CYP2D6, reduced activity of this enzyme would not lead to reduced metabolism of atenolol or an increased risk of side effects due to this pathway.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 4158,
    "user_query": "You MUST give a detailed answer to the following question: List versions of ExpansionHunter",
    "llama-7b_response": "I apologize, but I am unable to provide a detailed answer to your question as I am not aware of any specific versions of ExpansionHunter. Could you please provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 4164,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of Adamts18 in hormone receptor signaling?",
    "llama-7b_response": "Adamts18, also known as aggrecanase-1, is an enzyme that degrades the proteoglycan aggrecan, which is a major component of cartilage. Adamts18 has been shown to play a role in the regulation of hormone receptor signaling by affecting the expression and activity of hormone receptors.\n\nIn particular, Adamts18 has been shown to regulate the expression of estrogen receptors (ERs) and androgen receptors (ARs) in breast cancer cells. Studies have shown that Adamts18 can promote the degradation of ERs and ARs, leading to a decrease in their expression and activity. This, in turn, can reduce the ability of these hormone receptors to bind to their hormone ligands and activate downstream signaling pathways.\n\nAdditionally, Adamts18 has been shown to regulate the expression of other genes involved in hormone receptor signaling, such as those encoding for transcription factors and signaling molecules. For example, Adamts18 has been shown to regulate the expression of p53, a tumor suppressor protein that plays a role in the regulation of hormone receptor signaling.\n\nOverall, the role of Adamts18 in hormone receptor signaling is complex and involves both the regulation of hormone receptor expression and activity, as well as the regulation of the expression of other genes involved in hormone receptor signaling.",
    "llama-7b_fact_raw": "1. Adamts18 is an enzyme that degrades aggrecan, a major component of cartilage.\n2. Adamts18 regulates the expression of estrogen receptors (ERs) and androgen receptors (ARs) in breast cancer cells.\n3. Adamts18 can promote the degradation of ERs and ARs, leading to a decrease in their expression and activity.\n4. The reduction in ER and AR expression and activity by Adamts18 can affect the ability of these hormone receptors to bind to their hormone ligands.\n5. Adamts18 has been shown to regulate the expression of p53, a tumor suppressor protein involved in hormone receptor signaling.",
    "llama-7b_fact": [
      "Adamts18 is an enzyme that degrades aggrecan, a major component of cartilage.",
      "Adamts18 regulates the expression of estrogen receptors (ERs) and androgen receptors (ARs) in breast cancer cells.",
      "Adamts18 can promote the degradation of ERs and ARs, leading to a decrease in their expression and activity.",
      "The reduction in ER and AR expression and activity by Adamts18 can affect the ability of these hormone receptors to bind to their hormone ligands.",
      "Adamts18 has been shown to regulate the expression of p53, a tumor suppressor protein involved in hormone receptor signaling."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: ADAMTS18 is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family, but it is not specifically known for degrading aggrecan. Aggrecanases, such as ADAMTS4 and ADAMTS5, are more commonly associated with the degradation of aggrecan in cartilage.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements regarding ADAMTS18's specific roles in hormone receptor regulation and interaction with p53 are highly specialized and would require access to current scientific literature to verify. Without specific information from recent studies, the truthfulness of statements 2, 3, 4, and 5 cannot be determined.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "You MUST give a detailed answer to the following question: What is the mode of action of Thiazovivin?",
    "llama-7b_response": "Thiazovivin is an antibiotic that belongs to the class of drugs known as thiazolidinones. It is used to treat a variety of bacterial infections, including those of the respiratory tract, urinary tract, and skin.\n\nThe mode of action of Thiazovivin is similar to that of other antibiotics. It works by interfering with the ability of bacteria to produce a key component of their cell walls, called peptidoglycan. Without this component, the bacterial cell wall becomes weakened and the bacteria eventually die.\n\nThiazovivin also has some activity against certain types of fungal infections. However, its effectiveness against fungal infections is generally not as strong as its effectiveness against bacterial infections.\n\nOverall, Thiazovivin is an effective antibiotic that can be used to treat a variety of bacterial infections. However, like all antibiotics, it should only be used to treat bacterial infections, as it is not effective against viral infections.",
    "llama-7b_fact_raw": "1. Thiazovivin is an antibiotic.\n2. Thiazovivin belongs to the class of drugs known as thiazolidinones.\n3. Thiazovivin is used to treat bacterial infections of the respiratory tract, urinary tract, and skin.\n4. Thiazovivin works by interfering with the production of peptidoglycan in bacterial cell walls.\n5. Thiazovivin is not effective against viral infections.",
    "llama-7b_fact": [
      "Thiazovivin is an antibiotic.",
      "Thiazovivin belongs to the class of drugs known as thiazolidinones.",
      "Thiazovivin is used to treat bacterial infections of the respiratory tract, urinary tract, and skin.",
      "Thiazovivin works by interfering with the production of peptidoglycan in bacterial cell walls.",
      "Thiazovivin is not effective against viral infections."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Thiazovivin is not an antibiotic; it is a small molecule inhibitor used in stem cell research.\n2. FALSE [correction]: Thiazovivin does not belong to the class of drugs known as thiazolidinones; it is a ROCK inhibitor that is used to improve the survival of human embryonic stem cells.\n3. FALSE [correction]: Thiazovivin is not used to treat bacterial infections as it is not an antibiotic.\n4. FALSE [correction]: Thiazovivin does not work by interfering with the production of peptidoglycan in bacterial cell walls; it inhibits the Rho-associated protein kinase (ROCK) pathway.\n5. TRUE (by default, since Thiazovivin is not an antibiotic and is not used to treat infections, it would not be effective against viral infections).",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  }
]